



Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp092, Report 2

Request ID: cder_mpl1r_wp092_nsdv_v01

Request Description: The goal of this request was to examine utilization of non-insulin antidiabetic drugs in the Sentinel Distributed Database (SDD). This is report 2 of 2. Report 1 contains estimates of the length of follow-up time for patients diagnosed with Type 2 Diabetes and for patients dispensed non-insulin antidiabetic drugs in the SDD.

Sentinel Modular Program Tool Used: Cohort Identification and Descriptive Analysis (CIDA) tool, version 5.4.2

Data Source: Data from January 1, 2008 to January 31, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on June 28, 2018. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: This request used a retrospective cohort design. The purpose of this request was to calculate summary statistics on antidiabetic drug dispensings, length of treatment episodes, and gaps between treatment episodes. Results were stratified by sex and age group.

Exposures of Interest: The exposures of interest were the following non-insulin antidiabetic drugs: albiglutide, alogliptin, canagliflozin, dapagliflozin, dulaglutide, empagliflozin, exenatide, glimepiride, glipizide, glyburide, linagliptin, liraglutide, metformin, pioglitazone, saxagliptin, sitagliptin. Exposures were defined using National Drug Codes (NDCs). Please see Appendix B for a list of generic and brand drug names used to define exposures in this request.

Cohort Eligibility Criteria: Patients included in the cohort were required to be continuously enrolled in health plans with drug coverage for at least 183 days prior to their first valid dispensing date (index date), during which gaps in coverage of up to 45 days were allowed. The following age groups were included in the cohort: 18-44, 45-54, 55-64, 65-74, and 75+ years. Patients were excluded if they did not have an incident dispensing during the study period. Incident use was defined as no dispensing of the same treatment in the prior 183 days.

Treatment Episode Creation: Treatment episode lengths were defined using outpatient pharmacy dispensing days supply to create a sequence of continuous exposure. Treatment episodes were considered continuous if gaps between consecutive dispensings were less than 10 days. During the study period, all valid treatment episodes following the first incident dispensing were included. Treatment episodes were truncated upon the first occurrence of any of the following: 1) health plan disenrollment; 2) death; or 3) the end of the study period.

Sensitivity Analysis: A sensitivity analysis assessed exposure utilization using a 25% episode gap for glyburide, liraglutide, metformin, and sitagliptin. For these exposures, episodes were considered continuous if gaps between dispensings were less than 25% of the days supply of the previous dispensing. See Table B's for this analysis.

Please see Appendix C for the specifications of parameters used in this request.

Limitations: Algorithms used to define exposures are imperfect and may not have been validated; thus, it is possible that cohort members may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms found in this Report and their Definitions
<u>Table 1a</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018
<u>Table 1b</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis
<u>Table 2a</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex
<u>Table 2b</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex
<u>Table 3a</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group
<u>Table 3b</u>	Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group
<u>Table 4a</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018
<u>Table 4b</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis
<u>Table 5a</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex
<u>Table 5b</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex
<u>Table 6a</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group
<u>Table 6b</u>	Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group
<u>Table 7a</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018
<u>Table 7b</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis
<u>Table 8a</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Table of Contents, continued

<u>Table 8b</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex
<u>Table 9a</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group
<u>Table 9b</u>	Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group
<u>Table 10a</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018
<u>Table 10b</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis
<u>Table 11a</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex
<u>Table 11b</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex
<u>Table 12a</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group
<u>Table 12b</u>	Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group
<u>Appendix A</u>	List of Dates of Available Data for Each Data Partner (DP) in the Sentinel Distributed Database (SDD) as of Request Distribution Date (June 28, 2018)
<u>Appendix B</u>	List of Generic and Brand Drug Names Used to Define Exposures in this Request
<u>Appendix C</u>	Specifications Defining Parameters in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Tool***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid treatment episode during the query period; (2) 02: Cohort includes all valid treatment episodes during the query period; (3) 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions - days are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*not all terms may be used in this report

Table 1a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	154,958	100%	160,233	100%	2,529,595	100%	621,652	100%	584,760	100%	688,327	100%
Days' Supply Categories												
1-29 Days	100,920	65.1%	9,285	5.8%	175,663	6.9%	40,744	6.6%	419,854	71.8%	66,354	9.6%
30 Days	43,278	27.9%	129,993	81.1%	1,992,602	78.8%	508,407	81.8%	89,623	15.3%	531,747	77.3%
31-89 Days	9,160	5.9%	2,913	1.8%	54,495	2.2%	11,649	1.9%	65,126	11.1%	20,256	2.9%
90 Days	1,547	1%	17,981	11.2%	305,414	12.1%	60,411	9.7%	9,770	1.7%	69,364	10.1%
91+ Days	53	0.03%	61	0.04%	1,421	0.1%	441	0.1%	387	0.1%	606	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		28		30	
Mean	31.2		36.4		36.9		35.4		33.6		35.5	
Median	28		30		30		30		28		30	
Mode	28		30		30		30		28		30	
75th Percentile	30		30		30		30		30		30	
90th Percentile	30		90		90		81		84		90	
Max	471		180		365		270		435		365	

Table 1a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	1,897,653	100%	15,126,850	100%	20,518,629	100%	5,982,296	100%	3,100,568	100%	3,966,181	100%
Days' Supply Categories												
1-29 Days	662,265	34.9%	819,022	5.4%	1,292,989	6.3%	312,299	5.2%	396,107	12.8%	384,811	9.7%
30 Days	996,082	52.5%	9,975,174	65.9%	12,373,466	60.3%	4,293,618	71.8%	2,209,909	71.3%	2,936,326	74%
31-89 Days	106,967	5.6%	628,226	4.2%	1,052,420	5.1%	221,323	3.7%	76,417	2.5%	184,161	4.6%
90 Days	130,912	6.9%	3,676,456	24.3%	4,543,991	22.1%	1,088,935	18.2%	412,383	13.3%	459,244	11.6%
91+ Days	1,427	0.1%	27,972	0.2%	1,255,763	6.1%	66,121	1.1%	5,752	0.2%	1,639	0.04%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		16		30	
25th Percentile	28		30		30		30		30		30	
Mean	35.5		45		48		41.9		36.8		37	
Median	30		30		30		30		30		30	
Mode	30		30		30		30		30		30	
75th Percentile	30		74		90		30		30		30	
90th Percentile	84		90		90		90		90		90	
Max	1400		900		1080		1023		600		900	

Table 1a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	71,316,729	100%	8,637,350	100%	3,807,159	100%	17,551,733	100%
Days' Supply Categories								
1-29 Days	4,098,050	5.7%	441,249	5.1%	217,401	5.7%	1,827,431	10.4%
30 Days	47,626,798	66.8%	6,282,838	72.7%	3,048,884	80.1%	12,671,731	72.2%
31-89 Days	2,864,442	4%	248,759	2.9%	64,288	1.7%	425,816	2.4%
90 Days	14,914,537	20.9%	1,531,442	17.7%	475,238	12.5%	2,613,242	14.9%
91+ Days	1,812,902	2.5%	133,062	1.5%	1,348	0.04%	13,513	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		28	
25th Percentile	30		30		30		30	
Mean	44.5		41.7		37.1		38	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	60		30		30		30	
90th Percentile	90		90		90		90	
Max	1211		999		600		1080	

Table 1b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	5,982,296	100%	3,966,181	100%	71,316,729	100%	17,551,733	100%
Days' Supply Categories								
1-29 Days	312,299	5.2%	384,811	9.7%	4,098,050	5.7%	1,827,431	10.4%
30 Days	4,293,618	71.8%	2,936,326	74%	47,626,798	66.8%	12,671,731	72.2%
31-89 Days	221,323	3.7%	184,161	4.6%	2,864,442	4%	425,816	2.4%
90 Days	1,088,935	18.2%	459,244	11.6%	14,914,537	20.9%	2,613,242	14.9%
91+ Days	66,121	1.1%	1,639	0.04%	1,812,902	2.5%	13,513	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		28	
25th Percentile	30		30		30		30	
Mean	41.9		37		44.5		38	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	30		30		60		30	
90th Percentile	90		90		90		90	
Max	1,023		900		1211		1080	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	75,820	100%	67,784	100%	1,125,207	100%	268,921	100%	303,167	100%	288,461	100%
Days' Supply Categories												
1-29 Days	49,751	65.6%	4,357	6.4%	82,968	7.4%	18,461	6.9%	219,616	72.4%	27,801	9.6%
30 Days	21,245	28%	55,166	81.4%	894,333	79.5%	220,997	82.2%	47,045	15.5%	225,416	78.1%
31-89 Days	4,038	5.3%	1,246	1.8%	22,992	2%	4,870	1.8%	31,553	10.4%	7,894	2.7%
90 Days	762	1%	6,991	10.3%	124,424	11.1%	24,426	9.1%	4,765	1.6%	27,135	9.4%
91+ Days	24	0.03%	24	0.04%	490	0.04%	167	0.1%	188	0.1%	215	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		28		30	
Mean	30.9		35.7		36.1		35		33.2		35	
Median	28		30		30		30		28		30	
Mode	28		30		30		30		28		30	
75th Percentile	30		30		30		30		30		30	
90th Percentile	30		90		90		60		66		76	
Max	360		150		365		270		435		365	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	1,050,719	100%	7,662,703	100%	10,311,504	100%	2,965,334	100%	1,624,069	100%	2,193,730	100%
Days' Supply Categories												
1-29 Days	351,019	33.4%	445,073	5.8%	692,718	6.7%	162,355	5.5%	240,481	14.8%	217,121	9.9%
30 Days	576,201	54.8%	5,126,254	66.9%	6,392,867	62%	2,157,096	72.7%	1,142,878	70.4%	1,633,746	74.5%
31-89 Days	52,301	5%	322,709	4.2%	525,591	5.1%	111,812	3.8%	39,295	2.4%	104,937	4.8%
90 Days	70,448	6.7%	1,756,029	22.9%	2,146,538	20.8%	497,654	16.8%	199,147	12.3%	237,132	10.8%
91+ Days	750	0.1%	12,638	0.2%	553,790	5.4%	36,417	1.2%	2,268	0.1%	794	0.04%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		14		30	
25th Percentile	28		30		30		30		30		30	
Mean	35.1		44.1		46.5		41.1		35.8		36.5	
Median	30		30		30		30		30		30	
Mode	30		30		30		30		30		30	
75th Percentile	30		60		90		30		30		30	
90th Percentile	84		90		90		90		90		90	
Max	1400		480		999		999		600		900	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	37,123,315	100%	3,923,172	100%	1,941,782	100%	9,328,443	100%
Days' Supply Categories								
1-29 Days	2,200,810	5.9%	222,030	5.7%	126,577	6.5%	1,117,445	12%
30 Days	25,109,644	67.6%	2,890,391	73.7%	1,553,314	80%	6,700,418	71.8%
31-89 Days	1,490,968	4%	113,682	2.9%	32,216	1.7%	222,129	2.4%
90 Days	7,470,546	20.1%	641,789	16.4%	229,118	11.8%	1,282,355	13.7%
91+ Days	851,347	2.3%	55,280	1.4%	557	0.03%	6,096	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		19	
25th Percentile	30		30		30		30	
Mean	43.8		40.7		36.5		37	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	45		30		30		30	
90th Percentile	90		90		90		90	
Max	999		900		600		874	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	79,138	100%	92,449	100%	1,404,388	100%	352,731	100%	281,593	100%	399,866	100%
Days' Supply Categories												
1-29 Days	51,169	64.7%	4,928	5.3%	92,695	6.6%	22,283	6.3%	200,238	71.1%	38,553	9.6%
30 Days	22,033	27.8%	74,827	80.9%	1,098,269	78.2%	287,410	81.5%	42,578	15.1%	306,331	76.6%
31-89 Days	5,122	6.5%	1,667	1.8%	31,503	2.2%	6,779	1.9%	33,573	11.9%	12,362	3.1%
90 Days	785	1%	10,990	11.9%	180,990	12.9%	35,985	10.2%	5,005	1.8%	42,229	10.6%
91+ Days	29	0.04%	37	0.04%	931	0.1%	274	0.1%	199	0.1%	391	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		28		30	
Mean	31.5		36.9		37.4		35.8		34.1		35.9	
Median	28		30		30		30		28		30	
Mode	28		30		30		30		28		30	
75th Percentile	30		30		30		30		30		30	
90th Percentile	30		90		90		90		84		90	
Max	471		180		365		240		300		365	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	846,934	100%	7,464,147	100%	10,207,125	100%	3,016,962	100%	1,476,499	100%	1,772,451	100%
Days' Supply Categories												
1-29 Days	311,246	36.7%	373,949	5%	600,271	5.9%	149,944	5%	155,626	10.5%	167,690	9.5
30 Days	419,881	49.6%	4,848,920	65%	5,980,599	58.6%	2,136,522	70.8%	1,067,031	72.3%	1,302,580	73.5
31-89 Days	54,666	6.5%	305,517	4.1%	526,829	5.2%	109,511	3.6%	37,122	2.5%	79,224	4.5
90 Days	60,464	7.1%	1,920,427	25.7%	2,397,453	23.5%	591,281	19.6%	213,236	14.4%	222,112	12.5
91+ Days	677	0.1%	15,334	0.2%	701,973	6.9%	29,704	1%	3,484	0.2%	845	0.05%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		30		30	
Mean	36		45.9		49.4		42.6		37.9		37.6	
Median	30		30		30		30		30		30	
Mode	30		30		30		30		30		30	
75th Percentile	30		90		90		30		30		30	
90th Percentile	84		90		90		90		90		90	
Max	600		900		1080		1023		450		480	

Table 2a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	34,193,414	100%	4,714,178	100%	1,865,377	100%	8,223,290	100%
Days' Supply Categories								
1-29 Days	1,897,240	5.5%	219,219	4.7%	90,824	4.9%	709,986	8.6%
30 Days	22,517,154	65.9%	3,392,447	72%	1,495,570	80.2%	5,971,313	72.6%
31-89 Days	1,373,474	4%	135,077	2.9%	32,072	1.7%	203,687	2.5%
90 Days	7,443,991	21.8%	889,653	18.9%	246,120	13.2%	1,330,887	16.2%
91+ Days	961,555	2.8%	77,782	1.6%	791	0.04%	7,417	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	45.2		42.5		37.6		39.1	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	76		30		30		30	
90th Percentile	90		90		90		90	
Max	1211		999		480		1080	

Table 2b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Female	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	2,965,334	100%	2,193,730	100%	37,123,315	100%	9,328,443	100%
Days' Supply Categories								
1-29 Days	162,355	5.5%	217,121	9.9%	2,200,810	5.9%	1,117,445	12%
30 Days	2,157,096	72.7%	1,633,746	74.5%	25,109,644	67.6%	6,700,418	71.8%
31-89 Days	111,812	3.8%	104,937	4.8%	1,490,968	4%	222,129	2.4%
90 Days	497,654	16.8%	237,132	10.8%	7,470,546	20.1%	1,282,355	13.7%
91+ Days	36,417	1.2%	794	0.04%	851,347	2.3%	6,096	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		19	
25th Percentile	30		30		30		30	
Mean	41.1		36.5		43.8		37	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	30		30		45		30	
90th Percentile	90		90		90		90	
Max	999		900		999		874	

Table 2b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Male	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	3,016,962	100%	1,772,451	100%	34,193,414	100%	8,223,290	100%
Days' Supply Categories								
1-29 Days	149,944	5%	167,690	9.5%	1,897,240	5.5%	709,986	8.6%
30 Days	2,136,522	70.8%	1,302,580	73.5%	22,517,154	65.9%	5,971,313	72.6%
31-89 Days	109,511	3.6%	79,224	4.5%	1,373,474	4%	203,687	2.5%
90 Days	591,281	19.6%	222,112	12.5%	7,443,991	21.8%	1,330,887	16.2%
91+ Days	29,704	1%	845	0.05%	961,555	2.8%	7,417	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	42.6		37.6		45.2		39.1	
Median	30		30		30		30	
Mode	30		30		30		30	
75th Percentile	30		30		76		30	
90th Percentile	90		90		90		90	
Max	1023		480		1211		1080	

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Albiglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	22,865	100%	45,492	100%	57,095	100%	22,081	100%	7,425	100%
Days' Supply Categories										
1-29 Days	15,224	66.6%	29,866	65.7%	37,270	65.3%	13,707	62.1%	4,853	65.4%
30 Days	6,832	29.9%	13,208	29%	15,905	27.9%	5,515	25%	1,818	24.5%
31-89 Days	655	2.9%	2,061	4.5%	3,331	5.8%	2,489	11.3%	624	8.4%
90 Days	*****	*****	338	0.7%	566	1%	*****	*****	*****	*****
91+ Days	*****	*****	19	0.04%	23	0.04%	*****	*****	*****	*****
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	28		28		28		27		25	
25th Percentile	28		28		28		28		28	
Mean	29.6		30.6		31.3		33.8		32	
Median	28		28		28		28		28	
Mode	28		28		28		28		28	
75th Percentile	30		30		30		30		30	
90th Percentile	30		30		30		84		35	
Max	360		120		471		168		112	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Alogliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	18,713	100%	39,292	100%	50,361	100%	33,752	100%	18,115	100%
Days' Supply Categories										
1-29 Days	955	5.1%	1,914	4.9%	2,689	5.3%	2,103	6.2%	1,624	9%
30 Days	16,479	88.1%	33,739	85.9%	41,364	82.1%	24,917	73.8%	13,494	74.5%
31-89 Days	158	0.8%	523	1.3%	791	1.6%	953	2.8%	488	2.7%
90 Days	*****	*****	*****	*****	5,493	10.9%	5,758	17.1%	*****	*****
91+ Days	*****	*****	*****	*****	24	0.05%	21	0.1%	*****	*****
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	33.1		34.4		36.2		40.1		37.7	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		30		90		90		90	
Max	180		180		180		120		120	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Canagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	272,612	100%	603,750	100%	767,114	100%	676,652	100%	209,467	100%
Days' Supply Categories										
1-29 Days	16,836	6.2%	33,872	5.6%	46,868	6.1%	52,021	7.7%	26,066	12.4%
30 Days	233,525	85.7%	508,693	84.3%	622,800	81.2%	482,138	71.3%	145,446	69.4%
31-89 Days	3,763	1.4%	9,009	1.5%	13,684	1.8%	21,678	3.2%	6,361	3%
90 Days	18,409	6.8%	51,889	8.6%	83,278	10.9%	120,353	17.8%	31,485	15%
91+ Days	79	0.03%	287	0.05%	484	0.1%	462	0.1%	109	0.1%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		20	
25th Percentile	30		30		30		30		30	
Mean	33.5		34.8		36.2		40.5		38	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		31		90		90		90	
Max	365		360		365		225		180	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dapagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	84,479	100%	182,273	100%	225,380	100%	103,013	100%	26,507	100%
Days' Supply Categories										
1-29 Days	5,259	6.2%	10,424	5.7%	13,067	5.8%	8,791	8.5%	3,203	12.1%
30 Days	73,005	86.4%	154,662	84.9%	186,569	82.8%	75,403	73.2%	18,768	70.8%
31-89 Days	1,028	1.2%	2,487	1.4%	3,822	1.7%	3,361	3.3%	951	3.6%
90 Days	5,147	6.1%	14,566	8%	21,751	9.7%	15,383	14.9%	3,564	13.4%
91+ Days	40	0.05%	134	0.1%	171	0.1%	75	0.1%	21	0.1%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		23	
25th Percentile	30		30		30		30		30	
Mean	33.1		34.4		35.5		38.7		37.3	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		30		77		90		90	
Max	240		220		240		270		180	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dulaglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	71,067	100%	145,757	100%	193,975	100%	135,135	100%	38,826	100%
Days' Supply Categories										
1-29 Days	53,179	74.8%	107,983	74.1%	139,050	71.7%	92,673	68.6%	26,969	69.5%
30 Days	11,742	16.5%	22,134	15.2%	29,190	15%	20,318	15%	6,239	16.1%
31-89 Days	5,136	7.2%	13,219	9.1%	22,308	11.5%	19,529	14.5%	4,934	12.7%
90 Days	967	1.4%	2,333	1.6%	3,267	1.7%	2,538	1.9%	665	1.7%
91+ Days	43	0.1%	88	0.1%	160	0.1%	77	0.1%	19	0.05%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		26	
25th Percentile	28		28		28		28		28	
Mean	31.5		32.5		33.9		35.4		34.1	
Median	28		28		28		28		28	
Mode	28		28		28		28		28	
75th Percentile	30		30		30		30		30	
90th Percentile	30		50		84		84		84	
Max	315		300		435		250		174	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Empagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	81,673	100%	194,459	100%	261,992	100%	118,844	100%	31,359	100%
Days' Supply Categories										
1-29 Days	7,397	9.1%	17,155	8.8%	24,304	9.3%	13,162	11.1%	4,336	13.8%
30 Days	67,538	82.7%	157,716	81.1%	204,483	78%	81,273	68.4%	20,737	66.1%
31-89 Days	1,534	1.9%	4,412	2.3%	7,172	2.7%	5,548	4.7%	1,590	5.1%
90 Days	5,147	6.3%	15,026	7.7%	25,779	9.8%	18,739	15.8%	4,673	14.9%
91+ Days	57	0.1%	150	0.1%	254	0.1%	122	0.1%	23	0.1%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		27		20	
25th Percentile	30		30		30		30		30	
Mean	33		34		35.4		39.2		38.3	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		31		88		90		90	
Max	180		240		365		365		220	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	248,874	100%	466,047	100%	551,045	100%	499,274	100%	132,413	100%
Days' Supply Categories										
1-29 Days	88,174	35.4%	164,972	35.4%	194,160	35.2%	164,762	33%	50,197	37.9%
30 Days	140,788	56.6%	250,156	53.7%	285,715	51.8%	254,236	50.9%	65,187	49.2%
31-89 Days	8,960	3.6%	22,303	4.8%	31,967	5.8%	35,742	7.2%	7,995	6%
90 Days	10,796	4.3%	28,262	6.1%	38,780	7%	44,148	8.8%	8,926	6.7%
91+ Days	156	0.1%	354	0.1%	423	0.1%	386	0.1%	108	0.1%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		28	
25th Percentile	28		28		28		28		28	
Mean	32.9		34.6		35.7		37.4		35.4	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		60		84		84		84	
Max	960		420		1400		600		498	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glimepiride	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	845,429	100%	1,887,826	100%	2,690,024	100%	5,577,757	100%	4,125,814	100%
Days' Supply Categories										
1-29 Days	46,590	5.5%	94,509	5%	137,803	5.1%	249,493	4.5%	290,627	7%
30 Days	690,723	81.7%	1,485,385	78.7%	1,968,957	73.2%	3,263,696	58.5%	2,566,413	62.2%
31-89 Days	21,580	2.6%	51,189	2.7%	87,677	3.3%	254,347	4.6%	213,433	5.2%
90 Days	84,392	10%	251,892	13.3%	487,879	18.1%	1,801,462	32.3%	1,050,831	25.5%
91+ Days	2,144	0.3%	4,851	0.3%	7,708	0.3%	8,759	0.2%	4,510	0.1%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	35.9		38.1		41.2		50.1		45.6	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		90		90	
90th Percentile	90		90		90		90		90	
Max	365		401		400		900		720	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glipizide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	1,313,818	100%	2,787,128	100%	3,860,805	100%	7,059,766	100%	5,497,112	100%
Days' Supply Categories										
1-29 Days	76,671	5.8%	149,972	5.4%	211,469	5.5%	376,410	5.3%	478,467	8.7%
30 Days	889,567	67.7%	1,822,773	65.4%	2,361,024	61.2%	4,001,128	56.7%	3,298,974	60%
31-89 Days	56,755	4.3%	125,116	4.5%	189,658	4.9%	366,215	5.2%	314,676	5.7%
90 Days	142,648	10.9%	390,041	14%	701,174	18.2%	2,044,533	29%	1,265,595	23%
91+ Days	148,177	11.3%	299,226	10.7%	397,480	10.3%	271,480	3.8%	139,400	2.5%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	44.6		46.3		48.6		50.7		45.7	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	50		80		90		90		90	
90th Percentile	100		100		100		90		90	
Max	936		999		999		676		1080	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glyburide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	659,487	100%	1,039,106	100%	1,274,298	100%	1,754,804	100%	1,254,601	100%
Days' Supply Categories										
1-29 Days	42,142	6.4%	53,731	5.2%	64,456	5.1%	69,646	4%	82,324	6.6%
30 Days	536,321	81.3%	829,948	79.9%	963,721	75.6%	1,138,374	64.9%	825,254	65.8%
31-89 Days	21,393	3.2%	27,831	2.7%	39,374	3.1%	71,250	4.1%	61,475	4.9%
90 Days	39,428	6%	111,381	10.7%	190,090	14.9%	467,501	26.6%	280,535	22.4%
91+ Days	20,203	3.1%	16,215	1.6%	16,657	1.3%	8,033	0.5%	5,013	0.4%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	35.5		37.4		39.9		46.8		44	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		90		60	
90th Percentile	60		90		90		90		90	
Max	999		540		576		900		1023	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Linagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	151,371	100%	382,548	100%	627,294	100%	985,815	100%	953,540	100%
Days' Supply Categories										
1-29 Days	10,626	7%	29,607	7.7%	55,744	8.9%	109,245	11.1%	190,885	20%
30 Days	125,800	83.1%	305,909	80%	476,852	76%	689,714	70%	611,634	64.1%
31-89 Days	2,810	1.9%	7,404	1.9%	13,528	2.2%	26,980	2.7%	25,695	2.7%
90 Days	11,840	7.8%	38,567	10.1%	79,110	12.6%	158,351	16.1%	124,515	13.1%
91+ Days	295	0.2%	1,061	0.3%	2,060	0.3%	1,525	0.2%	811	0.1%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		25		14	
25th Percentile	30		30		30		30		30	
Mean	34.2		35.6		37		38.8		35.4	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		90		90		90		90	
Max	365		437		365		600		450	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Liraglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	474,014	100%	895,798	100%	1,083,960	100%	1,195,396	100%	317,013	100%
Days' Supply Categories										
1-29 Days	45,495	9.6%	84,008	9.4%	103,033	9.5%	112,662	9.4%	39,613	12.5%
30 Days	379,273	80%	696,249	77.7%	807,965	74.5%	834,872	69.8%	217,967	68.8%
31-89 Days	14,903	3.1%	31,396	3.5%	44,925	4.1%	72,113	6%	20,824	6.6%
90 Days	34,168	7.2%	83,813	9.4%	127,430	11.8%	175,309	14.7%	38,524	12.2%
91+ Days	175	0.04%	332	0.04%	607	0.1%	440	0.04%	85	0.03%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		28	
25th Percentile	30		30		30		30		30	
Mean	34		35.4		37		39.2		37.5	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	33		60		90		90		90	
Max	360		900		480		420		180	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	9,091,547	100%	13,136,598	100%	15,148,813	100%	22,316,905	100%	11,622,866	100%
Days' Supply Categories										
1-29 Days	561,587	6.2%	722,045	5.5%	833,645	5.5%	1,097,461	4.9%	883,312	7.6%
30 Days	7,127,263	78.4%	9,841,357	74.9%	10,556,468	69.7%	12,950,005	58%	7,151,705	61.5%
31-89 Days	279,955	3.1%	409,442	3.1%	552,571	3.6%	1,037,550	4.6%	584,924	5%
90 Days	825,189	9.1%	1,700,159	12.9%	2,649,555	17.5%	6,876,305	30.8%	2,863,329	24.6%
91+ Days	297,553	3.3%	463,595	3.5%	556,574	3.7%	355,584	1.6%	139,596	1.2%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	37.5		40.2		43.2		50.1		45.7	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		90		90	
90th Percentile	90		90		90		90		90	
Max	999		999		999		1211		900	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	638,740	100%	1,419,014	100%	1,861,196	100%	2,934,488	100%	1,783,912	100%
Days' Supply Categories										
1-29 Days	31,993	5%	64,430	4.5%	87,404	4.7%	128,617	4.4%	128,805	7.2%
30 Days	524,294	82.1%	1,127,398	79.4%	1,393,470	74.9%	1,991,888	67.9%	1,245,788	69.8%
31-89 Days	13,344	2.1%	31,037	2.2%	47,554	2.6%	92,712	3.2%	64,112	3.6%
90 Days	57,094	8.9%	165,225	11.6%	287,317	15.4%	690,196	23.5%	331,610	18.6%
91+ Days	12,015	1.9%	30,924	2.2%	45,451	2.4%	31,075	1.1%	13,597	0.8%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	36.4		38.3		40.9		45.1		41.5	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		76		30	
90th Percentile	90		90		90		90		90	
Max	608		667		900		720		999	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Saxagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	263,565	100%	602,961	100%	808,698	100%	1,233,137	100%	898,798	100%
Days' Supply Categories										
1-29 Days	12,013	4.6%	26,201	4.3%	37,266	4.6%	57,158	4.6%	84,763	9.4%
30 Days	233,314	88.5%	522,888	86.7%	675,960	83.6%	944,853	76.6%	671,869	74.8%
31-89 Days	3,157	1.2%	7,416	1.2%	11,892	1.5%	23,101	1.9%	18,722	2.1%
90 Days	15,009	5.7%	46,264	7.7%	83,216	10.3%	207,580	16.8%	123,169	13.7%
91+ Days	72	0.03%	192	0.03%	364	0.05%	445	0.04%	275	0.03%
Summary Statistics										
	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	33		34.2		35.9		39.9		37.3	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	30		30		90		90		90	
Max	480		270		600		578		180	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Sitagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	1,077,206	100%	2,435,371	100%	3,402,641	100%	5,903,480	100%	4,733,035	100%
Days' Supply Categories										
1-29 Days	65,845	6.1%	153,968	6.3%	260,365	7.7%	503,341	8.5%	843,912	17.8%
30 Days	893,274	82.9%	1,954,561	80.3%	2,580,287	75.8%	4,149,487	70.3%	3,094,122	65.4%
31-89 Days	20,030	1.9%	45,993	1.9%	75,791	2.2%	152,803	2.6%	131,199	2.8%
90 Days	97,333	9%	278,467	11.4%	481,866	14.2%	1,094,063	18.5%	661,513	14%
91+ Days	724	0.1%	2,382	0.1%	4,332	0.1%	3,786	0.1%	2,289	0.05%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		14	
25th Percentile	30		30		30		30		30	
Mean	35		36.4		38		40.5		36.2	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	46		90		90		90		90	
Max	900		1080		1080		900		874	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	659,487	100%	1,039,106	100%	1,274,298	100%	1,754,804	100%	1,254,601	100%
Days' Supply Categories										
1-29 Days	42,142	6.4%	53,731	5.2%	64,456	5.1%	69,646	4%	82,324	6.6%
30 Days	536,321	81.3%	829,948	79.9%	963,721	75.6%	1,138,374	64.9%	825,254	65.8%
31-89 Days	21,393	3.2%	27,831	2.7%	39,374	3.1%	71,250	4.1%	61,475	4.9%
90 Days	39,428	6%	111,381	10.7%	190,090	14.9%	467,501	26.6%	280,535	22.4%
91+ Days	20,203	3.1%	16,215	1.6%	16,657	1.3%	8,033	0.5%	5,013	0.4%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	35.5		37.4		39.9		46.8		44	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		90		60	
90th Percentile	60		90		90		90		90	
Max	999		540		576		900		1,023	

Table 3b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Liraglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	474,014	100%	895,798	100%	1,083,960	100%	1,195,396	100%	317,013	100%
Days' Supply Categories										
1-29 Days	45,495	9.6%	84,008	9.4%	103,033	9.5%	112,662	9.4%	39,613	12.5%
30 Days	379,273	80%	696,249	77.7%	807,965	74.5%	834,872	69.8%	217,967	68.8%
31-89 Days	14,903	3.1%	31,396	3.5%	44,925	4.1%	72,113	6%	20,824	6.6%
90 Days	34,168	7.2%	83,813	9.4%	127,430	11.8%	175,309	14.7%	38,524	12.2%
91+ Days	175	0.02%	332	0.04%	607	0.1%	440	0.04%	85	0.03%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		28	
25th Percentile	30		30		30		30		30	
Mean	34		35.4		37		39.2		37.5	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	33		60		90		90		90	
Max	360		900		480		420		180	

Table 3b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	9,091,547	100%	13,136,598	100%	15,148,813	100%	22,316,905	100%	11,622,866	100%
Days' Supply Categories										
1-29 Days	561,587	6.2%	722,045	5.5%	833,645	5.5%	1,097,461	4.9%	883,312	7.6%
30 Days	7,127,263	78.4%	9,841,357	74.9%	10,556,468	69.7%	12,950,005	58%	7,151,705	61.5%
31-89 Days	279,955	3.1%	409,442	3.1%	552,571	3.6%	1,037,550	4.6%	584,924	5%
90 Days	825,189	9.1%	1,700,159	12.9%	2,649,555	17.5%	6,876,305	30.8%	2,863,329	24.6%
91+ Days	297,553	3.3%	463,595	3.5%	556,574	3.7%	355,584	1.6%	139,596	1.2%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	37.5		40.2		43.2		50.1		45.7	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		90		90	
90th Percentile	90		90		90		90		90	
Max	999		999		999		1211		900	

Table 3b. Days' Supply per Drug Dispensing of Non-Insulin Antidiabetic Drug Treatment in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Sitagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Dispensings	1,077,206	100%	2,435,371	100%	3,402,641	100%	5,903,480	100%	4,733,035	100%
Days' Supply Categories										
1-29 Days	65,845	6.1%	153,968	6.3%	260,365	7.7%	503,341	8.5%	843,912	17.8%
30 Days	893,274	82.9%	1,954,561	80.3%	2,580,287	75.8%	4,149,487	70.3%	3,094,122	65.4%
31-89 Days	20,030	1.9%	45,993	1.9%	75,791	2.2%	152,803	2.6%	131,199	2.8%
90 Days	97,333	9%	278,467	11.4%	481,866	14.2%	1,094,063	18.5%	661,513	14%
91+ Days	724	0.1%	2,382	0.1%	4,332	0.1%	3,786	0.1%	2,289	0.05%
Summary Statistics	Days' Supply		Days' Supply		Days' Supply		Days' Supply		Days' Supply	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		14	
25th Percentile	30		30		30		30		30	
Mean	35		36.4		38		40.5		36.2	
Median	30		30		30		30		30	
Mode	30		30		30		30		30	
75th Percentile	30		30		30		30		30	
90th Percentile	46		90		90		90		90	
Max	900		1080		1080		900		874	

Table 4a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	25,894	100%	23,662	100%	345,528	100%	95,470	100%	103,279	100%	126,913	100%
Episode Duration Categories												
1-30 Days	5,060	19.5%	4,547	19.2%	53,744	15.6%	17,619	18.5%	19,048	18.4%	23,478	18.5%
31-90 Days	5,336	20.6%	4,295	18.2%	59,679	17.3%	18,029	18.9%	23,306	22.6%	27,245	21.5%
91-180 Days	5,367	20.7%	4,192	17.7%	59,884	17.3%	17,625	18.5%	21,267	20.6%	26,002	20.5%
181-270 Days	3,470	13.4%	2,694	11.4%	44,002	12.7%	11,744	12.3%	13,447	13%	17,311	13.6%
271-365 Days	2,628	10.1%	2,129	9%	33,892	9.8%	9,244	9.7%	8,781	8.5%	11,757	9.3%
366+ Days	4,033	15.6%	5,805	24.5%	94,327	27.3%	21,209	22.2%	17,430	16.9%	21,120	16.6%
Summary Statistics												
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	56		60		69		60		56		60	
Mean	191.9		252.4		275.5		236.4		194.9		197.2	
Median	130		154		180		151		126		129	
Mode	28		30		30		30		28		30	
75th Percentile	277		360		393		338		274		277	
90th Percentile	443		630		673		578		483		463	
Max	1172		1627		1709		1404		1139		1258	

Table 4a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	274,344	100%	1,423,976	100%	1,961,364	100%	720,925	100%	380,034	100%	462,593	100%
Episode Duration Categories												
1-30 Days	59,305	21.6%	159,182	11.2%	224,691	11.5%	126,281	17.5%	59,544	15.7%	74,749	16.2%
31-90 Days	59,325	21.6%	189,135	13.3%	253,996	12.9%	131,138	18.2%	63,349	16.7%	83,082	18%
91-180 Days	48,513	17.7%	181,416	12.7%	253,729	12.9%	107,750	14.9%	61,998	16.3%	75,138	16.2%
181-270 Days	28,622	10.4%	137,290	9.6%	189,776	9.7%	68,272	9.5%	45,516	12%	50,122	10.8%
271-365 Days	20,423	7.4%	121,957	8.6%	165,514	8.4%	55,490	7.7%	37,058	9.8%	38,594	8.3%
366+ Days	58,156	21.2%	634,996	44.6%	873,658	44.5%	231,994	32.2%	112,569	29.6%	140,908	30.5%
Summary Statistics												
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	30		30		30		30		30		30	
25th Percentile	56		93		94		60		71		62	
Mean	251.7		485.6		508.6		353.1		306		325	
Median	120		303		301		180		187		180	
Mode	30		30		30		30		30		30	
75th Percentile	313		708		721		484		434		450	
90th Percentile	649		1208		1282		935		768		829	
Max	3565		3586		3733		3664		2328		2878	

Table 4a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	6,502,864	100%	922,176	100%	356,525	100%	1,603,305	100%
Episode Duration Categories								
1-30 Days	766,060	11.8%	129,058	14%	50,887	14.3%	214,067	13.4%
31-90 Days	908,413	14%	145,598	15.8%	50,921	14.3%	235,949	14.7%
91-180 Days	867,788	13.3%	140,797	15.3%	51,184	14.4%	227,775	14.2%
181-270 Days	618,043	9.5%	99,248	10.8%	36,567	10.3%	165,442	10.3%
271-365 Days	517,912	8%	81,234	8.8%	30,418	8.5%	133,775	8.3%
366+ Days	2,824,648	43.4%	326,241	35.4%	136,548	38.3%	626,297	39.1%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	90		90		90		90	
Mean	495.1		397.4		404.6		423.4	
Median	285		217		242		247	
Mode	30		30		30		30	
75th Percentile	710		538		583		604	
90th Percentile	1269		1020		1036		1092	
Max	3740		3643		2945		3586	

Table 4b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	720,925	100%	462,593	100%	6,502,864	100%	1,603,305	100%
Episode Duration Categories								
1-30 Days	126,383	17.5%	74,802	16.2%	766,508	11.8%	214,294	13.4%
31-90 Days	132,619	18.4%	84,547	18.3%	920,439	14.2%	239,530	14.9%
91-180 Days	106,129	14.7%	74,350	16.1%	857,295	13.2%	224,336	14%
181-270 Days	67,905	9.4%	49,914	10.8%	615,443	9.5%	165,085	10.3%
271-365 Days	55,520	7.7%	38,731	8.4%	517,932	8%	133,922	8.4%
366+ Days	232,369	32.2%	140,249	30.3%	2,825,247	43.4%	626,138	39.1%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	60		60		90		90	
Mean	352.9		323.5		495.8		422.8	
Median	180		180		285		246	
Mode	30		30		30		30	
75th Percentile	484		449		710		603	
90th Percentile	935		826		1272		1091	
Max	3664		2852		3740		3586	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	13,447	100%	10,602	100%	164,617	100%	44,402	100%	54,087	100%	55,488	100%
Episode Duration Categories												
1-30 Days	2,852	21.2%	2,252	21.2%	28,594	17.4%	9,078	20.4%	10,235	18.9%	11,117	20%
31-90 Days	2,917	21.7%	2,011	19%	30,200	18.3%	8,875	20%	12,273	22.7%	12,476	22.5%
91-180 Days	2,781	20.7%	1,883	17.8%	29,608	18%	8,447	19%	11,335	21%	11,545	20.8%
181-270 Days	1,804	13.4%	1,226	11.6%	21,058	12.8%	5,379	12.1%	6,957	12.9%	7,204	13%
271-365 Days	1,288	9.6%	890	8.4%	15,560	9.5%	4,018	9%	4,532	8.4%	4,773	8.6%
366+ Days	1,805	13.4%	2,340	22.1%	39,597	24.1%	8,605	19.4%	8,755	16.2%	8,373	15.1%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	56		60		60		60		56		54	
Mean	178.9		233.8		252.3		217		190.4		186.5	
Median	120		135		162		128		122		120	
Mode	28		30		30		30		28		30	
75th Percentile	256		331		360		303		267		261	
90th Percentile	414		582		620		536		471		444	
Max	1172		1627		1709		1404		1139		1180	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	155,430	100%	721,649	100%	974,781	100%	386,765	100%	196,868	100%	262,868	100%
Episode Duration Categories												
1-30 Days	35,038	22.5%	85,200	11.8%	114,743	11.8%	75,139	19.4%	31,686	16.1%	44,627	17%
31-90 Days	34,138	22%	98,131	13.6%	127,565	13.1%	77,841	20.1%	32,974	16.7%	48,128	18.3%
91-180 Days	27,464	17.7%	92,234	12.8%	126,334	13%	59,834	15.5%	31,979	16.2%	43,177	16.4%
181-270 Days	16,034	10.3%	69,016	9.6%	94,666	9.7%	35,237	9.1%	23,629	12%	28,465	10.8%
271-365 Days	11,337	7.3%	61,069	8.5%	81,095	8.3%	27,456	7.1%	19,269	9.8%	21,676	8.2%
366+ Days	31,419	20.2%	315,999	43.8%	430,378	44.2%	111,258	28.8%	57,331	29.1%	76,795	29.2%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	30		30		30		30		30		30	
25th Percentile	56		90		91		60		67		60	
Mean	242.9		475.5		499		319.9		300.9		312.3	
Median	120		297		300		150		185		180	
Mode	30		30		30		30		30		30	
75th Percentile	300		694		713		432		425.5		429	
90th Percentile	627		1190		1256		870		760		801	
Max	3565		3586		3679		3585		2328		2793	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	3,497,705	100%	442,726	100%	182,898	100%	836,112	100%
Episode Duration Categories								
1-30 Days	449,605	12.9%	68,510	15.5%	27,571	15.1%	114,795	13.7%
31-90 Days	516,763	14.8%	74,291	16.8%	26,195	14.3%	123,235	14.7%
91-180 Days	479,065	13.7%	69,683	15.7%	26,110	14.3%	118,628	14.2%
181-270 Days	331,254	9.5%	47,709	10.8%	18,720	10.2%	85,202	10.2%
271-365 Days	272,210	7.8%	38,227	8.6%	15,478	8.5%	68,260	8.2%
366+ Days	1,448,808	41.4%	144,306	32.6%	68,824	37.6%	325,992	39%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	90		80		90		90	
Mean	471.8		366.7		396.1		420.4	
Median	270		193		236		244	
Mode	30		30		30		30	
75th Percentile	673		484		573		604	
90th Percentile	1225		947		1016		1089	
Max	3711		3643		2945		3586	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	12,447	100%	13,060	100%	180,911	100%	51,068	100%	49,192	100%	71,425	100%
Episode Duration Categories												
1-30 Days	2,208	17.7%	2,295	17.6%	25,150	13.9%	8,541	16.7%	8,813	17.9%	12,361	17.3%
31-90 Days	2,419	19.4%	2,284	17.5%	29,479	16.3%	9,154	17.9%	11,033	22.4%	14,769	20.7%
91-180 Days	2,586	20.8%	2,309	17.7%	30,276	16.7%	9,178	18%	9,932	20.2%	14,457	20.2%
181-270 Days	1,666	13.4%	1,468	11.2%	22,944	12.7%	6,365	12.5%	6,490	13.2%	10,107	14.2%
271-365 Days	1,340	10.8%	1,239	9.5%	18,332	10.1%	5,226	10.2%	4,249	8.6%	6,984	9.8%
366+ Days	2,228	17.9%	3,465	26.5%	54,730	30.3%	12,604	24.7%	8,675	17.6%	12,747	17.8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	58		60		88		62		56		60	
Mean	205.9		267.5		296.7		253.2		199.7		205.5	
Median	145		170		200		169		132		143	
Mode	28		30		30		30		28		30	
75th Percentile	301		388		429		363		282		292	
90th Percentile	471		663		719		613		495		480	
Max	1127		1600		1704		1390		1097		1258	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	118,914	100%	702,327	100%	986,583	100%	334,160	100%	183,166	100%	199,725	100%
Episode Duration Categories												
1-30 Days	24,267	20.4%	73,982	10.5%	109,948	11.1%	51,142	15.3%	27,858	15.2%	30,122	15.1%
31-90 Days	25,187	21.2%	91,004	13%	126,431	12.8%	53,297	15.9%	30,375	16.6%	34,954	17.5%
91-180 Days	21,049	17.7%	89,182	12.7%	127,395	12.9%	47,916	14.3%	30,019	16.4%	31,961	16%
181-270 Days	12,588	10.6%	68,274	9.7%	95,110	9.6%	33,035	9.9%	21,887	11.9%	21,657	10.8%
271-365 Days	9,086	7.6%	60,888	8.7%	84,419	8.6%	28,034	8.4%	17,789	9.7%	16,918	8.5%
366+ Days	26,737	22.5%	318,997	45.4%	443,280	44.9%	120,736	36.1%	55,238	30.2%	64,113	32.1%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	30		30		30		30		30		30	
25th Percentile	58		101		98		90		77		70	
Mean	263.3		495.9		518.1		391.5		311.5		341.6	
Median	129		314		305		217		190		189	
Mode	30		30		30		30		30		30	
75th Percentile	333		720		730		547		443		472	
90th Percentile	678		1228		1308		1008		777		870	
Max	3397		3584		3733		3664		2317		2878	

Table 5a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	3,005,159	100%	479,450	100%	173,627	100%	767,193	100%
Episode Duration Categories								
1-30 Days	316,455	10.5%	60,548	12.6%	23,316	13.4%	99,272	12.9%
31-90 Days	391,650	13%	71,307	14.9%	24,726	14.2%	112,714	14.7%
91-180 Days	388,723	12.9%	71,114	14.8%	25,074	14.4%	109,147	14.2%
181-270 Days	286,789	9.5%	51,539	10.7%	17,847	10.3%	80,240	10.5%
271-365 Days	245,702	8.2%	43,007	9%	14,940	8.6%	65,515	8.5%
366+ Days	1,375,840	45.8%	181,935	37.9%	67,724	39%	300,305	39.1%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	100		90		90		90	
Mean	522.3		425.7		413.6		426.7	
Median	314		245		249		250	
Mode	30		30		30		30	
75th Percentile	749		577		598		603	
90th Percentile	1318		1083		1062		1095	
Max	3740		3632		2881		3583	

Table 5b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Female	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	386,765	100%	262,868	100%	3,497,705	100%	836,112	100%
Episode Duration Categories								
1-30 Days	75,204	19.4%	44,651	17%	449,868	12.9%	114,933	13.7%
31-90 Days	78,656	20.3%	48,982	18.6%	523,737	15%	125,086	15%
91-180 Days	58,930	15.2%	42,756	16.3%	473,264	13.5%	117,009	14%
181-270 Days	35,080	9.1%	28,358	10.8%	329,840	9.4%	84,882	10.2%
271-365 Days	27,537	7.1%	21,692	8.3%	272,216	7.8%	68,460	8.2%
366+ Days	111,358	28.8%	76,429	29.1%	1,448,780	41.4%	325,742	39%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	60		60		90		90	
Mean	319.7		310.8		472.3		419.6	
Median	150		180		270		243	
Mode	30		30		30		30	
75th Percentile	431		426		673		603	
90th Percentile	870		797		1228		1088	
Max	3585		2786		3722		3586	

Table 5b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Male	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	334,160	100%	199,725	100%	3,005,159	100%	767,193	100%
Episode Duration Categories								
1-30 Days	51,179	15.3%	30,151	15.1%	316,640	10.5%	99,361	13%
31-90 Days	53,963	16.1%	35,565	17.8%	396,702	13.2%	114,444	14.9%
91-180 Days	47,199	14.1%	31,594	15.8%	384,031	12.8%	107,327	14%
181-270 Days	32,825	9.8%	21,556	10.8%	285,603	9.5%	80,203	10.5%
271-365 Days	27,983	8.4%	17,039	8.5%	245,716	8.2%	65,462	8.5%
366+ Days	121,011	36.2%	63,820	32%	1,376,467	45.8%	300,396	39.2%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	89		69		99		90	
Mean	391.5		340.2		523.1		426.2	
Median	216		187		313		248	
Mode	30		30		30		30	
75th Percentile	548		470		750		602	
90th Percentile	1010		868		1321		1095	
Max	3664		2852		3740		3583	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Albiglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	4,036	100%	6,987	100%	8,592	100%	4,651	100%	1,628	100%
Episode Duration Categories										
1-30 Days	846	21%	1,238	17.7%	1,544	18%	1,023	22%	409	25.1%
31-90 Days	939	23.3%	1,348	19.3%	1,610	18.7%	1,054	22.7%	385	23.6%
91-180 Days	849	21%	1,454	20.8%	1,669	19.4%	1,053	22.6%	342	21%
181-270 Days	493	12.2%	965	13.8%	1,144	13.3%	640	13.8%	228	14%
271-365 Days	391	9.7%	742	10.6%	965	11.2%	396	8.5%	134	8.2%
366+ Days	518	12.8%	1,240	17.7%	1,660	19.3%	485	10.4%	130	8%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		2	
10th Percentile	28		28		28		28		28	
25th Percentile	56		58		58		49		30	
Mean	173		204.8		213.3		164.2		149.4	
Median	115		144		150		113		95	
Mode	28		28		28		28		28	
75th Percentile	252		297		316		228		215	
90th Percentile	403		472		494		371		332	
Max	956		1109		1172		1090		1099	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Alogliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	2,807	100%	5,247	100%	6,655	100%	5,740	100%	3,213	100%
Episode Duration Categories										
1-30 Days	623	22.2%	953	18.2%	1,118	16.8%	1,144	19.9%	709	22.1%
31-90 Days	547	19.5%	921	17.6%	1,153	17.3%	1,066	18.6%	608	18.9%
91-180 Days	520	18.5%	946	18%	1,136	17.1%	992	17.3%	598	18.6%
181-270 Days	314	11.2%	618	11.8%	762	11.5%	645	11.2%	355	11%
271-365 Days	231	8.2%	455	8.7%	608	9.1%	535	9.3%	300	9.3%
366+ Days	572	20.4%	1,354	25.8%	1,878	28.2%	1,358	23.7%	643	20%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	57		60		63		60		60	
Mean	227.6		265.1		281		240.1		216.2	
Median	123		157		180		153		130	
Mode	30		30		30		30		30	
75th Percentile	305		376		408		350.5		308	
90th Percentile	586		669		697		584.5		527	
Max	1599		1627		1600		1596		1547	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Canagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	34,937	100%	68,643	100%	91,708	100%	113,338	100%	36,902	100%
Episode Duration Categories										
1-30 Days	5,830	16.7%	9,463	13.8%	12,823	14%	18,502	16.3%	7,126	19.3%
31-90 Days	6,110	17.5%	10,460	15.2%	14,509	15.8%	21,030	18.6%	7,570	20.5%
91-180 Days	6,130	17.5%	11,142	16.2%	15,056	16.4%	20,681	18.2%	6,875	18.6%
181-270 Days	4,355	12.5%	8,451	12.3%	11,101	12.1%	15,372	13.6%	4,723	12.8%
271-365 Days	3,280	9.4%	6,913	10.1%	8,995	9.8%	11,340	10%	3,364	9.1%
366+ Days	9,232	26.4%	22,214	32.4%	29,224	31.9%	26,413	23.3%	7,244	19.6%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		89		87		65		60	
Mean	268.7		313.7		309		245.8		218.9	
Median	176		212		210		171		140	
Mode	30		30		30		30		30	
75th Percentile	383		455		450		353		305	
90th Percentile	670		766		759		581		536	
Max	1691		1709		1690		1686		1704	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Dapagliflozin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	13,126	100%	24,953	100%	30,904	100%	20,518	100%	5,969	100%
Episode Duration Categories										
1-30 Days	2,595	19.8%	4,065	16.3%	4,948	16%	4,476	21.8%	1,535	25.7%
31-90 Days	2,657	20.2%	4,429	17.7%	5,251	17%	4,293	20.9%	1,399	23.4%
91-180 Days	2,486	18.9%	4,521	18.1%	5,618	18.2%	3,856	18.8%	1,144	19.2%
181-270 Days	1,648	12.6%	3,113	12.5%	3,791	12.3%	2,540	12.4%	652	10.9%
271-365 Days	1,147	8.7%	2,559	10.3%	3,120	10.1%	1,939	9.5%	479	8%
366+ Days	2,593	19.8%	6,266	25.1%	8,176	26.5%	3,414	16.6%	760	12.7%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		61		65		52		30	
Mean	219.3		258		264.9		197.7		168.7	
Median	130		170		180		121		93	
Mode	30		30		30		30		30	
75th Percentile	305		366		381		279		238	
90th Percentile	545		629		638		466		407	
Max	1371		1390		1404		1356		1276	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dulaglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	12,821	100%	23,898	100%	31,738	100%	26,696	100%	8,126	100%
Episode Duration Categories										
1-30 Days	2,515	19.6%	4,085	17.1%	5,316	16.7%	5,276	19.8%	1,856	22.8%
31-90 Days	3,029	23.6%	5,195	21.7%	6,783	21.4%	6,283	23.5%	2,016	24.8%
91-180 Days	2,687	21%	4,882	20.4%	6,239	19.7%	5,739	21.5%	1,720	21.2%
181-270 Days	1,676	13.1%	3,218	13.5%	4,214	13.3%	3,367	12.6%	972	12%
271-365 Days	1,101	8.6%	2,197	9.2%	2,968	9.4%	2,000	7.5%	515	6.3%
366+ Days	1,813	14.1%	4,321	18.1%	6,218	19.6%	4,031	15.1%	1,047	12.9%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		28	
25th Percentile	55		56		58		56		42	
Mean	179.3		203.6		212		182.8		166.3	
Median	116		140		144		117		100	
Mode	28		28		28		28		28	
75th Percentile	252		292		308		252		225	
90th Percentile	431		491		518		463		425	
Max	1139		1094		1093		1097		1087	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Empagliflozin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	14,738	100%	31,831	100%	44,159	100%	27,975	100%	8,210	100%
Episode Duration Categories										
1-30 Days	2,895	19.6%	5,426	17%	7,242	16.4%	5,884	21%	2,031	24.7%
31-90 Days	3,288	22.3%	6,222	19.5%	8,682	19.7%	6,928	24.8%	2,125	25.9%
91-180 Days	3,025	20.5%	6,396	20.1%	8,899	20.2%	5,911	21.1%	1,771	21.6%
181-270 Days	1,901	12.9%	4,458	14%	6,280	14.2%	3,650	13%	1,022	12.4%
271-365 Days	1,374	9.3%	3,205	10.1%	4,463	10.1%	2,187	7.8%	528	6.4%
366+ Days	2,255	15.3%	6,124	19.2%	8,593	19.5%	3,415	12.2%	733	8.9%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	55		60		60		48		32	
Mean	188.5		213.4		214.8		169.7		148.8	
Median	121		150		151		106		90	
Mode	30		30		30		30		30	
75th Percentile	270		308		310		231		196	
90th Percentile	449		499		496		400		344.5	
Max	1179		1197		1258		1170		1084	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	41,173	100%	64,990	100%	75,001	100%	73,653	100%	19,527	100%
Episode Duration Categories										
1-30 Days	10,127	24.6%	13,761	21.2%	15,191	20.3%	15,641	21.2%	4,585	23.5%
31-90 Days	9,743	23.7%	13,810	21.2%	15,591	20.8%	15,883	21.6%	4,298	22%
91-180 Days	7,864	19.1%	11,779	18.1%	13,165	17.6%	12,528	17%	3,177	16.3%
181-270 Days	4,241	10.3%	6,973	10.7%	7,811	10.4%	7,656	10.4%	1,941	9.9%
271-365 Days	2,772	6.7%	4,823	7.4%	5,831	7.8%	5,601	7.6%	1,396	7.1%
366+ Days	6,426	15.6%	13,844	21.3%	17,412	23.2%	16,344	22.2%	4,130	21.2%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		28	
25th Percentile	35		56		58		56		50	
Mean	204.7		254.8		268.6		259.8		245.7	
Median	96		123		132		124		120	
Mode	30		30		30		30		30	
75th Percentile	244		313		342		330		311	
90th Percentile	507		646		690		681		650	
Max	3238		3382		3503		3565		3283	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glimepiride	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	89,466	100%	173,332	100%	254,079	100%	522,616	100%	384,483	100%
Episode Duration Categories										
1-30 Days	15,238	17%	23,392	13.5%	31,068	12.2%	48,144	9.2%	41,340	10.8%
31-90 Days	15,353	17.2%	25,257	14.6%	35,286	13.9%	63,550	12.2%	49,689	12.9%
91-180 Days	14,366	16.1%	25,457	14.7%	35,578	14%	60,203	11.5%	45,812	11.9%
181-270 Days	9,556	10.7%	17,970	10.4%	26,118	10.3%	47,910	9.2%	35,736	9.3%
271-365 Days	7,232	8.1%	14,807	8.5%	22,283	8.8%	44,633	8.5%	33,002	8.6%
366+ Days	27,721	31%	66,449	38.3%	103,746	40.8%	258,176	49.4%	178,904	46.5%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		42		30	
25th Percentile	60		90		90		120		101	
Mean	348.1		424.5		444.2		541.8		496.1	
Median	180		242		270		360		330	
Mode	30		30		30		30		30	
75th Percentile	463		593		630		803		732	
90th Percentile	913		1090		1118		1314		1208	
Max	3557		3561		3584		3586		3579	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glipizide</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	146,246	100%	263,732	100%	370,229	100%	667,700	100%	513,457	100%
Episode Duration Categories										
1-30 Days	23,050	15.8%	33,410	12.7%	43,856	11.8%	66,115	9.9%	58,260	11.3%
31-90 Days	22,674	15.5%	35,769	13.6%	48,568	13.1%	81,479	12.2%	65,506	12.8%
91-180 Days	23,373	16%	37,812	14.3%	50,925	13.8%	79,277	11.9%	62,342	12.1%
181-270 Days	15,107	10.3%	26,103	9.9%	36,779	9.9%	62,905	9.4%	48,882	9.5%
271-365 Days	11,580	7.9%	21,464	8.1%	30,982	8.4%	57,118	8.6%	44,370	8.6%
366+ Days	50,462	34.5%	109,174	41.4%	159,119	43%	320,806	48%	234,097	45.6%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		32		30	
25th Percentile	68		90		91		120		97	
Mean	408.1		497.3		514		542.5		495.1	
Median	200		270		284		347		315	
Mode	30		30		30		30		30	
75th Percentile	533		684		708		785		720	
90th Percentile	1090		1308		1326		1334		1213	
Max	3644		3652		3733		3659		3679	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glyburide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	124,547	100%	101,800	100%	132,029	100%	206,862	100%	155,687	100%
Episode Duration Categories										
1-30 Days	33,678	27%	17,872	17.6%	20,873	15.8%	28,580	13.8%	25,278	16.2%
31-90 Days	36,229	29.1%	16,247	16%	20,878	15.8%	31,774	15.4%	26,010	16.7%
91-180 Days	23,226	18.6%	15,313	15%	19,312	14.6%	28,113	13.6%	21,786	14%
181-270 Days	9,412	7.6%	10,026	9.8%	13,110	9.9%	20,312	9.8%	15,412	9.9%
271-365 Days	5,449	4.4%	7,825	7.7%	10,687	8.1%	18,307	8.8%	13,222	8.5%
366+ Days	16,553	13.3%	34,517	33.9%	47,169	35.7%	79,776	38.6%	53,979	34.7%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		60		75		90		79	
Mean	192		390.3		392.3		402.4		358.9	
Median	90		190		210		251		210	
Mode	30		30		30		30		30	
75th Percentile	182		525		546		577		514	
90th Percentile	484		1048		1020		1010		912	
Max	3482		3664		3564		3529		3609	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Linagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	20,769	100%	45,263	100%	74,131	100%	128,281	100%	111,590	100%
Episode Duration Categories										
1-30 Days	4,017	19.3%	7,181	15.9%	11,071	14.9%	19,832	15.5%	17,443	15.6%
31-90 Days	3,911	18.8%	7,527	16.6%	11,906	16.1%	21,722	16.9%	18,283	16.4%
91-180 Days	3,716	17.9%	7,583	16.8%	12,212	16.5%	20,969	16.3%	17,518	15.7%
181-270 Days	2,448	11.8%	5,289	11.7%	8,642	11.7%	15,475	12.1%	13,662	12.2%
271-365 Days	1,819	8.8%	4,343	9.6%	7,347	9.9%	12,692	9.9%	10,857	9.7%
366+ Days	4,858	23.4%	13,340	29.5%	22,953	31%	37,591	29.3%	33,827	30.3%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		66		78		76		74	
Mean	256.4		308.2		320.1		303.5		307.9	
Median	150		184		197		186		194	
Mode	30		30		30		30		30	
75th Percentile	346		428		450		430		450	
90th Percentile	645		773		799		760		776	
Max	2317		2320		2299		2328		2218	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Liraglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	61,966	100%	97,046	100%	118,511	100%	145,175	100%	39,895	100%
Episode Duration Categories										
1-30 Days	12,082	19.5%	15,432	15.9%	18,405	15.5%	21,828	15%	7,002	17.6%
31-90 Days	12,531	20.2%	16,653	17.2%	20,012	16.9%	26,198	18%	7,688	19.3%
91-180 Days	11,137	18%	15,955	16.4%	18,573	15.7%	23,208	16%	6,265	15.7%
181-270 Days	6,736	10.9%	10,595	10.9%	12,818	10.8%	15,890	10.9%	4,083	10.2%
271-365 Days	4,963	8%	8,200	8.4%	10,038	8.5%	12,112	8.3%	3,281	8.2%
366+ Days	14,517	23.4%	30,211	31.1%	38,665	32.6%	45,939	31.6%	11,576	29%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		62		67		75		60	
Mean	267.1		335.7		346.9		330.3		304.2	
Median	138		183		194		186		176	
Mode	30		30		30		30		30	
75th Percentile	345		457		480		463		428	
90th Percentile	686		855		888		837		782	
Max	2807		2878		2774		2786		2672	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	1,030,270	100%	1,100,240	100%	1,322,261	100%	1,981,146	100%	1,068,947	100%
Episode Duration Categories										
1-30 Days	188,705	18.3%	134,435	12.2%	148,320	11.2%	176,824	8.9%	117,776	11%
31-90 Days	194,681	18.9%	153,152	13.9%	176,462	13.3%	239,988	12.1%	144,130	13.5%
91-180 Days	172,811	16.8%	154,214	14%	179,330	13.6%	229,720	11.6%	131,713	12.3%
181-270 Days	104,934	10.2%	108,458	9.9%	129,640	9.8%	176,294	8.9%	98,717	9.2%
271-365 Days	76,330	7.4%	88,171	8%	108,946	8.2%	158,354	8%	86,111	8.1%
366+ Days	292,809	28.4%	461,810	42%	579,563	43.8%	999,966	50.5%	490,500	45.9%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		45		30	
25th Percentile	60		90		93		120		94	
Mean	338.1		488.7		502.4		571.2		503	
Median	155		270		294		371		316	
Mode	30		30		30		30		30	
75th Percentile	424		682		709		840		735	
90th Percentile	908		1271		1275		1390		1255	
Max	3711		3740		3730		3733		3645	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	75,881	100%	141,525	100%	192,803	100%	320,105	100%	191,862	100%
Episode Duration Categories										
1-30 Days	14,851	19.6%	21,931	15.5%	26,863	13.9%	39,768	12.4%	25,645	13.4%
31-90 Days	13,834	18.2%	21,924	15.5%	29,530	15.3%	49,519	15.5%	30,791	16%
91-180 Days	12,947	17.1%	22,323	15.8%	29,856	15.5%	47,061	14.7%	28,610	14.9%
181-270 Days	8,035	10.6%	15,039	10.6%	20,757	10.8%	34,617	10.8%	20,800	10.8%
271-365 Days	5,969	7.9%	11,852	8.4%	17,032	8.8%	29,080	9.1%	17,301	9%
366+ Days	20,245	26.7%	48,456	34.2%	68,765	35.7%	120,060	37.5%	68,715	35.8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		75		90		90		90	
Mean	314		393.3		402.5		419.5		391.3	
Median	150		208		219		244		225	
Mode	30		30		30		30		30	
75th Percentile	393		516		540		570		540	
90th Percentile	814		1017		1026		1072		997	
Max	3619		3583		3643		3632		3583	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Saxagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	26,763	100%	52,854	100%	73,014	100%	121,439	100%	82,455	100%
Episode Duration Categories										
1-30 Days	4,692	17.5%	7,486	14.2%	9,798	13.4%	16,883	13.9%	12,028	14.6%
31-90 Days	4,326	16.2%	7,644	14.5%	10,283	14.1%	17,349	14.3%	11,319	13.7%
91-180 Days	4,456	16.6%	8,075	15.3%	10,815	14.8%	16,795	13.8%	11,043	13.4%
181-270 Days	2,913	10.9%	5,508	10.4%	7,659	10.5%	12,151	10%	8,336	10.1%
271-365 Days	2,181	8.1%	4,437	8.4%	6,354	8.7%	10,510	8.7%	6,936	8.4%
366+ Days	8,195	30.6%	19,704	37.3%	28,105	38.5%	47,751	39.3%	32,793	39.8%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		90		90		90		90	
Mean	335.5		401.9		407.1		413.2		413.9	
Median	180		227		245.5		253		255	
Mode	30		30		30		30		30	
75th Percentile	450		564		576		607		615	
90th Percentile	878		1039		1022		1059		1059	
Max	2800		2877		2945		2944		2759	

Table 6a. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Sitagliptin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	111,059	100%	216,655	100%	309,603	100%	558,774	100%	407,214	100%
Episode Duration Categories										
1-30 Days	18,606	16.8%	29,711	13.7%	40,486	13.1%	70,160	12.6%	55,104	13.5%
31-90 Days	19,000	17.1%	32,184	14.9%	44,957	14.5%	80,834	14.5%	58,974	14.5%
91-180 Days	17,806	16%	32,081	14.8%	45,013	14.5%	77,699	13.9%	55,176	13.5%
181-270 Days	11,980	10.8%	22,896	10.6%	32,168	10.4%	57,475	10.3%	40,923	10%
271-365 Days	9,059	8.2%	17,958	8.3%	26,293	8.5%	47,264	8.5%	33,201	8.2%
366+ Days	34,608	31.2%	81,825	37.8%	120,686	39%	225,342	40.3%	163,836	40.2%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		90		90		90		90	
Mean	348		419.4		425.6		435.3		428.1	
Median	181		238		248		269		259	
Mode	30		30		30		30		30	
75th Percentile	461		580		598		630		629	
90th Percentile	907		1083		1086		1117		1106	
Max	3546		3559		3572		3586		3543	

Table 6b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	124,547	100%	101,800	100%	132,029	100%	206,862	100%	155,687	100%
Episode Duration Categories										
1-30 Days	33,716	27.1%	17,880	17.6%	20,883	15.8%	28,600	13.8%	25,304	16.3%
31-90 Days	36,562	29.4%	16,516	16.2%	21,189	16%	32,147	15.5%	26,205	16.8%
91-180 Days	23,024	18.5%	15,147	14.9%	19,073	14.4%	27,498	13.3%	21,387	13.7%
181-270 Days	9,335	7.5%	10,004	9.8%	13,009	9.9%	20,173	9.8%	15,384	9.9%
271-365 Days	5,453	4.4%	7,863	7.7%	10,710	8.1%	18,307	8.8%	13,187	8.5%
366+ Days	16,457	13.2%	34,390	33.8%	47,165	35.7%	80,137	38.7%	54,220	34.8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		60		75		90		79	
Mean	191.1		388.9		391.7		403.2		359.3	
Median	90		188		210		250		210	
Mode	30		30		30		30		30	
75th Percentile	181		522		546		578		514	
90th Percentile	481		1044		1020		1015		915	
Max	3482		3664		3564		3529		3609	

Table 6b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Liraglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	61,966	100%	97,046	100%	118,511	100%	145,175	100%	39,895	100%
Episode Duration Categories										
1-30 Days	12,084	19.5%	15,437	15.9%	18,419	15.5%	21,842	15%	7,020	17.6%
31-90 Days	12,799	20.7%	17,011	17.5%	20,362	17.2%	26,595	18.3%	7,780	19.5%
91-180 Days	11,066	17.9%	15,807	16.3%	18,386	15.5%	22,873	15.8%	6,218	15.6%
181-270 Days	6,645	10.7%	10,535	10.9%	12,806	10.8%	15,872	10.9%	4,056	10.2%
271-365 Days	5,005	8.1%	8,244	8.5%	10,054	8.5%	12,151	8.4%	3,277	8.2%
366+ Days	14,367	23.2%	30,012	30.9%	38,484	32.5%	45,842	31.6%	11,544	28.9%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		61		65		74		60	
Mean	265.1		333.6		345.3		329.4		303.1	
Median	137		182		192		185		175	
Mode	30		30		30		30		30	
75th Percentile	341		454		479		462		425	
90th Percentile	679		849		883		835		781	
Max	2790		2852		2758		2786		2727	

Table 6b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Metformin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	1,030,270	100%	1,100,240	100%	1,322,261	100%	1,981,146	100%	1,068,947	100%
Episode Duration Categories										
1-30 Days	188,817	18.3%	134,501	12.2%	148,398	11.2%	176,917	8.9%	117,875	11%
31-90 Days	198,358	19.3%	155,644	14.1%	178,867	13.5%	242,157	12.2%	145,413	13.6%
91-180 Days	170,995	16.6%	152,939	13.9%	177,486	13.4%	226,108	11.4%	129,767	12.1%
181-270 Days	104,387	10.1%	108,079	9.8%	129,278	9.8%	175,463	8.9%	98,236	9.2%
271-365 Days	76,429	7.4%	88,396	8%	108,994	8.2%	157,978	8%	86,135	8.1%
366+ Days	291,284	28.3%	460,681	41.9%	579,238	43.8%	1,002,523	50.6%	491,521	46%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		45		30	
25th Percentile	60		90		92		120		93	
Mean	337		488.1		502.8		573.4		504.3	
Median	153		270		293		373		316	
Mode	30		30		30		30		30	
75th Percentile	421		680		708		842		739	
90th Percentile	906		1270		1277		1398		1260	
Max	3722		3740		3730		3733		3645	

Table 6b. Cumulative Treatment Episode Duration for Non-Insulin Antidiabetic Drug Dispensings in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Sitagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	111,059	100%	216,655	100%	309,603	100%	558,774	100%	407,214	100%
Episode Duration Categories										
1-30 Days	18,613	16.8%	29,718	13.7%	40,515	13.1%	70,246	12.6%	55,202	13.6%
31-90 Days	19,446	17.5%	32,881	15.2%	45,678	14.8%	81,878	14.7%	59,647	14.6%
91-180 Days	17,581	15.8%	31,664	14.6%	44,437	14.4%	76,261	13.6%	54,393	13.4%
181-270 Days	11,894	10.7%	22,786	10.5%	32,035	10.3%	57,458	10.3%	40,912	10%
271-365 Days	9,084	8.2%	18,035	8.3%	26,352	8.5%	47,207	8.4%	33,244	8.2%
366+ Days	34,441	31%	81,571	37.7%	120,586	38.9%	225,724	40.4%	163,816	40.2%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	60		90		90		90		90	
Mean	346.2		417.9		424.8		435.3		427.6	
Median	180		236		246		268		257	
Mode	30		30		30		30		30	
75th Percentile	458		577		596		630		627	
90th Percentile	904		1080		1085		1118		1106	
Max	3546		3559		3578		3586		3543	

Table 7a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	25,894	100%	23,662	100%	345,528	100%	95,470	100%	103,279	100%	126,913	100%
Episode Duration Categories												
1-30 Days	9,507	36.7%	9,535	40.3%	111,501	32.3%	35,072	36.7%	36,023	34.9%	44,388	35%
31-90 Days	6,012	23.2%	5,224	22.1%	75,094	21.7%	21,308	22.3%	26,820	26%	30,835	24.3%
91-180 Days	4,714	18.2%	3,747	15.8%	57,100	16.5%	15,889	16.6%	18,408	17.8%	22,140	17.4%
181-270 Days	2,337	9%	1,751	7.4%	33,430	9.7%	8,424	8.8%	9,138	8.8%	12,115	9.5%
271-365 Days	1,442	5.6%	1,167	4.9%	22,172	6.4%	5,389	5.6%	5,045	4.9%	7,145	5.6%
366+ Days	1,882	7.3%	2,238	9.5%	46,231	13.4%	9,388	9.8%	7,845	7.6%	10,290	8.1%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		28		30	
Mean	125		137.3		170.7		141.9		126.5		130.9	
Median	66		65		90		72		75		78	
Mode	28		30		30		30		28		30	
75th Percentile	166		161		214		180		165		175	
90th Percentile	315		360		443		364		315		330	
Max	1172		1627		1709		1404		1139		1197	

Table 7a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	274,344	100%	1,423,976	100%	1,961,364	100%	720,925	100%	380,034	100%	462,593	100%
Episode Duration Categories												
1-30 Days	119,841	43.7%	379,558	26.7%	520,345	26.5%	258,221	35.8%	122,790	32.3%	208,455	45.1%
31-90 Days	67,608	24.6%	341,654	24%	455,159	23.2%	192,370	26.7%	85,844	22.6%	108,787	23.5%
91-180 Days	40,285	14.7%	208,714	14.7%	324,827	16.6%	104,719	14.5%	60,842	16%	60,862	13.2%
181-270 Days	17,544	6.4%	125,669	8.8%	171,597	8.7%	50,229	7%	35,633	9.4%	29,206	6.3%
271-365 Days	10,371	3.8%	91,392	6.4%	121,427	6.2%	32,635	4.5%	24,637	6.5%	17,436	3.8%
366+ Days	18,695	6.8%	276,989	19.5%	368,009	18.8%	82,751	11.5%	50,288	13.2%	37,847	8.2%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		30		30	
25th Percentile	30		30		30		30		30		30	
Mean	120.4		239.8		241.6		163.9		175.9		128.1	
Median	60		90		91		90		90		60	
Mode	30		30		30		30		30		30	
75th Percentile	122		277		270		180		211		126	
90th Percentile	281		641		642		412		451		315	
Max	3505		3586		3733		3664		2325		2827	

Table 7a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	6,502,864	100%	922,176	100%	356,525	100%	1,603,305	100%
Episode Duration Categories								
1-30 Days	2,138,690	32.9%	286,108	31%	119,933	33.6%	503,132	31.4%
31-90 Days	1,615,008	24.8%	217,315	23.6%	74,640	20.9%	364,159	22.7%
91-180 Days	968,776	14.9%	147,666	16%	54,504	15.3%	245,719	15.3%
181-270 Days	499,191	7.7%	80,133	8.7%	30,209	8.5%	140,701	8.8%
271-365 Days	329,252	5.1%	53,897	5.8%	20,713	5.8%	92,843	5.8%
366+ Days	951,947	14.6%	137,057	14.9%	56,526	15.9%	256,751	16%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	200.2		197.8		200.3		206.6	
Median	90		90		90		90	
Mode	30		30		30		30	
75th Percentile	199		215		225		233	
90th Percentile	518		500		540		541	
Max	3740		3643		2944		3586	

Table 7b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	720,925	100%	462,593	100%	6,502,864	100%	1,603,305	100%
Episode Duration Categories								
1-30 Days	274,353	38.1%	225,204	48.7%	2,300,796	35.4%	548,044	34.2%
31-90 Days	182,801	25.4%	103,174	22.3%	1,522,934	23.4%	349,032	21.8%
91-180 Days	98,179	13.6%	55,282	12%	896,866	13.8%	232,755	14.5%
181-270 Days	49,345	6.8%	27,044	5.8%	482,151	7.4%	134,759	8.4%
271-365 Days	31,721	4.4%	16,039	3.5%	316,441	4.9%	88,174	5.5%
366+ Days	84,526	11.7%	35,850	7.7%	983,676	15.1%	250,541	15.6%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	163.9		121.8		204.5		201.4	
Median	65		42		90		90	
Mode	30		30		30		30	
75th Percentile	175		120		199		217	
90th Percentile	420		300		541		540	
Max	3664		2827		3740		3586	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	13,447	100%	10,602	100%	164,617	100%	44,402	100%	54,087	100%	55,488	100%
Episode Duration Categories												
1-30 Days	5,137	38.2%	4,428	41.8%	56,570	34.4%	17,411	39.2%	19,232	35.6%	20,500	36.9%
31-90 Days	3,178	23.6%	2,351	22.2%	36,282	22%	10,025	22.6%	14,003	25.9%	13,694	24.7%
91-180 Days	2,387	17.8%	1,618	15.3%	27,377	16.6%	7,268	16.4%	9,751	18%	9,569	17.2%
181-270 Days	1,203	8.9%	768	7.2%	15,478	9.4%	3,685	8.3%	4,656	8.6%	4,935	8.9%
271-365 Days	711	5.3%	515	4.9%	9,825	6%	2,239	5%	2,553	4.7%	2,814	5.1%
366+ Days	831	6.2%	922	8.7%	19,085	11.6%	3,774	8.5%	3,892	7.2%	3,976	7.2%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	28		30		30		30		28		30	
Mean	117.9		132.1		157.2		130.9		123.2		122.7	
Median	62		63		90		65		69		68	
Mode	28		30		30		30		28		30	
75th Percentile	152		154		190		158		156		155	
90th Percentile	291		340		399		335		304		305	
Max	1172		1627		1709		1404		1139		1180	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	155,430	100%	721,649	100%	974,781	100%	386,765	100%	196,868	100%	262,868	100%
Episode Duration Categories												
1-30 Days	70,266	45.2%	200,542	27.8%	266,282	27.3%	142,511	36.8%	64,820	32.9%	121,649	46.3%
31-90 Days	37,884	24.4%	173,067	24%	224,310	23%	105,598	27.3%	44,155	22.4%	61,465	23.4%
91-180 Days	22,303	14.3%	104,695	14.5%	159,431	16.4%	57,193	14.8%	31,542	16%	34,475	13.1%
181-270 Days	9,652	6.2%	62,785	8.7%	84,610	8.7%	25,677	6.6%	18,276	9.3%	16,148	6.1%
271-365 Days	5,582	3.6%	44,790	6.2%	59,017	6.1%	15,991	4.1%	12,686	6.4%	9,390	3.6%
366+ Days	9,743	6.3%	135,770	18.8%	181,131	18.6%	39,795	10.3%	25,389	12.9%	19,741	7.5%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		30		30	
25th Percentile	30		30		30		30		30		30	
Mean	115.2		233.4		238.2		153.1		172.6		122	
Median	60		90		90		67		90		56	
Mode	30		30		30		30		30		30	
75th Percentile	120		271		270		150		210		120	
90th Percentile	270		631		637		372		446		295	
Max	3505		3586		3679		3585		2325		2793	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Female	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	3,497,705	100%	442,726	100%	182,898	100%	836,112	100%
Episode Duration Categories								
1-30 Days	1,221,110	34.9%	145,759	32.9%	63,255	34.6%	267,579	32%
31-90 Days	868,256	24.8%	104,949	23.7%	37,553	20.5%	187,885	22.5%
91-180 Days	508,771	14.5%	70,768	16%	27,837	15.2%	128,416	15.4%
181-270 Days	256,134	7.3%	37,312	8.4%	15,319	8.4%	72,350	8.7%
271-365 Days	166,424	4.8%	24,412	5.5%	10,446	5.7%	47,213	5.6%
366+ Days	477,010	13.6%	59,526	13.4%	28,488	15.6%	132,669	15.9%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	189.6		183.9		196.6		204.4	
Median	90		90		90		90	
Mode	30		30		30		30	
75th Percentile	184		197		219		225	
90th Percentile	483		457		527		540	
Max	3709		3643		2944		3586	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Albiglutide		Alogliptin		Canagliflozin		Dapagliflozin		Dulaglutide		Empagliflozin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	12,447	100%	13,060	100%	180,911	100%	51,068	100%	49,192	100%	71,425	100%
Episode Duration Categories												
1-30 Days	4,370	35.1%	5,107	39.1%	54,931	30.4%	17,661	34.6%	16,791	34.1%	23,888	33.4%
31-90 Days	2,834	22.8%	2,873	22%	38,812	21.5%	11,283	22.1%	12,817	26.1%	17,141	24%
91-180 Days	2,327	18.7%	2,129	16.3%	29,723	16.4%	8,621	16.9%	8,657	17.6%	12,571	17.6%
181-270 Days	1,134	9.1%	983	7.5%	17,952	9.9%	4,739	9.3%	4,482	9.1%	7,180	10.1%
271-365 Days	731	5.9%	652	5%	12,347	6.8%	3,150	6.2%	2,492	5.1%	4,331	6.1%
366+ Days	1,051	8.4%	1,316	10.1%	27,146	15%	5,614	11%	3,953	8%	6,314	8.8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		28		30	
25th Percentile	30		30		30		30		28		30	
Mean	132.6		141.6		183		151.5		130.1		137.2	
Median	83		68		90		90		81		90	
Mode	28		30		30		30		28		30	
75th Percentile	173		171		240		187		168		180	
90th Percentile	338		367		473		382		325		348	
Max	1113		1600		1704		1371		1097		1197	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Exenatide		Glimepiride		Glipizide		Glyburide		Linagliptin		Liraglutide	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	118,914	100%	702,327	100%	986,583	100%	334,160	100%	183,166	100%	199,725	100%
Episode Duration Categories												
1-30 Days	49,575	41.7%	179,016	25.5%	254,063	25.8%	115,710	34.6%	57,970	31.6%	86,806	43.5%
31-90 Days	29,724	25%	168,587	24%	230,849	23.4%	86,772	26%	41,689	22.8%	47,322	23.7%
91-180 Days	17,982	15.1%	104,019	14.8%	165,396	16.8%	47,526	14.2%	29,300	16%	26,387	13.2%
181-270 Days	7,892	6.6%	62,884	9%	86,987	8.8%	24,552	7.3%	17,357	9.5%	13,058	6.5%
271-365 Days	4,789	4%	46,602	6.6%	62,410	6.3%	16,644	5%	11,951	6.5%	8,046	4%
366+ Days	8,952	7.5%	141,219	20.1%	186,878	18.9%	42,956	12.9%	24,899	13.6%	18,106	9.1%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1		1	
10th Percentile	28		30		30		30		30		30	
25th Percentile	30		30		30		30		30		30	
Mean	127.2		246.4		245		176.4		179.4		136.1	
Median	60		92		94		90		90		60	
Mode	30		30		30		30		30		30	
75th Percentile	132		289		273		181		215		135	
90th Percentile	302		658		648		451		459		345	
Max	3397		3584		3733		3664		2299		2827	

Table 8a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Male	Metformin		Pioglitazone		Saxagliptin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	3,005,159	100%	479,450	100%	173,627	100%	767,193	100%
Episode Duration Categories								
1-30 Days	917,580	30.5%	140,349	29.3%	56,678	32.6%	235,553	30.7%
31-90 Days	746,752	24.8%	112,366	23.4%	37,087	21.4%	176,274	23%
91-180 Days	460,005	15.3%	76,898	16%	26,667	15.4%	117,303	15.3%
181-270 Days	243,057	8.1%	42,821	8.9%	14,890	8.6%	68,351	8.9%
271-365 Days	162,828	5.4%	29,485	6.1%	10,267	5.9%	45,630	5.9%
366+ Days	474,937	15.8%	77,531	16.2%	28,038	16.1%	124,082	16.2%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	212.5		210.6		204.2		209.1	
Median	90		90		90		90	
Mode	30		30		30		30	
75th Percentile	216		240		238		240	
90th Percentile	550		540		541		544	
Max	3740		3619		2881		3583	

Table 8b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Female	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	386,765	100%	262,868	100%	3,497,705	100%	836,112	100%
Episode Duration Categories								
1-30 Days	150,848	39%	131,083	49.9%	1,309,279	37.4%	291,399	34.9%
31-90 Days	101,077	26.1%	58,559	22.3%	821,239	23.5%	181,118	21.7%
91-180 Days	53,851	13.9%	31,227	11.9%	470,908	13.5%	121,698	14.6%
181-270 Days	25,182	6.5%	14,921	5.7%	247,408	7.1%	68,946	8.2%
271-365 Days	15,596	4%	8,558	3.3%	159,811	4.6%	44,783	5.4%
366+ Days	40,211	10.4%	18,520	7%	489,060	14%	128,168	15.3%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	152.1		115.4		192.4		197.7	
Median	62		31		85		90	
Mode	30		30		30		30	
75th Percentile	150		105		184		212	
90th Percentile	376		276		501		526	
Max	3585		2786		3722		3586	

Table 8b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Male</u>	Glyburide		Liraglutide		Metformin		Sitagliptin	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	334,160	100%	199,725	100%	3,005,159	100%	767,193	100%
Episode Duration Categories								
1-30 Days	123,505	37%	94,121	47.1%	991,517	33%	256,645	33.5%
31-90 Days	81,724	24.5%	44,615	22.3%	701,695	23.3%	167,914	21.9%
91-180 Days	44,328	13.3%	24,055	12%	425,958	14.2%	111,057	14.5%
181-270 Days	24,163	7.2%	12,123	6.1%	234,743	7.8%	65,813	8.6%
271-365 Days	16,125	4.8%	7,481	3.7%	156,630	5.2%	43,391	5.7%
366+ Days	44,315	13.3%	17,330	8.7%	494,616	16.5%	122,373	16%
Summary Statistics								
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1	
10th Percentile	30		30		30		30	
25th Percentile	30		30		30		30	
Mean	177.6		130.2		218.5		205.4	
Median	90		50		90		90	
Mode	30		30		30		30	
75th Percentile	182		123		218		225	
90th Percentile	460		330		583		543	
Max	3664		2827		3740		3583	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Albiglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	4,036	100%	6,987	100%	8,592	100%	4,651	100%	1,628	100%
Episode Duration Categories										
1-30 Days	1,648	40.8%	2,552	36.5%	2,961	34.5%	1,700	36.6%	646	39.7%
31-90 Days	1,003	24.9%	1,558	22.3%	1,886	22%	1,134	24.4%	431	26.5%
91-180 Days	710	17.6%	1,304	18.7%	1,542	17.9%	887	19.1%	271	16.6%
181-270 Days	279	6.9%	659	9.4%	825	9.6%	434	9.3%	140	8.6%
271-365 Days	194	4.8%	387	5.5%	563	6.6%	222	4.8%	76	4.7%
366+ Days	202	5%	527	7.5%	815	9.5%	274	5.9%	64	3.9%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		28	
25th Percentile	28		29		30		28		28	
Mean	106		127.2		139.6		118.4		104	
Median	60		67		84		69		60	
Mode	28		28		28		28		28	
75th Percentile	126		168		189		156		130	
90th Percentile	268		320		357		280		256	
Max	897		1100		1172		1016		930	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Alogliptin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	2,807	100%	5,247	100%	6,655	100%	5,740	100%	3,213	100%
Episode Duration Categories										
1-30 Days	1,362	48.5%	2,251	42.9%	2,537	38.1%	2,130	37.1%	1,255	39.1%
31-90 Days	586	20.9%	1,108	21.1%	1,461	22%	1,328	23.1%	741	23.1%
91-180 Days	418	14.9%	836	15.9%	1,086	16.3%	904	15.7%	503	15.7%
181-270 Days	180	6.4%	391	7.5%	510	7.7%	441	7.7%	229	7.1%
271-365 Days	97	3.5%	238	4.5%	322	4.8%	327	5.7%	183	5.7%
366+ Days	164	5.8%	423	8.1%	739	11.1%	610	10.6%	302	9.4%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	106.7		128.8		149.4		146.2		137.1	
Median	50		61		70		90		85	
Mode	30		30		30		30		30	
75th Percentile	110		144		180		180		178	
90th Percentile	256		321		390		380		360	
Max	1411		1627		1600		1596		1547	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Canagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	34,937	100%	68,643	100%	91,708	100%	113,338	100%	36,902	100%
Episode Duration Categories										
1-30 Days	13,473	38.6%	22,473	32.7%	28,073	30.6%	35,145	31%	12,337	33.4%
31-90 Days	7,271	20.8%	13,694	19.9%	18,761	20.5%	26,491	23.4%	8,877	24.1%
91-180 Days	5,713	16.4%	11,499	16.8%	15,079	16.4%	18,690	16.5%	6,119	16.6%
181-270 Days	2,950	8.4%	6,557	9.6%	8,873	9.7%	11,523	10.2%	3,527	9.6%
271-365 Days	1,825	5.2%	4,508	6.6%	6,240	6.8%	7,416	6.5%	2,183	5.9%
366+ Days	3,705	10.6%	9,912	14.4%	14,682	16%	14,073	12.4%	3,859	10.5%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	146.3		178.5		189.9		164.9		149.6	
Median	66		90		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	180		225		247		210		185	
90th Percentile	378		463		497		420		376	
Max	1691		1709		1690		1683		1704	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dapagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	13,126	100%	24,953	100%	30,904	100%	20,518	100%	5,969	100%
Episode Duration Categories										
1-30 Days	5,614	42.8%	9,265	37.1%	10,427	33.7%	7,423	36.2%	2,343	39.3%
31-90 Days	2,996	22.8%	5,386	21.6%	6,559	21.2%	4,876	23.8%	1,491	25%
91-180 Days	2,038	15.5%	4,232	17%	5,377	17.4%	3,258	15.9%	984	16.5%
181-270 Days	1,012	7.7%	2,158	8.6%	2,906	9.4%	1,903	9.3%	445	7.5%
271-365 Days	559	4.3%	1,365	5.5%	1,960	6.3%	1,219	5.9%	286	4.8%
366+ Days	907	6.9%	2,547	10.2%	3,675	11.9%	1,839	9%	420	7%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	117.4		144		158.1		137		119.7	
Median	60		68		90		88		65	
Mode	30		30		30		30		30	
75th Percentile	133		180		196		180		150	
90th Percentile	290		368		397		350		300	
Max	1371		1368		1404		1356		1269	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dulaglutide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	12,821	100%	23,898	100%	31,738	100%	26,696	100%	8,126	100%
Episode Duration Categories										
1-30 Days	4,925	38.4%	8,267	34.6%	10,488	33%	9,294	34.8%	3,049	37.5%
31-90 Days	3,303	25.8%	5,999	25.1%	7,876	24.8%	7,294	27.3%	2,348	28.9%
91-180 Days	2,252	17.6%	4,393	18.4%	5,613	17.7%	4,798	18%	1,352	16.6%
181-270 Days	1,094	8.5%	2,142	9%	3,023	9.5%	2,260	8.5%	619	7.6%
271-365 Days	560	4.4%	1,242	5.2%	1,792	5.6%	1,183	4.4%	268	3.3%
366+ Days	687	5.4%	1,855	7.8%	2,946	9.3%	1,867	7%	490	6%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		28	
25th Percentile	28		28		28		28		28	
Mean	111		128.4		138.3		122.8		111.5	
Median	60		74		84		80		63	
Mode	28		28		28		28		28	
75th Percentile	142		168		178		154		135	
90th Percentile	267		321		350		295		262	
Max	1139		1086		1082		1097		1087	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Empagliflozin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	14,738	100%	31,831	100%	44,159	100%	27,975	100%	8,210	100%
Episode Duration Categories										
1-30 Days	6,041	41%	11,325	35.6%	14,416	32.6%	9,594	34.3%	3,012	36.7%
31-90 Days	3,468	23.5%	7,224	22.7%	10,014	22.7%	7,846	28%	2,283	27.8%
91-180 Days	2,406	16.3%	5,551	17.4%	7,883	17.9%	4,841	17.3%	1,459	17.8%
181-270 Days	1,160	7.9%	3,034	9.5%	4,596	10.4%	2,579	9.2%	746	9.1%
271-365 Days	716	4.9%	1,876	5.9%	2,869	6.5%	1,349	4.8%	335	4.1%
366+ Days	947	6.4%	2,821	8.9%	4,381	9.9%	1,766	6.3%	375	4.6%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	114.6		134.6		143.9		120.8		109.9	
Median	60		74		90		78		71	
Mode	30		30		30		30		30	
75th Percentile	137		180		189		155		134	
90th Percentile	288		347		365		286		256.5	
Max	1132		1197		1185		1152		1084	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	41,173	100%	64,990	100%	75,001	100%	73,653	100%	19,527	100%
Episode Duration Categories										
1-30 Days	20,884	50.7%	29,420	45.3%	31,593	42.1%	29,810	40.5%	8,134	41.7%
31-90 Days	9,730	23.6%	15,453	23.8%	18,037	24%	19,353	26.3%	5,035	25.8%
91-180 Days	5,685	13.8%	9,646	14.8%	11,169	14.9%	10,975	14.9%	2,810	14.4%
181-270 Days	2,159	5.2%	3,999	6.2%	5,103	6.8%	4,969	6.7%	1,314	6.7%
271-365 Days	1,085	2.6%	2,313	3.6%	3,130	4.2%	3,082	4.2%	761	3.9%
366+ Days	1,630	4%	4,159	6.4%	5,969	8%	5,464	7.4%	1,473	7.5%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	28		28		28		28		28	
25th Percentile	30		30		30		30		30	
Mean	92.9		115.6		129.7		128.6		127	
Median	30		59		60		62		60	
Mode	30		30		30		30		30	
75th Percentile	92		120		138		135		134	
90th Percentile	208		270		314		301		300	
Max	2059		3263		3397		3505		3283	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glimepiride</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	89,466	100%	173,332	100%	254,079	100%	522,616	100%	384,483	100%
Episode Duration Categories										
1-30 Days	37,003	41.4%	60,719	35%	77,181	30.4%	116,672	22.3%	87,983	22.9%
31-90 Days	20,796	23.2%	39,139	22.6%	58,311	22.9%	130,798	25%	92,610	24.1%
91-180 Days	13,747	15.4%	27,568	15.9%	39,312	15.5%	73,423	14%	54,664	14.2%
181-270 Days	6,179	6.9%	13,986	8.1%	22,395	8.8%	47,835	9.2%	35,274	9.2%
271-365 Days	3,585	4%	8,934	5.2%	15,319	6%	36,444	7%	27,110	7.1%
366+ Days	8,156	9.1%	22,986	13.3%	41,561	16.4%	117,444	22.5%	86,842	22.6%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		60		53	
Mean	143.2		182.2		211		271.2		264.6	
Median	61		90		90		107		116	
Mode	30		30		30		30		30	
75th Percentile	146		188		240		333		334	
90th Percentile	340		458		549		725		714	
Max	3491		3561		3584		3586		3579	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glipizide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	146,246	100%	263,732	100%	370,229	100%	667,700	100%	513,457	100%
Episode Duration Categories										
1-30 Days	53,900	36.9%	84,337	32%	105,180	28.4%	155,992	23.4%	120,936	23.6%
31-90 Days	31,585	21.6%	56,838	21.6%	81,884	22.1%	163,608	24.5%	121,244	23.6%
91-180 Days	29,641	20.3%	51,530	19.5%	67,609	18.3%	100,327	15%	75,720	14.7%
181-270 Days	10,774	7.4%	21,474	8.1%	32,034	8.7%	60,206	9%	47,109	9.2%
271-365 Days	6,079	4.2%	13,360	5.1%	21,522	5.8%	44,933	6.7%	35,533	6.9%
366+ Days	14,267	9.8%	36,193	13.7%	62,000	16.7%	142,634	21.4%	112,915	22%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		49		45	
Mean	156.9		198.9		228.5		267.6		263.3	
Median	70		90		90		100		100	
Mode	30		30		30		30		30	
75th Percentile	150		196		240		307		322	
90th Percentile	360		489		584		720		708	
Max	3644		3652		3733		3659		3679	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glyburide</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	124,547	100%	101,800	100%	132,029	100%	206,862	100%	155,687	100%
Episode Duration Categories										
1-30 Days	53,988	43.3%	43,286	42.5%	49,683	37.6%	62,815	30.4%	48,449	31.1%
31-90 Days	37,370	30%	22,788	22.4%	31,619	23.9%	57,426	27.8%	43,167	27.7%
91-180 Days	20,773	16.7%	15,231	15%	19,515	14.8%	27,964	13.5%	21,236	13.6%
181-270 Days	5,834	4.7%	6,720	6.6%	9,337	7.1%	16,169	7.8%	12,169	7.8%
271-365 Days	2,471	2%	3,882	3.8%	6,111	4.6%	11,642	5.6%	8,529	5.5%
366+ Days	4,111	3.3%	9,893	9.7%	15,764	11.9%	30,846	14.9%	22,137	14.2%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	92.9		149		169.8		194.4		184.7	
Median	60		60		70		90		90	
Mode	30		30		30		30		30	
75th Percentile	96		136		180		210		201	
90th Percentile	180		360		428		507		477	
Max	3450		3664		3564		3529		3609	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Linagliptin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	20,769	100%	45,263	100%	74,131	100%	128,281	100%	111,590	100%
Episode Duration Categories										
1-30 Days	8,922	43%	16,314	36%	24,161	32.6%	39,907	31.1%	33,486	30%
31-90 Days	4,445	21.4%	9,768	21.6%	16,162	21.8%	30,067	23.4%	25,402	22.8%
91-180 Days	3,259	15.7%	7,295	16.1%	12,077	16.3%	20,457	15.9%	17,754	15.9%
181-270 Days	1,467	7.1%	3,927	8.7%	6,788	9.2%	12,355	9.6%	11,096	9.9%
271-365 Days	971	4.7%	2,660	5.9%	4,817	6.5%	8,500	6.6%	7,689	6.9%
366+ Days	1,705	8.2%	5,299	11.7%	10,126	13.7%	16,995	13.2%	16,163	14.5%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	130.3		162.2		178.9		177.9		185.5	
Median	60		90		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	147		186		214		214		235	
90th Percentile	325		404		458		452		482	
Max	2111		2320		2280		2325		2173	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Liraglutide</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	61,966	100%	97,046	100%	118,511	100%	145,175	100%	39,895	100%
Episode Duration Categories										
1-30 Days	31,911	51.5%	45,372	46.8%	52,603	44.4%	61,103	42.1%	17,466	43.8%
31-90 Days	13,259	21.4%	20,867	21.5%	26,379	22.3%	37,755	26%	10,527	26.4%
91-180 Days	8,146	13.1%	13,096	13.5%	15,757	13.3%	18,893	13%	4,970	12.5%
181-270 Days	3,444	5.6%	6,143	6.3%	7,806	6.6%	9,462	6.5%	2,351	5.9%
271-365 Days	1,851	3%	3,763	3.9%	4,888	4.1%	5,525	3.8%	1,409	3.5%
366+ Days	3,355	5.4%	7,805	8%	11,078	9.3%	12,437	8.6%	3,172	8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	102.4		126		137.6		133.3		125.9	
Median	30		55		60		60		60	
Mode	30		30		30		30		30	
75th Percentile	97		126		142		130		120	
90th Percentile	240		310		357		330		303	
Max	2807		2827		2722		2786		2323	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	1,030,270	100%	1,100,240	100%	1,322,261	100%	1,981,146	100%	1,068,947	100%
Episode Duration Categories										
1-30 Days	484,485	47%	420,905	38.3%	442,614	33.5%	508,833	25.7%	281,853	26.4%
31-90 Days	232,353	22.6%	247,945	22.5%	310,655	23.5%	540,270	27.3%	283,785	26.5%
91-180 Days	154,908	15%	175,304	15.9%	206,453	15.6%	279,728	14.1%	152,383	14.3%
181-270 Days	58,630	5.7%	79,621	7.2%	103,925	7.9%	166,143	8.4%	90,872	8.5%
271-365 Days	31,645	3.1%	48,005	4.4%	67,430	5.1%	117,932	6%	64,240	6%
366+ Days	68,249	6.6%	128,460	11.7%	191,184	14.5%	368,240	18.6%	195,814	18.3%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	119.9		172.2		199.3		241.3		231.4	
Median	57		68		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	101		171		200		270		270	
90th Percentile	269		420		507		643		627	
Max	3663		3740		3730		3733		3645	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	75,881	100%	141,525	100%	192,803	100%	320,105	100%	191,862	100%
Episode Duration Categories										
1-30 Days	33,203	43.8%	52,084	36.8%	61,013	31.6%	87,271	27.3%	52,537	27.4%
31-90 Days	16,449	21.7%	30,126	21.3%	42,897	22.2%	80,492	25.1%	47,351	24.7%
91-180 Days	11,822	15.6%	23,386	16.5%	31,802	16.5%	50,489	15.8%	30,167	15.7%
181-270 Days	4,966	6.5%	11,171	7.9%	16,604	8.6%	29,555	9.2%	17,837	9.3%
271-365 Days	2,815	3.7%	6,930	4.9%	11,182	5.8%	20,560	6.4%	12,410	6.5%
366+ Days	6,626	8.7%	17,828	12.6%	29,305	15.2%	51,738	16.2%	31,560	16.4%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	138.1		176.3		200.5		212.4		209.9	
Median	60		89		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	127		182		217		245		250	
90th Percentile	330		443		510		540		540	
Max	3619		3583		3643		3607		3583	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Saxagliptin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	26,763	100%	52,854	100%	73,014	100%	121,439	100%	82,455	100%
Episode Duration Categories										
1-30 Days	11,803	44.1%	19,905	37.7%	24,839	34%	37,877	31.2%	25,509	30.9%
31-90 Days	5,268	19.7%	10,454	19.8%	14,667	20.1%	26,993	22.2%	17,258	20.9%
91-180 Days	4,183	15.6%	8,406	15.9%	11,357	15.6%	18,397	15.1%	12,161	14.7%
181-270 Days	1,828	6.8%	4,209	8%	6,313	8.6%	10,469	8.6%	7,390	9%
271-365 Days	1,062	4%	2,681	5.1%	4,242	5.8%	7,620	6.3%	5,108	6.2%
366+ Days	2,619	9.8%	7,199	13.6%	11,596	15.9%	20,083	16.5%	15,029	18.2%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	144.1		180.7		199.3		208.6		219.9	
Median	60		70		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	150		190		228		245		270	
90th Percentile	360		468		530		550		599	
Max	2800		2877		2889		2944		2658	

Table 9a. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Sitagliptin</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	111,059	100%	216,655	100%	309,603	100%	558,774	100%	407,214	100%
Episode Duration Categories										
1-30 Days	47,769	43%	78,851	36.4%	99,060	32%	161,773	29%	115,679	28.4%
31-90 Days	23,848	21.5%	46,401	21.4%	67,558	21.8%	133,554	23.9%	92,798	22.8%
91-180 Days	16,339	14.7%	33,390	15.4%	48,184	15.6%	85,665	15.3%	62,141	15.3%
181-270 Days	7,671	6.9%	17,485	8.1%	26,687	8.6%	51,373	9.2%	37,485	9.2%
271-365 Days	4,527	4.1%	11,084	5.1%	18,062	5.8%	33,997	6.1%	25,173	6.2%
366+ Days	10,905	9.8%	29,444	13.6%	50,052	16.2%	92,412	16.5%	73,938	18.2%
Summary Statistics										
	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	147.4		184.7		207.1		214.2		223.7	
Median	60		86		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	150		190		234		245		270	
90th Percentile	362		471		540		553		600	
Max	3542		3559		3572		3586		3393	

Table 9b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	124,547	100%	101,800	100%	132,029	100%	206,862	100%	155,687	100%
Episode Duration Categories										
1-30 Days	56,647	45.5%	46,180	45.4%	53,107	40.2%	66,930	32.4%	51,489	33.1%
31-90 Days	36,551	29.3%	22,077	21.7%	30,282	22.9%	53,425	25.8%	40,466	26%
91-180 Days	19,572	15.7%	14,141	13.9%	18,141	13.7%	26,212	12.7%	20,113	12.9%
181-270 Days	5,624	4.5%	6,387	6.3%	9,106	6.9%	16,044	7.8%	12,184	7.8%
271-365 Days	2,330	1.9%	3,580	3.5%	5,800	4.4%	11,573	5.6%	8,438	5.4%
366+ Days	3,823	3.1%	9,435	9.3%	15,593	11.8%	32,678	15.8%	22,997	14.8%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	89.6		143.4		166.8		199.2		187.4	
Median	60		60		63		90		90	
Mode	30		30		30		30		30	
75th Percentile	91		125		172		215		210	
90th Percentile	180		344		423		536		488	
Max	3450		3664		3564		3529		3609	

Table 9b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Liraglutide</u>	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	61,966	100%	97,046	100%	118,511	100%	145,175	100%	39,895	100%
Episode Duration Categories										
1-30 Days	34,276	55.3%	49,352	50.9%	56,981	48.1%	65,837	45.4%	18,758	47%
31-90 Days	12,854	20.7%	19,991	20.6%	25,114	21.2%	35,374	24.4%	9,841	24.7%
91-180 Days	7,252	11.7%	11,754	12.1%	14,363	12.1%	17,311	11.9%	4,602	11.5%
181-270 Days	3,013	4.9%	5,563	5.7%	7,222	6.1%	9,024	6.2%	2,222	5.6%
271-365 Days	1,637	2.6%	3,347	3.4%	4,467	3.8%	5,197	3.6%	1,391	3.5%
366+ Days	2,934	4.7%	7,039	7.3%	10,364	8.7%	12,432	8.6%	3,081	7.7%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	93.9		116.9		130.2		130.1		122	
Median	30		30		45		60		45	
Mode	30		30		30		30		30	
75th Percentile	90		114		124		123		120	
90th Percentile	212		284		331		325		298	
Max	2762		2827		2722		2786		2609	

Table 9b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	1,030,270	100%	1,100,240	100%	1,322,261	100%	1,981,146	100%	1,068,947	100%
Episode Duration Categories										
1-30 Days	516,434	50.1%	453,660	41.2%	477,472	36.1%	548,928	27.7%	304,302	28.5%
31-90 Days	224,852	21.8%	239,433	21.8%	296,225	22.4%	497,468	25.1%	264,956	24.8%
91-180 Days	139,869	13.6%	160,792	14.6%	190,984	14.4%	261,744	13.2%	143,477	13.4%
181-270 Days	54,809	5.3%	75,354	6.8%	100,005	7.6%	162,667	8.2%	89,316	8.4%
271-365 Days	29,299	2.8%	45,260	4.1%	64,593	4.9%	114,716	5.8%	62,573	5.9%
366+ Days	65,007	6.3%	125,741	11.4%	192,982	14.6%	395,623	20%	204,323	19.1%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	115.4		169.5		201.1		254.3		238.3	
Median	30		61		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	100		156		195		278		270	
90th Percentile	247		411		517		702		652	
Max	3722		3740		3730		3733		3645	

Table 9b. Duration of First Treatment Episode with Non-Insulin Antidiabetic Drugs per Patient in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Sitagliptin	18-44 years		45-54 years		55-64 years		65-74 years		75+ years	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total Patients	111,059	100%	216,655	100%	309,603	100%	558,774	100%	407,214	100%
Episode Duration Categories										
1-30 Days	51,668	46.5%	86,205	39.8%	108,216	35%	175,547	31.4%	126,408	31%
31-90 Days	23,338	21%	45,164	20.8%	65,161	21%	126,173	22.6%	89,196	21.9%
91-180 Days	15,070	13.6%	31,312	14.5%	45,497	14.7%	81,360	14.6%	59,516	14.6%
181-270 Days	7,051	6.3%	16,214	7.5%	25,443	8.2%	49,773	8.9%	36,278	8.9%
271-365 Days	4,050	3.6%	10,114	4.7%	17,025	5.5%	32,913	5.9%	24,072	5.9%
366+ Days	9,882	8.9%	27,646	12.8%	48,261	15.6%	93,008	16.6%	71,744	17.6%
Summary Statistics	Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)		Episode Duration (Days)	
Min	1		1		1		1		1	
10th Percentile	30		30		30		30		30	
25th Percentile	30		30		30		30		30	
Mean	137.2		174.9		200.6		213		217.7	
Median	60		64		90		90		90	
Mode	30		30		30		30		30	
75th Percentile	125		180		215		241		253	
90th Percentile	333		451		534		561		588	
Max	3542		3559		3578		3586		3393	

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Albiglutide

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	46,920	100%	25	105.8	179.5
Gap Number					
1	10,301	22.0%	23	43.4	62.1
2	4,933	10.5%	24	40.5	53.1
3	2,570	5.5%	24	38.7	44.8
4	1,416	3.0%	24	38.9	42.1
5	787	1.7%	25	38.2	38.3
6	454	1.0%	25	35.8	33.6
7	262	0.6%	26	36.6	30.3
8	143	0.3%	26	35.9	40.1
9	71	0.2%	23	40.1	39.4
10	38	0.1%	22	31.1	28.0
11	24	0.1%	30	47.4	44.6
12	13	0.0%	24	29.2	17.6
13	*****	*****	22	22.3	8.6
14	*****	*****	22	37.8	33.5
15	*****	*****	17	21.7	9.0
16	*****	*****	*****	*****	*****
Gap from last episode until censoring	25,894	55.2%	35	158.2	223.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Alogliptin

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	49,804	100%	27	132.0	241.5
Gap Number					
1	10,884	21.9%	26	49.3	75.2
2	5,745	11.5%	26	46.8	67.9
3	3,310	6.6%	26	43.6	56.6
4	2,037	4.1%	26	42.1	50.7
5	1,322	2.7%	26	40.7	53.3
6	899	1.8%	26	39.6	45.8
7	593	1.2%	25	38.4	45.2
8	416	0.8%	25	37.9	40.2
9	287	0.6%	25	35.2	30.9
10	202	0.4%	23	33.6	35.0
11	151	0.3%	26	33.7	27.2
12	102	0.2%	24	33.8	37.4
13	74	0.1%	22	31.3	32.0
14	48	0.1%	22	24.3	14.2
15	28	0.1%	22	26.4	12.5
16	19	0.0%	26	29.5	15.0
17	11	0.0%	35	34.2	15.0
18	*****	*****	22	23.0	7.6
19	*****	*****	23	29.8	22.5
20	*****	*****	41	40.5	38.9
21	*****	*****	*****	*****	*****
22	*****	*****	*****	*****	*****
Gap from last episode until censoring	23,662	47.5%	53	227.4	317.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Canagliflozin

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	669,422	100%	24	110.6	209.5
Gap Number					
1	145,144	21.7%	25	54.4	91.3
2	72,454	10.8%	25	47.8	72.3
3	40,248	6.0%	26	44.9	63.5
4	23,727	3.5%	26	43.4	56.7
5	14,698	2.2%	26	41.5	54.7
6	9,453	1.4%	25	40.5	50.8
7	6,172	0.9%	25	39.4	46.5
8	4,100	0.6%	25	38.0	42.4
9	2,733	0.4%	25	36.4	37.6
10	1,817	0.3%	25	35.6	35.9
11	1,213	0.2%	24	35.6	34.5
12	796	0.1%	26	36.1	36.9
13	517	0.1%	24	34.6	34.0
14	331	0.0%	23	32.0	33.1
15	203	0.0%	22	31.7	32.3
16	118	0.0%	24	32.8	30.6
17	63	0.0%	24	38.6	55.2
18	39	0.0%	19	26.1	15.6
19	24	0.0%	19	21.3	9.7
20	15	0.0%	17	22.2	17.3
21	12	0.0%	22	24.0	9.0
22	*****	*****	22	29.0	23.3
23	*****	*****	26	31.0	21.0
24	*****	*****	43	42.5	26.2
25	*****	*****	15	14.5	0.7
26	*****	*****	*****	*****	*****
Gap from last episode until censoring	345,528	51.6%	9	168.3	269.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Dapagliflozin

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	182,142	100%	24	115.7	211.4
Gap Number					
1	39,894	21.9%	25	53.5	87.3
2	19,584	10.8%	25	48.9	77.3
3	10,720	5.9%	25	45.5	66.7
4	6,180	3.4%	25	42.6	56.5
5	3,758	2.1%	25	42.4	58.0
6	2,350	1.3%	25	39.9	48.4
7	1,510	0.8%	24	37.8	43.7
8	980	0.5%	25	39.2	45.3
9	623	0.3%	24	34.9	37.6
10	392	0.2%	23	33.1	30.2
11	256	0.1%	24	37.3	38.7
12	160	0.1%	23	27.5	18.8
13	97	0.1%	24	30.1	23.7
14	66	0.0%	19	25.6	15.0
15	46	0.0%	26	31.7	25.1
16	25	0.0%	29	29.6	14.7
17	14	0.0%	21	30.9	22.9
18	*****	*****	22	41.1	32.7
19	*****	*****	33	32.8	16.6
20	*****	*****	22	27.3	13.4
21	*****	*****	28	28.0	2.8
Gap from last episode until censoring	95,470	52.4%	12	176.3	268.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Dulaglutide

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	176,971	100%	15	62.6	127.9
Gap Number					
1	38,633	21.8%	22	44.1	66.6
2	16,938	9.6%	24	43.1	58.7
3	8,381	4.7%	24	40.0	48.0
4	4,466	2.5%	25	38.3	42.8
5	2,469	1.4%	24	36.3	37.1
6	1,350	0.8%	23	35.5	35.6
7	717	0.4%	24	36.0	39.9
8	383	0.2%	23	32.1	25.1
9	188	0.1%	23	32.4	28.7
10	90	0.1%	24	32.0	26.5
11	41	0.0%	27	34.1	30.8
12	18	0.0%	21	28.4	24.4
13	*****	*****	21	26.2	15.6
14	*****	*****	25	31.5	24.4
15	*****	*****	27	26.5	7.8
Gap from last episode until censoring	103,279	58.4%	0	77.0	158.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Empagliflozin					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	213,908	100%	15	61.6	131.5
Gap Number					
1	45,851	21.4%	23	45.1	70.1
2	19,583	9.2%	23	41.3	57.2
3	9,598	4.5%	24	39.4	50.6
4	5,130	2.4%	24	37.9	46.4
5	2,869	1.3%	25	37.8	43.7
6	1,647	0.8%	24	37.5	41.1
7	979	0.5%	23	35.8	37.8
8	567	0.3%	24	33.6	29.4
9	331	0.2%	23	31.3	26.2
10	201	0.1%	25	31.9	26.4
11	117	0.1%	25	33.6	29.8
12	61	0.0%	20	26.1	24.3
13	30	0.0%	21	26.2	16.7
14	12	0.0%	20	24.9	18.1
15	*****	*****	19	23.2	16.4
16	*****	*****	20	19.8	6.5
17	*****	*****	11	14.3	5.8
18	*****	*****	*****	*****	*****
19	*****	*****	*****	*****	*****
Gap from last episode until censoring	126,913	59.3%	0	74.6	161.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Exenatide					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	689,038	100%	39	265.7	507.0
Gap Number					
1	134,190	19.5%	28	84.3	198.6
2	81,121	11.8%	29	76.1	173.4
3	53,861	7.8%	29	70.7	153.9
4	37,421	5.4%	30	67.5	142.2
5	26,808	3.9%	30	65.0	134.2
6	19,646	2.9%	30	61.4	123.0
7	14,566	2.1%	29	60.5	124.5
8	10,954	1.6%	30	58.3	121.0
9	8,207	1.2%	30	56.7	106.4
10	6,186	0.9%	30	54.6	101.8
11	4,733	0.7%	30	53.2	103.6
12	3,610	0.5%	29	49.1	81.4
13	2,857	0.4%	30	52.5	93.3
14	2,258	0.3%	30	51.1	85.4
15	1,753	0.3%	28	53.0	111.1
16	1,346	0.2%	30	47.2	76.7
17	1,059	0.2%	29	48.1	82.5
18	833	0.1%	30	49.3	90.9
19	665	0.1%	30	46.7	64.8
20	533	0.1%	29	41.7	46.9
21	407	0.1%	27	38.1	38.9
22	324	0.0%	29	37.8	36.2
23	272	0.0%	29	47.9	102.2
24	216	0.0%	30	47.0	85.2
25	179	0.0%	29	46.7	68.5
26	147	0.0%	30	41.7	46.4
27	113	0.0%	32	42.9	49.7
28	85	0.0%	31	44.4	48.6
29	65	0.0%	29	37.8	32.0
30	55	0.0%	30	35.4	23.4
31	45	0.0%	28	33.7	28.2
32	39	0.0%	31	45.2	45.3
33	32	0.0%	30	35.0	25.9
34	28	0.0%	26	40.0	43.5
35	23	0.0%	34	34.9	20.7
36	19	0.0%	33	34.3	26.2
37	14	0.0%	34	54.5	78.4
38	*****	*****	24	47.0	56.0
39	*****	*****	33	32.3	2.5
40	*****	*****	33	50.0	50.0
41	*****	*****	33	31.7	16.0
42	*****	*****	32	34.7	7.4
43	*****	*****	25	24.5	17.7
44	*****	*****	24	24.0	12.7
Gap from last episode until censoring	274,344	39.8%	290	557.3	680.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Glimepiride					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	3,809,387	100%	29	147.4	337.9
Gap Number					
1	751,173	19.7%	33	103.8	219.5
2	470,457	12.3%	32	81.7	168.6
3	314,977	8.3%	31	73.1	146.5
4	218,989	5.7%	31	67.5	132.9
5	156,233	4.1%	31	64.0	123.9
6	113,734	3.0%	30	60.9	114.1
7	83,982	2.2%	30	58.9	108.3
8	62,714	1.6%	30	56.6	104.1
9	47,597	1.2%	30	55.1	99.8
10	36,050	0.9%	29	53.6	96.7
11	27,831	0.7%	29	51.6	90.6
12	21,589	0.6%	29	49.6	82.9
13	16,838	0.4%	29	50.2	86.6
14	13,207	0.3%	29	48.0	77.4
15	10,371	0.3%	29	48.8	81.7
16	8,213	0.2%	29	48.3	85.7
17	6,459	0.2%	29	47.7	76.3
18	5,093	0.1%	28	46.4	82.6
19	4,064	0.1%	28	45.0	74.9
20	3,247	0.1%	28	42.7	62.6
21	2,551	0.1%	28	44.0	71.9
22	2,032	0.1%	29	41.7	58.7
23	1,627	0.0%	28	41.3	53.6
24	1,317	0.0%	29	41.5	56.6
25	1,052	0.0%	27	39.2	43.1
26	826	0.0%	29	39.3	47.4
27	660	0.0%	28	38.8	39.5
28	528	0.0%	27	39.7	61.7
29	424	0.0%	27	38.5	51.7
30	340	0.0%	27	35.8	39.3
31	276	0.0%	28	40.1	52.5
32	217	0.0%	30	42.1	77.6
33	181	0.0%	26	32.9	29.0
34	149	0.0%	26	37.9	34.8
35	103	0.0%	28	37.4	31.6
36	73	0.0%	24	33.8	26.1
37	58	0.0%	28	38.2	34.4
38	49	0.0%	21	29.8	27.2
39	30	0.0%	20	31.4	27.9
40	21	0.0%	21	36.3	44.8
41	16	0.0%	22	22.2	9.0
42	14	0.0%	28	29.2	17.3
43	11	0.0%	19	21.8	9.5
44	*****	*****	22	20.9	7.5
45	*****	*****	15	17.3	6.9
46	*****	*****	18	22.7	13.1
47	*****	*****	41	66.3	71.9
48	*****	*****	21	21.7	11.0
49	*****	*****	14	18.0	7.8
50	*****	*****	12	15.7	7.2
51	*****	*****	13	17.0	6.9
52	*****	*****	44	43.5	19.1

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Glimepiride, continued					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Gap from last episode until censoring	1,423,976	37.4%	0	260.5	487.0

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Glipizide					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	5,462,543	100%	30	150.7	346.0
Gap Number					
1	1,050,678	19.2%	35	111.9	238.9
2	670,294	12.3%	33	86.0	177.0
3	458,388	8.4%	33	77.6	154.3
4	326,184	6.0%	33	72.2	138.8
5	237,946	4.4%	32	68.0	125.6
6	176,819	3.2%	32	65.6	121.6
7	133,358	2.4%	32	62.5	110.8
8	101,510	1.9%	32	60.4	104.1
9	77,515	1.4%	32	58.6	98.6
10	59,659	1.1%	31	56.2	92.5
11	46,124	0.8%	31	54.3	83.8
12	35,704	0.7%	31	54.0	85.3
13	27,716	0.5%	30	53.0	84.5
14	21,533	0.4%	30	50.7	80.0
15	16,806	0.3%	30	49.6	77.1
16	13,068	0.2%	29	47.8	68.8
17	10,193	0.2%	30	46.9	68.8
18	7,982	0.1%	29	46.7	63.7
19	6,224	0.1%	29	44.8	59.5
20	4,878	0.1%	29	46.5	67.0
21	3,815	0.1%	28	42.9	59.9
22	3,033	0.1%	28	44.1	67.2
23	2,359	0.0%	28	44.6	69.3
24	1,875	0.0%	28	43.3	53.1
25	1,498	0.0%	28	41.3	53.4
26	1,208	0.0%	27	39.3	49.5
27	969	0.0%	28	42.5	57.2
28	778	0.0%	28	42.2	51.2
29	615	0.0%	28	38.9	45.4
30	488	0.0%	27	37.4	38.7
31	395	0.0%	28	36.0	32.7
32	323	0.0%	27	39.6	39.3
33	265	0.0%	27	37.1	32.2
34	202	0.0%	28	35.9	30.8
35	164	0.0%	27	34.8	28.1
36	133	0.0%	30	37.4	26.5
37	108	0.0%	27	34.6	20.9
38	86	0.0%	28	34.2	25.1
39	65	0.0%	30	36.0	25.4
40	51	0.0%	33	37.8	24.8
41	41	0.0%	26	33.0	19.4
42	30	0.0%	22	30.9	27.9
43	25	0.0%	22	31.9	24.2
44	21	0.0%	25	31.2	19.9
45	18	0.0%	26	40.1	43.5
46	13	0.0%	26	33.3	28.2
47	*****	*****	31	30.0	11.2
48	*****	*****	20	21.5	6.9
49	*****	*****	18	18.0	7.0
50	*****	*****	*****	*****	*****
51	*****	*****	*****	*****	*****
52	*****	*****	*****	*****	*****
53	*****	*****	*****	*****	*****
54	*****	*****	*****	*****	*****
Gap from last episode until censoring	1,961,364	35.9%	1	269.2	504.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Glyburide					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,940,131	100%	43	252.5	479.4
Gap Number					
1	362,191	18.7%	36	104.2	206.9
2	231,055	11.9%	34	83.1	160.7
3	158,421	8.2%	33	75.0	143.0
4	112,906	5.8%	33	69.2	127.1
5	82,408	4.2%	32	65.8	121.6
6	61,157	3.2%	32	62.1	113.5
7	46,120	2.4%	31	59.3	108.5
8	35,124	1.8%	31	56.5	97.5
9	27,046	1.4%	31	56.0	99.9
10	20,986	1.1%	31	55.0	96.5
11	16,431	0.8%	30	52.7	93.5
12	13,002	0.7%	30	52.0	97.1
13	10,320	0.5%	30	52.1	88.8
14	8,215	0.4%	29	49.7	84.0
15	6,516	0.3%	30	49.2	82.8
16	5,189	0.3%	29	46.6	74.9
17	4,180	0.2%	29	46.7	78.3
18	3,394	0.2%	29	46.1	78.6
19	2,758	0.1%	29	47.6	86.1
20	2,228	0.1%	28	44.5	76.3
21	1,798	0.1%	28	44.6	80.4
22	1,463	0.1%	27	40.4	54.9
23	1,195	0.1%	27	44.4	78.8
24	955	0.0%	28	41.5	66.9
25	759	0.0%	27	40.4	64.3
26	630	0.0%	27	40.4	68.8
27	504	0.0%	27	47.7	93.5
28	409	0.0%	25	32.5	28.1
29	333	0.0%	28	37.9	43.4
30	275	0.0%	26	37.3	42.7
31	228	0.0%	29	38.2	44.1
32	194	0.0%	26	32.6	27.7
33	159	0.0%	25	31.7	23.5
34	127	0.0%	27	38.9	42.4
35	111	0.0%	28	44.0	49.0
36	88	0.0%	27	35.2	28.6
37	68	0.0%	28	32.4	22.0
38	56	0.0%	22	29.7	26.6
39	45	0.0%	26	33.9	25.1
40	37	0.0%	22	33.2	25.9
41	25	0.0%	20	27.3	19.7
42	20	0.0%	21	25.0	12.8
43	17	0.0%	19	21.5	9.3
44	16	0.0%	18	22.4	11.2
45	*****	*****	20	23.1	10.3
46	*****	*****	15	15.2	3.3
47	*****	*****	17	19.2	6.0
48	*****	*****	29	34.7	24.8
49	*****	*****	21	21.3	4.0
50	*****	*****	23	25.0	8.2
51	*****	*****	33	28.3	12.7
52	*****	*****	49	52.0	35.6

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Glyburide, continued					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
53	*****	*****	19	19.0	1.4
54	*****	*****	23	22.5	10.6
55	*****	*****	*****	*****	*****
56	*****	*****	*****	*****	*****
Gap from last episode until censoring	720,925	37.2%	287	544.6	663.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Linagliptin					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	766,479	100%	24	126.9	259.4
Gap Number					
1	167,002	21.8%	27	62.9	118.7
2	85,814	11.2%	26	53.9	93.4
3	48,465	6.3%	26	50.6	83.5
4	29,035	3.8%	26	46.9	72.1
5	18,332	2.4%	27	45.9	66.5
6	11,892	1.6%	26	43.6	61.7
7	7,959	1.0%	27	43.7	59.1
8	5,335	0.7%	26	42.3	65.4
9	3,640	0.5%	26	39.4	46.6
10	2,549	0.3%	26	38.6	47.9
11	1,810	0.2%	25	37.7	46.1
12	1,282	0.2%	25	37.9	47.9
13	920	0.1%	26	37.7	41.1
14	664	0.1%	26	36.4	39.6
15	485	0.1%	26	34.6	39.9
16	350	0.0%	27	36.7	34.1
17	249	0.0%	26	36.0	37.9
18	189	0.0%	23	35.7	44.9
19	136	0.0%	29	35.5	27.2
20	99	0.0%	25	32.2	24.7
21	66	0.0%	27	35.2	31.4
22	46	0.0%	27	34.2	26.6
23	38	0.0%	27	33.8	23.8
24	28	0.0%	22	26.1	16.3
25	19	0.0%	23	30.9	30.2
26	14	0.0%	27	28.2	13.1
27	*****	*****	23	25.1	11.7
28	*****	*****	23	28.3	20.5
29	*****	*****	33	33.7	8.0
30	*****	*****	21	25.3	9.3
31	*****	*****	*****	*****	*****
32	*****	*****	*****	*****	*****
33	*****	*****	*****	*****	*****
34	*****	*****	*****	*****	*****
35	*****	*****	*****	*****	*****
Gap from last episode until censoring	380,034	49.6%	5	199.7	339.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Liraglutide					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,420,028	100%	29	140.8	304.6
Gap Number					
1	272,790	19.2%	29	70.9	148.1
2	181,011	12.7%	28	64.7	129.9
3	127,555	9.0%	29	61.3	117.1
4	92,386	6.5%	29	58.3	106.1
5	68,189	4.8%	29	56.4	100.8
6	50,805	3.6%	28	53.4	89.7
7	38,283	2.7%	28	52.0	87.0
8	29,086	2.0%	28	51.7	89.1
9	22,225	1.6%	27	49.5	85.7
10	17,132	1.2%	27	47.8	78.1
11	13,054	0.9%	27	45.9	71.8
12	10,087	0.7%	27	45.7	74.7
13	7,771	0.5%	26	44.4	69.5
14	6,044	0.4%	26	41.8	60.1
15	4,689	0.3%	26	39.7	50.2
16	3,607	0.3%	25	41.4	66.8
17	2,827	0.2%	26	39.8	59.4
18	2,200	0.2%	25	38.6	52.8
19	1,750	0.1%	25	38.3	58.0
20	1,372	0.1%	25	39.2	61.5
21	1,058	0.1%	25	36.1	37.6
22	829	0.1%	24	36.6	45.1
23	632	0.0%	25	34.1	31.7
24	491	0.0%	24	35.4	38.6
25	379	0.0%	23	33.4	30.1
26	285	0.0%	23	33.4	42.8
27	230	0.0%	21	31.2	26.9
28	158	0.0%	21	30.0	25.5
29	123	0.0%	21	29.0	28.7
30	94	0.0%	22	29.2	23.9
31	66	0.0%	23	28.0	16.6
32	49	0.0%	24	28.0	13.7
33	41	0.0%	24	27.2	14.5
34	32	0.0%	19	23.8	12.6
35	27	0.0%	21	23.6	8.1
36	22	0.0%	23	26.2	14.2
37	18	0.0%	21	23.3	10.0
38	11	0.0%	18	28.7	33.9
39	*****	*****	23	22.4	7.4
40	*****	*****	20	21.4	7.7
41	*****	*****	19	18.8	6.7
42	*****	*****	21	23.7	5.5
43	*****	*****	18	17.7	1.5
Gap from last episode until censoring	462,593	32.6%	57	305.5	463.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Metformin					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	21,606,812	100%	31	131.0	302.6
Gap Number					
1	3,938,342	18.2%	37	127.7	266.9
2	2,707,942	12.5%	35	99.0	207.2
3	1,953,733	9.0%	34	87.4	180.6
4	1,452,236	6.7%	33	79.9	161.3
5	1,097,188	5.1%	33	74.6	147.4
6	840,674	3.9%	33	70.8	137.3
7	649,314	3.0%	32	67.6	128.2
8	506,123	2.3%	32	64.8	121.2
9	396,805	1.8%	32	62.0	112.6
10	312,733	1.4%	32	60.5	110.0
11	247,864	1.1%	31	58.7	104.4
12	197,272	0.9%	31	56.5	98.8
13	157,362	0.7%	31	55.5	97.3
14	125,445	0.6%	31	54.3	93.8
15	100,582	0.5%	30	53.1	91.4
16	80,686	0.4%	30	51.9	86.4
17	64,685	0.3%	30	50.2	81.9
18	52,057	0.2%	30	49.6	81.0
19	42,015	0.2%	30	48.8	81.4
20	34,091	0.2%	30	47.7	75.6
21	27,593	0.1%	29	46.4	69.5
22	22,338	0.1%	29	45.7	67.3
23	18,187	0.1%	29	44.9	64.4
24	14,783	0.1%	29	44.6	66.9
25	12,072	0.1%	29	43.3	60.3
26	9,894	0.0%	28	42.4	60.4
27	8,088	0.0%	29	43.3	64.4
28	6,584	0.0%	29	41.9	53.4
29	5,396	0.0%	28	39.4	45.3
30	4,343	0.0%	28	40.9	52.8
31	3,525	0.0%	29	40.2	48.3
32	2,860	0.0%	28	39.6	57.7
33	2,303	0.0%	28	37.0	44.4
34	1,821	0.0%	28	38.6	47.1
35	1,460	0.0%	28	37.2	47.1
36	1,182	0.0%	28	38.2	55.9
37	939	0.0%	27	36.4	36.3
38	753	0.0%	27	36.8	39.4
39	603	0.0%	29	36.4	32.2
40	473	0.0%	27	36.9	39.6
41	357	0.0%	27	33.0	31.0
42	273	0.0%	27	31.8	21.1
43	217	0.0%	27	32.0	22.9
44	179	0.0%	25	30.3	25.4
45	134	0.0%	25	28.6	18.0
46	106	0.0%	24	27.4	22.5
47	79	0.0%	22	24.6	11.4
48	65	0.0%	25	31.4	23.3
49	50	0.0%	18	23.9	18.4
50	38	0.0%	20	21.8	9.9
51	29	0.0%	21	22.9	10.7

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Metformin, continued					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
52	23	0.0%	17	21.4	10.0
53	15	0.0%	20	27.0	20.3
54	13	0.0%	20	23.1	13.7
55	*****	*****	20	24.8	11.8
56	*****	*****	18	23.4	8.9
57	*****	*****	18	18.8	3.0
58	*****	*****	17	16.5	4.9
59	*****	*****	14	13.5	0.7
60	*****	*****	15	15.0	4.2
61	*****	*****	*****	*****	*****
Gap from last episode until censoring	6,502,864	30.1%	0	222.1	450.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Pioglitazone					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	2,333,647	100%	35	264.6	538.2
Gap Number					
1	458,055	19.6%	32	101.8	226.1
2	275,895	11.8%	31	83.0	184.2
3	180,710	7.7%	31	74.6	161.1
4	124,146	5.3%	30	68.8	147.3
5	88,393	3.8%	30	65.1	137.2
6	64,493	2.8%	30	60.9	124.1
7	47,947	2.1%	30	59.3	123.9
8	36,211	1.6%	29	57.2	118.4
9	27,829	1.2%	29	55.0	109.9
10	21,591	0.9%	29	52.6	103.0
11	16,953	0.7%	29	50.9	99.3
12	13,392	0.6%	29	50.8	97.1
13	10,616	0.5%	29	47.6	84.0
14	8,429	0.4%	29	49.1	90.4
15	6,800	0.3%	28	45.7	75.0
16	5,552	0.2%	28	46.0	85.3
17	4,485	0.2%	28	44.8	79.6
18	3,618	0.2%	28	43.5	61.4
19	2,930	0.1%	28	43.4	65.9
20	2,377	0.1%	27	42.9	70.7
21	1,944	0.1%	28	41.9	65.7
22	1,586	0.1%	27	40.0	50.2
23	1,321	0.1%	29	42.5	57.3
24	1,088	0.0%	28	40.9	55.5
25	904	0.0%	28	40.0	43.6
26	721	0.0%	26	42.1	77.1
27	595	0.0%	27	36.3	37.5
28	501	0.0%	27	38.6	43.5
29	418	0.0%	26	39.6	59.9
30	352	0.0%	26	36.4	38.7
31	294	0.0%	28	37.5	34.2
32	248	0.0%	28	37.4	41.2
33	198	0.0%	26	34.7	33.2
34	163	0.0%	29	39.4	43.1
35	134	0.0%	29	33.2	20.4
36	105	0.0%	25	32.0	28.4
37	87	0.0%	26	29.2	16.7
38	75	0.0%	28	32.8	22.3
39	64	0.0%	23	28.8	18.8
40	51	0.0%	23	28.8	17.9
41	38	0.0%	26	26.2	11.4
42	32	0.0%	25	31.8	22.0
43	24	0.0%	25	33.5	42.3
44	21	0.0%	20	34.8	35.6
45	18	0.0%	25	33.4	26.5
46	14	0.0%	26	25.3	13.4
47	11	0.0%	21	29.0	18.6
48	*****	*****	18	25.7	16.7
49	*****	*****	25	25.0	7.1
50	*****	*****	21	21.4	6.3
51	*****	*****	18	20.7	10.5

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Pioglitazone, continued					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
52	*****	*****	34	33.3	6.6
53	*****	*****	56	55.5	17.7
54	*****	*****	*****	*****	*****
Gap from last episode until censoring	922,176	39.5%	154	547.2	742.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Saxagliptin					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	890,209	100%	32	226.6	419.6
Gap Number					
1	184,063	20.7%	27	67.4	137.5
2	108,972	12.2%	26	58.2	111.8
3	69,769	7.8%	27	54.0	97.7
4	46,994	5.3%	26	50.7	85.6
5	32,741	3.7%	27	48.8	78.6
6	23,402	2.6%	26	47.0	73.9
7	16,853	1.9%	26	46.3	74.1
8	12,463	1.4%	26	44.0	65.7
9	9,281	1.0%	26	43.6	62.8
10	6,939	0.8%	26	41.8	58.1
11	5,215	0.6%	26	42.1	62.7
12	3,965	0.4%	26	41.2	58.3
13	3,015	0.3%	26	39.4	49.9
14	2,306	0.3%	26	38.9	55.6
15	1,787	0.2%	26	38.3	54.6
16	1,374	0.2%	26	37.8	48.5
17	1,034	0.1%	26	37.8	44.9
18	796	0.1%	25	39.2	56.5
19	614	0.1%	26	36.1	35.5
20	493	0.1%	24	34.1	30.2
21	378	0.0%	25	32.5	27.6
22	301	0.0%	27	33.2	26.2
23	226	0.0%	25	30.8	27.1
24	172	0.0%	21	30.6	31.2
25	135	0.0%	27	30.9	21.4
26	102	0.0%	25	32.1	24.0
27	77	0.0%	26	33.7	31.6
28	61	0.0%	23	33.1	32.9
29	49	0.0%	23	28.9	16.6
30	31	0.0%	26	43.2	48.9
31	24	0.0%	20	25.0	13.4
32	17	0.0%	28	33.2	23.2
33	11	0.0%	22	27.5	15.7
34	*****	*****	21	21.1	7.6
35	*****	*****	20	22.7	8.4
36	*****	*****	18	23.0	12.2
37	*****	*****	18	17.3	2.1
38	*****	*****	23	27.0	6.9
Gap from last episode until censoring	356,525	40.0%	265	480.4	560.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Sitagliptin					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	4,193,964	100%	30	177.3	375.0
Gap Number					
1	835,023	19.9%	30	93.9	206.3
2	511,030	12.2%	29	75.7	162.2
3	337,312	8.0%	29	68.3	140.7
4	232,782	5.6%	29	63.8	129.0
5	165,590	3.9%	29	60.1	117.1
6	120,279	2.9%	29	57.8	112.2
7	89,134	2.1%	29	55.0	102.6
8	66,798	1.6%	29	53.1	97.2
9	50,731	1.2%	29	52.4	97.5
10	38,932	0.9%	29	50.8	91.1
11	29,976	0.7%	29	48.6	86.0
12	23,284	0.6%	28	49.0	90.4
13	18,146	0.4%	29	47.2	79.8
14	14,345	0.3%	28	45.6	74.2
15	11,318	0.3%	28	45.4	78.0
16	8,940	0.2%	28	43.3	64.0
17	7,104	0.2%	28	43.7	68.4
18	5,692	0.1%	28	43.9	77.4
19	4,571	0.1%	27	40.2	56.1
20	3,655	0.1%	27	40.7	70.1
21	2,929	0.1%	27	39.1	59.7
22	2,401	0.1%	26	39.8	66.2
23	1,955	0.0%	27	37.9	66.8
24	1,604	0.0%	26	38.5	52.6
25	1,313	0.0%	27	36.0	38.1
26	1,063	0.0%	27	37.6	61.3
27	877	0.0%	27	38.9	62.5
28	719	0.0%	27	35.5	55.1
29	603	0.0%	27	35.5	38.8
30	505	0.0%	27	35.3	34.2
31	404	0.0%	28	38.3	44.8
32	312	0.0%	27	32.1	24.7
33	254	0.0%	28	32.9	21.3
34	208	0.0%	27	32.7	26.1
35	170	0.0%	29	38.8	48.5
36	135	0.0%	27	30.2	19.2
37	106	0.0%	27	35.9	43.2
38	82	0.0%	25	32.9	33.5
39	68	0.0%	25	30.4	16.2
40	61	0.0%	28	32.0	21.0
41	49	0.0%	30	34.0	20.1
42	40	0.0%	26	28.9	18.2
43	35	0.0%	22	27.3	13.7
44	32	0.0%	28	27.9	13.1
45	24	0.0%	24	25.5	11.7
46	18	0.0%	27	34.0	30.4
47	15	0.0%	26	26.9	12.0
48	*****	*****	28	34.1	33.5
49	*****	*****	26	40.4	33.9
50	*****	*****	21	21.2	6.9
51	*****	*****	23	23.0	10.6
52	*****	*****	16	19.5	10.9

Table 10a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018

Sitagliptin, continued					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
53	*****	*****	17	16.3	3.1
54	*****	*****	*****	*****	*****
55	*****	*****	*****	*****	*****
Gap from last episode	1,603,305	38.2%	47	344.2	529.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Glyburide

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	2,011,348	100%	40	243.6	473.1
Gap Number					
1	364,438	18.1%	35	102.0	205.2
2	233,694	11.6%	33	81.0	160.3
3	162,311	8.1%	32	71.6	139.8
4	117,542	5.8%	31	66.2	129.4
5	87,602	4.4%	30	61.6	118.9
6	66,508	3.3%	29	58.0	112.7
7	51,294	2.6%	29	54.8	104.4
8	40,184	2.0%	28	51.9	96.4
9	31,693	1.6%	28	51.3	98.0
10	25,229	1.3%	27	48.9	91.6
11	20,223	1.0%	27	48.2	93.9
12	16,260	0.8%	27	47.5	92.4
13	13,119	0.7%	26	46.4	89.1
14	10,654	0.5%	26	45.8	84.3
15	8,665	0.4%	26	44.5	84.3
16	7,051	0.4%	25	42.9	80.7
17	5,771	0.3%	26	42.8	78.8
18	4,776	0.2%	25	41.5	74.5
19	3,951	0.2%	25	41.0	75.1
20	3,259	0.2%	25	40.7	74.6
21	2,734	0.1%	24	40.9	85.2
22	2,312	0.1%	24	38.8	67.6
23	1,886	0.1%	24	38.6	73.1
24	1,562	0.1%	23	35.6	55.8
25	1,299	0.1%	23	35.6	55.1
26	1,087	0.1%	22	34.7	57.2
27	889	0.0%	23	36.8	76.8
28	738	0.0%	21	34.8	56.3
29	615	0.0%	22	39.9	100.9
30	501	0.0%	21	33.1	42.9
31	422	0.0%	23	33.4	45.9
32	352	0.0%	20	29.2	27.8
33	304	0.0%	22	31.3	32.7
34	262	0.0%	23	28.8	21.8
35	214	0.0%	21	32.9	48.7
36	174	0.0%	21	33.2	38.7
37	139	0.0%	22	36.2	49.8
38	112	0.0%	21	27.4	28.4
39	97	0.0%	19	26.3	22.5
40	85	0.0%	24	35.9	43.6
41	73	0.0%	24	38.5	68.2
42	60	0.0%	19	28.4	25.1
43	51	0.0%	16	22.9	18.0

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Glyburide, continued

Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
44	40	0.0%	18	21.7	13.6
45	34	0.0%	13	17.6	12.8
46	28	0.0%	13	17.4	11.3
47	24	0.0%	15	15.8	6.1
48	22	0.0%	15	14.9	5.5
49	20	0.0%	16	20.5	16.5
50	12	0.0%	11	14.3	7.1
51	*****	*****	18	17.3	8.6
52	*****	*****	13	15.4	8.8
53	*****	*****	16	17.4	9.8
54	*****	*****	14	27.6	34.4
55	*****	*****	14	13.8	4.4
56	*****	*****	18	18.7	4.0
57	*****	*****	15	21.3	14.6
58	*****	*****	11	12.3	3.2
59	*****	*****	22	27.0	20.0
60	*****	*****	16	16.0	5.7
61	*****	*****	20	20.0	14.1
Gap from last episode until censoring	720,925	35.8%	287	544.6	663.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Liraglutide

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,525,249	100%	26	131.6	295.9
Gap Number					
1	279,734	18.3%	27	67.1	144.4
2	189,864	12.4%	26	60.1	125.4
3	136,691	9.0%	26	56.4	114.5
4	101,413	6.6%	26	53.6	104.3
5	76,996	5.0%	25	51.1	98.3
6	59,126	3.9%	24	48.7	92.3
7	45,770	3.0%	24	47.1	83.9
8	35,842	2.3%	24	45.1	81.7
9	28,153	1.8%	24	45.3	87.3
10	22,150	1.5%	23	42.2	75.7
11	17,607	1.2%	23	41.1	70.0
12	13,996	0.9%	22	40.4	72.0
13	11,164	0.7%	22	40.6	76.9
14	8,899	0.6%	22	37.5	61.1
15	7,098	0.5%	22	36.0	50.6
16	5,623	0.4%	21	36.1	57.4
17	4,474	0.3%	21	34.0	57.6
18	3,611	0.2%	21	34.3	51.5
19	2,890	0.2%	21	34.1	54.7
20	2,314	0.2%	20	34.0	62.3
21	1,867	0.1%	21	31.2	39.8
22	1,516	0.1%	21	33.5	55.2
23	1,207	0.1%	20	30.1	34.9
24	1,003	0.1%	20	31.9	46.3
25	805	0.1%	20	28.5	33.0
26	638	0.0%	19	31.4	44.0
27	497	0.0%	19	31.1	63.2
28	389	0.0%	19	25.1	21.9
29	307	0.0%	18	28.7	42.8
30	233	0.0%	19	28.4	31.0
31	175	0.0%	19	25.2	19.9
32	128	0.0%	19	25.0	18.4
33	107	0.0%	20	22.7	12.3
34	79	0.0%	21	24.6	15.5
35	63	0.0%	18	24.4	18.1
36	52	0.0%	18	23.9	18.9
37	41	0.0%	18	22.2	13.1
38	33	0.0%	17	20.8	13.1
39	25	0.0%	21	28.2	27.6
40	19	0.0%	21	20.7	9.1
41	17	0.0%	20	23.1	11.5
42	13	0.0%	20	25.8	19.8
43	*****	*****	22	22.2	12.1
44	*****	*****	17	23.2	16.1
45	*****	*****	19	13.4	9.6
46	*****	*****	11	14.2	11.2
47	*****	*****	19	19.0	1.4
48	*****	*****	*****	*****	*****
Gap from last episode until censoring	462,593	30.3%	57	305.5	463.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Metformin

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	22,089,634	100%	30	127.9	300.0
Gap Number					
1	3,926,226	17.8%	37	126.2	264.9
2	2,695,280	12.2%	35	98.1	207.5
3	1,951,005	8.8%	33	86.2	181.0
4	1,459,916	6.6%	33	78.3	162.3
5	1,116,680	5.1%	32	72.5	148.8
6	866,505	3.9%	31	68.5	139.9
7	680,721	3.1%	31	64.5	129.5
8	539,379	2.4%	30	61.7	123.3
9	431,186	2.0%	30	58.8	115.2
10	346,702	1.6%	29	56.8	111.8
11	280,416	1.3%	29	54.7	105.9
12	227,884	1.0%	28	52.7	100.8
13	186,190	0.8%	28	51.6	100.7
14	152,051	0.7%	27	50.1	95.4
15	124,863	0.6%	27	48.8	93.0
16	102,766	0.5%	27	47.5	89.6
17	84,901	0.4%	26	45.9	85.3
18	70,206	0.3%	26	45.1	82.4
19	57,966	0.3%	26	44.2	79.7
20	48,086	0.2%	26	43.8	79.5
21	39,926	0.2%	26	42.8	74.8
22	33,226	0.2%	26	42.1	72.9
23	27,682	0.1%	25	40.6	65.0
24	23,036	0.1%	25	40.0	66.9
25	19,237	0.1%	25	39.4	62.4
26	16,107	0.1%	24	37.6	56.2
27	13,455	0.1%	24	39.0	65.8
28	11,219	0.1%	24	37.7	61.6
29	9,337	0.0%	24	37.9	60.3
30	7,801	0.0%	24	36.2	51.7
31	6,529	0.0%	23	34.7	45.2
32	5,391	0.0%	23	35.1	49.8
33	4,508	0.0%	23	34.4	47.6
34	3,709	0.0%	23	35.2	56.2
35	3,099	0.0%	23	33.3	50.7
36	2,575	0.0%	22	32.0	41.6
37	2,087	0.0%	22	31.5	39.4
38	1,701	0.0%	22	31.8	49.3
39	1,370	0.0%	23	33.2	41.7
40	1,118	0.0%	23	33.9	42.3
41	904	0.0%	23	34.6	48.7
42	724	0.0%	21	29.1	29.7
43	593	0.0%	21	28.3	26.1
44	472	0.0%	22	27.8	27.5
45	391	0.0%	19	27.0	26.8
46	322	0.0%	21	27.4	25.7
47	247	0.0%	19	25.2	23.1
48	198	0.0%	19	25.5	19.9
49	176	0.0%	18	23.3	19.8
50	137	0.0%	19	23.1	17.0

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Metformin, continued

Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
51	110	0.0%	17	21.3	16.8
52	86	0.0%	18	23.4	19.5
53	67	0.0%	19	22.7	17.0
54	52	0.0%	16	23.5	21.0
55	45	0.0%	15	16.4	9.1
56	38	0.0%	15	17.6	12.7
57	31	0.0%	14	16.1	10.0
58	26	0.0%	14	16.0	11.0
59	21	0.0%	14	16.7	11.8
60	17	0.0%	15	16.8	9.1
61	17	0.0%	14	16.7	13.1
62	12	0.0%	16	16.3	9.7
63	*****	*****	18	14.4	9.0
64	*****	*****	10	11.0	9.4
65	*****	*****	9	12.0	11.0
66	*****	*****	12	12.8	11.0
67	*****	*****	9	9.6	6.2
68	*****	*****	13	15.5	9.7
69	*****	*****	9	14.3	13.8
70	*****	*****	*****	*****	*****
71	*****	*****	*****	*****	*****
72	*****	*****	*****	*****	*****
73	*****	*****	*****	*****	*****
Gap from last episode until censoring	6,502,864	29.4%	0	222.1	450.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Sitagliptin

	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	4,463,878	100%	27	166.8	365.8
Gap Number					
1	854,345	19.1%	29	89.4	202.0
2	535,956	12.0%	27	70.8	157.9
3	362,911	8.1%	27	63.3	139.2
4	257,244	5.8%	26	58.5	127.4
5	188,038	4.2%	26	53.9	112.6
6	140,728	3.2%	25	51.6	109.0
7	107,339	2.4%	25	49.0	101.4
8	83,016	1.9%	24	47.2	96.1
9	64,829	1.5%	24	45.2	89.8
10	51,121	1.1%	24	44.8	93.9
11	40,622	0.9%	24	43.1	88.6
12	32,467	0.7%	24	41.8	80.9
13	26,130	0.6%	24	40.9	78.7
14	21,022	0.5%	23	40.4	79.7
15	16,995	0.4%	23	39.3	77.5
16	13,833	0.3%	23	37.5	67.7
17	11,295	0.3%	23	38.1	68.5
18	9,163	0.2%	23	37.2	66.4
19	7,476	0.2%	22	35.7	64.6
20	6,132	0.1%	22	35.3	61.7
21	5,046	0.1%	21	33.8	56.2
22	4,145	0.1%	22	34.1	54.5
23	3,446	0.1%	22	33.1	51.2
24	2,861	0.1%	21	36.7	93.6
25	2,381	0.1%	21	32.2	45.1
26	1,974	0.0%	21	33.3	63.5
27	1,634	0.0%	21	30.8	45.4
28	1,393	0.0%	20	30.9	45.9
29	1,151	0.0%	21	30.2	40.8
30	981	0.0%	21	32.8	65.8
31	826	0.0%	21	30.4	36.3
32	681	0.0%	21	28.5	31.0
33	571	0.0%	21	28.1	29.6
34	485	0.0%	20	26.2	21.8
35	404	0.0%	19	26.8	30.3
36	337	0.0%	20	26.8	35.9
37	283	0.0%	20	26.2	20.7
38	238	0.0%	19	26.7	26.9
39	197	0.0%	20	24.9	22.8
40	159	0.0%	21	26.1	34.9
41	136	0.0%	19	24.6	23.6
42	104	0.0%	20	26.2	23.6
43	88	0.0%	21	23.7	15.1
44	73	0.0%	22	25.7	18.6
45	58	0.0%	15	19.8	12.9
46	48	0.0%	16	21.2	18.4
47	46	0.0%	16	20.6	21.6
48	34	0.0%	20	23.9	14.4
49	27	0.0%	21	21.2	11.1
50	21	0.0%	25	30.0	27.2

Table 10b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis

Sitagliptin, continued

Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
51	14	0.0%	21	28.3	28.4
52	12	0.0%	17	17.3	9.3
53	*****	*****	21	22.2	12.8
54	*****	*****	15	14.4	9.1
55	*****	*****	18	16.8	8.3
56	*****	*****	12	12.4	3.8
57	*****	*****	13	14.0	10.3
58	*****	*****	19	17.0	4.4
59	*****	*****	14	13.3	1.2
60	*****	*****	15	13.7	4.2
61	*****	*****	15	14.0	2.6
62	*****	*****	20	19.5	9.2
63	*****	*****	11	11.0	5.7
64	*****	*****	9	9.0	1.4
65	*****	*****	14	14.0	1.4
66	*****	*****	*****	*****	*****
67	*****	*****	*****	*****	*****
68	*****	*****	*****	*****	*****
69	*****	*****	*****	*****	*****
70	*****	*****	*****	*****	*****
71	*****	*****	*****	*****	*****
72	*****	*****	*****	*****	*****
Gap from last episode until censoring	1,603,305	35.9%	47	344.2	529.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Albiglutide</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	23,904	100%	26	111.3	184.6	23,016	100%	23	100.1	173.8
Gap Number										
1	5,216	21.8%	23	43.0	61.5	5,085	22.1%	23	43.7	62.8
2	2,442	10.2%	24	39.5	48.5	2,491	10.8%	24	41.5	57.2
3	1,243	5.2%	25	38.6	42.6	1,327	5.8%	24	38.9	46.7
4	675	2.8%	25	38.0	40.7	741	3.2%	24	39.7	43.3
5	377	1.6%	24	37.2	38.6	410	1.8%	26	39.2	38.1
6	221	0.9%	24	36.0	35.6	233	1.0%	26	35.6	31.7
7	122	0.5%	27	34.7	26.7	140	0.6%	25	38.3	33.0
8	71	0.3%	26	42.1	53.0	72	0.3%	26	29.8	19.2
9	38	0.2%	22	36.0	41.9	33	0.1%	31	44.8	36.5
10	21	0.1%	22	30.2	33.7	17	0.1%	23	32.2	19.8
11	*****	*****	27	40.7	33.8	*****	*****	45	60.8	61.4
12	*****	*****	23	30.5	20.2	*****	*****	24	27.0	14.5
13	*****	*****	24	24.0	17.0	*****	*****	22	21.5	5.0
14	*****	*****	54	53.5	48.8	*****	*****	22	22.0	0.0
15	*****	*****	17	16.5	0.7	*****	*****	*****	*****	*****
16	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	13,447	56.3%	47	166.1	226.9	12,447	54.1%	22	149.6	218.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Alogliptin</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	21,369	100%	29	140.4	246.6	28,435	100%	26	125.7	237.3
Gap Number										
1	4,609	21.6%	26	49.8	74.4	6,275	22.1%	25	48.9	75.8
2	2,408	11.3%	26	46.9	66.7	3,337	11.7%	25	46.7	68.8
3	1,357	6.4%	25	42.2	49.8	1,953	6.9%	26	44.6	60.8
4	805	3.8%	26	44.7	54.3	1,232	4.3%	26	40.4	48.2
5	511	2.4%	26	41.8	47.7	811	2.9%	25	40.1	56.6
6	345	1.6%	27	42.9	52.6	554	1.9%	24	37.5	41.0
7	228	1.1%	24	38.9	53.5	365	1.3%	26	38.2	39.3
8	162	0.8%	26	39.6	46.5	254	0.9%	24	36.8	35.7
9	107	0.5%	23	35.7	34.7	180	0.6%	26	34.9	28.5
10	75	0.4%	23	30.2	19.3	127	0.4%	24	35.7	41.5
11	56	0.3%	27	34.9	33.9	95	0.3%	26	33.0	22.5
12	37	0.2%	25	37.9	37.4	65	0.2%	24	31.5	37.4
13	24	0.1%	22	24.3	13.3	50	0.2%	24	34.7	37.5
14	20	0.1%	23	27.3	18.4	28	0.1%	21	22.1	10.0
15	11	0.1%	26	26.2	9.6	17	0.1%	22	26.5	14.4
16	*****	*****	25	24.7	8.8	*****	*****	28	31.8	16.9
17	*****	*****	27	24.7	11.7	*****	*****	40	37.8	15.2
18	*****	*****	30	29.5	7.8	*****	*****	19	19.8	5.9
19	*****	*****	*****	*****	*****	*****	*****	17	19.0	8.2
20	0	0.0%				*****	*****	41	40.5	38.9
21	0	0.0%				*****	*****	*****	*****	*****
22	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	10,602	49.6%	72	236.1	316.4	13,060	45.9%	40	220.4	317.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Canagliflozin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	311,931	100%	26	121.2	220.2	357,491	100%	22	101.3	199.2
Gap Number										
1	67,280	21.6%	25	54.1	88.8	77,864	21.8%	25	54.7	93.3
2	33,207	10.6%	26	47.2	69.5	39,247	11.0%	25	48.3	74.6
3	18,109	5.8%	26	45.6	64.0	22,139	6.2%	25	44.3	63.0
4	10,648	3.4%	26	43.3	55.9	13,079	3.7%	25	43.4	57.2
5	6,470	2.1%	26	41.8	56.7	8,228	2.3%	26	41.3	53.1
6	4,123	1.3%	26	41.9	52.7	5,330	1.5%	25	39.5	49.3
7	2,625	0.8%	26	40.2	46.3	3,547	1.0%	25	38.8	46.6
8	1,704	0.5%	25	39.7	44.7	2,396	0.7%	25	36.8	40.7
9	1,107	0.4%	25	38.1	39.6	1,626	0.5%	25	35.3	36.1
10	716	0.2%	26	37.5	35.4	1,101	0.3%	25	34.4	36.1
11	485	0.2%	25	36.4	34.7	728	0.2%	23	35.1	34.4
12	314	0.1%	27	39.1	40.8	482	0.1%	25	34.2	34.0
13	212	0.1%	24	33.3	28.1	305	0.1%	24	35.5	37.6
14	136	0.0%	25	33.0	32.5	195	0.1%	21	31.3	33.5
15	82	0.0%	23	30.4	22.9	121	0.0%	22	32.6	37.4
16	48	0.0%	26	34.6	35.1	70	0.0%	24	31.6	27.4
17	23	0.0%	19	35.1	35.6	40	0.0%	25	40.6	64.1
18	13	0.0%	32	33.8	20.4	26	0.0%	19	22.2	11.1
19	*****	*****	16	20.8	11.7	*****	*****	20	21.4	9.4
20	*****	*****	16	15.5	4.9	*****	*****	17	23.2	18.4
21	*****	*****	23	22.5	4.9	*****	*****	22	24.3	9.8
22	*****	*****	21	21.0	4.2	*****	*****	22	31.7	26.9
23	0	0.0%				*****	*****	26	31.0	21.0
24	0	0.0%				*****	*****	43	42.5	26.2
25	0	0.0%				*****	*****	15	14.5	0.7
26	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	164,617	52.8%	29	185.8	279.1	180,911	50.6%	0	152.4	259.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Dapagliflozin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	83,270	100%	25	124.4	221.5	98,872	100%	23	108.5	202.2
Gap Number										
1	18,045	21.7%	26	52.7	84.5	21,849	22.1%	25	54.2	89.5
2	8,703	10.5%	25	49.0	79.8	10,881	11.0%	25	48.8	75.3
3	4,764	5.7%	25	44.9	66.1	5,956	6.0%	25	45.9	67.2
4	2,716	3.3%	25	43.1	59.6	3,464	3.5%	25	42.2	53.9
5	1,690	2.0%	25	41.2	55.8	2,068	2.1%	25	43.4	59.8
6	1,061	1.3%	26	41.4	48.5	1,289	1.3%	24	38.7	48.4
7	691	0.8%	24	39.8	47.9	819	0.8%	24	36.1	39.7
8	432	0.5%	26	41.4	46.0	548	0.6%	24	37.4	44.8
9	275	0.3%	25	39.2	48.9	348	0.4%	23	31.5	25.1
10	181	0.2%	23	34.7	33.5	211	0.2%	23	31.8	27.1
11	119	0.1%	22	37.2	41.6	137	0.1%	24	37.4	36.2
12	69	0.1%	24	27.2	21.8	91	0.1%	22	27.6	16.3
13	44	0.1%	23	27.1	12.9	53	0.1%	24	32.5	29.7
14	33	0.0%	18	25.9	15.2	33	0.0%	19	25.3	15.1
15	23	0.0%	27	32.4	28.5	23	0.0%	24	31.1	21.9
16	11	0.0%	29	34.5	17.5	14	0.0%	23	25.9	11.3
17	*****	*****	20	30.7	18.8	*****	*****	22	31.1	26.9
18	*****	*****	58	57.5	24.7	*****	*****	20	34.6	35.5
19	*****	*****	*****	*****	*****	*****	*****	29	26.0	11.8
20	*****	*****	*****	*****	*****	*****	*****	19	28.3	16.2
21	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	44,402	53.3%	27	190.5	278.4	51,068	51.7%	3	163.9	259.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Dulaglutide</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	93,253	100%	16	64.3	129.7	83,718	100%	15	60.8	125.7
Gap Number										
1	20,390	21.9%	22	43.8	66.0	18,243	21.8%	23	44.4	67.2
2	8,965	9.6%	24	44.1	60.5	7,973	9.5%	23	41.9	56.6
3	4,540	4.9%	25	41.1	50.0	3,841	4.6%	24	38.8	45.6
4	2,436	2.6%	25	38.6	43.6	2,030	2.4%	25	38.0	42.0
5	1,328	1.4%	25	36.6	36.2	1,141	1.4%	23	35.9	38.0
6	728	0.8%	24	35.4	33.8	622	0.7%	23	35.7	37.5
7	390	0.4%	25	38.8	47.6	327	0.4%	23	32.6	27.7
8	203	0.2%	24	32.0	23.6	180	0.2%	22	32.2	26.7
9	97	0.1%	23	32.2	29.8	91	0.1%	24	32.6	27.6
10	48	0.1%	23	30.3	18.6	42	0.1%	28	34.0	33.4
11	21	0.0%	27	37.5	38.1	20	0.0%	25	30.6	21.2
12	*****	*****	19	30.0	30.2	*****	*****	25	26.0	12.5
13	*****	*****	23	29.2	19.4	*****	*****	20	21.8	7.6
14	*****	*****	45	45.0	46.7	*****	*****	25	24.8	9.0
15	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	54,087	58.0%	0	80.0	160.7	49,192	58.8%	0	73.8	154.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Empagliflozin</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	93,266	100%	16	69.3	141.9	120,642	100%	14	55.6	122.5
Gap Number										
1	19,914	21.4%	23	45.5	71.7	25,937	21.5%	23	44.9	68.9
2	8,543	9.2%	24	41.1	55.9	11,040	9.2%	23	41.4	58.2
3	4,204	4.5%	24	39.9	52.0	5,394	4.5%	24	39.0	49.6
4	2,232	2.4%	24	38.3	48.1	2,898	2.4%	24	37.6	45.0
5	1,236	1.3%	25	39.1	46.1	1,633	1.4%	25	36.9	41.9
6	695	0.7%	26	40.0	43.6	952	0.8%	23	35.7	39.0
7	398	0.4%	23	34.1	33.9	581	0.5%	24	37.0	40.3
8	243	0.3%	23	32.5	26.8	324	0.3%	25	34.4	31.3
9	133	0.1%	23	30.4	26.2	198	0.2%	23	31.8	26.2
10	86	0.1%	26	32.7	21.9	115	0.1%	23	31.3	29.4
11	47	0.1%	24	32.4	35.9	70	0.1%	27	34.4	25.1
12	24	0.0%	21	25.9	19.5	37	0.0%	20	26.2	27.3
13	11	0.0%	22	25.2	12.8	19	0.0%	20	26.8	19.0
14	*****	*****	18	23.0	16.6	*****	*****	22	26.3	20.3
15	*****	*****	19	17.0	3.5	*****	*****	21	26.3	19.8
16	*****	*****	*****	*****	*****	*****	*****	21	19.8	7.5
17	*****	*****	*****	*****	*****	*****	*****	16	16.0	7.1
18	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
19	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	55,488	59.5%	0	87.3	174.2	71,425	59.2%	0	64.8	150.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Exenatide	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	389,248	100%	41	276.0	518.0	299,790	100%	37	252.2	491.9
Gap Number										
1	76,056	19.5%	29	87.2	206.3	58,134	19.4%	28	80.5	188.1
2	45,865	11.8%	29	77.7	179.4	35,256	11.8%	29	73.9	165.1
3	30,479	7.8%	30	72.5	156.6	23,382	7.8%	29	68.3	150.2
4	21,136	5.4%	30	67.9	140.3	16,285	5.4%	29	66.8	144.6
5	15,110	3.9%	31	67.0	139.7	11,698	3.9%	29	62.3	126.6
6	11,009	2.8%	30	64.5	129.8	8,637	2.9%	29	57.5	113.7
7	8,105	2.1%	30	62.9	133.1	6,461	2.2%	29	57.5	112.7
8	6,080	1.6%	30	59.7	127.4	4,874	1.6%	29	56.5	112.5
9	4,561	1.2%	30	58.5	113.4	3,646	1.2%	30	54.4	96.9
10	3,425	0.9%	31	57.0	102.7	2,761	0.9%	29	51.6	100.7
11	2,597	0.7%	30	54.1	103.5	2,136	0.7%	30	52.2	103.8
12	1,983	0.5%	30	49.7	76.2	1,627	0.5%	28	48.3	87.4
13	1,586	0.4%	30	52.2	87.9	1,271	0.4%	29	52.9	99.8
14	1,246	0.3%	30	53.2	99.2	1,012	0.3%	31	48.6	64.5
15	964	0.2%	28	55.6	127.9	789	0.3%	29	49.9	86.1
16	739	0.2%	31	52.7	95.0	607	0.2%	29	40.5	44.5
17	574	0.1%	29	48.6	84.0	485	0.2%	30	47.5	80.9
18	445	0.1%	30	49.6	98.2	388	0.1%	29	48.9	81.9
19	357	0.1%	30	44.8	53.1	308	0.1%	30	49.0	76.1
20	284	0.1%	29	41.1	43.4	249	0.1%	29	42.4	50.6
21	220	0.1%	27	38.1	42.3	187	0.1%	27	38.2	34.7
22	182	0.0%	30	36.1	28.1	142	0.0%	28	40.0	44.5
23	154	0.0%	29	51.7	128.8	118	0.0%	30	43.0	49.4
24	132	0.0%	31	49.5	103.1	84	0.0%	28	43.0	44.6
25	112	0.0%	29	43.5	50.5	67	0.0%	30	52.0	91.4
26	94	0.0%	30	39.2	31.0	53	0.0%	30	46.1	65.5
27	72	0.0%	33	38.9	27.4	41	0.0%	26	49.9	74.3
28	53	0.0%	34	48.9	58.4	32	0.0%	30	37.0	24.3
29	36	0.0%	28	40.1	38.9	29	0.0%	35	34.8	20.9
30	31	0.0%	30	36.0	23.4	24	0.0%	27	34.5	23.9
31	24	0.0%	22	26.6	14.5	21	0.0%	30	41.8	37.1
32	19	0.0%	27	39.4	46.8	20	0.0%	35	50.6	44.4
33	17	0.0%	31	30.9	12.6	15	0.0%	26	39.6	35.5
34	15	0.0%	24	42.5	56.5	13	0.0%	43	37.1	22.8
35	*****	*****	34	34.4	18.5	*****	*****	30	35.6	24.4
36	*****	*****	33	41.1	30.0	*****	*****	17	22.6	12.6
37	*****	*****	29	30.4	10.2	*****	*****	46	86.7	116.9
38	*****	*****	25	52.4	60.8	*****	*****	*****	*****	*****
39	*****	*****	33	32.3	2.5	0	0.0%			
40	*****	*****	33	50.0	50.0	0	0.0%			
41	*****	*****	33	31.7	16.0	0	0.0%			
42	*****	*****	32	34.7	7.4	0	0.0%			
43	*****	*****	25	24.5	17.7	0	0.0%			
44	*****	*****	24	24.0	12.7	0	0.0%			
Gap from last episode until censoring	155,430	39.9%	313	578.6	689.7	118,914	39.7%	260	529.5	667.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,929,087	100%	30	155.8	350.2	1,880,300	100%	28	138.7	324.6
Gap Number										
1	379,958	19.7%	33	103.8	217.9	371,215	19.7%	33	103.8	221.1
2	238,546	12.4%	32	81.0	165.3	231,911	12.3%	32	82.4	171.9
3	160,039	8.3%	32	73.1	145.3	154,938	8.2%	31	73.1	147.7
4	111,436	5.8%	31	67.5	132.4	107,553	5.7%	31	67.6	133.4
5	79,391	4.1%	31	63.6	122.2	76,842	4.1%	31	64.3	125.7
6	57,957	3.0%	31	60.9	111.9	55,777	3.0%	30	60.9	116.3
7	42,776	2.2%	30	58.8	107.1	41,206	2.2%	30	58.9	109.6
8	31,785	1.6%	30	56.2	98.1	30,929	1.6%	30	57.0	109.9
9	24,079	1.2%	30	55.5	98.9	23,518	1.3%	30	54.6	100.6
10	18,122	0.9%	30	54.1	96.2	17,928	1.0%	29	53.1	97.3
11	13,931	0.7%	29	51.8	88.8	13,900	0.7%	29	51.5	92.3
12	10,781	0.6%	29	49.9	83.7	10,808	0.6%	29	49.3	82.1
13	8,345	0.4%	30	50.4	84.4	8,493	0.5%	29	50.0	88.7
14	6,522	0.3%	29	47.1	72.5	6,685	0.4%	29	48.8	81.9
15	5,065	0.3%	29	50.1	83.7	5,306	0.3%	28	47.6	79.8
16	3,978	0.2%	29	49.5	91.0	4,235	0.2%	29	47.2	80.3
17	3,089	0.2%	29	48.9	84.5	3,370	0.2%	28	46.6	68.0
18	2,398	0.1%	29	46.6	84.7	2,695	0.1%	28	46.3	80.6
19	1,911	0.1%	28	45.1	74.8	2,153	0.1%	28	44.9	75.1
20	1,524	0.1%	27	42.3	67.6	1,723	0.1%	28	43.0	57.9
21	1,198	0.1%	28	42.2	54.7	1,353	0.1%	28	45.6	84.3
22	957	0.0%	29	42.6	69.9	1,075	0.1%	28	41.0	46.5
23	760	0.0%	28	43.0	52.7	867	0.0%	27	39.9	54.3
24	600	0.0%	30	40.6	45.4	717	0.0%	28	42.3	64.5
25	463	0.0%	27	41.4	45.9	589	0.0%	26	37.3	40.8
26	366	0.0%	29	40.5	45.9	460	0.0%	28	38.3	48.6
27	294	0.0%	29	42.4	49.2	366	0.0%	28	36.0	29.3
28	240	0.0%	29	43.8	82.0	288	0.0%	27	36.2	36.8
29	202	0.0%	27	41.8	50.1	222	0.0%	27	35.5	53.0
30	153	0.0%	26	30.7	17.9	187	0.0%	27	39.9	50.1
31	121	0.0%	29	43.2	67.1	155	0.0%	27	37.7	37.5
32	99	0.0%	30	49.4	110.7	118	0.0%	29	35.9	27.7
33	83	0.0%	28	34.6	29.6	98	0.0%	25	31.5	28.5
34	67	0.0%	28	38.9	30.4	82	0.0%	24	37.0	38.3
35	49	0.0%	31	39.9	29.4	54	0.0%	25	35.2	33.6
36	34	0.0%	26	35.3	27.1	39	0.0%	23	32.4	25.5
37	28	0.0%	30	36.1	24.9	30	0.0%	26	40.2	41.7
38	28	0.0%	25	33.2	32.1	21	0.0%	19	25.1	18.7
39	17	0.0%	22	38.9	33.5	13	0.0%	13	21.6	14.2
40	*****	*****	32	33.3	18.0	*****	*****	19	39.6	63.8
41	*****	*****	28	25.6	6.4	*****	*****	15	19.6	10.1
42	*****	*****	28	33.3	16.4	*****	*****	20	25.1	18.5
43	*****	*****	19	21.8	11.1	*****	*****	20	21.8	9.1
44	*****	*****	25	24.8	4.9	*****	*****	14	17.0	8.3
45	*****	*****	26	22.7	5.8	*****	*****	12	12.0	1.0
46	*****	*****	20	24.3	15.0	*****	*****	15	21.0	14.0
47	*****	*****	108	107.5	91.2	*****	*****	25	25.0	19.8
48	*****	*****	*****	*****	*****	*****	*****	22	22.0	15.6

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Glimepiride, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
49	*****	*****	*****	*****	*****	*****	*****	20	20.0	9.9
50	*****	*****	*****	*****	*****	*****	*****	12	11.5	0.7
51	*****	*****	*****	*****	*****	*****	*****	19	19.0	8.5
52	0	0.0%				*****	*****	44	43.5	19.1
Gap from last episode until censoring	721,649	37.4%	5	283.0	505.0	702,327	37.4%	0	237.3	466.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Glipizide	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	2,696,187	100%	31	157.7	357.0	2,766,356	100%	30	143.9	334.8
Gap Number										
1	519,735	19.3%	34	110.4	234.9	530,943	19.2%	35	113.4	242.6
2	331,330	12.3%	33	84.6	172.4	338,964	12.3%	33	87.4	181.4
3	226,416	8.4%	33	76.6	151.7	231,972	8.4%	33	78.6	156.8
4	160,795	6.0%	33	71.1	135.3	165,389	6.0%	33	73.2	142.0
5	117,073	4.3%	32	67.6	125.0	120,873	4.4%	32	68.4	126.2
6	86,756	3.2%	32	65.3	120.0	90,063	3.3%	32	65.9	123.1
7	65,148	2.4%	32	63.1	111.6	68,210	2.5%	32	62.0	110.0
8	49,591	1.8%	32	60.1	100.1	51,919	1.9%	32	60.8	107.8
9	37,662	1.4%	32	58.6	99.9	39,853	1.4%	31	58.5	97.3
10	28,809	1.1%	31	56.5	92.7	30,850	1.1%	31	56.0	92.3
11	22,138	0.8%	31	54.4	81.7	23,986	0.9%	31	54.3	85.6
12	17,035	0.6%	31	53.2	81.4	18,669	0.7%	31	54.6	88.8
13	13,153	0.5%	30	53.3	84.6	14,563	0.5%	30	52.6	84.4
14	10,150	0.4%	31	50.8	78.8	11,383	0.4%	30	50.7	81.1
15	7,833	0.3%	30	48.7	69.9	8,973	0.3%	29	50.4	82.9
16	6,063	0.2%	29	47.4	61.5	7,005	0.3%	30	48.2	74.6
17	4,721	0.2%	29	47.2	69.9	5,472	0.2%	30	46.6	67.8
18	3,686	0.1%	29	47.2	62.3	4,296	0.2%	29	46.4	64.9
19	2,841	0.1%	30	46.3	60.5	3,383	0.1%	29	43.6	58.6
20	2,233	0.1%	29	45.7	59.6	2,645	0.1%	29	47.2	72.7
21	1,750	0.1%	29	44.4	59.7	2,065	0.1%	28	41.5	60.1
22	1,376	0.1%	29	46.2	79.7	1,657	0.1%	28	42.4	54.7
23	1,051	0.0%	29	46.0	67.6	1,308	0.0%	27	43.5	70.7
24	820	0.0%	29	43.5	50.7	1,055	0.0%	28	43.1	54.9
25	657	0.0%	28	39.8	41.7	841	0.0%	28	42.4	61.1
26	523	0.0%	27	40.4	52.4	685	0.0%	27	38.5	47.1
27	426	0.0%	29	44.6	54.2	543	0.0%	27	40.9	59.4
28	336	0.0%	29	42.5	48.1	442	0.0%	27	42.0	53.5
29	257	0.0%	28	40.9	58.1	358	0.0%	28	37.4	33.6
30	204	0.0%	28	38.1	33.3	284	0.0%	25	36.9	42.2
31	170	0.0%	29	36.7	30.2	225	0.0%	27	35.5	34.4
32	135	0.0%	28	39.1	34.2	188	0.0%	27	40.0	42.7
33	115	0.0%	27	39.7	33.7	150	0.0%	27	35.0	31.0
34	93	0.0%	31	38.3	29.7	109	0.0%	25	33.9	31.8
35	74	0.0%	27	35.1	29.1	90	0.0%	27	34.6	27.5
36	62	0.0%	30	38.2	28.2	71	0.0%	29	36.6	25.2
37	50	0.0%	27	35.0	21.7	58	0.0%	28	34.3	20.3
38	38	0.0%	34	40.4	33.0	48	0.0%	26	29.4	15.2
39	26	0.0%	31	37.3	24.6	39	0.0%	29	35.2	26.2
40	22	0.0%	28	30.6	16.2	29	0.0%	39	43.2	28.8
41	15	0.0%	28	33.3	16.2	26	0.0%	25	32.9	21.3
42	13	0.0%	31	42.5	37.5	17	0.0%	19	22.0	12.7
43	*****	*****	19	32.7	23.2	*****	*****	23	31.5	25.6
44	*****	*****	18	29.7	21.6	*****	*****	27	31.8	20.0
45	*****	*****	26	27.8	10.8	*****	*****	26	44.8	50.6
46	*****	*****	26	26.7	14.0	*****	*****	26	35.3	31.6
47	*****	*****	*****	*****	*****	*****	*****	30	29.3	11.9
48	*****	*****	*****	*****	*****	*****	*****	23	22.6	7.2

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Glipizide, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
49	0	0.0%				*****	*****	18	18.0	7.0
50	0	0.0%				*****	*****	*****	*****	*****
51	0	0.0%				*****	*****	*****	*****	*****
52	0	0.0%				*****	*****	*****	*****	*****
53	0	0.0%				*****	*****	*****	*****	*****
54	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	974,781	36.2%	7	288.7	520.9	986,583	35.7%	0	249.9	487.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Glyburide	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	974,136	100%	49	281.8	510.5	965,995	100%	39	222.9	443.9
Gap Number										
1	179,109	18.4%	36	107.5	216.7	183,082	19.0%	36	101.0	196.8
2	112,017	11.5%	34	82.7	160.1	119,038	12.3%	34	83.6	161.3
3	76,546	7.9%	33	74.7	140.3	81,875	8.5%	33	75.3	145.4
4	54,395	5.6%	33	68.6	124.4	58,511	6.1%	33	69.7	129.5
5	39,400	4.0%	32	65.7	120.0	43,008	4.5%	32	65.8	123.1
6	29,007	3.0%	32	62.0	114.2	32,150	3.3%	32	62.1	112.8
7	21,735	2.2%	31	58.3	101.0	24,385	2.5%	31	60.2	114.9
8	16,457	1.7%	32	57.2	95.1	18,667	1.9%	31	56.0	99.6
9	12,570	1.3%	31	56.0	97.4	14,476	1.5%	30	55.9	102.0
10	9,688	1.0%	31	55.7	97.0	11,298	1.2%	31	54.4	96.1
11	7,536	0.8%	31	53.4	95.6	8,895	0.9%	30	52.2	91.7
12	5,926	0.6%	30	53.2	101.2	7,076	0.7%	30	51.1	93.5
13	4,691	0.5%	30	51.9	89.4	5,629	0.6%	30	52.3	88.2
14	3,709	0.4%	30	49.4	78.1	4,506	0.5%	29	50.0	88.5
15	2,900	0.3%	30	50.0	79.2	3,616	0.4%	29	48.6	85.6
16	2,305	0.2%	30	48.8	88.6	2,884	0.3%	29	44.8	61.7
17	1,817	0.2%	29	47.7	84.2	2,363	0.2%	29	46.0	73.4
18	1,456	0.1%	28	45.4	77.6	1,938	0.2%	29	46.7	79.3
19	1,172	0.1%	29	48.9	87.5	1,586	0.2%	28	46.7	85.1
20	950	0.1%	28	43.8	64.0	1,278	0.1%	28	44.9	84.3
21	763	0.1%	28	41.3	48.1	1,035	0.1%	28	47.1	97.5
22	626	0.1%	27	41.5	54.4	837	0.1%	28	39.5	55.2
23	499	0.1%	29	43.6	54.4	696	0.1%	26	45.0	92.4
24	401	0.0%	30	50.3	89.7	554	0.1%	26	35.0	42.5
25	319	0.0%	28	44.7	87.0	440	0.0%	26	37.2	40.4
26	270	0.0%	28	43.8	70.8	360	0.0%	27	37.8	67.3
27	210	0.0%	27	42.3	66.7	294	0.0%	27	51.5	108.7
28	180	0.0%	26	33.5	30.1	229	0.0%	25	31.7	26.6
29	143	0.0%	28	40.4	50.2	190	0.0%	27	36.0	37.5
30	116	0.0%	28	42.0	56.6	159	0.0%	26	33.8	28.3
31	95	0.0%	30	43.8	60.1	133	0.0%	28	34.3	27.1
32	74	0.0%	26	37.2	33.6	120	0.0%	25	29.8	23.1
33	56	0.0%	25	35.4	31.3	103	0.0%	25	29.6	17.8
34	45	0.0%	24	38.8	46.9	82	0.0%	28	38.9	40.0
35	40	0.0%	32	55.2	61.1	71	0.0%	27	37.8	39.8
36	32	0.0%	24	35.1	34.0	56	0.0%	28	35.2	25.4
37	25	0.0%	25	30.4	21.4	43	0.0%	29	33.5	22.5
38	22	0.0%	25	31.0	24.7	34	0.0%	18	28.9	28.2
39	18	0.0%	29	35.1	28.9	27	0.0%	25	33.1	22.9
40	15	0.0%	33	37.8	28.0	22	0.0%	21	30.1	24.4
41	*****	*****	27	35.0	26.6	*****	*****	19	22.2	11.8
42	*****	*****	22	26.0	12.2	*****	*****	21	24.5	13.6
43	*****	*****	20	21.2	9.4	*****	*****	19	21.6	9.7
44	*****	*****	23	26.0	13.3	*****	*****	18	21.3	10.8
45	*****	*****	24	26.8	15.0	*****	*****	20	20.7	6.1
46	*****	*****	15	15.0	0.0	*****	*****	14	15.3	4.3
47	*****	*****	15	14.5	0.7	*****	*****	21	21.5	6.1

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Glyburide, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	*****	*****	59	58.5	34.6	*****	*****	24	22.8	7.5
49	0	0.0%				*****	*****	21	21.3	4.0
50	0	0.0%				*****	*****	23	25.0	8.2
51	0	0.0%				*****	*****	33	28.3	12.7
52	0	0.0%				*****	*****	49	52.0	35.6
53	0	0.0%				*****	*****	19	19.0	1.4
54	0	0.0%				*****	*****	23	22.5	10.6
55	0	0.0%				*****	*****	*****	*****	*****
56	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	386,765	39.7%	328	586.7	679.5	334,160	34.6%	230	495.9	640.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Linagliptin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	396,418	100%	25	127.6	259.1	370,061	100%	24	126.1	259.7
Gap Number										
1	86,519	21.8%	27	62.8	117.7	80,483	21.7%	27	63.0	119.8
2	44,415	11.2%	26	53.9	92.7	41,399	11.2%	26	53.9	94.1
3	25,235	6.4%	26	50.2	79.4	23,230	6.3%	26	51.1	87.7
4	15,074	3.8%	26	46.6	70.7	13,961	3.8%	26	47.1	73.5
5	9,485	2.4%	27	46.1	65.8	8,847	2.4%	26	45.6	67.2
6	6,111	1.5%	27	43.2	56.0	5,781	1.6%	26	43.9	67.2
7	4,058	1.0%	27	43.2	53.9	3,901	1.1%	26	44.3	64.0
8	2,660	0.7%	26	42.3	60.2	2,675	0.7%	26	42.3	70.2
9	1,793	0.5%	27	38.5	40.4	1,847	0.5%	25	40.2	51.9
10	1,246	0.3%	26	39.8	52.1	1,303	0.4%	26	37.4	43.6
11	854	0.2%	26	38.9	50.0	956	0.3%	25	36.6	42.2
12	606	0.2%	25	37.7	39.1	676	0.2%	25	38.2	54.7
13	428	0.1%	26	38.4	39.0	492	0.1%	25	37.1	42.8
14	307	0.1%	26	37.2	36.7	357	0.1%	26	35.6	42.0
15	219	0.1%	27	39.0	51.3	266	0.1%	25	31.0	26.8
16	161	0.0%	27	37.4	32.0	189	0.1%	26	36.1	35.8
17	107	0.0%	28	39.9	50.8	142	0.0%	26	33.1	23.8
18	81	0.0%	26	33.7	23.7	108	0.0%	23	37.1	55.8
19	56	0.0%	29	36.8	27.7	80	0.0%	30	34.6	27.0
20	35	0.0%	25	33.4	25.2	64	0.0%	26	31.5	24.5
21	29	0.0%	24	38.5	36.2	37	0.0%	27	32.7	27.3
22	21	0.0%	25	34.3	31.2	25	0.0%	28	34.0	22.6
23	16	0.0%	25	34.3	28.1	22	0.0%	30	33.5	20.8
24	12	0.0%	26	28.7	20.9	16	0.0%	20	24.1	12.2
25	*****	*****	18	22.4	10.9	*****	*****	29	37.1	38.2
26	*****	*****	28	30.7	14.1	*****	*****	25	26.4	12.9
27	*****	*****	12	20.3	15.3	*****	*****	25	27.5	10.3
28	*****	*****	16	19.3	10.4	*****	*****	28	35.0	25.1
29	*****	*****	*****	*****	*****	*****	*****	38	37.5	6.4
30	*****	*****	*****	*****	*****	*****	*****	28	27.5	12.0
31	0	0.0%				*****	*****	*****	*****	*****
32	0	0.0%				*****	*****	*****	*****	*****
33	0	0.0%				*****	*****	*****	*****	*****
34	0	0.0%				*****	*****	*****	*****	*****
35	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	196,868	49.7%	6	200.9	338.8	183,166	49.5%	4	198.4	340.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Liraglutide	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	808,608	100%	30	142.5	305.1	611,420	100%	28	138.6	304.0
Gap Number										
1	154,819	19.1%	29	71.4	148.0	117,971	19.3%	28	70.3	148.3
2	103,228	12.8%	29	65.2	129.5	77,783	12.7%	28	64.0	130.5
3	72,897	9.0%	29	62.4	119.4	54,658	8.9%	28	59.9	114.0
4	52,999	6.6%	29	59.7	107.7	39,387	6.4%	28	56.3	103.9
5	39,211	4.8%	29	58.0	103.4	28,978	4.7%	28	54.3	97.2
6	29,325	3.6%	29	54.8	91.7	21,480	3.5%	27	51.5	87.0
7	22,006	2.7%	28	53.3	90.5	16,277	2.7%	27	50.2	82.0
8	16,638	2.1%	29	53.0	89.6	12,448	2.0%	27	50.0	88.3
9	12,683	1.6%	28	50.2	81.5	9,542	1.6%	27	48.4	90.9
10	9,719	1.2%	27	48.9	81.2	7,413	1.2%	26	46.3	73.7
11	7,428	0.9%	27	45.7	70.3	5,626	0.9%	27	46.2	73.8
12	5,701	0.7%	27	46.3	77.8	4,386	0.7%	26	44.8	70.4
13	4,395	0.5%	27	43.8	61.1	3,376	0.6%	26	45.1	79.2
14	3,390	0.4%	26	43.9	65.0	2,654	0.4%	25	39.0	53.0
15	2,614	0.3%	26	41.2	54.2	2,075	0.3%	24	37.7	44.4
16	2,008	0.2%	25	41.2	57.8	1,599	0.3%	24	41.6	76.7
17	1,539	0.2%	26	41.9	69.8	1,288	0.2%	25	37.3	43.7
18	1,198	0.1%	25	41.5	60.7	1,002	0.2%	24	35.2	41.2
19	946	0.1%	25	38.6	61.4	804	0.1%	24	37.9	53.6
20	728	0.1%	25	41.7	73.7	644	0.1%	24	36.3	43.9
21	554	0.1%	25	35.9	35.3	504	0.1%	24	36.3	40.0
22	427	0.1%	25	37.7	45.0	402	0.1%	23	35.5	45.2
23	318	0.0%	26	37.4	35.1	314	0.1%	24	30.8	27.4
24	240	0.0%	24	38.1	44.6	251	0.0%	25	32.7	31.6
25	185	0.0%	25	34.8	30.7	194	0.0%	22	32.0	29.5
26	137	0.0%	24	32.7	22.9	148	0.0%	22	34.1	55.3
27	116	0.0%	21	33.1	30.5	114	0.0%	21	29.3	22.6
28	77	0.0%	21	29.4	25.2	81	0.0%	21	30.6	25.9
29	58	0.0%	21	24.7	13.2	65	0.0%	21	32.7	37.2
30	45	0.0%	23	31.5	27.8	49	0.0%	21	27.1	19.6
31	27	0.0%	21	26.7	18.8	39	0.0%	24	28.9	15.1
32	21	0.0%	28	28.0	9.8	28	0.0%	22	27.9	16.2
33	18	0.0%	25	25.4	9.7	23	0.0%	23	28.6	17.5
34	12	0.0%	25	23.3	11.4	20	0.0%	19	24.1	13.5
35	*****	*****	24	25.6	7.4	*****	*****	20	22.5	8.4
36	*****	*****	23	29.3	18.5	*****	*****	23	24.4	11.5
37	*****	*****	23	26.2	10.4	*****	*****	18	21.8	10.0
38	*****	*****	26	25.5	12.0	*****	*****	18	29.4	37.6
39	*****	*****	23	23.0	15.6	*****	*****	23	22.3	5.6
40	*****	*****	16	16.0	5.7	*****	*****	22	23.6	7.7
41	*****	*****	*****	*****	*****	*****	*****	17	18.0	7.4
42	*****	*****	*****	*****	*****	*****	*****	25	25.0	7.1
43	*****	*****	*****	*****	*****	*****	*****	18	17.5	2.1
Gap from last episode until censoring	262,868	32.5%	64	309.3	463.1	199,725	32.7%	47	300.5	462.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Metformin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	11,521,433	100%	32	139.7	316.6	10,085,379	100%	30	121.1	285.5
Gap Number										
1	2,104,669	18.3%	38	128.4	266.4	1,833,673	18.2%	36	126.8	267.5
2	1,443,504	12.5%	35	100.3	207.7	1,264,438	12.5%	34	97.4	206.7
3	1,041,052	9.0%	35	88.7	181.3	912,681	9.0%	33	85.9	179.7
4	773,979	6.7%	34	81.2	161.9	678,257	6.7%	33	78.5	160.6
5	584,526	5.1%	34	76.1	148.3	512,662	5.1%	32	73.0	146.4
6	447,199	3.9%	33	72.2	138.7	393,475	3.9%	32	69.1	135.6
7	344,641	3.0%	33	68.9	129.0	304,673	3.0%	32	66.1	127.1
8	268,108	2.3%	33	65.9	120.8	238,015	2.4%	32	63.5	121.7
9	209,551	1.8%	32	63.1	112.1	187,254	1.9%	31	60.8	113.0
10	164,588	1.4%	32	61.2	108.5	148,145	1.5%	31	59.7	111.6
11	129,936	1.1%	32	59.6	104.0	117,928	1.2%	31	57.7	104.8
12	103,030	0.9%	32	57.3	98.2	94,242	0.9%	31	55.6	99.4
13	81,732	0.7%	31	56.3	96.6	75,630	0.7%	30	54.6	97.9
14	64,863	0.6%	31	55.1	94.9	60,582	0.6%	30	53.5	92.5
15	51,866	0.5%	31	54.1	89.7	48,716	0.5%	30	52.1	93.2
16	41,425	0.4%	31	52.7	85.8	39,261	0.4%	30	51.1	87.0
17	33,017	0.3%	31	50.8	79.5	31,668	0.3%	29	49.5	84.4
18	26,373	0.2%	30	50.6	82.0	25,684	0.3%	30	48.6	80.0
19	21,129	0.2%	30	49.6	79.8	20,886	0.2%	29	48.0	82.9
20	17,110	0.1%	30	48.3	74.7	16,981	0.2%	29	47.0	76.5
21	13,796	0.1%	30	47.0	65.9	13,797	0.1%	29	45.9	72.9
22	11,076	0.1%	30	46.8	66.4	11,262	0.1%	29	44.6	68.1
23	8,932	0.1%	30	46.1	65.3	9,255	0.1%	28	43.7	63.6
24	7,222	0.1%	30	46.0	68.7	7,561	0.1%	28	43.2	65.0
25	5,891	0.1%	29	43.5	58.1	6,181	0.1%	28	43.1	62.3
26	4,803	0.0%	29	42.6	53.5	5,091	0.1%	28	42.2	66.2
27	3,928	0.0%	29	43.7	61.6	4,160	0.0%	28	43.0	66.9
28	3,201	0.0%	29	43.1	55.4	3,383	0.0%	28	40.8	51.5
29	2,621	0.0%	29	41.7	51.7	2,775	0.0%	28	37.3	38.1
30	2,075	0.0%	29	41.5	50.2	2,268	0.0%	27	40.3	55.1
31	1,673	0.0%	30	40.8	44.9	1,852	0.0%	27	39.7	51.2
32	1,319	0.0%	29	41.0	58.7	1,541	0.0%	27	38.4	56.8
33	1,043	0.0%	28	37.3	34.0	1,260	0.0%	27	36.9	51.5
34	803	0.0%	28	39.6	51.7	1,018	0.0%	29	37.8	43.0
35	642	0.0%	29	37.4	34.5	818	0.0%	27	36.9	55.0
36	530	0.0%	30	38.8	48.9	652	0.0%	26	37.7	61.1
37	423	0.0%	28	38.0	39.7	516	0.0%	27	35.1	33.4
38	336	0.0%	28	39.0	44.5	417	0.0%	27	35.0	34.7
39	264	0.0%	30	38.1	37.6	339	0.0%	28	35.1	27.2
40	201	0.0%	30	40.0	46.3	272	0.0%	27	34.6	33.7
41	153	0.0%	28	33.7	30.9	204	0.0%	27	32.5	31.1
42	114	0.0%	28	33.8	24.0	159	0.0%	27	30.4	18.6
43	85	0.0%	28	34.0	24.6	132	0.0%	26	30.8	21.7
44	68	0.0%	23	27.9	19.4	111	0.0%	26	31.8	28.4
45	52	0.0%	25	30.0	21.2	82	0.0%	25	27.8	15.7
46	41	0.0%	25	25.3	12.5	65	0.0%	22	28.7	27.0
47	34	0.0%	25	25.6	10.6	45	0.0%	20	23.8	12.0

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Metformin, continued			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	25	0.0%	22	31.0	25.8	40	0.0%	28	31.7	22.0
49	18	0.0%	18	18.7	6.6	32	0.0%	22	26.8	22.1
50	16	0.0%	21	24.4	12.9	22	0.0%	20	20.0	6.7
51	12	0.0%	22	21.1	7.7	17	0.0%	19	24.2	12.5
52	12	0.0%	21	22.4	8.6	11	0.0%	16	20.4	11.6
53	*****	*****	22	32.3	27.4	*****	*****	20	21.0	2.8
54	*****	*****	21	25.4	16.6	*****	*****	20	19.4	7.3
55	*****	*****	29	30.3	13.2	*****	*****	17	19.3	8.2
56	*****	*****	*****	*****	*****	*****	*****	18	19.8	4.2
57	0	0.0%				*****	*****	18	18.8	3.0
58	0	0.0%				*****	*****	17	16.5	4.9
59	0	0.0%				*****	*****	14	13.5	0.7
60	0	0.0%				*****	*****	15	15.0	4.2
61	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	3,497,705	30.4%	5	246.6	473.8	3,005,159	29.8%	0	193.7	418.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Pioglitazone</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,089,033	100%	39	290.2	564.1	1,244,614	100%	33	242.2	513.5
Gap Number										
1	214,724	19.7%	33	102.3	225.2	243,331	19.6%	32	101.4	226.9
2	127,707	11.7%	32	83.2	182.6	148,188	11.9%	31	82.8	185.5
3	83,057	7.6%	31	74.3	156.2	97,653	7.8%	30	74.8	165.1
4	56,762	5.2%	31	70.0	148.4	67,384	5.4%	30	67.9	146.4
5	40,094	3.7%	31	66.1	138.5	48,299	3.9%	29	64.3	136.1
6	29,053	2.7%	30	62.2	121.4	35,440	2.8%	29	59.8	126.2
7	21,426	2.0%	30	59.4	123.1	26,521	2.1%	29	59.2	124.7
8	16,034	1.5%	30	58.4	119.0	20,177	1.6%	28	56.2	118.0
9	12,239	1.1%	29	56.0	114.7	15,590	1.3%	29	54.2	106.0
10	9,427	0.9%	30	54.1	107.5	12,164	1.0%	28	51.5	99.4
11	7,358	0.7%	29	50.1	90.2	9,595	0.8%	28	51.5	105.7
12	5,736	0.5%	30	52.1	99.9	7,656	0.6%	28	49.9	95.1
13	4,502	0.4%	30	50.3	93.2	6,114	0.5%	28	45.7	76.5
14	3,494	0.3%	29	49.7	91.3	4,935	0.4%	28	48.7	89.8
15	2,776	0.3%	29	48.2	87.7	4,024	0.3%	28	44.0	64.8
16	2,254	0.2%	29	48.1	102.3	3,298	0.3%	28	44.5	71.4
17	1,810	0.2%	29	46.8	96.6	2,675	0.2%	28	43.4	65.6
18	1,455	0.1%	28	44.3	63.1	2,163	0.2%	28	43.0	60.2
19	1,175	0.1%	28	42.1	52.7	1,755	0.1%	28	44.2	73.4
20	931	0.1%	28	43.4	67.3	1,446	0.1%	27	42.6	72.8
21	748	0.1%	29	40.2	41.3	1,196	0.1%	27	43.0	77.1
22	605	0.1%	28	41.2	56.6	981	0.1%	27	39.3	45.8
23	498	0.0%	30	46.7	75.0	823	0.1%	28	40.0	43.1
24	421	0.0%	28	42.3	51.4	667	0.1%	27	39.9	58.0
25	345	0.0%	29	39.6	41.8	559	0.0%	26	40.3	44.7
26	279	0.0%	26	47.0	104.5	442	0.0%	26	39.0	52.8
27	226	0.0%	26	35.4	30.3	369	0.0%	27	36.9	41.4
28	197	0.0%	28	40.9	52.5	304	0.0%	27	37.1	36.4
29	164	0.0%	28	45.3	82.8	254	0.0%	24	35.9	38.3
30	134	0.0%	28	36.3	32.0	218	0.0%	24	36.4	42.3
31	112	0.0%	30	40.5	32.0	182	0.0%	26	35.6	35.5
32	97	0.0%	29	41.4	52.3	151	0.0%	28	34.9	32.2
33	70	0.0%	30	36.9	29.6	128	0.0%	25	33.5	35.1
34	64	0.0%	30	37.6	28.0	99	0.0%	29	40.6	50.6
35	55	0.0%	30	34.9	25.7	79	0.0%	28	31.9	15.7
36	45	0.0%	26	31.3	20.6	60	0.0%	24	32.5	33.2
37	42	0.0%	29	32.5	18.8	45	0.0%	22	26.2	14.0
38	35	0.0%	29	34.3	22.5	40	0.0%	24	31.5	22.4
39	29	0.0%	21	27.9	18.2	35	0.0%	24	29.6	19.5
40	24	0.0%	23	31.3	22.2	27	0.0%	23	26.5	12.9
41	20	0.0%	32	29.7	12.4	18	0.0%	18	22.3	8.9
42	17	0.0%	25	30.4	19.5	15	0.0%	28	33.4	25.2
43	12	0.0%	30	28.2	13.5	12	0.0%	24	38.8	59.2
44	*****	*****	21	42.7	48.5	*****	*****	20	27.6	17.3
45	*****	*****	27	41.2	35.1	*****	*****	25	25.7	11.2
46	*****	*****	18	21.0	8.1	*****	*****	33	29.6	16.7
47	*****	*****	33	37.2	21.0	*****	*****	14	19.2	9.6

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

<u>Pioglitazone, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	*****	*****	18	25.8	13.9	*****	*****	16	25.6	20.9
49	*****	*****	26	26.4	7.5	*****	*****	24	23.6	7.1
50	*****	*****	21	22.8	4.0	*****	*****	19	19.8	8.8
51	*****	*****	21	20.5	4.9	*****	*****	16	20.8	13.3
52	*****	*****	30	29.5	6.4	*****	*****	37	37.0	5.7
53	*****	*****	56	55.5	17.7	0	0.0%			
54	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	442,726	40.7%	226	595.7	760.4	479,450	38.5%	97	502.3	723.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Saxagliptin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	453,561	100%	34	237.7	428.4	436,648	100%	31	215.2	409.9
Gap Number										
1	93,889	20.7%	27	67.7	136.9	90,174	20.7%	27	67.0	138.2
2	55,725	12.3%	27	58.4	110.5	53,247	12.2%	26	58.0	113.3
3	35,723	7.9%	27	54.5	98.3	34,046	7.8%	26	53.4	97.0
4	23,960	5.3%	27	51.1	86.8	23,034	5.3%	26	50.2	84.4
5	16,605	3.7%	27	49.1	79.8	16,136	3.7%	26	48.5	77.4
6	11,818	2.6%	27	47.0	74.1	11,584	2.7%	26	46.9	73.6
7	8,476	1.9%	27	45.9	69.1	8,377	1.9%	26	46.6	78.9
8	6,222	1.4%	27	45.7	66.5	6,241	1.4%	26	42.3	64.9
9	4,599	1.0%	26	43.4	57.1	4,682	1.1%	26	43.9	68.0
10	3,404	0.8%	26	41.1	51.9	3,535	0.8%	26	42.5	63.5
11	2,535	0.6%	26	43.0	67.7	2,680	0.6%	26	41.3	57.5
12	1,873	0.4%	26	43.4	69.1	2,092	0.5%	26	39.2	46.6
13	1,402	0.3%	26	39.8	49.9	1,613	0.4%	25	38.9	49.9
14	1,051	0.2%	26	40.8	66.7	1,255	0.3%	26	37.3	44.2
15	795	0.2%	26	37.9	45.7	992	0.2%	25	38.6	60.8
16	605	0.1%	27	40.6	50.6	769	0.2%	25	35.6	46.7
17	457	0.1%	26	38.9	48.6	577	0.1%	26	37.0	41.7
18	351	0.1%	24	36.9	51.5	445	0.1%	26	41.0	60.1
19	261	0.1%	27	35.5	27.8	353	0.1%	25	36.5	40.2
20	221	0.0%	26	37.6	36.4	272	0.1%	22	31.2	23.7
21	166	0.0%	25	33.2	27.5	212	0.0%	24	32.0	27.7
22	132	0.0%	27	32.8	24.5	169	0.0%	26	33.5	27.4
23	99	0.0%	22	29.1	21.1	127	0.0%	26	32.2	30.9
24	76	0.0%	23	28.2	17.1	96	0.0%	19	32.5	38.9
25	60	0.0%	28	33.1	22.5	75	0.0%	24	29.2	20.5
26	43	0.0%	25	34.0	25.7	59	0.0%	24	30.7	22.7
27	30	0.0%	27	35.4	26.8	47	0.0%	22	32.7	34.5
28	26	0.0%	21	36.2	44.2	35	0.0%	24	30.8	21.3
29	22	0.0%	23	27.5	16.0	27	0.0%	24	30.0	17.3
30	13	0.0%	22	48.0	69.6	18	0.0%	31	39.7	27.6
31	*****	*****	18	25.3	14.7	*****	*****	23	24.8	12.9
32	*****	*****	33	42.2	33.5	*****	*****	28	29.4	17.9
33	*****	*****	18	20.3	4.9	*****	*****	27	30.3	17.7
34	*****	*****	22	22.0	15.6	*****	*****	21	20.8	5.0
35	*****	*****	*****	*****	*****	*****	*****	23	24.2	8.4
36	*****	*****	*****	*****	*****	*****	*****	22	24.3	13.8
37	*****	*****	*****	*****	*****	*****	*****	17	16.5	2.1
38	*****	*****	*****	*****	*****	*****	*****	29	29.0	8.5
Gap from last episode until censoring	182,898	40.3%	304	504.3	564.1	173,627	39.8%	217	455.3	555.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Sitagliptin	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	2,184,576	100%	31	181.0	378.8	2,009,388	100%	30	173.3	370.7
Gap Number										
1	435,972	20.0%	30	94.7	207.5	399,051	19.9%	30	93.1	204.9
2	267,575	12.2%	29	75.2	159.1	243,455	12.1%	29	76.3	165.5
3	176,439	8.1%	29	68.3	139.9	160,873	8.0%	29	68.3	141.5
4	121,628	5.6%	29	64.1	129.3	111,154	5.5%	29	63.5	128.7
5	86,354	4.0%	29	60.1	115.1	79,236	3.9%	29	60.0	119.3
6	62,511	2.9%	29	58.1	115.1	57,768	2.9%	29	57.4	108.9
7	46,251	2.1%	29	54.1	97.5	42,883	2.1%	29	56.0	107.8
8	34,553	1.6%	29	52.1	90.9	32,245	1.6%	29	54.2	103.5
9	26,051	1.2%	29	52.3	96.9	24,680	1.2%	29	52.5	98.1
10	19,916	0.9%	28	50.3	86.4	19,016	0.9%	29	51.3	95.8
11	15,317	0.7%	29	48.9	86.8	14,659	0.7%	28	48.4	85.2
12	11,832	0.5%	28	48.4	84.7	11,452	0.6%	29	49.7	96.1
13	9,205	0.4%	28	46.3	72.1	8,941	0.4%	29	48.1	87.0
14	7,217	0.3%	28	45.5	72.2	7,128	0.4%	28	45.7	76.1
15	5,657	0.3%	28	46.4	84.9	5,661	0.3%	28	44.3	70.5
16	4,445	0.2%	28	43.8	64.9	4,495	0.2%	29	42.8	63.2
17	3,497	0.2%	28	45.0	73.4	3,607	0.2%	28	42.5	63.1
18	2,789	0.1%	28	43.0	61.4	2,903	0.1%	27	44.8	90.1
19	2,204	0.1%	28	42.1	61.6	2,367	0.1%	27	38.4	50.4
20	1,726	0.1%	26	40.5	69.2	1,929	0.1%	28	40.9	70.8
21	1,385	0.1%	27	39.3	52.4	1,544	0.1%	27	39.0	65.5
22	1,133	0.1%	26	42.8	79.4	1,268	0.1%	26	37.1	51.6
23	898	0.0%	27	37.6	74.6	1,057	0.1%	27	38.2	59.4
24	720	0.0%	27	39.3	53.7	884	0.0%	26	37.9	51.7
25	595	0.0%	27	36.8	33.3	718	0.0%	27	35.2	41.7
26	480	0.0%	27	38.5	48.6	583	0.0%	27	36.8	70.1
27	394	0.0%	27	44.7	86.1	483	0.0%	26	34.2	31.7
28	320	0.0%	27	35.4	51.4	399	0.0%	27	35.5	58.0
29	272	0.0%	27	35.1	26.6	331	0.0%	28	35.7	46.6
30	222	0.0%	28	36.8	41.1	283	0.0%	26	34.2	27.7
31	175	0.0%	28	40.6	58.2	229	0.0%	28	36.5	30.8
32	137	0.0%	26	31.8	27.2	175	0.0%	27	32.4	22.7
33	107	0.0%	29	34.0	22.3	147	0.0%	26	32.1	20.5
34	84	0.0%	26	34.2	34.1	124	0.0%	28	31.7	18.9
35	76	0.0%	29	36.1	31.0	94	0.0%	29	40.9	59.1
36	61	0.0%	28	34.7	25.8	74	0.0%	26	26.4	10.0
37	49	0.0%	28	33.6	20.2	57	0.0%	26	37.8	56.1
38	40	0.0%	26	35.8	37.2	42	0.0%	22	30.1	29.7
39	34	0.0%	29	29.6	13.5	34	0.0%	25	31.1	18.6
40	31	0.0%	31	35.8	25.6	30	0.0%	27	28.1	14.1
41	25	0.0%	30	32.4	18.0	24	0.0%	31	35.8	22.3
42	19	0.0%	28	32.2	21.3	21	0.0%	18	25.9	14.7
43	17	0.0%	21	26.7	13.4	18	0.0%	23	27.9	14.3
44	14	0.0%	23	26.4	13.1	18	0.0%	30	29.0	13.4
45	11	0.0%	21	24.6	11.1	13	0.0%	27	26.2	12.5
46	*****	*****	31	31.4	9.6	*****	*****	18	36.1	40.8
47	*****	*****	27	25.8	6.4	*****	*****	23	27.6	15.1

Table 11a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Sex

Sitagliptin, continued			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	*****	*****	26	25.5	0.7	*****	*****	30	36.3	37.6
49	*****	*****	23	23.0	2.8	*****	*****	32	47.4	38.9
50	*****	*****	18	17.5	7.8	*****	*****	21	23.7	6.4
51	*****	*****	23	23.0	9.9	*****	*****	23	23.0	15.6
52	*****	*****	16	16.0	4.2	*****	*****	23	23.0	17.0
53	*****	*****	18	18.0	1.4	*****	*****	*****	*****	*****
54	0	0.0%				*****	*****	*****	*****	*****
55	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	836,112	38.3%	55	353.2	534.0	767,193	38.2%	40	334.5	525.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Glyburide</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,010,943	100%	44	271.6	503.8	1,000,405	100%	37	215.3	438.1
Gap Number										
1	181,371	17.9%	35	104.4	214.3	183,067	18.3%	36	99.5	195.7
2	113,953	11.3%	33	80.6	160.8	119,741	12.0%	33	81.5	159.9
3	78,897	7.8%	32	70.9	136.0	83,414	8.3%	32	72.4	143.3
4	56,967	5.6%	31	65.0	125.0	60,575	6.1%	31	67.3	133.4
5	42,225	4.2%	30	62.0	119.7	45,377	4.5%	30	61.2	118.2
6	31,856	3.2%	29	57.8	112.5	34,652	3.5%	30	58.3	112.9
7	24,322	2.4%	29	53.6	97.6	26,972	2.7%	29	56.0	110.2
8	18,979	1.9%	28	51.8	92.7	21,205	2.1%	28	52.1	99.6
9	14,857	1.5%	28	51.3	94.2	16,836	1.7%	28	51.3	101.2
10	11,738	1.2%	28	49.4	88.7	13,491	1.3%	27	48.5	94.1
11	9,300	0.9%	27	48.9	95.8	10,923	1.1%	26	47.6	92.3
12	7,446	0.7%	27	47.8	90.8	8,814	0.9%	27	47.2	93.8
13	5,954	0.6%	27	47.7	97.0	7,165	0.7%	26	45.3	82.0
14	4,792	0.5%	26	46.6	82.9	5,862	0.6%	26	45.2	85.4
15	3,870	0.4%	26	46.3	90.2	4,795	0.5%	26	43.1	79.2
16	3,126	0.3%	25	41.3	70.5	3,925	0.4%	26	44.1	88.0
17	2,553	0.3%	26	44.4	86.8	3,218	0.3%	26	41.7	71.8
18	2,096	0.2%	26	42.1	76.5	2,680	0.3%	25	41.1	72.9
19	1,715	0.2%	26	42.1	76.3	2,236	0.2%	25	40.1	74.1
20	1,392	0.1%	25	39.8	69.1	1,867	0.2%	24	41.4	78.5
21	1,152	0.1%	25	42.6	81.0	1,582	0.2%	23	39.5	88.1
22	966	0.1%	25	39.2	66.1	1,346	0.1%	24	38.6	68.6
23	801	0.1%	24	37.1	49.1	1,085	0.1%	24	39.7	86.6
24	653	0.1%	24	36.9	47.6	909	0.1%	22	34.7	60.9
25	541	0.1%	23	35.6	50.6	758	0.1%	22	35.6	58.0
26	461	0.0%	23	41.2	78.1	626	0.1%	22	30.0	33.6
27	369	0.0%	23	38.6	83.0	520	0.1%	22	35.5	72.1
28	315	0.0%	22	37.1	62.1	423	0.0%	21	33.1	51.6
29	261	0.0%	22	39.5	88.7	354	0.0%	21	40.3	109.1
30	211	0.0%	23	31.5	33.5	290	0.0%	21	34.3	48.6
31	179	0.0%	24	35.0	47.6	243	0.0%	21	32.1	44.7
32	148	0.0%	24	31.6	29.8	204	0.0%	19	27.5	26.3
33	129	0.0%	24	36.2	41.5	175	0.0%	20	27.7	23.7
34	106	0.0%	24	30.4	25.7	156	0.0%	22	27.8	18.7
35	81	0.0%	20	31.2	34.9	133	0.0%	22	34.0	55.6
36	64	0.0%	20	38.8	53.0	110	0.0%	22	29.9	26.9
37	53	0.0%	19	44.3	72.2	86	0.0%	24	31.3	27.9
38	43	0.0%	18	24.7	27.8	69	0.0%	24	29.1	28.8
39	39	0.0%	18	26.6	21.5	58	0.0%	19	26.0	23.4
40	35	0.0%	26	41.8	51.6	50	0.0%	22	31.7	36.9

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Glyburide, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
41	30	0.0%	20	48.3	100.1	43	0.0%	26	31.6	30.7
42	23	0.0%	25	27.3	19.9	37	0.0%	19	29.0	28.1
43	19	0.0%	17	25.1	19.1	32	0.0%	15	21.6	17.6
44	15	0.0%	14	16.3	9.4	25	0.0%	19	24.9	14.8
45	14	0.0%	14	17.2	10.0	20	0.0%	13	17.9	14.7
46	11	0.0%	11	14.3	6.9	17	0.0%	14	19.5	13.2
47	*****	*****	15	14.2	3.8	*****	*****	15	17.0	7.3
48	*****	*****	13	12.6	4.1	*****	*****	16	16.2	5.9
49	*****	*****	20	28.4	25.7	*****	*****	16	16.2	6.7
50	*****	*****	9	10.5	4.4	*****	*****	14	16.1	7.7
51	*****	*****	9	11.3	5.3	*****	*****	23	21.3	8.3
52	*****	*****	9	9.8	2.4	*****	*****	19	20.0	9.6
53	*****	*****	10	15.3	11.0	*****	*****	17	19.0	10.1
54	*****	*****	11	10.5	0.7	*****	*****	14	39.0	43.3
55	*****	*****	10	10.0	1.4	*****	*****	18	17.5	0.7
56	*****	*****	*****	*****	*****	*****	*****	21	20.5	3.5
57	*****	*****	*****	*****	*****	*****	*****	27	26.5	16.3
58	*****	*****	*****	*****	*****	*****	*****	13	13.0	4.2
59	*****	*****	*****	*****	*****	*****	*****	36	35.5	19.1
60	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
61	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	386,765	38.3%	328	586.7	679.5	334,160	33.4%	230	495.9	640.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Liraglutide</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	868,637	100%	27	133.1	296.4	656,612	100%	26	129.5	295.2
Gap Number										
1	158,950	18.3%	27	67.5	144.6	120,784	18.4%	27	66.5	144.3
2	108,307	12.5%	26	60.4	124.6	81,557	12.4%	25	59.7	126.6
3	78,251	9.0%	26	57.5	116.6	58,440	8.9%	25	55.0	111.5
4	58,185	6.7%	26	54.7	105.1	43,228	6.6%	25	52.1	103.1
5	44,243	5.1%	26	52.3	99.3	32,753	5.0%	24	49.3	96.9
6	34,049	3.9%	25	50.3	95.8	25,077	3.8%	24	46.6	87.3
7	26,276	3.0%	25	48.5	86.2	19,494	3.0%	24	45.2	80.7
8	20,499	2.4%	25	46.0	83.0	15,343	2.3%	23	44.0	80.0
9	16,094	1.9%	24	46.1	87.7	12,059	1.8%	23	44.2	86.8
10	12,646	1.5%	24	43.8	76.1	9,504	1.4%	22	40.1	75.3
11	10,053	1.2%	23	41.5	70.1	7,554	1.2%	22	40.6	70.0
12	7,911	0.9%	23	40.9	72.2	6,085	0.9%	22	39.7	71.8
13	6,297	0.7%	23	40.6	74.0	4,867	0.7%	22	40.8	80.5
14	5,004	0.6%	23	38.5	65.3	3,895	0.6%	21	36.2	55.1
15	3,952	0.5%	22	36.7	48.9	3,146	0.5%	21	35.1	52.7
16	3,125	0.4%	22	37.5	60.4	2,498	0.4%	21	34.4	53.4
17	2,445	0.3%	22	34.3	53.7	2,029	0.3%	20	33.7	62.0
18	1,971	0.2%	22	35.7	54.1	1,640	0.2%	21	32.6	48.1
19	1,579	0.2%	22	36.7	62.6	1,311	0.2%	20	31.0	43.3
20	1,239	0.1%	21	35.4	64.6	1,075	0.2%	20	32.3	59.5
21	980	0.1%	21	31.5	44.5	887	0.1%	21	30.8	33.8
22	801	0.1%	21	33.1	57.1	715	0.1%	21	34.0	52.9
23	629	0.1%	19	30.3	35.0	578	0.1%	20	29.9	34.8
24	513	0.1%	21	32.1	43.9	490	0.1%	20	31.6	48.7
25	411	0.0%	21	30.9	36.2	394	0.1%	19	26.1	29.1
26	319	0.0%	21	34.6	49.2	319	0.0%	17	28.3	37.8
27	244	0.0%	19	33.3	85.8	253	0.0%	20	29.0	27.6
28	189	0.0%	19	26.0	24.2	200	0.0%	19	24.2	19.5
29	149	0.0%	20	30.1	30.1	158	0.0%	18	27.4	52.0
30	114	0.0%	20	28.2	28.5	119	0.0%	19	28.6	33.3
31	86	0.0%	20	25.9	21.2	89	0.0%	19	24.5	18.6
32	61	0.0%	21	27.9	22.9	67	0.0%	18	22.4	12.8
33	51	0.0%	20	24.2	13.5	56	0.0%	19	21.3	11.0
34	37	0.0%	24	26.7	16.8	42	0.0%	18	22.7	14.3
35	27	0.0%	18	22.9	18.5	36	0.0%	19	25.6	17.9
36	22	0.0%	23	28.9	23.2	30	0.0%	15	20.3	14.3
37	16	0.0%	17	21.8	14.9	25	0.0%	24	22.6	12.2
38	*****	*****	17	21.6	19.3	*****	*****	17	20.4	9.8
39	*****	*****	22	20.1	9.9	*****	*****	18	32.0	32.5
40	*****	*****	15	19.9	8.9	*****	*****	22	21.3	9.5
41	*****	*****	20	16.6	8.6	*****	*****	22	25.8	11.8
42	*****	*****	20	20.5	5.8	*****	*****	20	28.2	23.6
43	*****	*****	23	20.0	7.0	*****	*****	19	23.3	14.5
44	*****	*****	31	31.0	26.9	*****	*****	17	18.0	7.5
45	*****	*****	13	12.5	13.4	*****	*****	19	14.0	9.5
46	*****	*****	12	12.0	12.7	*****	*****	11	15.7	12.7
47	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Liraglutide, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	262,868	30.3%	64	309.3	463.1	199,725	30.4%	47	300.5	462.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Metformin	Female					Male				
	Number of		Median	Mean	Standard	Number of		Median	Mean	Standard
	Episodes	Percent	Days per Gap	Days per Gap		Episodes	Percent	Days per Gap	Days per Gap	
Total Episodes	11,808,255	100%	31	136.1	313.5	10,281,379	100%	29	118.5	283.4
Gap Number										
1	2,106,194	17.8%	38	126.3	263.9	1,820,032	17.7%	37	126.0	266.0
2	1,445,339	12.2%	35	98.9	207.6	1,249,941	12.2%	34	97.2	207.4
3	1,046,159	8.9%	34	87.1	181.3	904,846	8.8%	33	85.1	180.7
4	782,777	6.6%	33	79.5	163.0	677,139	6.6%	32	76.9	161.4
5	597,576	5.1%	32	73.6	149.0	519,104	5.0%	31	71.2	148.6
6	463,021	3.9%	32	69.7	140.9	403,484	3.9%	31	67.1	138.6
7	362,662	3.1%	31	65.8	130.3	318,059	3.1%	30	63.1	128.6
8	286,827	2.4%	31	62.7	122.5	252,552	2.5%	30	60.7	124.3
9	228,866	1.9%	30	59.9	115.4	202,320	2.0%	29	57.6	114.8
10	183,287	1.6%	29	57.7	111.2	163,415	1.6%	29	55.9	112.4
11	147,734	1.3%	29	55.6	105.3	132,682	1.3%	28	53.6	106.5
12	119,337	1.0%	29	53.6	100.6	108,547	1.1%	28	51.7	101.0
13	96,980	0.8%	28	52.4	99.3	89,210	0.9%	27	50.7	102.3
14	78,791	0.7%	28	50.7	93.2	73,260	0.7%	27	49.4	97.6
15	64,505	0.5%	28	50.2	95.1	60,358	0.6%	27	47.4	90.8
16	52,756	0.4%	27	48.2	88.7	50,010	0.5%	26	46.7	90.6
17	43,366	0.4%	27	46.4	81.8	41,535	0.4%	26	45.4	88.7
18	35,733	0.3%	27	45.9	81.2	34,473	0.3%	26	44.4	83.7
19	29,289	0.2%	26	45.4	80.7	28,677	0.3%	25	43.0	78.8
20	24,109	0.2%	26	44.6	77.9	23,977	0.2%	25	42.9	81.1
21	19,842	0.2%	26	42.9	69.2	20,084	0.2%	25	42.7	80.0
22	16,364	0.1%	26	42.6	70.5	16,862	0.2%	25	41.5	75.2
23	13,616	0.1%	26	41.8	66.0	14,066	0.1%	24	39.5	64.1
24	11,245	0.1%	26	41.2	69.6	11,791	0.1%	24	38.9	64.3
25	9,359	0.1%	26	40.4	60.5	9,878	0.1%	24	38.5	64.1
26	7,776	0.1%	25	37.7	50.3	8,331	0.1%	24	37.4	61.2
27	6,467	0.1%	25	40.2	69.2	6,988	0.1%	24	37.8	62.5
28	5,352	0.0%	25	37.7	55.6	5,867	0.1%	24	37.7	66.7
29	4,463	0.0%	25	38.7	59.9	4,874	0.0%	23	37.2	60.6
30	3,756	0.0%	24	36.1	47.7	4,045	0.0%	23	36.3	55.2
31	3,141	0.0%	24	34.9	41.2	3,388	0.0%	23	34.6	48.6
32	2,588	0.0%	24	35.9	47.1	2,803	0.0%	22	34.3	52.1
33	2,160	0.0%	24	34.9	45.4	2,348	0.0%	23	33.8	49.6
34	1,746	0.0%	24	37.6	67.1	1,963	0.0%	23	33.0	44.4
35	1,437	0.0%	23	33.5	47.6	1,662	0.0%	22	33.2	53.4
36	1,175	0.0%	24	33.9	48.0	1,400	0.0%	21	30.4	35.3
37	958	0.0%	23	33.3	40.7	1,129	0.0%	21	30.0	38.2
38	761	0.0%	24	34.2	47.9	940	0.0%	21	29.9	50.4
39	617	0.0%	24	33.3	34.2	753	0.0%	22	33.1	47.0
40	492	0.0%	24	33.5	38.7	626	0.0%	23	34.2	45.0
41	389	0.0%	27	40.6	64.4	515	0.0%	21	30.1	31.4
42	301	0.0%	21	28.9	27.8	423	0.0%	21	29.3	31.0
43	242	0.0%	22	27.6	22.2	351	0.0%	20	28.7	28.4
44	190	0.0%	23	29.8	35.3	282	0.0%	21	26.5	20.6
45	156	0.0%	22	29.8	30.5	235	0.0%	18	25.2	23.9
46	124	0.0%	23	29.5	31.3	198	0.0%	20	26.1	21.5
47	93	0.0%	19	23.3	16.0	154	0.0%	19	26.4	26.5

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

Metformin, continued			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
48	75	0.0%	19	25.4	19.8	123	0.0%	18	25.6	20.0
49	68	0.0%	18	24.0	18.9	108	0.0%	18	22.9	20.3
50	53	0.0%	19	22.6	14.5	84	0.0%	18	23.3	18.6
51	42	0.0%	17	20.5	16.5	68	0.0%	16	21.9	17.0
52	34	0.0%	19	25.1	20.6	52	0.0%	17	22.3	18.9
53	28	0.0%	17	26.0	23.1	39	0.0%	19	20.3	10.3
54	22	0.0%	23	27.4	20.9	30	0.0%	14	20.6	21.0
55	19	0.0%	15	15.5	7.7	26	0.0%	16	17.0	10.1
56	16	0.0%	17	20.7	17.4	22	0.0%	14	15.3	7.5
57	14	0.0%	14	15.7	10.1	17	0.0%	16	16.4	10.3
58	12	0.0%	14	15.2	8.7	14	0.0%	15	16.8	12.9
59	*****	*****	10	11.5	6.8	*****	*****	19	19.9	13.3
60	*****	*****	12	16.1	11.8	*****	*****	20	17.3	7.3
61	*****	*****	10	15.3	14.2	*****	*****	14	17.7	13.0
62	*****	*****	15	17.2	12.8	*****	*****	17	15.6	7.8
63	*****	*****	9	12.7	11.9	*****	*****	18	15.4	8.1
64	*****	*****	7	7.0	5.0	*****	*****	22	15.0	12.1
65	*****	*****	8	7.3	3.1	*****	*****	18	16.7	15.0
66	*****	*****	8	8.3	6.5	*****	*****	25	17.3	14.2
67	*****	*****	11	10.5	2.1	*****	*****	8	9.0	8.5
68	*****	*****	18	18.0	15.6	*****	*****	13	13.0	4.2
69	*****	*****	7	6.5	3.5	*****	*****	*****	*****	*****
70	*****	*****	*****	*****	*****	0	0.0%			
71	*****	*****	*****	*****	*****	0	0.0%			
72	*****	*****	*****	*****	*****	0	0.0%			
73	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	3,497,705	29.6%	5	246.6	473.8	3,005,159	29.2%	0	193.7	418.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Sitagliptin</u>	Female					Male				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	2,337,069	100%	27	169.4	368.9	2,126,809	100%	27	163.9	362.4
Gap Number										
1	448,062	19.2%	29	89.5	202.5	406,283	19.1%	29	89.2	201.5
2	282,826	12.1%	27	70.0	155.5	253,130	11.9%	27	71.6	160.7
3	191,887	8.2%	26	62.7	138.1	171,024	8.0%	27	63.8	140.4
4	136,054	5.8%	26	58.3	126.4	121,190	5.7%	26	58.8	128.5
5	99,209	4.2%	25	53.5	111.0	88,829	4.2%	26	54.4	114.3
6	74,026	3.2%	25	51.8	110.6	66,702	3.1%	25	51.4	107.2
7	56,340	2.4%	24	48.3	98.8	50,999	2.4%	25	49.8	104.2
8	43,492	1.9%	24	46.3	92.4	39,524	1.9%	25	48.1	100.1
9	33,833	1.4%	24	45.1	88.9	30,996	1.5%	25	45.4	90.8
10	26,576	1.1%	23	43.6	88.3	24,545	1.2%	24	46.1	99.6
11	21,043	0.9%	23	42.1	82.4	19,579	0.9%	24	44.2	94.7
12	16,720	0.7%	23	41.0	74.8	15,747	0.7%	24	42.7	86.9
13	13,434	0.6%	23	39.3	69.7	12,696	0.6%	24	42.5	87.2
14	10,725	0.5%	24	41.1	80.1	10,297	0.5%	23	39.8	79.3
15	8,633	0.4%	23	39.6	79.0	8,362	0.4%	23	39.0	75.8
16	7,003	0.3%	23	37.1	60.6	6,830	0.3%	23	37.9	74.3
17	5,679	0.2%	23	38.7	76.1	5,616	0.3%	23	37.5	60.0
18	4,618	0.2%	22	35.9	59.4	4,545	0.2%	23	38.6	72.9
19	3,745	0.2%	23	36.0	63.4	3,731	0.2%	22	35.3	65.8
20	3,034	0.1%	22	35.5	60.8	3,098	0.1%	22	35.2	62.5
21	2,482	0.1%	21	35.1	59.0	2,564	0.1%	21	32.6	53.4
22	2,019	0.1%	22	35.5	58.6	2,126	0.1%	21	32.7	50.2
23	1,652	0.1%	21	32.0	40.5	1,794	0.1%	22	34.1	59.3
24	1,348	0.1%	20	37.5	92.1	1,513	0.1%	22	36.0	95.0
25	1,125	0.0%	21	32.8	49.9	1,256	0.1%	21	31.6	40.3
26	921	0.0%	21	31.3	59.4	1,053	0.0%	22	35.0	66.9
27	749	0.0%	21	31.3	37.3	885	0.0%	21	30.3	51.2
28	637	0.0%	20	31.6	57.5	756	0.0%	21	30.3	33.1
29	521	0.0%	20	31.6	42.1	630	0.0%	21	29.1	39.7
30	439	0.0%	22	31.7	63.3	542	0.0%	20	33.7	67.9
31	371	0.0%	20	33.5	46.0	455	0.0%	21	27.9	25.7
32	297	0.0%	20	30.3	39.1	384	0.0%	21	27.1	22.8
33	243	0.0%	20	29.7	37.3	328	0.0%	22	26.9	22.3
34	197	0.0%	19	27.5	25.1	288	0.0%	21	25.3	19.3
35	165	0.0%	19	29.7	41.5	239	0.0%	19	24.7	18.8
36	136	0.0%	20	24.9	24.1	201	0.0%	20	28.0	42.0
37	120	0.0%	19	25.6	20.9	163	0.0%	20	26.6	20.7
38	101	0.0%	19	28.9	28.7	137	0.0%	17	25.1	25.4
39	88	0.0%	22	24.7	17.3	109	0.0%	17	25.1	26.5
40	73	0.0%	22	23.3	17.3	86	0.0%	20	28.5	44.7
41	64	0.0%	21	28.6	30.9	72	0.0%	18	21.0	13.6
42	50	0.0%	21	28.6	27.9	54	0.0%	20	24.0	18.8
43	44	0.0%	23	26.6	16.3	44	0.0%	15	20.8	13.3
44	35	0.0%	21	26.7	18.0	38	0.0%	25	24.8	19.2
45	27	0.0%	18	20.0	14.2	31	0.0%	15	19.6	11.9
46	20	0.0%	17	18.3	9.6	28	0.0%	15	23.2	22.8

Table 11b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Sex

<u>Sitagliptin, continued</u>			Female			Male				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
47	19	0.0%	16	19.5	11.5	27	0.0%	15	21.4	26.7
48	11	0.0%	16	19.7	8.2	23	0.0%	20	26.0	16.4
49	*****	*****	22	21.4	7.4	*****	*****	20	21.2	12.5
50	*****	*****	25	22.6	8.1	*****	*****	26	33.6	32.6
51	*****	*****	20	18.6	8.0	*****	*****	27	38.0	38.2
52	*****	*****	17	17.3	7.7	*****	*****	16	17.2	11.4
53	*****	*****	16	21.8	14.1	*****	*****	26	22.8	13.2
54	*****	*****	18	20.3	7.4	*****	*****	8	6.7	3.2
55	*****	*****	18	17.7	1.5	*****	*****	16	15.5	16.3
56	*****	*****	12	13.3	3.2	*****	*****	11	11.0	5.7
57	*****	*****	13	13.0	8.5	*****	*****	15	15.0	15.6
58	*****	*****	16	16.0	5.7	*****	*****	*****	*****	*****
59	*****	*****	14	14.0	0.0	*****	*****	*****	*****	*****
60	*****	*****	16	16.0	1.4	*****	*****	*****	*****	*****
61	*****	*****	16	15.5	0.7	*****	*****	*****	*****	*****
62	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
63	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
64	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
65	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
66	*****	*****	*****	*****	*****	0	0.0%			
67	*****	*****	*****	*****	*****	0	0.0%			
68	*****	*****	*****	*****	*****	0	0.0%			
69	*****	*****	*****	*****	*****	0	0.0%			
70	*****	*****	*****	*****	*****	0	0.0%			
71	*****	*****	*****	*****	*****	0	0.0%			
72	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	836,112	35.8%	55	353.2	534.0	767,193	36.1%	40	334.5	525.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Albiglutide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	8,064	100%	30	118.5	186.0	13,869	100%	26	108.1	180.2	15,490	100%	24	109.0	185.4
Gap Number															
1	1,803	22.4%	24	48.2	71.0	3,140	22.6%	23	45.1	66.9	3,418	22.1%	23	42.3	58.5
2	970	12.0%	26	45.5	64.9	1,652	11.9%	23	40.4	51.6	1,621	10.5%	23	39.7	52.5
3	524	6.5%	26	38.4	39.7	912	6.6%	24	38.3	41.6	845	5.5%	24	40.1	51.3
4	301	3.7%	26	39.6	41.1	509	3.7%	25	40.7	48.0	456	2.9%	23	36.4	38.1
5	174	2.2%	24	37.9	34.6	295	2.1%	26	39.8	40.4	244	1.6%	26	36.9	36.0
6	102	1.3%	24	36.5	33.8	175	1.3%	24	35.0	33.1	142	0.9%	26	36.4	35.4
7	68	0.8%	28	40.4	32.5	96	0.7%	23	34.8	30.9	81	0.5%	29	35.0	27.4
8	42	0.5%	27	41.0	56.7	51	0.4%	27	36.6	32.6	40	0.3%	22	27.2	17.5
9	23	0.3%	22	40.1	39.7	23	0.2%	23	34.7	35.5	20	0.1%	25	37.4	23.9
10	11	0.1%	20	36.8	45.7	11	0.1%	23	30.8	22.3	13	0.1%	21	25.8	12.2
11	*****	*****	44	48.8	31.9	*****	*****	41	68.9	67.6	*****	*****	23	34.6	31.8
12	*****	*****	*****	*****	*****	*****	*****	26	30.4	21.9	*****	*****	25	31.3	17.6
13	*****	*****	*****	*****	*****	*****	*****	14	13.5	2.1	*****	*****	25	25.0	2.8
14	*****	*****	*****	*****	*****	*****	*****	55	55.0	46.7	*****	*****	*****	*****	*****
15	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
16	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	4,036	50.0%	97	192.3	233.3	6,987	50.4%	56	173.3	229.6	8,592	55.5%	33	164.1	230.0

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Albiglutide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	7,030	100%	19	87.7	162.6	2,467	100%	19	82.7	154.1
Gap Number										
1	1,439	20.5%	22	38.4	49.4	501	20.3%	22	37.6	52.0
2	497	7.1%	23	35.0	34.3	193	7.8%	23	37.3	40.1
3	212	3.0%	24	37.9	45.3	77	3.1%	22	32.9	36.1
4	112	1.6%	28	37.9	30.2	38	1.5%	24	40.7	41.4
5	56	0.8%	25	38.0	48.9	18	0.7%	28	36.5	34.3
6	*****	*****	29	37.8	31.0	*****	*****	16	22.7	13.5
7	*****	*****	28	40.1	32.4	*****	*****	35	34.5	31.8
8	*****	*****	17	44.7	57.3	*****	*****	*****	*****	*****
9	*****	*****	31	72.8	97.1	*****	*****	*****	*****	*****
10	*****	*****	25	24.5	4.9	*****	*****	*****	*****	*****
11	*****	*****	20	20.0	11.3	*****	*****	*****	*****	*****
12	*****	*****	*****	*****	*****	0	0.0%			
13	*****	*****	*****	*****	*****	0	0.0%			
14	0	0.0%				0	0.0%			
15	0	0.0%				0	0.0%			
16	0	0.0%				0	0.0%			
Gap from last episode until censoring	4,651	66.2%	1	113.3	192.3	1,628	66.0%	3	106.1	182.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Alogliptin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	6,833	100%	29	135.8	255.5	12,670	100%	26	123.5	240.1	14,291	100%	24	123.2	239.8
Gap Number															
1	1,485	21.7%	27	52.8	82.4	2,704	21.3%	25	48.8	78.8	3,147	22.0%	25	47.4	74.7
2	851	12.5%	25	46.8	70.1	1,561	12.3%	26	48.2	70.8	1,704	11.9%	25	46.4	73.0
3	539	7.9%	26	41.9	55.3	966	7.6%	26	44.1	59.2	1,005	7.0%	25	44.3	56.1
4	353	5.2%	27	46.9	62.9	652	5.1%	25	42.3	52.1	611	4.3%	25	40.1	46.5
5	242	3.5%	29	46.4	54.0	445	3.5%	23	36.4	43.9	397	2.8%	26	41.3	57.3
6	167	2.4%	25	42.2	53.1	320	2.5%	25	37.6	40.5	274	1.9%	25	42.4	52.3
7	111	1.6%	28	38.5	35.1	221	1.7%	25	38.7	44.7	175	1.2%	25	41.8	56.8
8	81	1.2%	23	36.2	40.3	162	1.3%	26	34.7	24.1	116	0.8%	26	42.9	46.3
9	60	0.9%	28	37.4	34.9	118	0.9%	23	31.8	23.0	68	0.5%	26	38.9	39.3
10	44	0.6%	23	42.0	62.2	85	0.7%	24	32.2	21.5	44	0.3%	27	32.5	25.7
11	33	0.5%	27	33.3	25.1	66	0.5%	27	36.9	33.3	30	0.2%	25	30.6	19.8
12	18	0.3%	22	27.7	21.8	44	0.3%	25	36.9	45.9	21	0.1%	22	29.9	31.3
13	15	0.2%	26	26.5	13.8	32	0.3%	27	43.7	44.3	15	0.1%	18	20.5	10.2
14	11	0.2%	25	31.0	21.8	18	0.1%	22	23.6	11.2	12	0.1%	15	20.5	11.5
15	*****	*****	28	31.5	18.2	*****	*****	24	25.7	11.5	*****	*****	22	23.8	6.8
16	*****	*****	40	38.5	19.2	*****	*****	22	25.0	12.6	*****	*****	26	28.5	11.1
17	*****	*****	30	30.0	21.2	*****	*****	35	33.5	12.8	*****	*****	47	47.0	21.2
18	0	0.0%				*****	*****	26	25.3	8.8	*****	*****	*****	*****	*****
19	0	0.0%				*****	*****	45	45.0	24.0	*****	*****	*****	*****	*****
20	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
21	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
22	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	2,807	41.1%	79	262.8	353.2	5,247	41.4%	45	234.8	334.6	6,655	46.6%	16	212.7	321.5

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Alogliptin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	10,473	100%	29	141.8	237.5	5,537	100%	34	151.2	236.3
Gap Number										
1	2,329	22.2%	26	48.7	66.2	1,219	22.0%	28	52.1	75.3
2	1,072	10.2%	27	44.6	54.5	557	10.1%	29	48.1	63.2
3	547	5.2%	25	42.5	52.6	253	4.6%	26	45.3	59.4
4	293	2.8%	26	41.6	45.4	128	2.3%	29	38.3	33.8
5	169	1.6%	28	41.2	45.0	69	1.2%	26	44.2	88.8
6	102	1.0%	28	34.4	28.2	36	0.7%	30	38.7	41.4
7	64	0.6%	22	32.9	31.2	22	0.4%	20	23.8	14.5
8	42	0.4%	19	40.5	67.2	15	0.3%	29	34.4	26.6
9	30	0.3%	24	37.3	32.8	11	0.2%	30	30.1	13.9
10	23	0.2%	18	25.7	16.3	*****	*****	22	31.5	19.1
11	18	0.2%	28	29.9	18.1	*****	*****	26	26.3	11.0
12	16	0.2%	24	38.8	37.2	*****	*****	25	26.0	5.6
13	11	0.1%	16	18.1	7.8	*****	*****	*****	*****	*****
14	*****	*****	22	21.9	8.1	0	0.0%			
15	*****	*****	19	21.8	6.9	0	0.0%			
16	*****	*****	21	20.5	7.8	0	0.0%			
17	*****	*****	*****	*****	*****	0	0.0%			
18	*****	*****	*****	*****	*****	0	0.0%			
19	*****	*****	*****	*****	*****	0	0.0%			
20	*****	*****	*****	*****	*****	0	0.0%			
21	0	0.0%				0	0.0%			
22	0	0.0%				0	0.0%			
Gap from last episode until censoring	5,740	54.8%	73	221.4	293.3	3,213	58.0%	105	225.5	282.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Canagliflozin	18-44 years					45-54 years					55-64 years					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	
Total Episodes	81,192	100%	25	105.5	204.6	152,587	100%	22	102.2	204.8	182,089	100%	22	111.3	216.3	
Gap Number																
1	17,603	21.7%	25	55.6	96.3	33,152	21.7%	24	54.9	98.9	39,840	21.9%	25	54.4	94.8	
2	10,184	12.5%	26	48.5	74.2	18,453	12.1%	24	47.5	76.6	20,181	11.1%	25	47.1	73.7	
3	6,333	7.8%	25	46.0	69.4	11,240	7.4%	25	44.1	62.4	11,329	6.2%	25	44.5	66.3	
4	4,045	5.0%	26	44.9	61.0	7,049	4.6%	25	42.2	55.2	6,677	3.7%	25	42.7	57.5	
5	2,660	3.3%	26	43.3	61.6	4,597	3.0%	25	41.7	56.7	4,157	2.3%	25	39.7	52.8	
6	1,766	2.2%	25	41.1	50.3	3,085	2.0%	25	39.7	49.5	2,708	1.5%	25	40.2	52.9	
7	1,204	1.5%	27	43.4	54.1	2,093	1.4%	25	39.2	51.0	1,788	1.0%	24	37.5	41.4	
8	821	1.0%	25	37.9	40.5	1,408	0.9%	23	37.5	44.9	1,217	0.7%	24	36.9	39.8	
9	563	0.7%	24	38.9	44.8	972	0.6%	24	35.9	35.7	812	0.4%	25	35.1	36.0	
10	378	0.5%	26	37.2	45.0	659	0.4%	25	35.1	32.1	552	0.3%	24	34.1	32.9	
11	240	0.3%	25	39.3	43.3	450	0.3%	23	34.8	31.9	385	0.2%	24	33.1	27.9	
12	159	0.2%	27	37.9	36.1	306	0.2%	26	38.4	43.1	259	0.1%	23	33.4	32.2	
13	108	0.1%	26	35.3	31.4	193	0.1%	23	34.1	32.9	178	0.1%	23	34.6	38.8	
14	67	0.1%	20	27.1	23.7	124	0.1%	25	29.8	25.0	118	0.1%	23	36.6	44.9	
15	42	0.1%	21	32.6	26.4	78	0.1%	25	34.7	43.0	72	0.0%	20	28.3	22.3	
16	29	0.0%	27	40.9	45.8	45	0.0%	22	28.9	19.9	39	0.0%	24	31.5	28.3	
17	17	0.0%	24	37.1	28.1	25	0.0%	32	52.0	81.6	19	0.0%	15	23.6	19.9	
18	12	0.0%	19	22.8	11.4	*****	*****	29	33.3	23.5	14	0.0%	21	23.8	10.0	
19	*****	*****	20	22.9	11.4	*****	*****	20	23.7	14.8	*****	*****	18	19.2	6.9	
20	*****	*****	16	22.0	18.8	*****	*****	*****	*****	*****	*****	*****	19	24.6	19.4	
21	*****	*****	25	25.8	8.5	0	0.0%	0	0.0%	0	0.0%	*****	*****	24	24.0	10.1
22	*****	*****	22	22.0	1.4	0	0.0%	0	0.0%	0	0.0%	*****	*****	21	31.3	27.1
23	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	27	33.3	25.1
24	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****
25	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****
26	0	0.0%	0	0.0%	0	0	0.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****
Gap from last episode until censoring	34,937	43.0%	16	180.0	281.5	68,643	45.0%	2	168.4	278.3	91,708	50.4%	2	173.3	280.9	

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Canagliflozin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	193,744	100%	25	113.6	206.5	59,810	100%	28	126.4	215.4
Gap Number										
1	42,024	21.7%	26	53.8	82.6	12,525	20.9%	27	53.3	77.7
2	18,464	9.5%	27	48.6	66.3	5,172	8.6%	26	48.1	67.6
3	8,948	4.6%	27	46.2	59.7	2,398	4.0%	27	42.8	49.9
4	4,727	2.4%	27	44.5	54.3	1,229	2.1%	28	44.6	53.8
5	2,616	1.4%	27	41.9	47.5	668	1.1%	27	41.8	49.5
6	1,510	0.8%	28	42.5	48.2	384	0.6%	26	40.2	58.4
7	861	0.4%	27	38.0	33.2	226	0.4%	28	40.5	37.5
8	524	0.3%	28	42.3	47.1	130	0.2%	31	38.1	26.7
9	309	0.2%	27	37.2	32.5	77	0.1%	25	35.3	38.5
10	186	0.1%	28	37.7	31.1	42	0.1%	28	39.1	54.1
11	110	0.1%	26	36.4	35.1	28	0.0%	32	49.3	58.0
12	59	0.0%	30	33.9	24.6	13	0.0%	25	25.8	12.4
13	*****	*****	27	36.3	23.6	*****	*****	28	26.2	12.3
14	*****	*****	33	33.5	18.0	*****	*****	33	42.0	17.3
15	*****	*****	22	25.0	12.5	*****	*****	48	48.0	19.8
16	*****	*****	28	25.7	8.7	*****	*****	41	41.0	17.0
17	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
19	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
20	*****	*****	*****	*****	*****	0	0.0%			
21	*****	*****	*****	*****	*****	0	0.0%			
22	0	0.0%				0	0.0%			
23	0	0.0%				0	0.0%			
24	0	0.0%				0	0.0%			
25	0	0.0%				0	0.0%			
26	0	0.0%				0	0.0%			
Gap from last episode until censoring	113,338	58.5%	13	158.6	253.5	36,902	61.7%	36	174.0	257.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dapagliflozin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	28,588	100%	26	119.4	215.2	53,095	100%	24	113.4	213.6	59,406	100%	23	116.4	215.2
Gap Number															
1	6,376	22.3%	26	56.4	93.2	11,887	22.4%	25	53.5	89.8	13,264	22.3%	25	54.4	89.5
2	3,509	12.3%	26	52.0	82.8	6,361	12.0%	25	49.2	82.7	6,507	11.0%	25	48.3	73.5
3	2,065	7.2%	26	47.8	64.9	3,722	7.0%	25	45.1	70.0	3,513	5.9%	25	46.1	69.4
4	1,248	4.4%	26	46.8	63.9	2,245	4.2%	25	42.6	59.3	1,987	3.3%	25	41.2	51.9
5	801	2.8%	25	41.7	59.7	1,394	2.6%	25	43.2	57.2	1,184	2.0%	25	41.9	56.9
6	520	1.8%	22	40.8	58.5	900	1.7%	25	39.1	48.0	736	1.2%	26	41.0	44.0
7	332	1.2%	24	39.3	48.1	586	1.1%	23	37.9	47.6	482	0.8%	24	37.5	36.9
8	210	0.7%	26	39.1	46.9	393	0.7%	25	39.2	45.6	317	0.5%	25	39.8	46.2
9	145	0.5%	25	39.2	51.4	249	0.5%	24	32.8	34.7	191	0.3%	26	34.6	28.5
10	88	0.3%	26	34.0	25.8	154	0.3%	21	33.9	35.6	124	0.2%	22	29.9	24.4
11	61	0.2%	24	38.5	38.4	91	0.2%	19	36.7	42.8	85	0.1%	27	38.6	37.8
12	37	0.1%	21	27.8	18.6	62	0.1%	22	25.3	14.3	49	0.1%	26	30.3	24.5
13	25	0.1%	21	32.6	38.5	36	0.1%	22	28.6	18.9	29	0.0%	26	29.7	13.2
14	19	0.1%	19	26.7	17.0	21	0.0%	17	25.8	16.3	19	0.0%	18	24.6	13.9
15	15	0.1%	29	38.1	23.6	17	0.0%	22	25.2	12.0	*****	*****	28	41.4	47.0
16	*****	*****	31	34.1	15.4	12	0.0%	23	27.8	15.6	*****	*****	27	26.5	17.7
17	*****	*****	23	34.3	22.3	*****	*****	20	33.5	31.3	*****	*****	17	16.5	0.7
18	0	0.0%				*****	*****	40	51.7	41.7	*****	*****	*****	*****	*****
19	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
20	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
21	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	13,126	45.9%	34	200.0	284.9	24,953	47.0%	12	186.6	282.7	30,904	52.0%	5	178.2	274.8

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dapagliflozin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	32,206	100%	23	112.7	198.4	8,847	100%	27	124.2	205.0
Gap Number										
1	6,634	20.6%	25	49.7	74.4	1,733	19.6%	27	51.1	73.8
2	2,607	8.1%	26	46.0	67.6	600	6.8%	28	46.3	62.8
3	1,148	3.6%	25	40.1	49.5	272	3.1%	29	48.0	60.6
4	565	1.8%	25	39.0	44.3	135	1.5%	26	38.7	40.3
5	316	1.0%	24	44.4	66.1	63	0.7%	23	32.6	27.5
6	162	0.5%	26	37.6	35.8	32	0.4%	25	36.4	30.5
7	95	0.3%	24	35.3	36.2	15	0.2%	24	28.1	16.0
8	*****	*****	26	37.3	33.1	*****	*****	20	32.2	30.3
9	*****	*****	23	33.9	34.9	*****	*****	20	34.7	36.1
10	*****	*****	28	42.6	35.4	*****	*****	20	27.7	17.8
11	*****	*****	29	31.3	21.0	*****	*****	*****	*****	*****
12	*****	*****	31	27.8	13.0	*****	*****	*****	*****	*****
13	*****	*****	32	29.8	10.3	*****	*****	*****	*****	*****
14	*****	*****	30	25.8	10.0	*****	*****	*****	*****	*****
15	*****	*****	22	21.6	5.5	*****	*****	*****	*****	*****
16	*****	*****	34	33.5	3.5	*****	*****	*****	*****	*****
17	*****	*****	38	37.5	16.3	*****	*****	*****	*****	*****
18	*****	*****	46	45.5	41.7	*****	*****	*****	*****	*****
19	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
20	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
21	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	20,518	63.7%	7	150.3	235.1	5,969	67.5%	28	160.7	236.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Dulaglutide</u>	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	23,718	100%	18	67.5	133.7	43,305	100%	15	58.8	125.4	54,250	100%	14	57.6	124.5
Gap Number															
1	5,327	22.5%	22	45.6	71.8	9,569	22.1%	22	43.4	68.1	11,864	21.9%	22	42.4	64.1
2	2,575	10.9%	25	44.8	61.7	4,508	10.4%	23	42.6	59.3	5,107	9.4%	23	42.1	58.4
3	1,362	5.7%	25	43.0	56.4	2,323	5.4%	25	39.4	46.1	2,528	4.7%	24	39.3	48.1
4	726	3.1%	26	41.0	46.1	1,318	3.0%	24	37.7	43.8	1,372	2.5%	24	38.1	41.6
5	432	1.8%	28	40.8	44.0	748	1.7%	23	33.4	29.4	757	1.4%	24	37.9	41.0
6	235	1.0%	26	43.2	48.6	428	1.0%	24	35.1	31.2	431	0.8%	22	32.9	31.1
7	115	0.5%	24	44.3	66.3	242	0.6%	22	34.2	35.2	226	0.4%	25	36.0	33.7
8	60	0.3%	22	30.3	20.3	145	0.3%	23	31.4	25.2	111	0.2%	23	34.0	28.4
9	36	0.2%	26	36.7	34.0	68	0.2%	24	30.3	29.5	53	0.1%	23	32.4	27.8
10	14	0.1%	24	30.8	14.7	37	0.1%	23	30.2	20.2	28	0.1%	28	37.2	39.1
11	*****	*****	27	36.0	21.8	*****	*****	28	28.2	10.1	17	0.0%	22	36.2	43.5
12	*****	*****	22	36.7	38.3	*****	*****	31	35.2	16.3	*****	*****	15	17.2	5.2
13	*****	*****	*****	*****	*****	*****	*****	30	29.5	3.5	*****	*****	18	24.3	18.4
14	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	19	18.8	6.7
15	0	0.0%				*****	*****	*****	*****	*****	*****	*****	27	26.5	7.8
Gap from last episode until censoring	12,821	54.1%	0	87.2	169.5	23,898	55.2%	0	72.8	158.6	31,738	58.5%	0	69.2	154.1

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Dulaglutide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	42,912	100%	16	67.7	129.7	12,786	100%	17	70.8	131.5
Gap Number										
1	9,205	21.5%	23	45.6	65.9	2,668	20.9%	24	45.7	62.7
2	3,692	8.6%	24	43.8	57.3	1,056	8.3%	26	43.2	55.3
3	1,689	3.9%	25	40.1	44.4	479	3.7%	23	37.9	42.0
4	813	1.9%	25	38.3	42.4	237	1.9%	25	35.7	35.1
5	412	1.0%	24	35.4	36.4	120	0.9%	23	31.8	24.6
6	202	0.5%	24	34.5	35.9	54	0.4%	20	30.5	28.2
7	103	0.2%	26	32.4	24.6	31	0.2%	25	30.6	18.0
8	*****	*****	29	32.9	22.4	*****	*****	17	29.1	25.4
9	*****	*****	21	33.0	22.9	*****	*****	25	25.5	7.0
10	*****	*****	21	26.8	15.2	0	0.0%			
11	*****	*****	29	41.0	30.9	0	0.0%			
12	*****	*****	*****	*****	*****	0	0.0%			
13	*****	*****	*****	*****	*****	0	0.0%			
14	0	0.0%				0	0.0%			
15	0	0.0%				0	0.0%			
Gap from last episode until censoring	26,696	62.2%	0	82.4	155.9	8,126	63.6%	0	86.7	157.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Empagliflozin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	28,121	100%	18	66.5	136.5	58,356	100%	15	58.0	127.5	73,986	100%	13	57.3	128.3
Gap Number															
1	6,327	22.5%	24	44.7	68.9	12,962	22.2%	23	44.6	72.2	15,983	21.6%	23	44.2	70.4
2	3,093	11.0%	25	41.6	55.3	6,132	10.5%	23	39.9	57.0	6,644	9.0%	22	40.8	58.7
3	1,659	5.9%	25	39.7	47.2	3,166	5.4%	23	39.1	51.2	3,244	4.4%	23	38.4	52.9
4	947	3.4%	24	39.1	47.5	1,751	3.0%	24	36.4	43.5	1,706	2.3%	23	38.0	49.9
5	560	2.0%	26	39.8	42.9	1,007	1.7%	23	36.4	45.2	946	1.3%	24	37.9	45.3
6	341	1.2%	26	39.2	40.9	604	1.0%	24	40.5	48.2	522	0.7%	24	35.1	36.5
7	202	0.7%	26	40.3	38.8	372	0.6%	22	34.0	36.4	317	0.4%	23	35.4	40.7
8	105	0.4%	24	35.6	28.5	228	0.4%	23	32.2	27.8	189	0.3%	27	34.2	31.4
9	63	0.2%	22	33.4	35.0	135	0.2%	24	31.4	23.5	113	0.2%	23	29.8	23.8
10	38	0.1%	24	34.6	27.8	79	0.1%	22	31.4	31.8	76	0.1%	26	32.1	20.1
11	25	0.1%	32	35.5	20.9	40	0.1%	21	23.2	11.0	45	0.1%	29	43.7	41.9
12	*****	*****	20	22.1	9.5	22	0.0%	23	28.2	33.3	21	0.0%	22	28.3	22.5
13	*****	*****	21	21.3	2.9	*****	*****	21	23.6	12.7	*****	*****	27	36.4	26.3
14	*****	*****	18	26.7	21.4	*****	*****	24	22.0	4.0	*****	*****	15	26.2	25.4
15	*****	*****	*****	*****	*****	*****	*****	21	31.3	23.2	*****	*****	20	17.8	4.6
16	0	0.0%				*****	*****	26	24.0	3.5	*****	*****	14	13.5	3.5
17	0	0.0%				*****	*****	*****	*****	*****	*****	*****	16	16.0	7.1
18	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
19	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	14,738	52.4%	0	88.5	177.0	31,831	54.5%	0	71.8	161.6	44,159	59.7%	0	67.7	156.8

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Empagliflozin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	41,849	100%	14	67.2	135.5	11,596	100%	15	74.0	141.5
Gap Number										
1	8,433	20.2%	25	46.5	66.1	2,146	18.5%	26	50.6	74.0
2	2,997	7.2%	26	43.8	56.0	717	6.2%	27	45.3	58.0
3	1,244	3.0%	26	41.7	46.9	285	2.5%	26	43.7	52.6
4	608	1.5%	26	38.2	39.8	118	1.0%	31	46.6	55.5
5	299	0.7%	29	39.2	37.2	57	0.5%	26	35.0	27.1
6	151	0.4%	24	30.6	22.4	29	0.3%	27	33.9	23.5
7	71	0.2%	23	36.2	32.5	17	0.1%	26	29.7	14.5
8	*****	*****	25	32.5	28.8	*****	*****	21	35.8	40.4
9	*****	*****	22	27.8	20.9	*****	*****	35	47.5	38.3
10	*****	*****	20	21.4	8.7	*****	*****	*****	*****	*****
11	*****	*****	22	20.6	5.9	0	0.0%			
12	*****	*****	15	18.0	8.5	0	0.0%			
13	*****	*****	20	20.0	9.0	0	0.0%			
14	0	0.0%				0	0.0%			
15	0	0.0%				0	0.0%			
16	0	0.0%				0	0.0%			
17	0	0.0%				0	0.0%			
18	0	0.0%				0	0.0%			
19	0	0.0%				0	0.0%			
Gap from last episode until censoring	27,975	66.8%	0	78.4	159.0	8,210	70.8%	0	84.7	161.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide	18-44 years					45-54 years					55-64 years					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	
Total Episodes	106,240	100%	45	280.4	530.8	174,507	100%	38	260.3	515.6	189,200	100%	36	248.7	487.0	
Gap Number																
1	21,311	20.1%	30	95.5	236.1	33,954	19.5%	28	88.6	219.7	36,988	19.5%	28	82.3	196.2	
2	13,095	12.3%	31	87.3	207.3	21,271	12.2%	29	82.8	201.2	22,171	11.7%	28	72.0	160.4	
3	8,606	8.1%	33	84.7	188.2	14,248	8.2%	30	74.6	174.6	14,800	7.8%	29	65.8	140.5	
4	5,960	5.6%	32	82.8	176.7	10,088	5.8%	30	71.8	157.6	10,271	5.4%	29	65.6	143.8	
5	4,195	3.9%	32	76.6	158.6	7,222	4.1%	30	68.9	154.4	7,409	3.9%	30	63.3	127.3	
6	3,021	2.8%	32	75.6	161.0	5,374	3.1%	30	63.4	136.2	5,387	2.8%	30	59.8	117.9	
7	2,227	2.1%	31	76.9	176.2	4,030	2.3%	30	64.3	142.2	3,993	2.1%	29	56.9	103.1	
8	1,672	1.6%	31	68.6	143.9	3,068	1.8%	30	62.6	137.2	3,017	1.6%	29	57.5	118.4	
9	1,224	1.2%	32	70.7	153.4	2,309	1.3%	30	60.3	112.8	2,272	1.2%	29	55.6	100.9	
10	911	0.9%	31	66.8	136.2	1,712	1.0%	31	61.0	131.6	1,740	0.9%	29	48.6	67.3	
11	684	0.6%	32	63.7	149.3	1,305	0.7%	30	55.6	109.6	1,333	0.7%	30	50.6	87.9	
12	486	0.5%	30	53.4	97.7	1,006	0.6%	30	52.7	84.4	1,027	0.5%	29	51.0	96.0	
13	369	0.3%	31	70.3	132.3	802	0.5%	30	57.8	114.3	826	0.4%	29	46.1	63.3	
14	288	0.3%	30	52.9	76.7	638	0.4%	30	52.9	114.8	644	0.3%	31	51.7	74.0	
15	228	0.2%	29	59.8	114.3	498	0.3%	28	56.5	135.5	502	0.3%	27	53.4	122.6	
16	174	0.2%	31	63.9	139.7	387	0.2%	28	44.9	67.6	387	0.2%	30	47.2	69.9	
17	133	0.1%	29	45.7	64.5	308	0.2%	28	49.3	98.3	304	0.2%	28	44.7	74.0	
18	104	0.1%	28	83.4	182.3	251	0.1%	30	46.2	55.1	232	0.1%	31	44.8	83.5	
19	80	0.1%	30	45.3	48.7	196	0.1%	31	45.5	52.7	193	0.1%	32	54.2	93.1	
20	65	0.1%	32	49.3	55.5	157	0.1%	28	43.1	51.1	152	0.1%	31	40.2	37.2	
21	50	0.0%	27	42.9	44.1	125	0.1%	28	38.9	33.1	113	0.1%	26	34.2	32.7	
22	39	0.0%	27	35.2	30.0	103	0.1%	32	41.9	37.2	87	0.0%	25	34.1	43.3	
23	28	0.0%	37	78.8	196.7	93	0.1%	27	39.7	50.0	71	0.0%	27	35.9	23.2	
24	*****	*****	19	29.2	18.6	75	0.0%	33	61.3	135.7	56	0.0%	30	47.9	46.9	
25	*****	*****	21	33.4	26.0	61	0.0%	34	66.2	106.3	46	0.0%	24	31.2	19.6	
26	*****	*****	33	44.8	30.3	48	0.0%	29	43.6	67.9	41	0.0%	30	38.3	27.5	
27	*****	*****	38	69.9	104.5	33	0.0%	34	46.2	48.2	35	0.0%	29	36.7	25.7	
28	*****	*****	28	42.9	39.0	27	0.0%	38	51.1	58.1	25	0.0%	27	40.4	37.3	
29	*****	*****	18	54.2	74.1	22	0.0%	36	41.0	30.3	17	0.0%	17	24.5	18.0	
30	*****	*****	18	18.0	1.6	19	0.0%	31	34.5	15.6	14	0.0%	22	34.0	30.4	
31	*****	*****	34	66.5	78.2	17	0.0%	29	29.6	13.2	*****	*****	18	23.3	13.5	
32	*****	*****	20	33.0	24.3	16	0.0%	47	46.2	20.5	*****	*****	20	23.7	11.2	
33	*****	*****	15	31.7	30.6	13	0.0%	26	31.6	17.2	*****	*****	32	30.2	13.9	
34	*****	*****	15	28.7	25.4	11	0.0%	41	50.5	62.0	*****	*****	13	17.2	7.7	

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide, continued			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	21	43.0	47.0	*****	*****	34	36.0	21.0	*****	*****	25	24.3	9.0
36	*****	*****	12	11.5	0.7	*****	*****	32	41.4	37.1	*****	*****	34	29.0	10.0
37	*****	*****	11	11.0	0.0	*****	*****	46	93.8	111.8	*****	*****	28	27.5	3.5
38	0	0.0%				*****	*****	23	22.5	3.5	*****	*****	22	22.0	0.0
39	0	0.0%				*****	*****	*****	*****	*****	*****	*****	33	32.5	0.7
40	0	0.0%				*****	*****	*****	*****	*****	*****	*****	33	33.0	8.5
41	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
42	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
43	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
44	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	41,173	38.8%	311	588.8	712.7	64,990	37.2%	281	569.5	710.1	75,001	39.6%	249	521.0	661.4

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	175,416	100%	41	278.6	509.8	43,675	100%	42	272.6	482.8
Gap Number										
1	33,713	19.2%	29	78.4	162.2	8,224	18.8%	29	70.3	136.5
2	19,881	11.3%	29	68.5	136.5	4,703	10.8%	28	65.8	121.3
3	13,147	7.5%	29	65.5	124.5	3,060	7.0%	27	58.6	109.9
4	9,005	5.1%	29	56.6	94.4	2,097	4.8%	28	58.9	107.6
5	6,493	3.7%	29	58.0	107.3	1,489	3.4%	29	52.3	77.9
6	4,784	2.7%	30	55.5	89.3	1,080	2.5%	27	46.8	70.3
7	3,497	2.0%	29	52.9	87.9	819	1.9%	29	47.6	74.7
8	2,578	1.5%	28	49.4	78.5	619	1.4%	28	49.8	122.9
9	1,955	1.1%	28	48.2	72.7	447	1.0%	31	42.6	42.6
10	1,481	0.8%	29	48.4	74.2	342	0.8%	32	47.2	60.1
11	1,149	0.7%	30	49.2	85.7	262	0.6%	29	45.9	64.5
12	883	0.5%	28	42.2	48.1	208	0.5%	29	41.1	51.9
13	699	0.4%	30	46.9	74.9	161	0.4%	30	42.3	58.4
14	559	0.3%	31	49.5	67.7	129	0.3%	29	42.6	49.2
15	418	0.2%	29	45.2	59.9	107	0.2%	32	51.7	65.9
16	315	0.2%	31	42.3	45.8	83	0.2%	30	40.9	44.0
17	250	0.1%	32	49.8	75.0	64	0.1%	32	56.6	99.3
18	193	0.1%	29	42.8	66.7	53	0.1%	29	40.5	43.1
19	154	0.1%	29	40.7	41.0	42	0.1%	27	43.0	53.8
20	122	0.1%	27	37.1	32.9	37	0.1%	31	43.6	77.5
21	91	0.1%	27	36.9	38.3	28	0.1%	24	46.1	68.7
22	74	0.0%	30	37.8	28.0	21	0.0%	22	38.1	36.4
23	67	0.0%	34	61.4	148.1	13	0.0%	29	36.5	31.2
24	54	0.0%	30	37.2	25.8	*****	*****	20	23.0	12.3
25	45	0.0%	33	43.8	44.6	*****	*****	34	36.0	15.6
26	34	0.0%	30	43.1	38.2	*****	*****	40	30.6	15.4
27	26	0.0%	32	33.6	21.3	*****	*****	34	29.3	12.5
28	21	0.0%	33	43.1	55.9	*****	*****	27	30.7	16.8
29	17	0.0%	36	39.9	23.1	*****	*****	46	44.0	3.5
30	*****	*****	33	40.5	27.9	*****	*****	38	45.0	13.9
31	13	0.0%	29	37.1	23.5	*****	*****	22	25.7	6.4
32	*****	*****	29	67.4	81.8	*****	*****	27	27.7	3.1
33	*****	*****	31	48.0	46.1	*****	*****	29	32.3	7.6
34	*****	*****	44	54.7	30.2	*****	*****	24	21.7	6.8

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Exenatide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	37	34.0	7.0	*****	*****	38	38.3	4.5
36	*****	*****	47	47.0	19.8	*****	*****	29	29.0	6.0
37	*****	*****	*****	*****	*****	*****	*****	38	36.0	12.1
38	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
39	0	0.0%				*****	*****	*****	*****	*****
40	0	0.0%				*****	*****	*****	*****	*****
41	0	0.0%				*****	*****	*****	*****	*****
42	0	0.0%				*****	*****	*****	*****	*****
43	0	0.0%				*****	*****	*****	*****	*****
44	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	73,653	42.0%	323	572.1	668.4	19,527	44.7%	303	534.0	617.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glimepiride	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	284,276	100%	32	166.7	372.4	541,233	100%	30	156.1	359.7	702,790	100%	29	145.6	335.3
Gap Number															
1	51,988	18.3%	33	116.7	260.6	100,494	18.6%	32	118.1	265.1	137,098	19.5%	33	111.0	240.1
2	35,225	12.4%	33	94.2	207.1	67,007	12.4%	32	92.9	207.8	87,247	12.4%	32	86.3	186.1
3	25,188	8.9%	32	83.3	179.9	47,428	8.8%	31	82.5	187.2	58,838	8.4%	31	75.5	154.1
4	18,533	6.5%	31	77.1	170.6	34,621	6.4%	31	74.6	161.6	41,494	5.9%	31	68.9	140.6
5	13,893	4.9%	31	73.9	164.2	25,973	4.8%	30	70.2	150.7	29,792	4.2%	30	65.7	133.5
6	10,551	3.7%	31	70.1	145.2	19,729	3.6%	30	67.1	144.3	21,947	3.1%	30	61.8	119.4
7	8,157	2.9%	30	67.4	140.0	15,218	2.8%	30	64.3	135.2	16,379	2.3%	30	60.3	117.0
8	6,344	2.2%	30	63.7	138.1	11,824	2.2%	29	59.9	119.3	12,408	1.8%	30	58.0	112.4
9	4,997	1.8%	29	60.4	126.0	9,241	1.7%	30	60.4	122.9	9,516	1.4%	30	54.5	100.1
10	3,921	1.4%	29	62.2	132.3	7,238	1.3%	29	57.4	117.5	7,297	1.0%	29	51.6	89.8
11	3,175	1.1%	28	55.2	106.9	5,737	1.1%	28	56.7	116.4	5,664	0.8%	29	51.4	91.0
12	2,515	0.9%	29	55.1	111.2	4,568	0.8%	28	50.3	88.2	4,427	0.6%	29	49.5	78.4
13	2,013	0.7%	28	55.9	111.1	3,693	0.7%	29	53.4	108.0	3,443	0.5%	29	48.9	82.9
14	1,601	0.6%	27	52.4	100.6	2,962	0.5%	27	47.5	78.0	2,702	0.4%	29	48.2	76.8
15	1,287	0.5%	28	51.1	89.5	2,376	0.4%	28	52.9	101.0	2,131	0.3%	29	45.6	66.4
16	1,026	0.4%	27	53.0	102.1	1,906	0.4%	28	53.3	112.4	1,722	0.2%	29	46.2	83.8
17	841	0.3%	27	47.7	66.4	1,527	0.3%	29	52.2	93.6	1,351	0.2%	29	45.1	62.6
18	683	0.2%	27	49.9	120.6	1,237	0.2%	28	47.4	84.7	1,073	0.2%	28	46.3	88.4
19	536	0.2%	27	40.2	40.2	1,019	0.2%	29	51.9	101.0	871	0.1%	27	43.9	59.5
20	433	0.2%	27	44.7	70.2	802	0.1%	28	45.4	66.9	705	0.1%	27	40.0	51.6
21	359	0.1%	26	43.5	67.0	644	0.1%	29	47.6	87.6	547	0.1%	29	45.6	69.3
22	289	0.1%	25	39.6	64.8	498	0.1%	29	44.0	55.8	446	0.1%	28	40.6	47.8
23	243	0.1%	24	41.0	77.1	409	0.1%	28	40.9	48.7	342	0.0%	28	43.1	61.1
24	197	0.1%	26	50.2	93.0	341	0.1%	31	41.4	51.9	270	0.0%	29	36.7	29.8
25	156	0.1%	26	34.2	32.0	288	0.1%	28	41.1	44.0	217	0.0%	26	40.6	47.1
26	118	0.0%	28	38.2	36.0	224	0.0%	27	41.5	60.3	174	0.0%	29	38.7	38.2
27	93	0.0%	26	40.6	54.4	178	0.0%	28	38.1	34.5	137	0.0%	27	35.2	30.8
28	78	0.0%	25	37.4	56.5	152	0.0%	25	36.6	30.4	100	0.0%	29	39.9	48.0
29	63	0.0%	22	28.7	21.1	119	0.0%	27	40.5	50.1	80	0.0%	27	30.2	18.4
30	51	0.0%	29	38.5	42.5	95	0.0%	27	37.3	44.2	68	0.0%	27	36.9	49.0
31	43	0.0%	19	35.0	36.9	77	0.0%	28	50.2	83.3	59	0.0%	29	36.4	34.6
32	35	0.0%	25	33.1	22.5	60	0.0%	28	58.2	140.1	45	0.0%	29	31.7	20.4
33	32	0.0%	21	27.8	19.3	53	0.0%	26	36.7	42.7	36	0.0%	24	29.9	18.7
34	28	0.0%	22	40.2	49.7	43	0.0%	27	37.2	31.7	26	0.0%	31	36.4	22.5

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glimepiride, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	23	0.0%	25	30.1	29.7	32	0.0%	32	41.9	35.7	*****	*****	24	37.1	36.8
36	18	0.0%	17	22.3	15.4	25	0.0%	25	34.8	30.4	*****	*****	24	27.2	14.0
37	14	0.0%	20	32.6	33.6	19	0.0%	26	30.0	17.6	*****	*****	36	42.8	37.0
38	11	0.0%	18	19.5	9.1	17	0.0%	24	38.3	40.8	*****	*****	21	28.9	21.6
39	*****	*****	13	34.9	43.8	*****	*****	24	31.0	19.2	*****	*****	27	29.5	17.1
40	*****	*****	18	19.2	6.8	*****	*****	31	34.6	25.0	*****	*****	31	74.3	97.7
41	*****	*****	15	15.4	2.5	*****	*****	18	20.0	10.1	*****	*****	25	26.0	15.5
42	*****	*****	11	23.2	19.2	*****	*****	32	31.5	29.0	*****	*****	48	47.5	20.5
43	*****	*****	15	20.4	8.9	*****	*****	*****	*****	*****	*****	*****	21	21.0	12.7
44	*****	*****	14	17.0	8.3	*****	*****	*****	*****	*****	0	0.0%			
45	*****	*****	12	12.0	1.0	*****	*****	*****	*****	*****	0	0.0%			
46	*****	*****	15	21.0	14.0	*****	*****	*****	*****	*****	0	0.0%			
47	*****	*****	25	25.0	19.8	*****	*****	*****	*****	*****	0	0.0%			
48	*****	*****	22	22.0	15.6	*****	*****	*****	*****	*****	0	0.0%			
49	*****	*****	20	20.0	9.9	*****	*****	*****	*****	*****	0	0.0%			
50	*****	*****	12	11.5	0.7	*****	*****	*****	*****	*****	0	0.0%			
51	*****	*****	19	19.0	8.5	*****	*****	*****	*****	*****	0	0.0%			
52	*****	*****	44	43.5	19.1	0	0.0%				0	0.0%			
Gap from last episode until censoring	89,466	31.5%	51	339.6	558.1	173,332	32.0%	16	303.4	536.2	254,079	36.2%	0	256.3	482.9

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glimepiride</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,363,768	100%	28	141.8	329.9	917,320	100%	28	145.8	326.7
Gap Number										
1	274,551	20.1%	33	100.8	204.9	187,042	20.4%	33	91.7	180.6
2	170,561	12.5%	32	78.5	152.6	110,417	12.0%	31	72.2	132.9
3	113,166	8.3%	32	70.4	130.8	70,357	7.7%	31	65.4	115.2
4	77,392	5.7%	31	65.3	118.3	46,949	5.1%	31	61.1	104.6
5	54,434	4.0%	31	61.2	105.5	32,141	3.5%	31	57.6	95.6
6	38,896	2.9%	31	58.4	98.4	22,611	2.5%	30	54.5	82.6
7	28,129	2.1%	31	56.2	88.2	16,099	1.8%	30	52.6	79.7
8	20,490	1.5%	30	53.9	89.6	11,648	1.3%	30	52.5	76.6
9	15,257	1.1%	30	52.7	84.6	8,586	0.9%	31	51.2	75.9
10	11,279	0.8%	30	51.1	81.2	6,315	0.7%	30	50.8	74.4
11	8,487	0.6%	30	49.1	75.8	4,768	0.5%	30	47.7	62.1
12	6,465	0.5%	30	48.5	77.7	3,614	0.4%	30	46.9	65.2
13	4,986	0.4%	30	48.2	67.5	2,703	0.3%	30	47.1	66.5
14	3,866	0.3%	30	47.5	69.3	2,076	0.2%	29	45.9	70.9
15	2,985	0.2%	29	48.2	75.1	1,592	0.2%	29	46.3	72.9
16	2,311	0.2%	30	44.7	57.5	1,248	0.1%	29	46.6	67.8
17	1,776	0.1%	29	46.5	67.5	964	0.1%	29	46.0	86.1
18	1,331	0.1%	29	45.0	62.9	769	0.1%	30	44.4	54.4
19	1,030	0.1%	28	43.0	75.5	608	0.1%	28	42.5	64.6
20	822	0.1%	28	44.6	73.0	485	0.1%	27	37.1	38.8
21	625	0.0%	28	41.0	67.9	376	0.0%	29	41.2	54.9
22	495	0.0%	29	44.6	77.0	304	0.0%	28	37.2	30.3
23	385	0.0%	30	39.7	36.6	248	0.0%	28	42.3	43.5
24	304	0.0%	29	39.4	45.4	205	0.0%	30	42.8	59.2
25	239	0.0%	26	36.0	38.3	152	0.0%	29	43.4	51.6
26	187	0.0%	31	37.1	31.9	123	0.0%	29	40.4	60.6
27	151	0.0%	29	40.6	44.3	101	0.0%	30	40.6	34.7

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glimepiride, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
28	118	0.0%	28	34.9	25.7	80	0.0%	30	54.3	127.9
29	97	0.0%	28	45.3	78.4	65	0.0%	32	44.3	51.3
30	75	0.0%	27	32.9	28.1	51	0.0%	26	33.1	23.3
31	58	0.0%	30	37.0	32.9	39	0.0%	28	36.1	28.8
32	50	0.0%	31	42.9	38.5	27	0.0%	32	33.4	18.8
33	39	0.0%	32	34.6	20.0	21	0.0%	26	33.3	27.5
34	33	0.0%	32	42.2	37.7	19	0.0%	20	30.4	24.4
35	21	0.0%	29	37.7	27.4	*****	*****	36	39.9	21.6
36	14	0.0%	40	45.4	27.7	*****	*****	39	45.0	30.8
37	*****	*****	34	52.6	51.0	*****	*****	26	46.8	40.7
38	*****	*****	32	31.4	16.0	*****	*****	19	23.3	13.2
39	*****	*****	20	24.0	12.7	*****	*****	42	42.0	43.8
40	*****	*****	34	31.4	14.7	*****	*****	*****	*****	*****
41	*****	*****	29	28.5	3.4	*****	*****	*****	*****	*****
42	*****	*****	28	28.8	8.6	*****	*****	*****	*****	*****
43	*****	*****	19	19.0	7.0	0	0.0%			
44	*****	*****	25	25.0	6.0	0	0.0%			
45	*****	*****	21	21.0	7.1	0	0.0%			
46	*****	*****	16	16.0	5.7	0	0.0%			
47	*****	*****	*****	*****	*****	0	0.0%			
48	0	0.0%				0	0.0%			
49	0	0.0%				0	0.0%			
50	0	0.0%				0	0.0%			
51	0	0.0%				0	0.0%			
52	0	0.0%				0	0.0%			
Gap from last episode until censoring	522,616	38.3%	0	244.8	477.0	384,483	41.9%	0	246.7	458.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glipizide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	485,352	100%	37	174.1	380.4	884,129	100%	33	157.4	361.8	1,100,973	100%	31	150.0	348.4
Gap Number															
1	86,375	17.8%	40	143.4	304.0	156,806	17.7%	37	132.1	286.8	205,404	18.7%	35	119.0	254.8
2	59,872	12.3%	38	111.3	231.2	108,791	12.3%	35	100.5	214.6	135,574	12.3%	34	90.5	187.9
3	43,715	9.0%	37	100.1	206.0	79,469	9.0%	35	88.8	182.8	95,136	8.6%	33	81.2	164.1
4	32,741	6.7%	36	90.3	180.9	59,922	6.8%	34	81.5	164.1	69,408	6.3%	33	74.9	144.5
5	25,048	5.2%	35	82.9	161.9	45,830	5.2%	34	76.2	146.9	51,754	4.7%	33	70.2	134.4
6	19,416	4.0%	35	78.9	153.0	35,505	4.0%	33	72.8	142.5	39,291	3.6%	33	67.5	126.0
7	15,175	3.1%	34	73.8	141.0	27,828	3.1%	33	68.4	127.1	30,102	2.7%	33	64.7	116.8
8	11,925	2.5%	33	70.6	127.0	21,983	2.5%	32	65.8	120.8	23,244	2.1%	32	61.4	106.3
9	9,378	1.9%	33	68.2	124.7	17,372	2.0%	32	63.4	116.2	17,945	1.6%	32	59.0	94.9
10	7,401	1.5%	33	63.6	108.1	13,732	1.6%	32	61.0	107.4	13,943	1.3%	32	56.0	88.1
11	5,844	1.2%	32	60.7	99.7	10,927	1.2%	31	57.7	97.1	10,892	1.0%	31	54.2	80.9
12	4,587	0.9%	32	62.0	110.9	8,718	1.0%	31	56.7	91.2	8,469	0.8%	31	54.3	85.7
13	3,653	0.8%	30	59.8	109.2	6,885	0.8%	31	55.6	93.1	6,598	0.6%	31	52.8	76.7
14	2,882	0.6%	30	55.7	95.8	5,428	0.6%	31	51.6	81.9	5,158	0.5%	31	51.6	79.4
15	2,235	0.5%	30	56.5	109.1	4,374	0.5%	30	50.8	83.6	3,986	0.4%	30	50.3	69.6
16	1,794	0.4%	29	50.7	82.0	3,457	0.4%	30	49.1	69.7	3,060	0.3%	30	47.9	66.7
17	1,432	0.3%	29	45.6	55.2	2,769	0.3%	29	49.2	83.2	2,342	0.2%	30	49.3	74.6
18	1,117	0.2%	29	48.4	77.6	2,161	0.2%	29	47.4	63.5	1,829	0.2%	29	46.8	59.8
19	865	0.2%	28	48.7	85.5	1,747	0.2%	29	45.8	61.3	1,404	0.1%	30	44.9	54.7
20	686	0.1%	28	46.3	66.0	1,355	0.2%	28	47.5	72.4	1,103	0.1%	29	44.5	52.9
21	550	0.1%	30	49.2	88.1	1,042	0.1%	27	40.9	54.5	859	0.1%	29	42.3	52.0
22	451	0.1%	28	43.3	56.0	866	0.1%	27	46.7	84.0	681	0.1%	29	43.4	57.4
23	356	0.1%	28	44.2	55.9	693	0.1%	27	44.3	73.4	519	0.0%	30	45.3	68.3
24	297	0.1%	28	49.4	64.0	550	0.1%	29	44.4	57.3	408	0.0%	28	43.1	55.9
25	255	0.1%	29	46.4	71.9	436	0.0%	26	37.5	39.9	316	0.0%	28	41.9	57.9
26	208	0.0%	28	42.2	64.7	361	0.0%	27	39.2	47.9	256	0.0%	26	38.7	40.6
27	167	0.0%	25	46.8	87.8	286	0.0%	30	37.9	31.7	210	0.0%	28	44.4	56.9
28	137	0.0%	28	39.9	33.2	224	0.0%	27	43.4	67.0	173	0.0%	26	45.5	58.1
29	108	0.0%	25	37.2	35.9	183	0.0%	26	36.7	60.1	139	0.0%	27	39.5	36.8
30	88	0.0%	26	42.3	60.1	145	0.0%	27	37.9	34.7	113	0.0%	25	32.5	24.8
31	74	0.0%	23	36.0	48.1	115	0.0%	26	34.8	29.3	91	0.0%	31	38.0	27.5
32	60	0.0%	24	35.1	41.3	94	0.0%	27	38.3	35.4	75	0.0%	29	43.5	44.5
33	48	0.0%	26	39.5	39.1	78	0.0%	27	38.2	34.1	62	0.0%	27	32.1	18.6
34	40	0.0%	27	37.0	36.2	53	0.0%	22	26.8	15.0	45	0.0%	28	35.0	22.2

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glipizide, continued			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	29	0.0%	22	31.8	29.5	41	0.0%	25	35.0	27.0	38	0.0%	28	33.8	22.7
36	21	0.0%	29	36.1	29.9	34	0.0%	27	33.0	19.1	34	0.0%	40	45.0	29.7
37	15	0.0%	24	24.3	13.7	32	0.0%	31	36.0	22.7	23	0.0%	34	37.7	18.2
38	*****	*****	28	31.9	14.7	27	0.0%	26	28.3	16.4	17	0.0%	41	53.0	38.5
39	*****	*****	30	29.7	9.4	18	0.0%	26	32.6	24.9	13	0.0%	40	47.2	26.5
40	*****	*****	32	30.7	11.2	14	0.0%	36	43.1	33.6	*****	*****	33	33.8	12.5
41	*****	*****	21	24.6	16.4	12	0.0%	31	31.5	13.8	*****	*****	28	36.3	16.2
42	*****	*****	23	23.8	6.3	*****	*****	24	28.4	19.8	*****	*****	30	33.5	17.6
43	*****	*****	19	24.3	14.9	*****	*****	34	32.5	18.8	*****	*****	18	17.0	2.6
44	*****	*****	26	29.5	15.5	*****	*****	33	35.9	27.2	*****	*****	*****	*****	*****
45	*****	*****	16	19.3	7.6	*****	*****	25	25.2	9.0	*****	*****	*****	*****	*****
46	*****	*****	25	22.7	7.8	*****	*****	23	23.0	10.0	*****	*****	*****	*****	*****
47	*****	*****	23	22.5	13.4	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
48	*****	*****	23	22.5	12.0	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
49	*****	*****	*****	*****	*****	0	0.0%				*****	*****	*****	*****	*****
50	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
51	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
52	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
53	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
54	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
Gap from last episode until censoring	146,246	30.1%	48	340.9	572.5	263,732	29.8%	16	308.7	555.2	370,229	33.6%	2	274.2	519.0

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glipizide</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,774,473	100%	28	144.7	337.7	1,217,616	100%	28	145.7	328.8
Gap Number										
1	353,669	19.9%	34	103.6	215.6	248,424	20.4%	33	94.3	190.6
2	220,393	12.4%	32	78.6	154.4	145,664	12.0%	31	72.0	134.9
3	147,635	8.3%	32	70.4	132.0	92,433	7.6%	31	65.1	114.7
4	102,451	5.8%	32	66.0	120.5	61,662	5.1%	31	60.5	101.0
5	72,756	4.1%	32	61.9	103.7	42,558	3.5%	31	58.1	94.0
6	52,591	3.0%	31	59.8	101.8	30,016	2.5%	31	56.3	92.6
7	38,664	2.2%	31	57.0	90.9	21,589	1.8%	30	53.9	83.2
8	28,745	1.6%	31	55.8	88.8	15,613	1.3%	30	52.2	77.7
9	21,356	1.2%	31	54.6	83.9	11,464	0.9%	30	50.0	71.5
10	16,057	0.9%	30	53.1	84.6	8,526	0.7%	30	48.5	69.3
11	12,118	0.7%	30	50.6	71.1	6,343	0.5%	31	50.0	68.0
12	9,209	0.5%	30	49.9	71.6	4,721	0.4%	30	48.3	66.8
13	6,999	0.4%	30	50.1	77.4	3,581	0.3%	29	46.9	61.6
14	5,381	0.3%	30	47.7	75.8	2,684	0.2%	30	48.1	65.2
15	4,182	0.2%	29	46.2	62.7	2,029	0.2%	29	44.9	58.3
16	3,197	0.2%	29	45.8	65.6	1,560	0.1%	29	46.0	60.0
17	2,489	0.1%	30	45.2	60.3	1,161	0.1%	29	42.1	46.5
18	1,972	0.1%	29	44.0	55.2	903	0.1%	30	48.9	69.9
19	1,534	0.1%	29	42.4	49.4	674	0.1%	30	42.5	41.6
20	1,193	0.1%	30	47.9	72.2	541	0.0%	29	45.7	68.6
21	927	0.1%	28	40.4	45.5	437	0.0%	30	45.9	68.7
22	708	0.0%	29	44.0	68.5	327	0.0%	28	40.3	43.1
23	541	0.0%	28	43.8	76.0	250	0.0%	29	46.5	62.0
24	421	0.0%	28	40.6	43.6	199	0.0%	28	36.8	30.1
25	329	0.0%	29	45.1	56.4	162	0.0%	27	34.1	29.8
26	261	0.0%	26	38.0	37.9	122	0.0%	30	38.9	61.9
27	210	0.0%	30	46.1	59.0	96	0.0%	29	36.8	42.9
28	168	0.0%	30	42.7	36.3	76	0.0%	26	34.1	31.6
29	124	0.0%	31	44.8	42.5	61	0.0%	29	34.9	30.7
30	93	0.0%	27	40.0	37.1	49	0.0%	25	33.7	29.5
31	72	0.0%	31	36.7	26.7	43	0.0%	29	33.5	28.3
32	60	0.0%	28	37.0	29.9	34	0.0%	30	47.2	48.1
33	48	0.0%	27	35.6	32.7	29	0.0%	30	43.0	37.0

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glipizide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
34	40	0.0%	32	46.4	46.9	24	0.0%	36	38.4	22.5
35	35	0.0%	27	34.3	27.0	21	0.0%	31	41.4	39.0
36	26	0.0%	31	35.4	21.6	18	0.0%	20	35.4	33.8
37	21	0.0%	26	33.4	21.3	17	0.0%	27	38.2	24.4
38	18	0.0%	19	27.3	15.8	*****	*****	25	33.4	26.1
39	16	0.0%	31	35.6	26.9	*****	*****	20	34.0	32.7
40	13	0.0%	35	42.0	30.4	*****	*****	33	32.1	15.9
41	*****	*****	29	41.9	29.0	*****	*****	26	26.4	12.3
42	*****	*****	19	25.3	17.5	*****	*****	23	53.3	66.9
43	*****	*****	32	46.0	36.9	*****	*****	22	22.7	11.0
44	*****	*****	27	33.3	18.3	*****	*****	18	17.5	4.9
45	*****	*****	41	54.7	55.5	*****	*****	72	72.0	80.6
46	*****	*****	41	50.4	41.2	*****	*****	*****	*****	*****
47	*****	*****	30	31.3	13.1	*****	*****	*****	*****	*****
48	*****	*****	26	25.5	3.5	0	0.0%	0	0.0%	0.0%
49	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0.0%
50	0	0.0%				0	0.0%			
51	0	0.0%				0	0.0%			
52	0	0.0%				0	0.0%			
53	0	0.0%				0	0.0%			
54	0	0.0%				0	0.0%			
Gap from last episode until censoring	667,700	37.6%	0	254.1	491.1	513,457	42.2%	0	244.3	459.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glyburide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	276,553	100%	59	320.9	562.0	349,903	100%	35	195.8	432.7	399,417	100%	36	201.6	423.9
Gap Number															
1	42,680	15.4%	37	157.4	319.5	60,070	17.2%	34	106.1	223.6	73,996	18.5%	35	99.1	195.0
2	25,745	9.3%	35	98.8	203.2	41,865	12.0%	33	86.6	184.8	49,479	12.4%	33	81.3	157.3
3	18,260	6.6%	34	85.7	177.7	30,808	8.8%	33	78.1	161.9	34,739	8.7%	33	73.6	140.9
4	13,617	4.9%	33	78.3	160.3	23,325	6.7%	32	69.9	134.8	25,306	6.3%	32	68.3	124.9
5	10,474	3.8%	33	73.2	144.5	18,055	5.2%	32	66.7	132.8	18,810	4.7%	32	63.3	111.3
6	8,091	2.9%	32	65.0	121.5	14,138	4.0%	31	63.0	120.2	14,218	3.6%	31	59.9	105.0
7	6,395	2.3%	31	62.0	107.6	11,151	3.2%	31	60.8	119.7	10,919	2.7%	31	57.1	96.8
8	5,044	1.8%	32	62.7	116.3	8,876	2.5%	31	56.8	101.0	8,359	2.1%	31	53.9	85.5
9	4,060	1.5%	30	57.6	103.0	7,157	2.0%	31	57.7	106.0	6,479	1.6%	30	55.3	95.8
10	3,264	1.2%	32	58.4	98.3	5,849	1.7%	31	55.9	99.1	5,082	1.3%	31	53.5	91.1
11	2,635	1.0%	30	59.2	116.7	4,738	1.4%	30	53.9	97.0	4,035	1.0%	30	50.0	80.2
12	2,106	0.8%	30	54.6	106.3	3,900	1.1%	30	52.1	93.1	3,195	0.8%	30	50.0	97.0
13	1,727	0.6%	30	53.6	95.0	3,210	0.9%	31	53.6	89.2	2,504	0.6%	30	49.8	76.8
14	1,427	0.5%	29	54.0	97.6	2,599	0.7%	29	49.5	83.5	1,988	0.5%	29	47.1	73.9
15	1,154	0.4%	30	52.4	103.2	2,120	0.6%	30	48.5	63.7	1,595	0.4%	29	48.3	85.5
16	952	0.3%	29	51.3	92.4	1,750	0.5%	29	44.1	60.9	1,253	0.3%	29	43.8	53.8
17	786	0.3%	30	49.3	74.3	1,462	0.4%	28	45.1	68.5	1,017	0.3%	29	44.7	58.5
18	636	0.2%	28	48.2	87.3	1,207	0.3%	30	48.3	78.6	830	0.2%	28	44.5	73.7
19	529	0.2%	27	49.2	98.6	991	0.3%	28	46.8	72.3	680	0.2%	30	44.5	69.0
20	439	0.2%	26	47.3	82.1	821	0.2%	28	43.4	81.7	552	0.1%	29	41.7	46.2
21	362	0.1%	27	39.6	54.1	688	0.2%	28	43.9	57.9	443	0.1%	28	44.9	82.0
22	291	0.1%	27	42.6	62.0	572	0.2%	27	44.2	66.6	371	0.1%	26	33.5	28.3
23	239	0.1%	26	42.2	59.9	471	0.1%	28	46.5	75.3	309	0.1%	28	39.4	43.8
24	190	0.1%	26	35.4	36.1	395	0.1%	29	42.4	49.3	243	0.1%	28	40.7	57.0
25	153	0.1%	25	37.6	48.9	318	0.1%	28	45.0	72.5	201	0.1%	27	34.5	29.1
26	127	0.0%	27	41.2	52.7	269	0.1%	28	34.7	26.9	161	0.0%	26	39.7	55.7
27	111	0.0%	25	43.9	94.2	221	0.1%	28	54.9	115.4	124	0.0%	27	42.8	54.2
28	92	0.0%	25	30.9	24.4	181	0.1%	25	33.2	32.4	101	0.0%	27	34.4	26.6
29	79	0.0%	27	41.5	45.8	152	0.0%	27	36.5	36.1	79	0.0%	28	38.2	56.2
30	63	0.0%	23	28.4	17.0	126	0.0%	30	37.9	35.9	69	0.0%	26	46.0	66.6
31	52	0.0%	34	37.9	24.1	107	0.0%	29	39.8	57.7	55	0.0%	27	35.4	26.6
32	43	0.0%	24	30.5	24.1	92	0.0%	27	33.6	27.1	46	0.0%	23	33.9	34.9
33	38	0.0%	22	31.8	29.6	77	0.0%	25	31.6	20.9	31	0.0%	25	32.3	22.6
34	31	0.0%	20	44.4	60.8	63	0.0%	31	41.5	39.7	23	0.0%	22	29.6	19.3

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Glyburide, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	27	0.0%	19	43.1	56.1	57	0.0%	33	43.6	41.9	20	0.0%	28	49.6	64.0
36	23	0.0%	19	23.3	12.1	45	0.0%	30	38.4	25.2	14	0.0%	26	46.4	50.4
37	15	0.0%	29	28.1	13.8	40	0.0%	28	33.7	23.7	*****	*****	32	34.4	29.6
38	*****	*****	21	30.0	33.9	35	0.0%	25	28.9	22.9	*****	*****	15	32.0	40.1
39	*****	*****	21	23.8	8.4	27	0.0%	28	38.0	29.1	*****	*****	26	23.2	8.0
40	*****	*****	16	18.2	8.4	22	0.0%	28	41.0	29.6	*****	*****	16	18.6	8.5
41	*****	*****	15	16.5	6.0	*****	*****	18	31.5	24.7	*****	*****	25	26.6	8.6
42	*****	*****	21	19.8	3.2	*****	*****	23	27.3	16.0	*****	*****	23	25.5	13.1
43	*****	*****	22	23.0	3.6	*****	*****	15	19.5	11.4	*****	*****	23	23.5	8.8
44	*****	*****	17	20.3	6.7	*****	*****	19	21.3	9.3	*****	*****	18	22.5	15.6
45	*****	*****	29	24.3	9.9	*****	*****	17	17.3	4.5	*****	*****	26	29.7	14.8
46	*****	*****	14	13.5	2.1	*****	*****	*****	*****	*****	*****	*****	19	18.5	3.5
47	*****	*****	16	16.0	1.4	*****	*****	*****	*****	*****	*****	*****	23	22.5	9.2
48	*****	*****	56	56.0	38.2	*****	*****	*****	*****	*****	*****	*****	22	21.5	10.6
49	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	22	21.5	6.4
50	0	0.0%				*****	*****	*****	*****	*****	*****	*****	29	28.5	7.8
51	0	0.0%				*****	*****	*****	*****	*****	*****	*****	36	35.5	3.5
52	0	0.0%				*****	*****	*****	*****	*****	*****	*****	69	69.0	28.3
53	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
54	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
55	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
56	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	124,547	45.0%	314	591.5	714.0	101,800	29.1%	160	482.8	678.4	132,029	33.1%	158	456.0	633.7

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glyburide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	545,801	100%	47	275.6	495.2	368,457	100%	52	275.9	475.8
Gap Number										
1	110,221	20.2%	36	94.8	173.7	75,224	20.4%	37	91.3	157.3
2	69,237	12.7%	34	80.1	145.6	44,729	12.1%	34	77.5	131.7
3	46,015	8.4%	34	72.4	127.1	28,599	7.8%	34	70.7	120.8
4	31,635	5.8%	33	68.1	118.3	19,023	5.2%	33	64.9	105.0
5	22,041	4.0%	33	64.9	112.8	13,028	3.5%	32	63.5	113.5
6	15,679	2.9%	32	62.6	118.2	9,031	2.5%	32	60.6	99.1
7	11,337	2.1%	31	60.5	117.6	6,318	1.7%	31	55.7	89.2
8	8,288	1.5%	32	56.6	98.8	4,557	1.2%	31	54.1	84.9
9	6,099	1.1%	31	55.1	95.9	3,251	0.9%	31	53.0	97.1
10	4,432	0.8%	31	55.7	104.7	2,359	0.6%	31	50.1	81.3
11	3,304	0.6%	31	51.2	88.4	1,719	0.5%	30	49.1	81.2
12	2,532	0.5%	30	53.2	98.6	1,269	0.3%	30	50.0	89.9
13	1,936	0.4%	31	53.1	97.8	943	0.3%	30	48.8	85.8
14	1,480	0.3%	30	48.6	72.1	721	0.2%	30	51.3	102.8
15	1,121	0.2%	30	50.6	95.2	526	0.1%	30	45.1	61.4
16	847	0.2%	29	48.7	95.1	387	0.1%	31	51.0	90.2
17	624	0.1%	30	51.5	115.4	291	0.1%	28	44.9	94.8
18	501	0.1%	28	41.5	60.3	220	0.1%	31	45.5	102.8
19	395	0.1%	31	55.3	123.4	163	0.0%	28	42.3	73.7
20	296	0.1%	29	50.4	104.0	120	0.0%	30	39.4	36.9
21	215	0.0%	30	43.8	97.4	90	0.0%	29	71.2	188.8
22	162	0.0%	30	38.8	46.8	67	0.0%	31	40.1	34.6
23	124	0.0%	28	42.1	68.3	52	0.0%	29	69.7	229.3
24	93	0.0%	28	37.2	69.7	34	0.0%	23	81.1	232.0
25	69	0.0%	27	31.6	22.5	18	0.0%	29	81.2	223.9
26	60	0.0%	27	62.1	175.7	13	0.0%	30	57.2	81.2
27	*****	*****	25	36.1	50.6	*****	*****	27	36.2	30.0
28	*****	*****	23	27.1	14.0	*****	*****	30	33.8	19.4
29	*****	*****	28	33.2	28.7	*****	*****	27	34.3	23.9
30	*****	*****	22	29.1	20.9	*****	*****	*****	*****	*****
31	*****	*****	29	39.8	41.6	*****	*****	*****	*****	*****
32	*****	*****	23	27.7	13.0	*****	*****	*****	*****	*****
33	*****	*****	25	30.4	24.3	*****	*****	*****	*****	*****
34	*****	*****	16	26.7	24.4	*****	*****	*****	*****	*****

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Glyburide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	21	35.4	30.0	0	0.0%			
36	*****	*****	24	30.5	18.1	0	0.0%			
37	*****	*****	33	30.5	12.1	0	0.0%			
38	*****	*****	30	32.3	18.9	0	0.0%			
39	*****	*****	35	42.3	30.4	0	0.0%			
40	*****	*****	24	31.0	19.8	0	0.0%			
41	*****	*****	22	21.5	12.0	0	0.0%			
42	*****	*****	23	23.0	9.9	0	0.0%			
43	*****	*****	23	23.0	12.7	0	0.0%			
44	*****	*****	30	29.5	20.5	0	0.0%			
45	*****	*****	*****	*****	*****	0	0.0%			
46	*****	*****	*****	*****	*****	0	0.0%			
47	*****	*****	*****	*****	*****	0	0.0%			
48	*****	*****	*****	*****	*****	0	0.0%			
49	0	0.0%				0	0.0%			
50	0	0.0%				0	0.0%			
51	0	0.0%				0	0.0%			
52	0	0.0%				0	0.0%			
53	0	0.0%				0	0.0%			
54	0	0.0%				0	0.0%			
55	0	0.0%				0	0.0%			
56	0	0.0%				0	0.0%			
Gap from last episode until censoring	206,862	37.9%	355	600.0	666.2	155,687	42.3%	323	549.0	618.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Linagliptin	18-44 years					45-54 years					55-64 years				
	Number		Median	Mean	Standard	Number		Median	Mean	Standard	Number		Median	Mean	Standard
	of	Percent	Days per	Days per	Deviation	of	Percent	Days per	Days per	Deviation	of	Percent	Days per	Days per	Deviation
Total Episodes	49,149	100%	27	132.2	273.9	104,493	100%	24	126.3	273.0	155,961	100%	23	122.2	262.2
Gap Number															
1	10,412	21.2%	26	61.9	120.6	22,146	21.2%	26	62.1	128.7	33,660	21.6%	26	60.7	120.0
2	5,964	12.1%	27	58.2	103.2	12,478	11.9%	25	53.5	107.0	17,996	11.5%	25	52.1	95.7
3	3,753	7.6%	27	53.1	92.3	7,693	7.4%	26	49.4	90.0	10,447	6.7%	26	49.8	87.6
4	2,440	5.0%	26	49.2	88.1	4,971	4.8%	26	47.9	80.7	6,413	4.1%	25	45.4	72.4
5	1,688	3.4%	27	48.9	74.6	3,361	3.2%	26	45.2	74.1	4,125	2.6%	26	46.2	69.8
6	1,153	2.3%	27	47.6	79.6	2,349	2.2%	25	43.4	62.4	2,738	1.8%	27	45.0	68.5
7	824	1.7%	28	46.2	61.1	1,654	1.6%	26	44.4	66.3	1,906	1.2%	26	43.8	65.2
8	566	1.2%	26	44.1	56.8	1,193	1.1%	25	43.9	76.5	1,299	0.8%	26	43.8	83.9
9	419	0.9%	25	42.4	54.2	871	0.8%	25	39.9	55.2	899	0.6%	26	37.7	42.8
10	303	0.6%	26	38.6	44.1	637	0.6%	25	38.9	50.1	653	0.4%	26	38.3	49.2
11	222	0.5%	27	42.8	54.8	478	0.5%	25	37.3	44.2	487	0.3%	24	37.6	54.0
12	169	0.3%	26	52.9	97.8	364	0.3%	25	36.2	35.1	326	0.2%	26	35.1	30.2
13	128	0.3%	23	37.9	52.0	271	0.3%	25	36.7	35.5	243	0.2%	25	36.0	38.4
14	93	0.2%	29	44.2	51.3	211	0.2%	25	36.5	39.4	172	0.1%	26	36.5	40.9
15	66	0.1%	30	41.9	45.4	162	0.2%	25	35.4	41.8	130	0.1%	25	35.4	49.2
16	51	0.1%	27	41.4	44.3	113	0.1%	26	37.2	37.1	101	0.1%	27	34.6	24.7
17	36	0.1%	27	35.9	27.3	86	0.1%	26	39.7	55.6	64	0.0%	26	33.3	22.7
18	27	0.1%	29	37.7	25.9	59	0.1%	23	33.0	28.5	53	0.0%	22	32.3	35.4
19	*****	*****	35	37.7	22.5	46	0.0%	23	34.5	32.2	36	0.0%	34	39.2	25.8
20	*****	*****	36	41.6	35.3	32	0.0%	23	31.9	22.7	27	0.0%	28	34.6	30.6
21	*****	*****	23	27.2	10.7	17	0.0%	26	40.4	41.0	18	0.0%	31	37.6	37.5
22	*****	*****	53	64.0	53.1	11	0.0%	23	32.5	26.9	11	0.0%	31	28.4	13.8
23	*****	*****	33	37.8	20.0	*****	*****	19	28.1	20.4	11	0.0%	27	35.5	28.2
24	*****	*****	32	49.0	31.2	*****	*****	16	20.8	13.4	*****	*****	23	27.8	16.4
25	*****	*****	29	32.0	10.8	*****	*****	17	18.5	7.6	*****	*****	26	26.0	8.3
26	*****	*****	*****	*****	*****	*****	*****	14	21.0	13.0	*****	*****	27	27.0	2.8
27	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	17	17.0	8.5
28	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
29	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
30	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
31	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
32	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
33	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
34	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Linagliptin, continued</u>	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
Gap from last episode until censoring	20,769	42.3%	29	236.8	380.1	45,263	43.3%	8	221.5	376.1	74,131	47.5%	0	198.2	350.0

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Linagliptin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	248,956	100%	25	132.0	258.9	207,920	100%	23	123.3	247.0
Gap Number										
1	54,912	22.1%	27	63.8	115.5	45,872	22.1%	28	64.0	116.0
2	27,335	11.0%	27	54.3	89.0	22,041	10.6%	27	54.0	85.3
3	14,815	6.0%	27	51.2	80.2	11,757	5.7%	27	50.6	76.1
4	8,683	3.5%	27	47.2	67.3	6,528	3.1%	27	46.3	63.6
5	5,290	2.1%	27	45.5	59.4	3,868	1.9%	27	45.2	61.0
6	3,321	1.3%	26	42.3	50.0	2,331	1.1%	27	42.0	57.2
7	2,125	0.9%	27	44.1	55.3	1,450	0.7%	27	40.9	43.9
8	1,383	0.6%	28	41.9	49.3	894	0.4%	26	37.4	41.0
9	884	0.4%	27	39.6	42.0	567	0.3%	25	38.7	37.8
10	598	0.2%	28	39.7	45.5	358	0.2%	25	36.6	49.0
11	404	0.2%	26	36.8	38.6	219	0.1%	25	35.4	31.6
12	283	0.1%	26	34.9	33.6	140	0.1%	23	37.2	40.6
13	185	0.1%	28	41.4	47.4	93	0.0%	29	37.8	31.4
14	126	0.1%	23	34.0	35.7	62	0.0%	23	28.7	15.3
15	87	0.0%	26	28.5	15.7	40	0.0%	27	30.4	19.0
16	56	0.0%	25	35.5	37.3	29	0.0%	31	35.8	21.6
17	41	0.0%	30	35.0	23.3	22	0.0%	28	31.4	22.9
18	36	0.0%	27	43.4	80.1	14	0.0%	21	35.8	40.0
19	26	0.0%	25	28.2	14.2	*****	*****	32	42.3	41.2
20	22	0.0%	25	26.0	12.1	*****	*****	27	26.5	7.3
21	16	0.0%	27	35.9	25.7	*****	*****	24	23.8	10.2
22	12	0.0%	31	31.7	12.3	*****	*****	22	22.8	7.3
23	*****	*****	28	32.0	19.8	*****	*****	31	41.2	33.9
24	*****	*****	24	23.4	9.7	*****	*****	21	21.0	3.0
25	*****	*****	25	43.8	52.4	*****	*****	25	25.0	17.0
26	*****	*****	32	30.5	14.7	*****	*****	22	22.0	1.4
27	*****	*****	19	23.7	9.9	*****	*****	41	41.0	4.2
28	*****	*****	23	23.0	12.7	*****	*****	51	51.0	28.3
29	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
30	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
31	0	0.0%				0	0.0%			
32	0	0.0%				0	0.0%			
33	0	0.0%				0	0.0%			
34	0	0.0%				0	0.0%			

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Linagliptin, continued</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	0	0.0%				0	0.0%			
Gap from last episode until censoring	128,281	51.5%	9	203.2	332.8	111,590	53.7%	1	180.8	313.6

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Liraglutide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	188,116	100%	31	149.6	318.6	314,243	100%	28	138.1	312.6	362,700	100%	27	130.9	294.8
Gap Number															
1	36,790	19.6%	29	76.8	168.8	59,321	18.9%	28	74.0	166.6	69,879	19.3%	28	69.0	147.9
2	24,165	12.8%	30	73.6	155.3	40,150	12.8%	28	67.5	148.8	46,180	12.7%	28	63.1	128.8
3	16,790	8.9%	30	69.5	139.5	28,837	9.2%	28	64.5	136.3	32,435	8.9%	28	60.1	118.2
4	12,015	6.4%	30	67.7	137.9	21,106	6.7%	29	61.4	122.4	23,494	6.5%	28	56.6	103.5
5	8,808	4.7%	30	65.7	133.5	15,692	5.0%	29	58.2	106.3	17,386	4.8%	28	55.7	103.4
6	6,552	3.5%	29	61.8	120.4	11,743	3.7%	28	55.1	100.4	12,902	3.6%	28	51.7	84.0
7	4,871	2.6%	29	61.7	120.0	8,954	2.8%	28	56.0	101.0	9,758	2.7%	27	49.1	82.5
8	3,693	2.0%	29	59.6	124.2	6,911	2.2%	28	53.5	93.2	7,329	2.0%	27	51.0	89.1
9	2,830	1.5%	28	52.5	86.9	5,361	1.7%	28	53.1	103.3	5,595	1.5%	27	49.8	93.1
10	2,177	1.2%	28	54.9	99.6	4,206	1.3%	27	50.8	88.5	4,355	1.2%	26	46.7	79.2
11	1,676	0.9%	27	51.1	91.9	3,256	1.0%	27	48.4	82.8	3,278	0.9%	26	44.0	66.8
12	1,284	0.7%	26	52.1	98.4	2,561	0.8%	27	51.8	94.6	2,532	0.7%	27	43.7	64.4
13	990	0.5%	26	51.0	95.7	1,958	0.6%	27	46.8	73.8	1,977	0.5%	26	42.8	65.9
14	781	0.4%	26	45.0	63.6	1,543	0.5%	26	41.5	54.8	1,555	0.4%	26	42.8	68.6
15	605	0.3%	26	42.5	61.9	1,202	0.4%	26	41.6	53.3	1,212	0.3%	24	37.3	41.5
16	463	0.2%	26	44.4	77.8	928	0.3%	23	44.9	87.4	926	0.3%	25	41.3	65.8
17	371	0.2%	26	47.5	89.1	734	0.2%	28	45.5	77.9	733	0.2%	24	35.5	39.3
18	301	0.2%	26	43.7	71.1	583	0.2%	26	41.8	62.1	567	0.2%	24	36.4	46.4
19	240	0.1%	26	39.8	49.7	466	0.1%	26	39.8	48.9	468	0.1%	24	37.9	81.0
20	192	0.1%	24	40.4	54.6	361	0.1%	26	41.6	72.6	377	0.1%	25	39.3	74.3
21	140	0.1%	24	34.0	32.4	287	0.1%	26	39.4	45.0	299	0.1%	24	35.9	39.4
22	109	0.1%	21	42.8	71.7	226	0.1%	23	34.0	41.2	226	0.1%	24	37.0	39.2
23	81	0.0%	29	38.4	31.7	189	0.1%	27	38.0	40.4	171	0.0%	24	31.2	25.3
24	66	0.0%	26	40.9	55.8	152	0.0%	25	35.3	34.3	121	0.0%	25	36.2	40.2
25	51	0.0%	26	36.7	42.6	121	0.0%	23	30.4	25.9	94	0.0%	25	34.9	26.8
26	36	0.0%	26	30.3	17.4	86	0.0%	27	34.0	29.1	72	0.0%	22	40.2	74.4
27	23	0.0%	21	32.0	19.9	68	0.0%	22	28.8	19.9	62	0.0%	22	30.9	30.2
28	*****	*****	24	31.5	19.8	51	0.0%	23	33.3	29.3	47	0.0%	21	27.1	21.3
29	*****	*****	15	24.0	23.0	41	0.0%	24	31.6	28.8	37	0.0%	22	32.1	40.0
30	*****	*****	21	19.3	4.8	*****	*****	26	37.1	31.0	28	0.0%	17	23.3	16.2
31	*****	*****	26	27.5	11.7	*****	*****	19	24.2	13.6	19	0.0%	23	30.2	23.0
32	*****	*****	21	22.0	7.0	14	0.0%	28	31.4	16.7	*****	*****	31	29.1	13.2
33	*****	*****	25	39.3	25.7	*****	*****	22	29.5	16.8	*****	*****	28	28.5	12.7
34	*****	*****	28	35.0	28.2	*****	*****	26	25.3	10.0	*****	*****	28	25.7	13.3

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Liraglutide, continued	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	23	22.5	7.8	*****	*****	19	21.2	5.6	*****	*****	27	26.2	9.2
36	*****	*****	*****	*****	*****	*****	*****	42	37.2	22.6	*****	*****	23	22.0	6.7
37	0	0.0%				*****	*****	15	15.3	3.9	*****	*****	27	28.5	11.0
38	0	0.0%				*****	*****	14	15.7	3.8	*****	*****	26	49.5	53.6
39	0	0.0%				*****	*****	26	24.3	6.7	*****	*****	20	22.0	11.1
40	0	0.0%				*****	*****	19	19.0	4.2	*****	*****	16	16.0	5.7
41	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
42	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
43	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	61,966	32.9%	76	313.7	474.4	97,046	30.9%	39	304.4	484.7	118,511	32.7%	26	277.5	451.7

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Liraglutide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	439,238	100%	31	144.8	300.3	115,731	100%	32	150.3	305.1
Gap Number										
1	84,805	19.3%	30	69.4	131.1	21,995	19.0%	30	64.5	116.6
2	56,103	12.8%	29	62.2	110.1	14,413	12.5%	29	56.9	96.3
3	39,421	9.0%	29	58.3	94.6	10,072	8.7%	29	54.7	89.2
4	28,546	6.5%	29	55.4	85.2	7,225	6.2%	28	50.0	69.8
5	20,920	4.8%	29	53.9	84.7	5,383	4.7%	28	48.3	63.0
6	15,594	3.6%	28	51.5	75.4	4,014	3.5%	29	47.2	61.9
7	11,679	2.7%	28	48.9	67.0	3,021	2.6%	28	45.3	53.9
8	8,827	2.0%	27	48.6	68.2	2,326	2.0%	29	48.0	78.7
9	6,690	1.5%	28	46.3	64.2	1,749	1.5%	27	44.5	69.2
10	5,057	1.2%	27	44.8	61.6	1,337	1.2%	27	41.3	48.0
11	3,839	0.9%	27	44.7	61.0	1,005	0.9%	26	39.9	42.8
12	2,948	0.7%	26	40.9	54.1	762	0.7%	27	39.5	44.7
13	2,249	0.5%	26	41.8	55.6	597	0.5%	26	40.5	60.7
14	1,700	0.4%	25	40.3	58.5	465	0.4%	25	39.4	43.5
15	1,313	0.3%	26	39.0	46.3	357	0.3%	26	38.8	56.8
16	1,009	0.2%	25	38.0	42.9	281	0.2%	26	37.3	34.0
17	777	0.2%	24	35.8	38.8	212	0.2%	26	36.2	31.9
18	593	0.1%	25	36.8	41.7	156	0.1%	23	32.0	24.5
19	465	0.1%	24	36.8	45.7	111	0.1%	24	36.5	34.6
20	356	0.1%	25	36.1	37.8	86	0.1%	23	38.4	39.7
21	269	0.1%	24	34.6	30.0	63	0.1%	24	32.8	31.0
22	221	0.1%	25	34.2	31.7	47	0.0%	28	44.8	60.8
23	156	0.0%	22	29.4	21.1	35	0.0%	23	38.6	41.4
24	123	0.0%	23	30.9	26.1	29	0.0%	20	38.9	49.4
25	89	0.0%	23	35.6	32.6	24	0.0%	21	27.7	18.2
26	71	0.0%	22	28.7	18.1	20	0.0%	19	28.5	29.0
27	62	0.0%	25	36.5	33.4	15	0.0%	15	20.4	15.8
28	36	0.0%	23	32.3	29.3	*****	*****	17	16.7	3.7
29	27	0.0%	21	24.7	9.4	*****	*****	19	21.1	10.6
30	26	0.0%	23	30.0	23.7	*****	*****	20	21.0	8.3
31	20	0.0%	26	28.9	12.9	*****	*****	37	36.5	26.2
32	16	0.0%	24	26.9	12.8	*****	*****	*****	*****	*****
33	13	0.0%	17	22.2	10.8	*****	*****	*****	*****	*****
34	11	0.0%	18	18.5	5.1	*****	*****	*****	*****	*****

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Liraglutide, continued</u>			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	21	23.4	8.4	*****	*****	*****	*****	*****
36	*****	*****	23	25.3	12.9	*****	*****	*****	*****	*****
37	*****	*****	17	21.4	9.0	*****	*****	*****	*****	*****
38	*****	*****	23	19.7	6.7	*****	*****	*****	*****	*****
39	*****	*****	19	18.5	6.4	*****	*****	*****	*****	*****
40	*****	*****	31	30.5	7.8	*****	*****	*****	*****	*****
41	*****	*****	17	16.5	3.5	*****	*****	*****	*****	*****
42	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
43	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	145,175	33.1%	82	318.2	454.2	39,895	34.5%	104	332.1	451.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	3,578,520	100%	36	158.5	342.3	4,252,587	100%	31	124.3	292.1	4,485,794	100%	30	119.6	281.9
Gap Number															
1	629,187	17.6%	39	150.9	318.9	717,517	16.9%	37	141.7	304.3	814,076	18.1%	36	128.5	269.9
2	436,532	12.2%	38	123.5	260.2	519,472	12.2%	35	108.7	236.4	563,112	12.6%	34	98.4	208.2
3	319,739	8.9%	37	109.6	231.0	391,977	9.2%	34	95.7	206.9	408,049	9.1%	33	86.0	177.7
4	241,937	6.8%	36	99.3	206.9	303,574	7.1%	34	86.2	182.4	304,140	6.8%	33	78.5	159.7
5	186,403	5.2%	35	91.5	188.6	237,434	5.6%	33	79.8	166.3	230,873	5.1%	33	73.2	145.6
6	145,532	4.1%	34	85.5	176.0	188,539	4.4%	33	75.5	153.6	177,762	4.0%	32	69.1	133.1
7	115,009	3.2%	34	81.3	163.2	150,033	3.5%	32	71.6	144.3	138,175	3.1%	32	65.9	124.4
8	91,520	2.6%	33	76.5	151.7	120,324	2.8%	32	68.3	136.1	108,299	2.4%	32	63.0	115.9
9	72,910	2.0%	33	72.8	143.8	97,231	2.3%	32	65.0	124.5	85,213	1.9%	32	60.3	105.6
10	58,514	1.6%	33	70.1	136.1	78,610	1.8%	32	63.2	120.8	67,443	1.5%	31	59.1	107.6
11	47,168	1.3%	32	67.4	129.7	63,867	1.5%	31	61.5	114.7	53,552	1.2%	31	56.6	97.1
12	38,097	1.1%	32	64.5	122.8	51,851	1.2%	31	58.5	108.9	42,715	1.0%	31	55.2	92.2
13	30,967	0.9%	31	63.3	120.6	42,243	1.0%	31	56.9	103.4	33,955	0.8%	31	53.9	93.6
14	25,115	0.7%	31	60.5	113.4	34,380	0.8%	30	56.0	102.5	26,848	0.6%	31	53.4	91.0
15	20,313	0.6%	31	58.2	105.6	28,174	0.7%	30	54.7	98.4	21,506	0.5%	30	52.6	91.4
16	16,598	0.5%	31	57.2	100.4	22,931	0.5%	30	52.7	93.1	17,108	0.4%	30	51.0	83.8
17	13,520	0.4%	30	55.3	92.4	18,698	0.4%	30	51.2	89.7	13,630	0.3%	30	48.7	78.4
18	11,003	0.3%	30	55.0	100.7	15,292	0.4%	30	50.9	87.9	10,922	0.2%	30	46.8	70.7
19	8,948	0.3%	29	52.9	93.3	12,507	0.3%	29	50.0	83.8	8,796	0.2%	30	48.0	83.8
20	7,294	0.2%	30	52.1	88.9	10,286	0.2%	29	47.2	76.6	7,137	0.2%	29	46.6	73.4
21	5,950	0.2%	29	50.2	80.4	8,493	0.2%	29	46.3	69.5	5,808	0.1%	29	44.4	60.2
22	4,888	0.1%	29	48.2	74.0	6,991	0.2%	29	47.0	74.1	4,679	0.1%	29	44.8	67.8
23	4,002	0.1%	29	48.1	74.4	5,783	0.1%	28	45.3	69.0	3,801	0.1%	29	43.5	60.0
24	3,259	0.1%	28	45.3	74.0	4,752	0.1%	28	45.3	69.6	3,046	0.1%	29	44.3	63.6
25	2,670	0.1%	29	45.6	62.3	3,908	0.1%	27	42.2	60.6	2,472	0.1%	28	43.4	67.7
26	2,223	0.1%	28	44.4	58.6	3,229	0.1%	27	41.6	66.7	2,029	0.0%	28	42.2	64.1
27	1,817	0.1%	28	46.4	74.2	2,652	0.1%	28	42.9	65.4	1,673	0.0%	28	43.0	66.3
28	1,463	0.0%	29	44.8	57.1	2,196	0.1%	28	41.4	55.0	1,363	0.0%	29	41.2	54.5
29	1,187	0.0%	27	39.3	47.3	1,820	0.0%	27	37.7	41.8	1,117	0.0%	28	41.1	51.9
30	939	0.0%	27	40.7	54.9	1,489	0.0%	27	40.1	51.9	875	0.0%	28	39.4	47.1
31	766	0.0%	27	39.0	40.1	1,214	0.0%	29	40.8	50.3	705	0.0%	28	41.1	56.6
32	620	0.0%	26	39.9	60.0	981	0.0%	27	39.5	58.8	574	0.0%	28	39.9	65.9
33	479	0.0%	24	35.4	39.9	798	0.0%	28	37.3	50.3	455	0.0%	28	33.3	24.4
34	371	0.0%	27	41.9	61.2	649	0.0%	27	36.8	44.8	353	0.0%	28	37.2	40.7

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin, continued			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	289	0.0%	24	33.2	33.8	515	0.0%	27	35.2	29.5	278	0.0%	28	42.2	83.9
36	229	0.0%	25	34.6	44.4	415	0.0%	27	37.4	40.8	226	0.0%	28	43.0	99.6
37	183	0.0%	26	34.4	26.2	327	0.0%	27	37.1	45.1	174	0.0%	28	34.3	31.2
38	142	0.0%	29	38.5	44.4	264	0.0%	26	36.4	42.1	135	0.0%	24	32.1	27.4
39	111	0.0%	29	34.2	23.5	208	0.0%	26	36.4	32.8	113	0.0%	28	32.0	20.4
40	85	0.0%	25	36.4	38.2	165	0.0%	26	33.1	35.1	82	0.0%	30	42.4	55.8
41	57	0.0%	26	40.9	45.1	129	0.0%	24	29.0	23.9	58	0.0%	30	36.2	44.3
42	43	0.0%	23	31.2	21.4	97	0.0%	26	32.1	19.9	43	0.0%	27	32.8	29.8
43	35	0.0%	28	35.0	20.3	77	0.0%	23	30.6	20.9	35	0.0%	27	31.9	24.8
44	29	0.0%	25	25.7	9.6	65	0.0%	20	29.1	23.2	29	0.0%	22	29.7	20.2
45	*****	*****	27	32.8	19.6	46	0.0%	19	24.2	12.6	27	0.0%	23	31.0	25.3
46	20	0.0%	23	31.7	31.3	35	0.0%	19	22.0	8.4	*****	*****	24	24.9	9.4
47	17	0.0%	21	25.1	13.8	24	0.0%	21	23.2	12.5	*****	*****	25	25.2	9.6
48	13	0.0%	29	36.1	32.2	22	0.0%	20	24.0	11.6	*****	*****	16	35.2	37.3
49	*****	*****	17	20.1	10.9	17	0.0%	18	20.5	7.5	*****	*****	17	31.3	33.9
50	*****	*****	20	21.0	5.4	13	0.0%	20	21.2	8.4	*****	*****	21	21.2	7.2
51	*****	*****	21	20.6	8.3	11	0.0%	15	18.3	7.0	*****	*****	26	26.3	11.4
52	*****	*****	14	16.6	7.7	*****	*****	17	19.6	7.5	*****	*****	15	25.3	20.6
53	*****	*****	17	19.7	5.5	*****	*****	24	24.4	10.1	*****	*****	20	19.5	0.7
54	*****	*****	12	11.5	0.7	*****	*****	18	18.8	8.3	*****	*****	22	21.5	12.0
55	*****	*****	*****	*****	*****	*****	*****	24	24.0	9.9	*****	*****	*****	*****	*****
56	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
57	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
58	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
59	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
60	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
61	0	0.0%				0	0.0%				0	0.0%			
Gap from last episode until censoring	1,030,270	28.8%	44	280.4	495.1	1,100,240	25.9%	0	204.0	432.6	1,322,261	29.5%	0	188.7	413.1

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	6,284,436	100%	30	121.8	288.0	3,005,475	100%	31	144.0	323.4
Gap Number										
1	1,192,777	19.0%	37	115.7	230.4	584,785	19.5%	36	108.6	213.3
2	811,125	12.9%	34	87.4	169.8	377,701	12.6%	33	82.8	157.4
3	575,505	9.2%	33	77.4	146.0	258,463	8.6%	33	72.0	130.8
4	419,416	6.7%	33	70.9	128.3	183,169	6.1%	32	67.1	116.6
5	310,242	4.9%	33	66.5	115.8	132,236	4.4%	32	63.0	105.9
6	231,742	3.7%	33	63.3	108.2	97,099	3.2%	32	60.3	99.4
7	174,288	2.8%	32	60.6	99.2	71,809	2.4%	32	57.3	90.2
8	132,315	2.1%	32	58.5	95.1	53,665	1.8%	32	56.0	89.3
9	100,910	1.6%	32	56.2	88.9	40,541	1.3%	31	53.4	78.1
10	77,397	1.2%	32	54.6	84.0	30,769	1.0%	31	52.8	83.2
11	59,740	1.0%	31	53.8	84.0	23,537	0.8%	31	51.1	75.6
12	46,503	0.7%	31	51.8	77.7	18,106	0.6%	31	49.6	69.0
13	36,134	0.6%	31	51.4	77.2	14,063	0.5%	31	48.8	70.9
14	28,191	0.4%	31	49.9	71.5	10,911	0.4%	31	48.5	68.2
15	22,088	0.4%	31	48.7	70.8	8,501	0.3%	31	48.8	76.3
16	17,417	0.3%	31	48.5	69.6	6,632	0.2%	31	46.9	67.9
17	13,674	0.2%	30	46.6	64.1	5,163	0.2%	31	46.6	73.4
18	10,805	0.2%	30	46.4	62.0	4,035	0.1%	31	46.1	61.0
19	8,602	0.1%	30	45.5	68.0	3,162	0.1%	30	44.3	58.2
20	6,856	0.1%	31	46.7	67.7	2,518	0.1%	30	42.3	52.2
21	5,379	0.1%	30	45.6	66.5	1,963	0.1%	29	43.7	66.9
22	4,213	0.1%	30	43.1	48.2	1,567	0.1%	29	42.5	54.1
23	3,364	0.1%	29	43.0	52.0	1,237	0.0%	30	41.6	49.1
24	2,740	0.0%	30	42.5	49.2	986	0.0%	30	45.8	79.8
25	2,224	0.0%	30	43.8	54.9	798	0.0%	30	39.3	37.1
26	1,790	0.0%	30	41.8	48.5	623	0.0%	30	41.9	50.0
27	1,456	0.0%	30	40.6	51.0	490	0.0%	30	43.5	46.0
28	1,172	0.0%	29	40.4	42.1	390	0.0%	30	40.5	57.1
29	959	0.0%	30	40.3	38.4	313	0.0%	31	41.0	50.3
30	782	0.0%	30	43.4	56.2	258	0.0%	29	44.0	58.2
31	637	0.0%	30	40.9	46.5	203	0.0%	28	36.3	38.1
32	523	0.0%	29	37.8	45.3	162	0.0%	31	43.8	45.8
33	436	0.0%	29	40.7	50.0	135	0.0%	29	41.8	54.0

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Metformin, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
34	347	0.0%	31	40.9	45.1	101	0.0%	29	34.1	22.6
35	291	0.0%	31	41.5	39.2	87	0.0%	28	31.3	21.3
36	236	0.0%	30	39.4	33.6	76	0.0%	28	35.1	25.7
37	192	0.0%	29	37.0	31.9	63	0.0%	29	42.1	37.0
38	161	0.0%	29	38.8	42.0	51	0.0%	32	39.7	26.6
39	132	0.0%	31	39.2	37.5	39	0.0%	32	45.7	51.9
40	107	0.0%	27	38.0	35.4	34	0.0%	32	39.8	26.5
41	88	0.0%	30	31.9	18.0	25	0.0%	28	32.6	17.7
42	74	0.0%	29	31.4	18.1	16	0.0%	32	31.8	11.1
43	56	0.0%	28	33.2	28.1	14	0.0%	30	27.8	8.4
44	45	0.0%	28	35.4	37.3	11	0.0%	30	30.3	17.2
45	31	0.0%	29	28.1	12.9	*****	*****	29	38.2	25.7
46	27	0.0%	27	33.2	32.8	*****	*****	29	26.0	6.9
47	22	0.0%	25	25.2	8.9	*****	*****	19	26.0	17.6
48	19	0.0%	28	32.7	17.6	*****	*****	53	53.0	17.0
49	13	0.0%	19	26.4	21.7	*****	*****	27	26.5	6.4
50	*****	*****	19	20.5	8.4	*****	*****	38	38.0	33.9
51	*****	*****	26	25.5	11.3	*****	*****	*****	*****	*****
52	*****	*****	28	26.3	7.9	0	0.0%			
53	*****	*****	20	37.0	33.6	0	0.0%			
54	*****	*****	30	31.8	17.2	0	0.0%			
55	*****	*****	26	27.5	16.2	0	0.0%			
56	*****	*****	18	24.7	11.5	0	0.0%			
57	*****	*****	21	20.5	3.5	0	0.0%			
58	*****	*****	*****	*****	*****	0	0.0%			
59	*****	*****	*****	*****	*****	0	0.0%			
60	*****	*****	*****	*****	*****	0	0.0%			
61	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	1,981,146	31.5%	0	204.4	438.4	1,068,947	35.6%	3	258.9	478.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	220,721	100%	36	246.7	524.8	415,051	100%	33	239.3	522.9	495,883	100%	33	244.4	516.8
Gap Number															
1	41,343	18.7%	31	104.3	247.7	77,411	18.7%	30	102.2	244.3	97,395	19.6%	31	100.3	230.1
2	26,706	12.1%	31	85.6	197.7	50,039	12.1%	30	84.6	205.6	59,266	12.0%	30	80.6	185.0
3	18,454	8.4%	31	79.1	182.4	34,523	8.3%	30	74.7	171.3	38,826	7.8%	30	71.3	158.3
4	13,363	6.1%	30	70.5	160.9	24,913	6.0%	29	68.9	157.8	26,759	5.4%	30	68.1	149.6
5	9,832	4.5%	30	66.7	149.2	18,471	4.5%	29	66.1	147.9	19,100	3.9%	29	63.9	138.4
6	7,383	3.3%	29	64.9	144.0	14,054	3.4%	29	61.3	136.2	13,968	2.8%	29	60.1	123.1
7	5,635	2.6%	29	63.1	143.1	10,804	2.6%	29	59.0	130.0	10,371	2.1%	29	59.3	129.0
8	4,376	2.0%	29	60.2	124.8	8,423	2.0%	28	56.5	116.1	7,831	1.6%	29	56.2	125.2
9	3,435	1.6%	28	58.2	115.9	6,665	1.6%	28	56.9	122.4	6,059	1.2%	29	52.2	100.6
10	2,729	1.2%	28	59.0	132.6	5,261	1.3%	28	54.4	108.9	4,739	1.0%	29	52.2	105.8
11	2,191	1.0%	28	60.3	144.1	4,208	1.0%	28	49.2	93.9	3,694	0.7%	28	49.6	91.6
12	1,748	0.8%	28	57.4	130.6	3,385	0.8%	29	51.1	95.0	2,914	0.6%	28	51.3	112.5
13	1,397	0.6%	27	50.1	104.4	2,750	0.7%	27	48.7	96.3	2,304	0.5%	28	45.7	68.4
14	1,116	0.5%	27	53.3	113.1	2,188	0.5%	27	50.5	88.5	1,857	0.4%	28	46.4	83.7
15	901	0.4%	28	50.1	87.7	1,794	0.4%	27	45.9	83.7	1,490	0.3%	27	42.7	57.1
16	745	0.3%	28	50.0	94.5	1,473	0.4%	27	43.9	66.4	1,232	0.2%	27	49.7	119.3
17	614	0.3%	28	48.7	82.1	1,214	0.3%	26	43.1	79.4	994	0.2%	27	46.4	96.7
18	499	0.2%	28	48.5	86.1	970	0.2%	27	40.1	49.4	801	0.2%	28	43.9	65.6
19	395	0.2%	27	45.0	65.5	795	0.2%	26	42.8	75.2	665	0.1%	26	43.4	72.3
20	325	0.1%	26	46.4	70.9	656	0.2%	25	36.7	54.9	538	0.1%	28	49.2	102.6
21	264	0.1%	30	46.9	71.3	564	0.1%	26	40.5	68.5	440	0.1%	29	44.1	76.3
22	218	0.1%	30	44.1	50.9	483	0.1%	25	37.5	47.0	344	0.1%	28	37.5	31.4
23	187	0.1%	28	48.9	91.0	412	0.1%	25	38.7	44.8	279	0.1%	29	44.3	62.0
24	156	0.1%	26	47.5	101.9	347	0.1%	25	36.5	36.7	232	0.0%	27	41.8	47.0
25	132	0.1%	29	44.2	46.5	291	0.1%	25	39.5	51.0	190	0.0%	29	38.9	32.1
26	110	0.0%	26	41.2	64.1	237	0.1%	23	44.3	102.7	143	0.0%	26	39.4	42.0
27	95	0.0%	24	32.1	21.4	192	0.0%	25	40.0	54.3	119	0.0%	25	31.8	24.7
28	83	0.0%	28	34.7	23.2	158	0.0%	24	34.5	52.6	103	0.0%	30	39.6	39.5
29	65	0.0%	27	48.4	117.8	136	0.0%	23	32.5	33.3	91	0.0%	27	40.2	47.1
30	60	0.0%	23	34.9	34.7	114	0.0%	21	28.7	24.3	72	0.0%	32	42.0	50.1
31	50	0.0%	22	26.6	15.0	99	0.0%	27	35.1	27.1	58	0.0%	26	38.3	36.2
32	45	0.0%	27	43.9	50.3	83	0.0%	25	32.4	48.0	47	0.0%	26	34.5	31.6
33	32	0.0%	24	27.6	19.5	70	0.0%	25	30.5	22.8	37	0.0%	27	42.3	54.6
34	24	0.0%	28	33.9	21.9	60	0.0%	26	31.6	21.9	31	0.0%	32	42.3	51.7

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Pioglitazone, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	21	0.0%	23	26.1	13.5	51	0.0%	33	32.8	14.2	21	0.0%	25	29.9	18.9
36	17	0.0%	26	25.6	12.3	39	0.0%	23	28.6	21.7	16	0.0%	26	39.9	46.7
37	14	0.0%	24	25.6	14.1	35	0.0%	27	27.2	12.5	11	0.0%	21	23.1	7.7
38	13	0.0%	28	30.5	25.0	31	0.0%	21	28.3	18.0	*****	*****	21	21.1	8.2
39	11	0.0%	26	26.3	17.5	27	0.0%	22	30.9	22.6	*****	*****	14	19.4	12.5
40	*****	*****	19	21.7	9.6	22	0.0%	22	26.5	13.8	*****	*****	21	26.0	18.2
41	*****	*****	16	19.7	8.2	15	0.0%	18	26.3	13.5	*****	*****	35	29.6	11.5
42	*****	*****	24	29.2	20.2	*****	*****	17	22.4	13.0	*****	*****	33	37.0	23.0
43	*****	*****	24	21.8	5.7	*****	*****	25	24.5	9.3	*****	*****	23	23.0	11.3
44	*****	*****	25	24.4	9.3	*****	*****	18	25.8	18.7	*****	*****	83	83.0	100.4
45	*****	*****	20	22.8	11.6	*****	*****	25	34.7	17.2	*****	*****	68	67.5	78.5
46	*****	*****	11	18.3	12.7	*****	*****	30	26.7	9.5	*****	*****	*****	*****	*****
47	*****	*****	12	16.7	9.0	*****	*****	26	34.0	21.9	*****	*****	*****	*****	*****
48	*****	*****	12	13.0	2.6	*****	*****	28	34.4	19.4	*****	*****	*****	*****	*****
49	*****	*****	23	20.3	6.4	*****	*****	26	27.2	3.6	*****	*****	*****	*****	*****
50	*****	*****	14	18.3	10.2	*****	*****	23	22.8	2.8	*****	*****	*****	*****	*****
51	*****	*****	13	21.3	16.2	*****	*****	18	18.0	1.4	0	0.0%			
52	*****	*****	37	37.0	5.7	*****	*****	*****	*****	*****	0	0.0%			
53	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
54	0	0.0%				0	0.0%				0	0.0%			
Gap from last episode until censoring	75,881	34.4%	192	563.3	759.9	141,525	34.1%	147	551.0	765.3	192,803	38.9%	112	505.7	723.6

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	773,977	100%	36	281.1	557.1	428,015	100%	40	291.9	546.9
Gap Number										
1	155,057	20.0%	34	105.1	223.9	86,849	20.3%	34	96.1	195.8
2	90,925	11.7%	32	85.6	181.4	48,959	11.4%	32	77.8	154.8
3	58,406	7.5%	32	77.0	160.1	30,501	7.1%	32	71.2	139.0
4	39,251	5.1%	31	70.7	148.1	19,860	4.6%	31	64.9	116.2
5	27,450	3.5%	31	66.1	135.1	13,540	3.2%	31	62.3	113.0
6	19,665	2.5%	31	61.5	117.0	9,423	2.2%	30	56.9	101.8
7	14,436	1.9%	31	59.5	114.6	6,701	1.6%	30	55.8	106.6
8	10,701	1.4%	30	57.7	117.6	4,880	1.1%	30	56.2	106.7
9	8,098	1.0%	30	55.8	113.7	3,572	0.8%	30	51.3	81.8
10	6,173	0.8%	29	50.8	92.1	2,689	0.6%	30	47.7	70.1
11	4,787	0.6%	29	49.5	87.6	2,073	0.5%	30	49.8	89.6
12	3,775	0.5%	29	49.2	79.5	1,570	0.4%	30	45.9	57.7
13	2,987	0.4%	30	47.1	78.5	1,178	0.3%	31	47.4	65.3
14	2,367	0.3%	30	48.8	91.0	901	0.2%	31	46.9	74.0
15	1,906	0.2%	29	46.2	78.9	709	0.2%	30	44.7	53.8
16	1,537	0.2%	30	44.5	75.3	565	0.1%	30	41.8	42.2
17	1,240	0.2%	29	43.5	68.4	423	0.1%	30	43.7	60.4
18	995	0.1%	29	44.5	59.3	353	0.1%	31	42.3	41.3
19	797	0.1%	30	43.1	53.8	278	0.1%	30	43.6	52.8
20	642	0.1%	30	42.0	54.3	216	0.1%	30	43.8	55.9
21	510	0.1%	29	41.8	58.6	166	0.0%	29	33.3	22.9
22	408	0.1%	29	44.8	69.1	133	0.0%	28	34.2	21.8
23	337	0.0%	32	42.3	43.9	106	0.0%	30	41.7	47.3
24	271	0.0%	30	43.2	51.0	82	0.0%	30	36.1	23.3
25	223	0.0%	28	40.0	45.2	68	0.0%	30	37.5	21.0
26	176	0.0%	29	44.5	78.0	55	0.0%	30	34.4	19.9
27	146	0.0%	30	39.3	30.5	43	0.0%	28	31.9	18.6
28	118	0.0%	34	46.0	46.7	39	0.0%	31	38.1	32.9
29	94	0.0%	30	45.1	47.9	32	0.0%	25	34.2	31.6
30	76	0.0%	31	47.6	49.4	30	0.0%	24	26.7	13.3
31	59	0.0%	31	49.9	51.7	28	0.0%	32	37.3	23.0
32	49	0.0%	33	37.9	23.3	24	0.0%	33	47.2	42.4
33	40	0.0%	31	38.6	32.2	19	0.0%	25	38.9	29.6
34	32	0.0%	35	55.1	70.3	16	0.0%	29	40.3	32.3

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Pioglitazone, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	27	0.0%	36	43.4	32.6	14	0.0%	29	30.1	14.1
36	22	0.0%	34	42.2	33.8	11	0.0%	17	21.5	10.2
37	18	0.0%	36	38.3	18.5	*****	*****	25	32.3	30.5
38	14	0.0%	35	47.0	27.9	*****	*****	38	39.8	22.4
39	11	0.0%	34	37.0	16.4	*****	*****	21	22.9	6.3
40	*****	*****	37	41.2	25.1	*****	*****	23	32.2	24.6
41	*****	*****	31	31.0	5.2	*****	*****	22	24.0	14.5
42	*****	*****	28	46.1	32.4	*****	*****	24	27.8	13.0
43	*****	*****	32	63.0	81.3	*****	*****	22	25.0	12.8
44	*****	*****	40	51.8	39.6	*****	*****	15	15.0	2.8
45	*****	*****	34	34.3	7.5	*****	*****	15	15.0	4.2
46	*****	*****	44	43.5	21.9	*****	*****	20	19.5	4.9
47	*****	*****	*****	*****	*****	0	0.0%			
48	*****	*****	*****	*****	*****	0	0.0%			
49	*****	*****	*****	*****	*****	0	0.0%			
50	*****	*****	*****	*****	*****	0	0.0%			
51	*****	*****	*****	*****	*****	0	0.0%			
52	*****	*****	*****	*****	*****	0	0.0%			
53	*****	*****	*****	*****	*****	0	0.0%			
54	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	320,105	41.4%	150	561.7	755.1	191,862	44.8%	201	555.3	714.7

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Saxagliptin</u>	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	78,525	100%	29	189.1	390.8	150,899	100%	27	186.9	393.1	185,126	100%	28	195.7	395.1
Gap Number															
1	15,235	19.4%	26	68.6	153.9	29,586	19.6%	25	66.9	150.3	38,126	20.6%	25	65.0	139.7
2	9,836	12.5%	26	60.4	125.4	18,567	12.3%	25	55.9	119.7	22,318	12.1%	25	55.9	114.7
3	6,819	8.7%	26	55.2	109.5	12,544	8.3%	25	50.9	102.1	14,305	7.7%	25	51.8	101.2
4	4,856	6.2%	26	53.4	102.9	8,944	5.9%	25	48.7	89.3	9,759	5.3%	25	47.3	84.5
5	3,566	4.5%	26	50.5	92.9	6,614	4.4%	25	48.3	87.6	6,931	3.7%	25	44.9	71.0
6	2,646	3.4%	25	47.1	94.2	4,966	3.3%	25	44.8	72.9	5,006	2.7%	25	46.3	79.4
7	1,987	2.5%	25	48.8	97.0	3,725	2.5%	25	44.1	75.8	3,665	2.0%	25	43.4	69.4
8	1,511	1.9%	25	44.1	72.3	2,873	1.9%	24	42.1	65.5	2,779	1.5%	25	42.3	67.4
9	1,182	1.5%	25	45.0	68.6	2,222	1.5%	24	43.6	69.8	2,107	1.1%	25	41.0	59.9
10	902	1.1%	25	40.5	60.1	1,725	1.1%	25	42.7	68.0	1,586	0.9%	24	38.7	45.4
11	686	0.9%	25	45.7	88.2	1,358	0.9%	25	40.5	58.3	1,189	0.6%	25	40.6	56.8
12	548	0.7%	25	42.0	68.7	1,064	0.7%	25	40.3	61.1	939	0.5%	25	39.7	59.1
13	440	0.6%	25	37.5	42.9	827	0.5%	25	41.2	60.1	731	0.4%	24	37.1	45.9
14	350	0.4%	24	36.5	53.1	646	0.4%	26	40.4	72.9	568	0.3%	26	37.5	48.2
15	277	0.4%	24	38.3	44.2	506	0.3%	25	38.5	52.9	451	0.2%	26	39.5	76.9
16	220	0.3%	26	38.6	43.5	412	0.3%	23	35.1	42.2	343	0.2%	23	40.9	69.5
17	158	0.2%	26	37.2	42.7	314	0.2%	26	39.4	55.4	268	0.1%	23	36.3	43.5
18	120	0.2%	26	43.9	54.6	240	0.2%	24	40.6	75.8	220	0.1%	26	37.8	49.9
19	94	0.1%	26	38.0	45.2	188	0.1%	25	34.4	31.0	172	0.1%	24	33.1	32.2
20	78	0.1%	24	32.6	25.9	153	0.1%	23	34.0	32.2	145	0.1%	22	34.0	34.8
21	57	0.1%	24	30.6	23.4	124	0.1%	25	31.8	28.0	119	0.1%	23	31.3	28.7
22	49	0.1%	31	34.1	21.8	106	0.1%	23	31.9	23.9	91	0.0%	24	32.0	31.1
23	38	0.0%	27	29.1	13.2	77	0.1%	21	31.1	34.3	69	0.0%	26	30.7	24.2
24	29	0.0%	19	29.2	23.1	64	0.0%	21	31.9	41.5	50	0.0%	20	29.1	21.7
25	25	0.0%	27	35.4	27.3	51	0.0%	25	28.6	18.3	36	0.0%	25	31.1	22.6
26	18	0.0%	27	36.6	28.3	37	0.0%	21	29.1	21.1	30	0.0%	29	36.3	26.8
27	*****	*****	27	37.3	31.9	27	0.0%	22	34.7	42.6	26	0.0%	27	31.5	19.7
28	*****	*****	27	30.4	17.0	20	0.0%	27	35.4	32.7	23	0.0%	20	35.2	42.0
29	*****	*****	23	30.4	15.7	19	0.0%	24	30.4	17.4	18	0.0%	23	23.9	11.3
30	*****	*****	36	36.0	12.0	*****	*****	29	53.3	64.7	13	0.0%	22	38.8	43.4
31	*****	*****	34	34.0	17.0	*****	*****	20	24.6	14.9	*****	*****	20	23.9	11.2
32	*****	*****	*****	*****	*****	*****	*****	27	36.9	31.4	*****	*****	33	30.5	6.0
33	*****	*****	*****	*****	*****	*****	*****	32	35.4	19.2	*****	*****	17	17.8	6.2
34	0	0.0%				*****	*****	22	20.7	7.1	*****	*****	21	25.0	6.9

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Saxagliptin, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	0	0.0%				*****	*****	29	27.3	9.6	*****	*****	20	19.5	4.9
36	0	0.0%				*****	*****	27	26.5	20.5	*****	*****	22	22.0	11.3
37	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
38	0	0.0%				*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Gap from last episode until censoring	26,763	34.1%	179	444.1	566.8	52,854	35.0%	147	432.7	568.9	73,014	39.4%	129	412.6	546.9

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Saxagliptin</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	289,476	100%	38	260.2	444.6	186,183	100%	39	253.4	429.3
Gap Number										
1	61,517	21.3%	28	69.6	134.5	39,599	21.3%	28	66.1	122.5
2	35,899	12.4%	28	59.6	106.8	22,352	12.0%	28	59.1	103.4
3	22,428	7.7%	28	56.5	94.8	13,673	7.3%	28	54.3	87.8
4	14,570	5.0%	28	52.0	81.2	8,865	4.8%	28	52.9	79.5
5	9,802	3.4%	28	50.1	75.0	5,828	3.1%	29	50.8	72.4
6	6,810	2.4%	28	48.8	66.9	3,974	2.1%	28	47.4	62.8
7	4,752	1.6%	28	48.3	67.0	2,724	1.5%	28	47.9	70.3
8	3,408	1.2%	28	45.9	61.0	1,892	1.0%	28	46.1	65.8
9	2,446	0.8%	28	45.9	59.5	1,324	0.7%	28	42.6	55.1
10	1,778	0.6%	28	44.5	56.8	948	0.5%	28	41.6	57.9
11	1,271	0.4%	28	45.4	67.0	711	0.4%	26	38.3	36.9
12	906	0.3%	28	41.7	47.4	508	0.3%	29	43.8	56.7
13	667	0.2%	28	41.5	49.4	350	0.2%	27	37.9	39.2
14	485	0.2%	27	39.3	46.8	257	0.1%	29	40.7	36.4
15	363	0.1%	28	38.3	38.9	190	0.1%	26	34.9	29.1
16	250	0.1%	30	38.3	32.1	149	0.1%	29	36.1	33.2
17	186	0.1%	28	39.0	36.8	108	0.1%	32	36.2	26.3
18	141	0.0%	27	36.0	33.6	75	0.0%	26	37.5	36.3
19	100	0.0%	29	36.2	29.9	60	0.0%	33	46.5	46.5
20	72	0.0%	31	37.3	23.6	45	0.0%	23	32.3	23.4
21	54	0.0%	30	37.7	29.3	24	0.0%	26	35.0	24.8
22	38	0.0%	31	39.2	27.8	17	0.0%	27	31.8	17.5
23	27	0.0%	26	34.7	31.5	15	0.0%	28	28.1	14.0
24	17	0.0%	22	33.8	32.0	12	0.0%	24	29.3	16.9
25	12	0.0%	31	35.9	24.1	11	0.0%	28	25.8	11.4
26	*****	*****	17	19.0	9.2	*****	*****	22	37.1	25.0
27	*****	*****	18	23.7	17.0	*****	*****	56	50.7	32.3
28	*****	*****	24	24.4	12.7	*****	*****	13	29.3	30.0
29	*****	*****	24	24.0	11.8	*****	*****	66	52.7	31.2
30	*****	*****	23	22.5	14.8	*****	*****	*****	*****	*****
31	*****	*****	*****	*****	*****	0	0.0%			
32	*****	*****	*****	*****	*****	0	0.0%			
33	*****	*****	*****	*****	*****	0	0.0%			
34	*****	*****	*****	*****	*****	0	0.0%			

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Saxagliptin, continued</u>		65-74 years				75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	*****	*****	*****	*****	*****	0	0.0%			
36	*****	*****	*****	*****	*****	0	0.0%			
37	*****	*****	*****	*****	*****	0	0.0%			
38	*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	121,439	42.0%	352	537.5	567.7	82,455	44.3%	316	498.8	543.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

Sitagliptin	18-44 years					45-54 years					55-64 years					
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	
Total Episodes	342,068	100%	31	176.6	390.9	651,126	100%	29	171.1	388.0	820,251	100%	28	169.1	371.7	
Gap Number																
1	63,969	18.7%	29	95.9	234.3	122,930	18.9%	29	94.5	228.5	162,536	19.8%	29	92.2	213.2	
2	42,157	12.3%	29	80.5	191.1	79,977	12.3%	28	77.3	183.3	99,451	12.1%	28	73.9	168.2	
3	29,605	8.7%	30	74.3	167.6	55,446	8.5%	28	69.4	160.9	65,842	8.0%	28	65.7	141.0	
4	21,613	6.3%	29	70.5	163.6	40,043	6.1%	28	63.7	143.7	45,742	5.6%	28	62.2	132.8	
5	15,995	4.7%	29	65.3	144.5	29,572	4.5%	28	61.1	138.2	32,749	4.0%	28	59.4	120.1	
6	12,195	3.6%	29	61.2	135.0	22,317	3.4%	28	58.4	124.4	23,958	2.9%	28	57.4	119.6	
7	9,357	2.7%	28	59.8	127.1	17,136	2.6%	28	56.4	122.6	17,829	2.2%	28	52.9	100.5	
8	7,287	2.1%	29	57.7	121.3	13,247	2.0%	28	54.7	120.8	13,454	1.6%	28	51.0	91.0	
9	5,729	1.7%	28	56.8	127.7	10,480	1.6%	28	52.4	105.9	10,347	1.3%	27	51.1	100.6	
10	4,532	1.3%	28	57.3	125.6	8,294	1.3%	27	51.6	100.6	8,013	1.0%	28	49.8	93.6	
11	3,598	1.1%	28	51.7	102.6	6,611	1.0%	27	49.8	102.8	6,215	0.8%	28	48.8	92.5	
12	2,903	0.8%	28	53.9	108.1	5,257	0.8%	27	50.1	108.7	4,864	0.6%	29	50.4	97.0	
13	2,277	0.7%	27	51.8	104.2	4,185	0.6%	28	46.9	85.7	3,810	0.5%	28	47.0	81.6	
14	1,841	0.5%	27	46.3	85.1	3,377	0.5%	27	48.5	95.5	3,040	0.4%	27	43.2	65.4	
15	1,463	0.4%	27	46.1	74.9	2,758	0.4%	27	48.8	99.3	2,426	0.3%	28	45.4	85.6	
16	1,167	0.3%	28	50.6	92.6	2,221	0.3%	27	41.5	52.9	1,928	0.2%	29	45.2	80.5	
17	952	0.3%	26	45.6	78.2	1,813	0.3%	27	44.9	78.9	1,517	0.2%	28	45.1	75.7	
18	769	0.2%	28	49.8	106.4	1,480	0.2%	26	43.1	65.8	1,240	0.2%	26	44.5	88.1	
19	624	0.2%	26	44.7	79.5	1,224	0.2%	26	41.4	65.8	1,003	0.1%	27	38.9	54.8	
20	506	0.1%	26	40.4	68.7	1,006	0.2%	26	40.0	66.7	822	0.1%	26	39.9	57.7	
21	418	0.1%	24	37.4	70.5	839	0.1%	26	43.5	82.4	676	0.1%	26	36.7	44.0	
22	349	0.1%	26	44.1	91.4	720	0.1%	26	38.0	55.1	559	0.1%	24	45.0	90.5	
23	298	0.1%	26	41.7	124.6	596	0.1%	26	35.9	44.6	466	0.1%	25	37.8	69.0	
24	258	0.1%	26	38.7	47.0	499	0.1%	24	35.4	37.8	379	0.0%	26	42.6	78.7	
25	207	0.1%	25	33.3	31.6	423	0.1%	26	37.1	51.1	316	0.0%	27	33.3	25.2	
26	168	0.0%	27	46.3	122.9	350	0.1%	25	33.7	37.8	259	0.0%	26	36.8	50.4	
27	136	0.0%	25	45.1	90.2	292	0.0%	25	39.7	77.0	229	0.0%	27	36.3	37.3	
28	107	0.0%	19	28.8	22.0	252	0.0%	25	35.7	67.4	183	0.0%	27	37.9	61.9	
29	90	0.0%	24	40.6	81.1	216	0.0%	27	33.3	23.9	146	0.0%	29	35.0	25.7	
30	75	0.0%	20	33.2	37.9	179	0.0%	26	33.9	32.3	127	0.0%	28	34.5	27.2	
31	62	0.0%	26	32.2	24.1	147	0.0%	28	38.1	43.4	102	0.0%	25	32.1	25.1	
32	51	0.0%	26	28.2	13.9	108	0.0%	24	30.4	21.6	83	0.0%	26	33.4	24.3	
33	43	0.0%	22	27.3	14.9	83	0.0%	28	33.9	24.0	70	0.0%	26	31.4	18.3	
34	35	0.0%	26	28.3	13.4	63	0.0%	25	30.4	17.1	57	0.0%	25	32.3	24.7	

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Sitagliptin, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	30	0.0%	22	27.0	13.2	55	0.0%	30	48.4	77.8	45	0.0%	27	35.0	26.2
36	24	0.0%	26	30.0	16.4	45	0.0%	24	28.2	19.4	36	0.0%	28	32.9	23.1
37	22	0.0%	30	36.2	26.4	37	0.0%	26	29.1	12.1	21	0.0%	28	45.7	84.2
38	17	0.0%	30	43.8	48.2	31	0.0%	18	25.1	19.5	18	0.0%	25	35.8	45.1
39	15	0.0%	33	35.0	18.5	26	0.0%	23	27.7	12.4	16	0.0%	26	28.9	15.5
40	*****	*****	32	36.6	16.5	24	0.0%	25	26.9	11.8	16	0.0%	30	38.4	33.8
41	*****	*****	42	43.0	21.5	18	0.0%	23	28.5	21.8	13	0.0%	31	32.2	15.3
42	*****	*****	26	28.8	15.0	17	0.0%	20	24.1	12.2	*****	*****	28	26.7	10.6
43	*****	*****	24	30.6	16.4	15	0.0%	19	25.3	14.9	*****	*****	26	28.8	11.3
44	*****	*****	23	25.0	12.2	15	0.0%	31	29.9	13.8	*****	*****	23	27.6	14.8
45	*****	*****	32	32.2	15.3	13	0.0%	21	23.2	9.8	*****	*****	27	28.5	14.0
46	*****	*****	25	50.2	55.4	*****	*****	28	28.0	12.0	*****	*****	34	31.0	10.5
47	*****	*****	26	33.0	19.0	*****	*****	24	23.5	9.3	*****	*****	31	28.0	8.5
48	*****	*****	29	23.7	11.0	*****	*****	28	27.0	9.2	*****	*****	76	75.5	71.4
49	*****	*****	33	32.5	21.9	*****	*****	26	27.7	3.8	*****	*****	68	67.5	65.8
50	*****	*****	*****	*****	*****	*****	*****	23	24.3	6.1	*****	*****	*****	*****	*****
51	0	0.0%				*****	*****	30	25.3	11.7	*****	*****	*****	*****	*****
52	0	0.0%				*****	*****	13	19.7	13.3	*****	*****	*****	*****	*****
53	0	0.0%				*****	*****	16	16.0	4.2	*****	*****	*****	*****	*****
54	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
55	0	0.0%				*****	*****	*****	*****	*****	0	0.0%			
Gap from last episode until censoring	111,059	32.5%	86	386.2	580.2	216,655	33.3%	46	368.5	576.7	309,603	37.7%	26	329.2	529.1

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Sitagliptin</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,421,888	100%	32	185.3	377.5	958,631	100%	31	176.8	358.5
Gap Number										
1	288,853	20.3%	31	95.7	198.7	196,735	20.5%	31	91.8	186.0
2	175,175	12.3%	30	77.3	154.0	114,270	11.9%	30	72.1	140.0
3	114,188	8.0%	30	69.8	135.1	72,231	7.5%	30	65.0	118.3
4	77,550	5.5%	30	64.8	118.6	47,834	5.0%	30	60.9	109.2
5	54,439	3.8%	30	60.2	105.9	32,835	3.4%	30	57.1	93.9
6	38,796	2.7%	30	58.3	104.1	23,013	2.4%	30	54.8	89.1
7	28,356	2.0%	30	54.6	89.5	16,456	1.7%	30	53.8	86.2
8	20,774	1.5%	30	53.4	86.7	12,036	1.3%	29	50.5	72.2
9	15,387	1.1%	30	53.0	88.3	8,788	0.9%	30	50.0	72.8
10	11,580	0.8%	30	49.7	72.3	6,513	0.7%	29	48.3	75.3
11	8,692	0.6%	29	47.5	67.8	4,860	0.5%	30	46.8	65.5
12	6,613	0.5%	29	46.3	65.4	3,647	0.4%	29	46.8	74.7
13	5,070	0.4%	30	48.1	73.0	2,804	0.3%	29	42.4	52.2
14	3,891	0.3%	30	45.5	60.9	2,196	0.2%	29	43.8	57.7
15	3,006	0.2%	29	44.0	62.6	1,665	0.2%	29	41.4	48.4
16	2,357	0.2%	29	41.7	49.0	1,267	0.1%	29	39.7	41.5
17	1,838	0.1%	30	42.1	52.3	984	0.1%	29	40.6	49.2
18	1,456	0.1%	29	43.5	72.8	747	0.1%	28	39.3	46.1
19	1,138	0.1%	29	37.4	32.5	582	0.1%	30	40.3	40.0
20	866	0.1%	28	42.0	88.5	455	0.0%	29	41.3	59.1
21	657	0.0%	29	37.9	37.4	339	0.0%	30	37.8	35.1
22	509	0.0%	28	34.8	30.6	264	0.0%	30	37.5	36.4
23	403	0.0%	30	37.8	32.4	192	0.0%	29	39.2	38.3
24	320	0.0%	28	37.6	43.2	148	0.0%	30	40.3	37.2
25	253	0.0%	30	39.1	34.6	114	0.0%	30	36.9	28.2
26	198	0.0%	31	38.3	33.9	88	0.0%	31	36.7	27.8
27	148	0.0%	31	36.0	34.0	72	0.0%	29	38.4	37.4
28	123	0.0%	33	35.8	20.3	54	0.0%	28	38.5	66.7
29	109	0.0%	30	36.1	26.0	42	0.0%	30	35.5	25.9
30	89	0.0%	32	43.4	46.6	35	0.0%	29	29.8	13.5
31	64	0.0%	35	54.7	76.4	29	0.0%	28	37.6	39.2
32	48	0.0%	29	39.3	39.1	22	0.0%	28	29.6	17.6
33	39	0.0%	31	38.9	25.3	19	0.0%	32	34.9	20.6
34	35	0.0%	32	44.4	46.3	18	0.0%	28	27.6	13.9

Table 12a. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, by Age Group

<u>Sitagliptin, continued</u>			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	26	0.0%	35	42.2	27.5	14	0.0%	28	31.9	20.0
36	17	0.0%	28	31.2	18.1	13	0.0%	29	28.3	14.3
37	15	0.0%	28	42.7	41.1	11	0.0%	20	30.0	24.7
38	*****	*****	36	34.8	14.5	*****	*****	31	31.6	16.2
39	*****	*****	33	39.2	27.2	*****	*****	20	24.6	10.0
40	*****	*****	29	32.0	18.4	*****	*****	27	25.2	7.1
41	*****	*****	49	47.3	19.6	*****	*****	31	24.7	11.0
42	*****	*****	49	53.8	40.0	*****	*****	30	30.0	18.4
43	*****	*****	25	29.0	14.4	*****	*****	*****	*****	*****
44	*****	*****	30	29.5	13.4	*****	*****	*****	*****	*****
45	*****	*****	18	18.0	4.2	0	0.0%			
46	*****	*****	*****	*****	*****	0	0.0%			
47	*****	*****	*****	*****	*****	0	0.0%			
48	*****	*****	*****	*****	*****	0	0.0%			
49	0	0.0%				0	0.0%			
50	0	0.0%				0	0.0%			
51	0	0.0%				0	0.0%			
52	0	0.0%				0	0.0%			
53	0	0.0%				0	0.0%			
54	0	0.0%				0	0.0%			
55	0	0.0%				0	0.0%			
Gap from last episode until censoring	558,774	39.3%	59	354.4	527.7	407,214	42.5%	41	317.5	489.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	292,686	100%	51	303.6	551.0	373,302	100%	32	183.9	421.5	419,439	100%	33	192.2	415.8
Gap Number															
1	44,454	15.2%	33	147.3	311.6	61,236	16.4%	32	100.6	218.1	75,062	17.9%	34	95.6	192.1
2	27,150	9.3%	32	93.5	202.0	43,421	11.6%	31	82.1	181.7	50,704	12.1%	32	78.1	155.7
3	19,466	6.7%	32	79.9	169.9	32,501	8.7%	31	73.3	158.9	36,250	8.6%	31	68.6	133.8
4	14,723	5.0%	30	74.0	163.4	25,023	6.7%	30	65.9	135.2	26,831	6.4%	30	65.1	127.7
5	11,545	3.9%	29	65.9	138.3	19,626	5.3%	29	62.0	129.7	20,261	4.8%	30	59.8	111.4
6	9,188	3.1%	29	61.8	125.4	15,668	4.2%	29	58.9	119.5	15,594	3.7%	29	56.8	111.1
7	7,335	2.5%	28	57.3	111.9	12,607	3.4%	28	56.3	117.1	12,259	2.9%	28	52.2	90.7
8	5,955	2.0%	28	57.0	113.1	10,220	2.7%	27	52.4	104.8	9,624	2.3%	28	49.7	85.1
9	4,816	1.6%	27	51.6	95.3	8,361	2.2%	27	53.1	105.9	7,676	1.8%	28	51.2	94.5
10	3,938	1.3%	28	53.5	98.9	6,907	1.9%	27	48.1	85.9	6,139	1.5%	27	47.9	93.9
11	3,264	1.1%	26	51.0	103.4	5,751	1.5%	26	49.6	102.8	4,961	1.2%	27	46.0	84.9
12	2,678	0.9%	26	51.0	99.4	4,801	1.3%	27	48.5	99.0	4,006	1.0%	26	44.1	75.4
13	2,214	0.8%	25	48.1	101.2	4,011	1.1%	27	47.5	86.7	3,244	0.8%	26	43.8	86.2
14	1,841	0.6%	25	45.5	82.2	3,338	0.9%	26	47.5	94.4	2,629	0.6%	26	44.3	77.5
15	1,550	0.5%	25	45.9	97.2	2,749	0.7%	25	43.9	69.7	2,151	0.5%	25	42.1	78.9
16	1,285	0.4%	25	48.0	104.0	2,321	0.6%	25	40.8	70.7	1,733	0.4%	25	40.8	69.8
17	1,077	0.4%	25	46.6	95.8	2,005	0.5%	25	40.0	64.0	1,395	0.3%	26	43.1	68.9
18	910	0.3%	26	46.4	87.5	1,708	0.5%	24	41.2	72.0	1,145	0.3%	24	40.1	68.6
19	763	0.3%	25	44.3	84.4	1,424	0.4%	25	39.8	61.4	939	0.2%	24	38.8	70.3
20	642	0.2%	24	45.4	101.8	1,193	0.3%	24	38.8	56.8	786	0.2%	24	37.5	56.2
21	554	0.2%	23	40.2	73.0	1,024	0.3%	24	40.8	85.3	655	0.2%	24	38.8	75.8
22	471	0.2%	24	40.1	61.5	887	0.2%	24	40.2	64.0	566	0.1%	24	35.6	64.1
23	380	0.1%	25	42.3	66.0	730	0.2%	23	36.9	54.7	483	0.1%	24	34.3	40.6
24	308	0.1%	21	32.3	42.3	619	0.2%	22	36.5	51.3	414	0.1%	25	36.9	69.4
25	253	0.1%	24	39.3	70.5	529	0.1%	23	38.5	61.7	344	0.1%	21	32.6	40.7
26	211	0.1%	22	32.3	37.6	453	0.1%	23	34.3	42.2	284	0.1%	21	34.0	59.9
27	176	0.1%	24	31.9	30.4	383	0.1%	24	36.7	59.5	224	0.1%	21	34.5	62.4
28	157	0.1%	21	35.7	65.0	320	0.1%	21	33.7	40.5	183	0.0%	22	34.9	49.7

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Glyburide, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
29	137	0.0%	22	33.4	62.9	270	0.1%	22	45.4	118.4	150	0.0%	21	31.6	33.3
30	113	0.0%	21	30.3	27.8	226	0.1%	23	38.1	54.1	120	0.0%	19	29.5	35.1
31	99	0.0%	21	28.5	30.2	185	0.0%	25	33.3	33.7	102	0.0%	22	38.4	70.1
32	80	0.0%	21	26.5	20.0	154	0.0%	22	30.4	31.4	91	0.0%	20	30.1	27.8
33	70	0.0%	24	29.1	25.6	134	0.0%	21	31.9	37.6	75	0.0%	24	33.3	28.3
34	57	0.0%	23	31.5	25.3	119	0.0%	24	29.2	20.6	65	0.0%	20	27.6	22.1
35	46	0.0%	21	46.5	92.7	103	0.0%	24	30.8	26.1	51	0.0%	20	27.4	24.4
36	41	0.0%	17	22.4	29.5	86	0.0%	26	35.6	36.2	37	0.0%	22	41.6	53.3
37	35	0.0%	19	41.8	49.0	68	0.0%	24	31.3	28.9	27	0.0%	20	45.0	87.3
38	30	0.0%	19	21.2	11.1	55	0.0%	22	29.4	32.0	20	0.0%	23	32.6	37.5
39	24	0.0%	18	22.9	15.3	49	0.0%	19	27.4	23.8	17	0.0%	19	27.2	26.2
40	18	0.0%	18	43.6	66.6	45	0.0%	27	37.3	39.3	16	0.0%	15	26.7	27.6
41	14	0.0%	16	39.3	45.0	41	0.0%	26	44.6	85.7	13	0.0%	19	26.3	27.4
42	*****	*****	12	14.5	5.7	35	0.0%	26	35.9	29.8	*****	*****	18	20.3	11.3
43	*****	*****	15	15.1	5.1	28	0.0%	20	27.9	22.4	*****	*****	16	17.9	7.7
44	*****	*****	19	20.0	10.0	18	0.0%	14	23.2	16.5	*****	*****	17	20.6	11.4
45	*****	*****	13	15.1	6.8	15	0.0%	13	18.3	16.4	*****	*****	17	21.3	13.0
46	*****	*****	14	16.3	8.1	*****	*****	16	22.4	16.0	*****	*****	10	12.5	5.9
47	*****	*****	15	16.6	6.6	*****	*****	14	15.7	6.6	*****	*****	18	17.6	6.5
48	*****	*****	10	12.7	4.8	*****	*****	16	16.8	6.7	*****	*****	16	16.6	4.0
49	*****	*****	15	25.0	28.8	*****	*****	17	18.5	7.0	*****	*****	13	16.0	8.8
50	*****	*****	17	18.0	1.7	*****	*****	9	12.0	6.8	*****	*****	11	16.3	11.0
51	*****	*****	19	18.5	14.8	*****	*****	19	18.8	8.6	*****	*****	17	17.7	8.0
52	*****	*****	18	18.0	7.1	*****	*****	8	11.7	6.4	*****	*****	16	20.0	12.5
53	*****	*****	*****	*****	*****	*****	*****	23	23.0	7.1	*****	*****	16	19.7	11.9
54	0	0.0%				*****	*****	*****	*****	*****	*****	*****	14	38.0	44.2
55	0	0.0%				*****	*****	*****	*****	*****	*****	*****	14	14.0	4.2
56	0	0.0%				*****	*****	*****	*****	*****	*****	*****	19	19.0	5.7
57	0	0.0%				*****	*****	*****	*****	*****	*****	*****	25	24.5	19.1
58	0	0.0%				*****	*****	*****	*****	*****	*****	*****	11	10.5	0.7

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Glyburide, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
59	0	0.0%				*****	*****	*****	*****	*****	*****	*****	30	29.5	27.6
60	0	0.0%				0	0.0%				*****	*****	16	16.0	5.7
61	0	0.0%				0	0.0%				*****	*****	20	20.0	14.1
Gap from last episode until censoring	124,547	42.6%	314	591.5	714.0	101,800	27.3%	160	482.8	678.4	132,029	31.5%	158	456.0	633.7

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	551,545	100%	46	272.5	493.6	374,376	100%	50	271.4	473.4
Gap Number										
1	108,702	19.7%	38	96.0	175.8	74,984	20.0%	38	91.2	158.3
2	67,964	12.3%	35	80.2	146.1	44,455	11.9%	35	77.1	132.5
3	45,380	8.2%	33	71.4	127.4	28,714	7.7%	33	68.4	118.6
4	31,567	5.7%	32	66.4	121.5	19,398	5.2%	31	61.8	104.9
5	22,559	4.1%	32	61.9	111.3	13,611	3.6%	31	59.3	107.5
6	16,435	3.0%	30	57.6	109.2	9,623	2.6%	30	55.8	95.7
7	12,157	2.2%	30	55.9	105.1	6,936	1.9%	30	52.5	92.6
8	9,218	1.7%	29	52.2	97.2	5,167	1.4%	29	48.7	74.0
9	7,006	1.3%	29	50.8	96.6	3,834	1.0%	28	48.4	92.4
10	5,317	1.0%	28	48.0	88.0	2,928	0.8%	28	48.5	95.9
11	4,063	0.7%	28	49.3	97.7	2,184	0.6%	27	43.0	61.0
12	3,128	0.6%	28	48.0	92.6	1,647	0.4%	27	45.7	98.1
13	2,417	0.4%	28	48.7	96.3	1,233	0.3%	28	42.3	62.8
14	1,888	0.3%	27	46.5	76.6	958	0.3%	27	43.5	82.8
15	1,483	0.3%	27	48.1	102.7	732	0.2%	26	43.7	79.2
16	1,159	0.2%	26	43.2	76.9	553	0.1%	28	45.6	95.8
17	886	0.2%	27	44.5	98.0	408	0.1%	25	42.6	79.9
18	701	0.1%	26	36.8	53.3	312	0.1%	26	45.0	102.8
19	588	0.1%	26	44.9	104.8	237	0.1%	26	35.9	38.3
20	455	0.1%	28	45.0	101.1	183	0.0%	30	39.9	52.7
21	356	0.1%	27	46.0	116.2	145	0.0%	26	40.7	78.2
22	275	0.0%	25	35.3	55.5	113	0.0%	27	47.0	132.2
23	208	0.0%	25	36.8	83.4	85	0.0%	23	65.7	216.1
24	160	0.0%	23	31.8	48.5	61	0.0%	26	44.4	70.9
25	129	0.0%	25	28.2	22.2	44	0.0%	19	24.4	20.7
26	105	0.0%	26	37.7	71.2	34	0.0%	18	52.3	164.3
27	80	0.0%	24	43.3	124.9	26	0.0%	17	71.4	251.2

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
28	60	0.0%	22	40.2	108.2	18	0.0%	23	28.0	24.7
29	46	0.0%	21	30.5	45.9	12	0.0%	21	132.8	374.6
30	33	0.0%	14	22.7	17.6	*****	*****	25	30.9	22.9
31	28	0.0%	21	24.8	10.1	*****	*****	22	61.9	104.7
32	23	0.0%	20	23.6	14.7	*****	*****	24	50.5	61.6
33	21	0.0%	18	30.5	38.7	*****	*****	15	17.0	9.1
34	17	0.0%	16	23.3	18.6	*****	*****	24	21.8	9.3
35	11	0.0%	15	26.2	26.7	*****	*****	12	16.0	10.6
36	*****	*****	22	26.9	18.0	*****	*****	19	19.0	12.7
37	*****	*****	25	27.7	14.4	*****	*****	19	18.5	14.8
38	*****	*****	20	26.3	17.4	*****	*****	*****	*****	*****
39	*****	*****	13	29.8	29.9	*****	*****	*****	*****	*****
40	*****	*****	26	30.0	17.2	*****	*****	*****	*****	*****
41	*****	*****	19	19.3	8.9	*****	*****	*****	*****	*****
42	*****	*****	23	22.3	8.5	*****	*****	*****	*****	*****
43	*****	*****	21	20.5	10.1	*****	*****	*****	*****	*****
44	*****	*****	20	24.5	13.4	*****	*****	*****	*****	*****
45	*****	*****	15	15.3	2.5	*****	*****	*****	*****	*****
46	*****	*****	17	16.3	5.0	*****	*****	*****	*****	*****
47	*****	*****	13	12.5	3.5	*****	*****	*****	*****	*****
48	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
49	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
50	0	0.0%				*****	*****	*****	*****	*****
51	0	0.0%				*****	*****	*****	*****	*****
52	0	0.0%				*****	*****	*****	*****	*****
53	0	0.0%				*****	*****	*****	*****	*****
54	0	0.0%				*****	*****	*****	*****	*****
55	0	0.0%				*****	*****	*****	*****	*****
56	0	0.0%				0	0.0%			

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Glyburide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
57	0	0.0%				0	0.0%			
58	0	0.0%				0	0.0%			
59	0	0.0%				0	0.0%			
60	0	0.0%				0	0.0%			
61	0	0.0%				0	0.0%			
Gap from last episode until censoring	206,862	37.5%	355	600.0	666.2	155,687	41.6%	323	549.0	618.5

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Liraglutide	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	204,222	100%	27	138.4	308.2	341,681	100%	25	127.6	301.9	391,385	100%	25	121.8	285.6
Gap Number															
1	38,149	18.7%	26	71.4	163.9	61,295	17.9%	26	68.8	161.1	71,859	18.4%	26	64.8	143.6
2	25,785	12.6%	26	66.5	147.8	42,580	12.5%	25	61.7	141.6	48,551	12.4%	25	58.8	124.5
3	18,408	9.0%	27	63.9	138.6	31,320	9.2%	25	58.8	132.6	34,929	8.9%	25	54.6	113.9
4	13,504	6.6%	26	60.8	127.7	23,468	6.9%	25	56.1	118.6	25,954	6.6%	25	52.2	106.1
5	10,165	5.0%	26	58.3	124.9	17,941	5.3%	25	53.3	110.0	19,784	5.1%	24	49.7	98.2
6	7,725	3.8%	25	57.2	127.8	13,824	4.0%	24	49.8	100.6	15,242	3.9%	24	46.7	85.5
7	5,938	2.9%	26	54.9	104.2	10,796	3.2%	24	50.1	99.1	11,801	3.0%	24	45.5	82.1
8	4,613	2.3%	24	50.7	103.2	8,556	2.5%	24	47.2	90.4	9,216	2.4%	23	43.3	78.5
9	3,642	1.8%	24	53.0	118.0	6,813	2.0%	24	47.3	97.3	7,210	1.8%	23	44.8	88.3
10	2,867	1.4%	23	49.0	101.6	5,434	1.6%	24	45.5	88.8	5,697	1.5%	22	40.0	72.6
11	2,267	1.1%	23	44.8	85.4	4,369	1.3%	23	44.1	80.0	4,556	1.2%	22	40.1	73.0
12	1,819	0.9%	23	46.9	90.9	3,551	1.0%	23	42.9	82.0	3,606	0.9%	21	38.4	70.7
13	1,422	0.7%	22	41.6	86.5	2,872	0.8%	23	42.8	86.1	2,868	0.7%	22	41.0	80.8
14	1,151	0.6%	23	43.8	78.7	2,307	0.7%	22	38.7	61.4	2,307	0.6%	22	36.5	63.4
15	910	0.4%	21	37.1	53.9	1,862	0.5%	23	37.6	54.5	1,850	0.5%	22	35.2	48.9
16	742	0.4%	20	41.1	78.6	1,466	0.4%	21	37.1	60.2	1,471	0.4%	22	36.1	56.9
17	605	0.3%	21	40.4	89.1	1,171	0.3%	22	36.1	67.0	1,155	0.3%	21	33.3	52.7
18	496	0.2%	21	37.0	70.0	945	0.3%	22	37.0	61.6	943	0.2%	21	32.8	46.2
19	406	0.2%	22	35.5	56.0	774	0.2%	21	36.6	72.1	765	0.2%	21	32.0	47.3
20	322	0.2%	21	35.9	59.6	629	0.2%	22	39.1	94.9	619	0.2%	20	31.1	42.6
21	263	0.1%	21	31.1	33.4	519	0.2%	23	34.5	54.2	506	0.1%	21	29.7	31.3
22	217	0.1%	22	40.8	69.9	426	0.1%	22	35.2	50.8	405	0.1%	21	34.7	71.4
23	176	0.1%	20	29.8	34.1	338	0.1%	20	32.9	44.0	320	0.1%	20	28.5	28.8
24	147	0.1%	19	31.4	42.4	285	0.1%	21	31.2	33.2	262	0.1%	21	36.2	63.6
25	122	0.1%	18	32.0	50.6	232	0.1%	20	28.1	25.8	210	0.1%	23	30.4	35.8
26	101	0.0%	15	32.0	50.2	195	0.1%	21	28.5	29.2	167	0.0%	18	28.9	34.4
27	71	0.0%	19	27.1	22.7	156	0.0%	20	28.9	29.0	133	0.0%	19	37.8	113.5
28	56	0.0%	24	25.4	14.9	118	0.0%	19	25.2	23.2	105	0.0%	18	24.1	20.1
29	45	0.0%	18	24.4	17.8	94	0.0%	22	30.4	27.6	84	0.0%	18	32.3	71.2
30	32	0.0%	17	29.0	32.9	69	0.0%	20	29.7	30.2	68	0.0%	20	27.1	32.6
31	21	0.0%	16	23.8	19.2	49	0.0%	22	26.3	21.5	57	0.0%	18	23.1	16.6
32	*****	*****	17	22.0	14.5	36	0.0%	20	30.3	25.5	37	0.0%	19	23.9	16.8
33	*****	*****	23	27.5	18.6	29	0.0%	24	23.7	10.5	32	0.0%	19	21.7	10.5

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Liraglutide, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
34	*****	*****	21	23.9	13.3	24	0.0%	20	25.5	17.9	22	0.0%	22	27.3	19.7
35	*****	*****	12	20.4	20.9	21	0.0%	19	29.0	24.2	18	0.0%	18	22.7	13.7
36	*****	*****	10	18.4	21.0	17	0.0%	20	30.1	26.9	13	0.0%	26	26.5	11.5
37	*****	*****	23	21.6	7.6	*****	*****	24	27.0	19.6	11	0.0%	20	21.5	8.1
38	*****	*****	22	26.7	21.4	*****	*****	16	20.1	17.9	11	0.0%	19	23.7	11.3
39	*****	*****	57	56.5	43.1	*****	*****	18	21.7	16.8	*****	*****	26	36.8	37.9
40	*****	*****	26	26.0	5.7	*****	*****	21	22.2	11.6	*****	*****	18	19.3	7.8
41	*****	*****	37	37.0	17.0	*****	*****	16	21.8	15.6	*****	*****	21	22.8	7.7
42	*****	*****	*****	*****	*****	*****	*****	19	33.6	31.4	*****	*****	20	19.7	2.5
43	0	0.0%				*****	*****	32	31.8	10.7	*****	*****	19	18.5	9.2
44	0	0.0%				*****	*****	34	33.5	23.3	*****	*****	*****	*****	*****
45	0	0.0%				*****	*****	12	11.5	12.0	*****	*****	*****	*****	*****
46	0	0.0%				*****	*****	17	16.5	19.1	*****	*****	*****	*****	*****
47	0	0.0%				0	0.0%				*****	*****	*****	*****	*****
48	0	0.0%				0	0.0%				0	0.0%			
Gap from last episode until censoring	61,966	30.3%	76	313.7	474.4	97,046	28.4%	39	304.4	484.7	118,511	30.3%	26	277.5	451.7

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Liraglutide</u>	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	464,558	100%	28	137.1	293.7	123,403	100%	29	141.3	297.5
Gap Number										
1	85,975	18.5%	29	67.2	129.6	22,456	18.2%	29	61.7	114.4
2	57,952	12.5%	27	58.8	108.2	14,996	12.2%	27	54.0	95.9
3	41,329	8.9%	26	54.4	92.4	10,705	8.7%	26	50.6	86.3
4	30,591	6.6%	26	51.8	85.1	7,896	6.4%	25	45.6	68.7
5	23,051	5.0%	25	48.9	80.6	6,055	4.9%	25	45.0	65.6
6	17,718	3.8%	25	47.8	78.6	4,617	3.7%	25	41.9	58.8
7	13,662	2.9%	25	44.3	66.3	3,573	2.9%	24	41.5	56.5
8	10,653	2.3%	24	43.9	69.0	2,804	2.3%	24	40.2	67.1
9	8,301	1.8%	24	42.1	62.2	2,187	1.8%	23	39.7	69.5
10	6,414	1.4%	23	39.5	55.9	1,738	1.4%	23	37.8	49.6
11	5,044	1.1%	23	39.1	53.4	1,371	1.1%	22	36.3	47.7
12	3,971	0.9%	23	38.1	56.8	1,049	0.9%	22	36.6	51.6
13	3,143	0.7%	23	39.1	64.0	859	0.7%	23	36.4	53.6
14	2,461	0.5%	21	35.6	53.5	673	0.5%	21	32.9	38.3
15	1,931	0.4%	22	35.3	49.3	545	0.4%	22	33.8	41.1
16	1,515	0.3%	22	33.8	43.2	429	0.3%	20	32.4	48.8
17	1,201	0.3%	21	31.4	33.3	342	0.3%	19	27.3	23.9
18	964	0.2%	21	32.8	37.0	263	0.2%	20	30.0	28.3
19	747	0.2%	21	33.4	43.8	198	0.2%	19	31.3	33.0
20	587	0.1%	21	31.7	38.5	157	0.1%	19	29.2	31.8
21	457	0.1%	19	29.6	35.2	122	0.1%	21	28.9	24.9
22	374	0.1%	20	28.3	29.4	94	0.1%	16	25.1	23.2
23	302	0.1%	20	29.1	29.2	71	0.1%	18	28.8	35.3
24	246	0.1%	20	30.4	43.6	63	0.1%	16	24.2	25.8
25	187	0.0%	18	25.7	21.4	54	0.0%	15	25.0	32.2
26	136	0.0%	20	31.5	40.5	39	0.0%	22	55.5	98.8
27	105	0.0%	19	28.3	25.0	32	0.0%	17	31.5	36.8

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Liraglutide, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
28	85	0.0%	19	27.3	26.9	25	0.0%	17	20.0	17.0
29	65	0.0%	20	28.7	27.2	19	0.0%	14	14.9	6.0
30	49	0.0%	19	29.3	30.8	15	0.0%	16	23.7	26.4
31	37	0.0%	23	30.7	23.8	11	0.0%	14	15.3	7.9
32	29	0.0%	26	24.9	12.5	*****	*****	15	14.4	6.1
33	25	0.0%	19	23.8	12.6	*****	*****	12	11.6	3.8
34	18	0.0%	23	22.8	7.7	*****	*****	18	17.3	8.4
35	13	0.0%	18	20.2	6.1	*****	*****	20	31.3	20.5
36	13	0.0%	15	18.3	7.1	*****	*****	11	11.0	9.9
37	*****	*****	16	19.6	9.1	*****	*****	11	10.5	2.1
38	*****	*****	16	16.9	6.6	*****	*****	14	14.0	1.4
39	*****	*****	14	20.5	15.7	*****	*****	12	11.5	7.8
40	*****	*****	23	24.3	11.1	*****	*****	12	11.5	3.5
41	*****	*****	20	19.5	7.8	*****	*****	17	17.0	2.8
42	*****	*****	25	24.5	7.8	*****	*****	16	16.0	9.9
43	*****	*****	*****	*****	*****	*****	*****	10	10.0	2.8
44	0	0.0%				*****	*****	19	18.5	10.6
45	0	0.0%				*****	*****	11	11.0	11.3
46	0	0.0%				*****	*****	9	8.5	3.5
47	0	0.0%				*****	*****	*****	*****	*****
48	0	0.0%				*****	*****	*****	*****	*****
Gap from last episode until censoring	145,175	31.3%	82	318.2	454.2	39,895	32.3%	104	332.1	451.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
	Gap Number														
Total Episodes	3,786,132	100%	33	150.1	334.6	4,465,978	100%	29	118.5	286.2	4,622,785	100%	29	116.0	278.5
1	643,202	17.0%	35	143.0	311.7	726,382	16.3%	35	136.2	298.9	817,171	17.7%	36	125.8	267.3
2	452,725	12.0%	35	117.4	255.6	530,581	11.9%	33	104.8	233.6	567,475	12.3%	33	96.7	207.9
3	335,535	8.9%	34	104.2	228.1	404,343	9.1%	33	92.0	204.8	413,891	9.0%	33	83.9	177.3
4	256,934	6.8%	33	94.0	203.8	315,685	7.1%	32	82.6	181.6	311,087	6.7%	32	76.0	158.8
5	200,748	5.3%	32	86.6	187.3	250,550	5.6%	31	75.8	165.1	238,846	5.2%	31	70.4	145.3
6	158,848	4.2%	31	80.9	175.6	200,976	4.5%	31	72.3	156.7	186,066	4.0%	31	66.5	135.1
7	127,075	3.4%	31	76.1	163.2	162,469	3.6%	30	67.0	143.0	146,630	3.2%	30	62.6	124.7
8	102,395	2.7%	30	72.6	154.0	132,273	3.0%	29	64.6	138.2	116,286	2.5%	30	59.7	117.6
9	83,188	2.2%	30	67.7	143.0	108,143	2.4%	29	61.1	126.3	93,063	2.0%	29	57.2	110.3
10	67,735	1.8%	29	65.1	136.0	88,874	2.0%	29	59.5	124.8	74,932	1.6%	29	55.0	106.3
11	55,407	1.5%	28	62.2	130.0	73,219	1.6%	28	57.2	116.8	60,719	1.3%	28	52.2	97.0
12	45,565	1.2%	28	60.2	123.8	60,610	1.4%	28	54.1	110.2	49,078	1.1%	28	51.4	96.7
13	37,711	1.0%	28	57.8	121.7	50,364	1.1%	27	53.4	108.7	40,071	0.9%	28	50.0	99.1
14	31,192	0.8%	27	56.6	119.0	41,855	0.9%	27	51.4	102.6	32,541	0.7%	27	48.3	87.7
15	25,952	0.7%	27	53.9	109.6	34,947	0.8%	26	50.3	102.9	26,601	0.6%	27	47.3	88.4
16	21,614	0.6%	26	52.6	108.9	29,279	0.7%	26	48.4	94.6	21,772	0.5%	26	46.1	86.1
17	18,065	0.5%	26	51.2	101.6	24,649	0.6%	26	46.8	92.6	17,944	0.4%	26	44.5	81.4
18	15,050	0.4%	26	49.0	91.0	20,746	0.5%	25	45.5	86.6	14,758	0.3%	26	44.2	83.4
19	12,617	0.3%	26	47.9	91.3	17,356	0.4%	25	44.9	84.3	12,205	0.3%	25	42.8	80.0
20	10,571	0.3%	26	48.0	96.3	14,547	0.3%	25	43.5	79.5	10,124	0.2%	26	42.1	78.1
21	8,850	0.2%	25	45.5	79.9	12,274	0.3%	25	43.8	82.5	8,370	0.2%	25	41.0	65.1
22	7,476	0.2%	25	45.9	85.4	10,365	0.2%	25	42.8	78.0	6,951	0.2%	25	40.0	68.1
23	6,287	0.2%	24	43.4	78.0	8,807	0.2%	25	40.5	66.8	5,791	0.1%	25	38.6	56.8
24	5,252	0.1%	25	42.4	72.6	7,411	0.2%	24	40.1	71.3	4,799	0.1%	25	38.3	62.9
25	4,383	0.1%	24	41.4	66.6	6,294	0.1%	24	39.5	67.3	4,020	0.1%	24	38.6	64.5
26	3,704	0.1%	24	38.5	56.5	5,336	0.1%	24	37.1	57.2	3,377	0.1%	24	37.2	58.9
27	3,111	0.1%	24	41.3	74.3	4,491	0.1%	23	38.1	68.4	2,819	0.1%	24	38.8	65.3
28	2,605	0.1%	24	39.4	63.4	3,806	0.1%	23	37.2	66.7	2,347	0.1%	24	38.1	63.8
29	2,138	0.1%	24	39.5	60.9	3,219	0.1%	23	37.8	63.6	1,937	0.0%	24	36.0	58.6
30	1,798	0.0%	23	36.7	53.6	2,707	0.1%	22	36.5	57.6	1,604	0.0%	23	35.9	50.2
31	1,507	0.0%	23	35.7	55.2	2,262	0.1%	22	33.1	37.2	1,319	0.0%	23	33.8	42.3
32	1,217	0.0%	23	36.4	50.7	1,898	0.0%	22	34.8	51.5	1,098	0.0%	23	33.9	48.3
33	1,017	0.0%	23	32.7	34.8	1,598	0.0%	23	34.6	52.7	907	0.0%	23	33.2	46.0
34	821	0.0%	22	34.2	46.3	1,335	0.0%	22	34.8	62.2	733	0.0%	23	35.5	66.9

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Metformin, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	690	0.0%	20	31.9	51.1	1,117	0.0%	22	32.4	46.3	625	0.0%	24	35.1	62.9
36	579	0.0%	20	32.1	53.6	926	0.0%	22	31.1	35.0	506	0.0%	23	34.2	48.4
37	462	0.0%	22	32.1	42.4	763	0.0%	22	32.7	45.8	410	0.0%	22	29.5	33.3
38	375	0.0%	20	27.0	22.5	628	0.0%	20	29.8	36.3	310	0.0%	23	37.7	89.1
39	292	0.0%	21	33.8	47.4	513	0.0%	21	31.5	33.6	239	0.0%	23	32.7	56.9
40	230	0.0%	21	36.3	55.3	420	0.0%	21	33.5	43.1	200	0.0%	25	30.9	36.6
41	181	0.0%	21	35.3	58.5	345	0.0%	23	34.8	53.2	165	0.0%	21	26.9	25.9
42	144	0.0%	20	27.1	21.1	262	0.0%	20	27.1	26.7	141	0.0%	20	27.1	33.2
43	113	0.0%	20	28.1	24.5	215	0.0%	19	26.3	21.8	116	0.0%	20	29.1	32.6
44	87	0.0%	23	24.6	16.6	174	0.0%	21	28.3	29.8	90	0.0%	21	26.6	21.5
45	76	0.0%	18	30.7	43.0	138	0.0%	18	24.8	18.7	70	0.0%	21	25.4	17.9
46	68	0.0%	19	23.2	15.3	112	0.0%	18	28.5	29.5	58	0.0%	21	28.0	30.3
47	53	0.0%	20	29.0	26.5	87	0.0%	16	22.6	16.7	*****	*****	18	23.9	18.0
48	41	0.0%	22	30.2	23.7	71	0.0%	19	24.4	17.4	*****	*****	16	22.5	20.5
49	38	0.0%	18	25.2	23.1	62	0.0%	19	21.9	12.7	*****	*****	16	20.4	13.0
50	*****	*****	19	24.6	15.8	44	0.0%	18	18.6	8.7	29	0.0%	22	25.6	23.8
51	*****	*****	17	20.9	13.1	41	0.0%	16	18.6	9.1	23	0.0%	14	22.4	25.0
52	*****	*****	21	23.4	15.6	31	0.0%	18	21.7	13.9	19	0.0%	13	25.3	29.9
53	12	0.0%	23	24.3	18.7	28	0.0%	19	21.8	15.7	*****	*****	15	15.5	7.1
54	*****	*****	13	21.6	27.5	21	0.0%	20	24.3	16.7	*****	*****	12	13.3	8.7
55	*****	*****	11	13.3	6.4	17	0.0%	13	17.0	10.5	*****	*****	14	12.5	4.6
56	*****	*****	13	21.1	24.5	13	0.0%	15	16.5	8.8	*****	*****	17	15.8	6.3
57	*****	*****	16	15.7	7.7	11	0.0%	13	14.0	10.3	*****	*****	14	16.0	12.5
58	*****	*****	9	11.4	5.9	*****	*****	15	16.6	10.0	*****	*****	11	11.7	5.8
59	*****	*****	16	15.6	8.5	*****	*****	16	15.1	8.8	*****	*****	13	17.4	18.4
60	*****	*****	18	17.5	4.9	*****	*****	13	12.8	4.4	*****	*****	13	12.6	7.2
61	*****	*****	15	14.5	0.7	*****	*****	9	10.0	5.4	*****	*****	16	15.0	10.7
62	*****	*****	21	20.5	7.8	*****	*****	17	14.0	6.6	*****	*****	*****	*****	*****
63	*****	*****	*****	*****	*****	*****	*****	9	10.3	8.1	*****	*****	*****	*****	*****
64	*****	*****	*****	*****	*****	*****	*****	12	12.0	10.0	*****	*****	*****	*****	*****
65	*****	*****	*****	*****	*****	*****	*****	8	14.3	14.6	*****	*****	*****	*****	*****
66	*****	*****	*****	*****	*****	*****	*****	8	12.0	12.5	*****	*****	*****	*****	*****
67	*****	*****	*****	*****	*****	*****	*****	14	13.5	6.4	*****	*****	*****	*****	*****
68	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
69	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****
70	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Metformin, continued</u>			18-44 years			45-54 years				55-64 years					
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
71	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
72	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
73	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
Gap from last episode until censoring	1,030,270	27.2%	44	280.4	495.1	1,100,240	24.6%	0	204.0	432.6	1,322,261	28.6%	0	188.7	413.1

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	6,202,840	100%	30	122.7	289.8	3,011,899	100%	31	143.2	323.3
Gap Number										
1	1,161,661	18.7%	41	119.1	232.4	577,810	19.2%	38	109.7	214.1
2	775,441	12.5%	37	90.3	173.4	369,058	12.3%	34	83.6	159.1
3	545,825	8.8%	35	79.0	147.9	251,411	8.3%	33	72.1	131.7
4	397,480	6.4%	34	71.7	131.6	178,730	5.9%	32	66.4	118.6
5	296,117	4.8%	33	66.5	118.7	130,419	4.3%	31	61.9	110.0
6	223,662	3.6%	32	62.6	110.4	96,953	3.2%	31	57.9	98.5
7	171,377	2.8%	32	59.4	102.0	73,170	2.4%	30	54.8	91.9
8	132,463	2.1%	31	56.3	95.8	55,962	1.9%	30	52.1	84.7
9	103,462	1.7%	30	54.1	90.9	43,330	1.4%	29	50.7	82.4
10	81,356	1.3%	30	52.2	87.4	33,805	1.1%	29	48.5	80.1
11	64,426	1.0%	30	50.7	85.9	26,645	0.9%	29	47.4	76.2
12	51,492	0.8%	29	48.6	78.9	21,139	0.7%	28	45.3	68.2
13	41,256	0.7%	29	47.8	78.2	16,788	0.6%	28	45.4	72.3
14	33,090	0.5%	28	46.4	74.0	13,373	0.4%	28	44.3	70.4
15	26,584	0.4%	28	45.1	71.4	10,779	0.4%	28	44.7	70.8
16	21,502	0.3%	28	44.3	69.1	8,599	0.3%	28	42.8	70.1
17	17,373	0.3%	27	42.5	66.0	6,870	0.2%	28	40.9	58.8
18	14,154	0.2%	27	42.7	69.0	5,498	0.2%	27	42.1	68.9
19	11,433	0.2%	27	42.2	65.0	4,355	0.1%	28	40.2	55.6
20	9,309	0.2%	28	42.5	65.2	3,535	0.1%	27	40.3	59.3
21	7,572	0.1%	27	41.1	66.6	2,860	0.1%	26	40.7	70.9
22	6,157	0.1%	27	40.0	56.6	2,277	0.1%	27	38.1	55.2
23	4,973	0.1%	27	40.3	54.7	1,824	0.1%	27	39.1	56.9
24	4,088	0.1%	27	38.9	52.8	1,486	0.0%	27	40.0	70.9
25	3,351	0.1%	27	38.7	49.7	1,189	0.0%	27	35.8	40.3
26	2,749	0.0%	26	37.9	53.0	941	0.0%	26	36.7	47.7
27	2,273	0.0%	26	37.7	51.2	761	0.0%	27	38.8	52.9

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin, continued						65-74 years					75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
28	1,846	0.0%	26	36.3	49.7	615	0.0%	26	36.1	41.4					
29	1,538	0.0%	27	37.4	45.0	505	0.0%	27	40.7	79.6					
30	1,271	0.0%	27	35.6	40.2	421	0.0%	26	35.7	39.0					
31	1,088	0.0%	26	37.1	48.9	353	0.0%	26	37.6	42.7					
32	892	0.0%	25	34.3	40.8	286	0.0%	23	38.5	63.4					
33	754	0.0%	26	36.8	51.0	232	0.0%	25	36.6	53.9					
34	626	0.0%	25	36.3	43.9	194	0.0%	27	36.7	41.3					
35	516	0.0%	27	33.3	37.5	151	0.0%	26	38.7	62.7					
36	432	0.0%	26	32.6	31.2	132	0.0%	21	27.9	20.1					
37	350	0.0%	23	31.1	28.4	102	0.0%	24	29.6	25.8					
38	305	0.0%	26	36.7	44.8	83	0.0%	25	28.8	21.0					
39	258	0.0%	28	34.3	29.8	68	0.0%	28	41.8	45.8					
40	209	0.0%	27	34.3	31.6	59	0.0%	30	35.9	27.5					
41	168	0.0%	29	39.2	47.2	45	0.0%	32	41.3	33.9					
42	142	0.0%	28	37.2	38.8	35	0.0%	24	28.0	17.3					
43	122	0.0%	24	30.0	29.0	27	0.0%	32	32.6	17.2					
44	101	0.0%	24	31.1	36.1	20	0.0%	28	27.5	15.8					
45	87	0.0%	19	27.6	25.8	20	0.0%	26	32.3	24.8					
46	68	0.0%	26	28.3	24.0	16	0.0%	25	31.7	22.8					
47	53	0.0%	23	26.7	32.0	*****	*****	29	28.8	10.2					
48	40	0.0%	19	24.9	19.4	*****	*****	23	30.2	20.3					
49	39	0.0%	20	26.9	28.9	*****	*****	19	15.3	9.1					
50	33	0.0%	20	24.2	17.9	*****	*****	41	37.0	27.2					
51	23	0.0%	17	25.0	20.5	*****	*****	*****	*****	*****					
52	19	0.0%	20	24.6	19.2	*****	*****	*****	*****	*****					
53	15	0.0%	20	26.4	21.4	*****	*****	*****	*****	*****					
54	13	0.0%	22	29.8	26.2	0	0.0%								
55	11	0.0%	19	20.8	10.0	0	0.0%								
56	*****	*****	16	17.7	7.5	0	0.0%								

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Metformin, continued			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
57	*****	*****	15	19.4	10.4	0	0.0%			
58	*****	*****	18	22.4	15.8	0	0.0%			
59	*****	*****	17	20.0	14.3	0	0.0%			
60	*****	*****	25	27.8	10.4	0	0.0%			
61	*****	*****	30	30.0	19.7	0	0.0%			
62	*****	*****	17	20.8	11.8	0	0.0%			
63	*****	*****	18	19.0	1.7	0	0.0%			
64	*****	*****	*****	*****	*****	0	0.0%			
65	*****	*****	*****	*****	*****	0	0.0%			
66	*****	*****	*****	*****	*****	0	0.0%			
67	*****	*****	*****	*****	*****	0	0.0%			
68	*****	*****	*****	*****	*****	0	0.0%			
69	*****	*****	*****	*****	*****	0	0.0%			
70	0	0.0%				0	0.0%			
71	0	0.0%				0	0.0%			
72	0	0.0%				0	0.0%			
73	0	0.0%				0	0.0%			
Gap from last episode until censoring	1,981,146	31.9%	0	204.4	438.4	1,068,947	35.5%	3	258.9	478.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Sitagliptin	18-44 years					45-54 years					55-64 years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
	Gap Number														
Total Episodes	372,047	100%	27	162.9	377.7	706,337	100%	25	158.2	375.1	877,358	100%	25	158.4	361.7
1	66,281	17.8%	26	88.9	227.3	127,153	18.0%	26	87.6	220.7	166,779	19.0%	27	87.1	208.3
2	45,017	12.1%	26	72.8	179.3	84,797	12.0%	25	71.3	177.3	104,815	11.9%	26	68.6	162.8
3	32,450	8.7%	26	67.6	163.9	60,285	8.5%	25	63.8	157.5	71,380	8.1%	25	61.0	141.7
4	24,228	6.5%	26	64.8	159.2	44,720	6.3%	25	59.1	145.2	50,853	5.8%	25	56.9	130.7
5	18,387	4.9%	26	59.6	143.6	33,932	4.8%	24	53.7	123.3	37,499	4.3%	25	52.9	115.4
6	14,262	3.8%	25	56.4	136.6	26,371	3.7%	24	52.9	127.0	28,208	3.2%	24	50.5	107.3
7	11,211	3.0%	25	52.5	118.4	20,790	2.9%	24	50.3	119.0	21,665	2.5%	24	48.1	101.0
8	8,966	2.4%	25	53.1	124.2	16,395	2.3%	24	49.5	119.5	16,784	1.9%	24	45.7	95.1
9	7,184	1.9%	24	50.1	118.3	13,154	1.9%	23	46.3	105.2	13,179	1.5%	24	44.2	88.4
10	5,769	1.6%	24	51.7	128.0	10,672	1.5%	23	45.9	104.6	10,529	1.2%	23	44.2	97.3
11	4,731	1.3%	24	48.1	107.0	8,749	1.2%	23	45.0	103.1	8,369	1.0%	24	44.2	98.6
12	3,852	1.0%	24	45.1	98.6	7,122	1.0%	23	43.8	93.4	6,771	0.8%	23	40.7	81.2
13	3,183	0.9%	23	44.2	93.7	5,865	0.8%	23	42.5	93.9	5,482	0.6%	23	40.6	80.4
14	2,591	0.7%	23	44.0	103.0	4,794	0.7%	23	40.9	85.5	4,430	0.5%	24	42.7	92.0
15	2,155	0.6%	23	45.0	95.3	3,955	0.6%	22	41.5	99.4	3,596	0.4%	23	38.1	68.7
16	1,756	0.5%	23	41.2	74.5	3,296	0.5%	22	39.2	84.3	2,952	0.3%	23	36.6	63.1
17	1,465	0.4%	22	40.7	74.1	2,748	0.4%	23	41.2	82.4	2,432	0.3%	24	40.2	81.4
18	1,205	0.3%	21	41.1	77.5	2,290	0.3%	23	38.6	75.1	1,969	0.2%	23	38.3	77.7
19	994	0.3%	22	42.4	109.6	1,918	0.3%	22	36.2	59.8	1,618	0.2%	22	35.0	56.8
20	826	0.2%	23	39.5	81.6	1,618	0.2%	21	36.4	72.9	1,343	0.2%	20	33.6	56.2
21	678	0.2%	20	33.9	57.1	1,363	0.2%	20	35.3	65.0	1,135	0.1%	21	36.0	64.6
22	568	0.2%	22	38.0	75.6	1,147	0.2%	21	34.2	51.6	951	0.1%	21	35.7	63.5
23	492	0.1%	21	32.9	52.0	982	0.1%	22	33.4	52.6	792	0.1%	21	34.5	60.1
24	417	0.1%	21	40.9	125.8	857	0.1%	21	34.9	72.0	664	0.1%	20	40.9	113.4
25	357	0.1%	21	30.1	40.3	729	0.1%	20	33.2	49.7	556	0.1%	21	33.3	50.1
26	302	0.1%	20	43.7	128.0	615	0.1%	22	33.4	42.2	469	0.1%	20	31.4	54.2
27	251	0.1%	20	28.8	30.5	516	0.1%	20	30.2	37.2	395	0.0%	21	34.1	70.4
28	214	0.1%	20	38.0	71.3	456	0.1%	20	30.9	49.7	344	0.0%	19	29.1	34.9
29	179	0.0%	20	30.0	35.1	383	0.1%	21	30.3	43.9	284	0.0%	19	31.7	52.2
30	156	0.0%	19	33.3	65.5	327	0.0%	20	31.6	69.8	248	0.0%	20	35.0	80.6
31	133	0.0%	18	28.9	29.3	276	0.0%	21	30.2	31.3	207	0.0%	23	29.3	25.7
32	110	0.0%	17	30.1	54.4	236	0.0%	22	27.0	19.8	173	0.0%	21	27.7	22.0
33	95	0.0%	20	24.7	18.9	202	0.0%	21	27.9	24.8	145	0.0%	23	27.3	23.9
34	85	0.0%	21	24.0	16.5	171	0.0%	19	25.5	21.5	120	0.0%	21	28.1	24.8

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Sitagliptin, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	69	0.0%	19	22.0	13.8	139	0.0%	19	28.4	39.1	102	0.0%	23	27.5	21.3
36	57	0.0%	18	20.9	11.0	116	0.0%	20	31.8	55.0	85	0.0%	21	24.8	15.8
37	48	0.0%	23	28.7	21.9	94	0.0%	20	25.4	16.6	77	0.0%	19	26.1	23.9
38	41	0.0%	21	27.7	22.7	79	0.0%	18	24.7	20.3	64	0.0%	19	29.0	33.8
39	33	0.0%	22	33.9	37.6	62	0.0%	19	22.3	16.8	55	0.0%	20	21.9	12.9
40	27	0.0%	23	28.8	18.9	51	0.0%	21	25.7	20.6	44	0.0%	22	29.5	59.5
41	24	0.0%	24	28.9	23.6	43	0.0%	19	27.9	33.3	40	0.0%	15	18.3	11.3
42	19	0.0%	20	28.5	21.8	32	0.0%	19	24.5	19.1	33	0.0%	18	23.7	26.8
43	16	0.0%	24	26.8	14.9	30	0.0%	17	20.4	11.6	29	0.0%	22	24.8	18.9
44	*****	*****	16	22.8	15.3	28	0.0%	25	26.0	14.8	21	0.0%	18	23.6	18.2
45	*****	*****	14	16.4	8.6	23	0.0%	14	18.3	12.1	15	0.0%	18	23.3	16.1
46	*****	*****	15	23.5	18.8	20	0.0%	16	21.9	22.0	*****	*****	20	23.1	15.9
47	*****	*****	15	30.0	40.4	20	0.0%	16	20.0	10.0	*****	*****	14	18.0	10.0
48	*****	*****	22	24.2	15.0	13	0.0%	20	27.6	16.2	*****	*****	23	22.7	12.8
49	*****	*****	18	20.4	13.3	11	0.0%	27	26.1	8.3	*****	*****	21	19.4	11.7
50	*****	*****	29	27.4	18.3	*****	*****	22	21.9	8.3	*****	*****	32	52.4	46.2
51	*****	*****	18	25.0	25.0	*****	*****	25	24.3	6.6	*****	*****	20	47.3	58.0
52	*****	*****	11	11.0	7.8	*****	*****	24	23.0	9.5	*****	*****	15	15.0	8.5
53	*****	*****	11	10.5	7.8	*****	*****	30	29.0	12.7	*****	*****	17	17.0	7.1
54	*****	*****	9	9.0	8.5	*****	*****	9	12.0	6.1	*****	*****	24	23.5	10.6
55	*****	*****	11	11.0	9.9	*****	*****	*****	*****	*****	*****	*****	18	17.5	2.1
56	*****	*****	9	9.0	2.8	*****	*****	*****	*****	*****	*****	*****	15	14.5	3.5
57	*****	*****	6	5.5	2.1	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
58	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
59	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
60	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
61	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
62	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****
63	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****
64	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****
65	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****
66	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****
67	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****
68	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****
69	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****
70	*****	*****	*****	*****	*****	0	0.0%	*****	*****	*****	0	0.0%	*****	*****	*****

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Sitagliptin, continued</u>			18-44 years			45-54 years					55-64 years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
71	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
72	*****	*****	*****	*****	*****	0	0.0%				0	0.0%			
Gap from last episode until censoring	111,059	29.9%	86	386.2	580.2	216,655	30.7%	46	368.5	576.7	309,603	35.3%	26	329.2	529.1

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

Sitagliptin	65-74 years					75+ years				
	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
Total Episodes	1,482,855	100%	30	177.7	371.5	1,025,281	100%	28	165.5	349.3
Gap Number										
1	291,039	19.6%	31	93.2	196.9	203,093	19.8%	30	86.9	182.1
2	179,484	12.1%	29	73.9	152.3	121,843	11.9%	27	66.9	137.7
3	119,262	8.0%	28	66.3	135.0	79,534	7.8%	26	58.5	115.1
4	82,877	5.6%	28	60.1	117.3	54,566	5.3%	26	54.2	105.2
5	59,610	4.0%	27	55.2	104.1	38,610	3.8%	25	50.3	94.1
6	43,710	2.9%	27	52.9	101.1	28,177	2.7%	25	47.3	85.9
7	32,777	2.2%	26	49.8	93.7	20,896	2.0%	24	45.6	83.0
8	25,132	1.7%	26	47.3	79.9	15,739	1.5%	24	42.7	72.0
9	19,255	1.3%	25	45.3	77.8	12,057	1.2%	24	42.2	68.5
10	14,870	1.0%	25	45.0	81.4	9,281	0.9%	23	39.7	66.3
11	11,580	0.8%	25	41.9	71.9	7,193	0.7%	23	38.3	64.5
12	9,096	0.6%	25	42.2	70.1	5,626	0.5%	23	37.8	64.7
13	7,143	0.5%	25	41.7	69.6	4,457	0.4%	22	35.5	51.7
14	5,686	0.4%	25	40.2	66.4	3,521	0.3%	23	34.7	48.8
15	4,499	0.3%	24	38.4	60.4	2,790	0.3%	22	34.8	59.5
16	3,638	0.2%	24	37.3	59.7	2,191	0.2%	22	33.4	49.9
17	2,873	0.2%	24	35.5	45.3	1,777	0.2%	21	32.4	48.9
18	2,299	0.2%	24	35.5	45.6	1,400	0.1%	22	32.8	50.7
19	1,844	0.1%	24	35.2	56.3	1,102	0.1%	22	30.3	33.9
20	1,472	0.1%	24	34.8	42.4	873	0.1%	23	33.0	51.4
21	1,174	0.1%	23	33.2	47.3	696	0.1%	22	28.3	29.2
22	944	0.1%	24	32.3	41.3	535	0.1%	22	29.8	31.6
23	743	0.1%	24	33.4	47.5	437	0.0%	21	29.3	31.7
24	585	0.0%	24	34.1	90.9	338	0.0%	21	32.4	44.5
25	473	0.0%	22	31.8	39.8	266	0.0%	21	30.6	34.3
26	379	0.0%	23	30.7	32.6	209	0.0%	20	26.7	23.4
27	300	0.0%	24	31.8	34.8	172	0.0%	19	26.1	23.4
28	241	0.0%	25	30.4	30.7	138	0.0%	20	25.4	21.1
29	194	0.0%	25	30.7	25.3	111	0.0%	19	25.9	24.0
30	164	0.0%	23	31.8	27.6	86	0.0%	23	31.9	55.3
31	145	0.0%	20	35.0	58.4	65	0.0%	21	27.7	34.3
32	110	0.0%	21	29.2	24.4	52	0.0%	25	33.1	41.4
33	90	0.0%	20	34.2	50.2	39	0.0%	21	26.8	28.7
34	74	0.0%	22	29.5	24.8	35	0.0%	16	21.3	16.0

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Sitagliptin, continued</u>			65-74 years			75+ years				
Gap Number	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes	Percent	Median Days per Gap	Mean Days per Gap	Standard Deviation
35	61	0.0%	17	29.3	37.6	33	0.0%	17	23.1	18.7
36	52	0.0%	20	25.4	19.0	27	0.0%	15	26.2	35.4
37	42	0.0%	20	23.4	17.7	22	0.0%	20	29.4	27.4
38	35	0.0%	17	28.2	34.2	19	0.0%	20	22.1	16.9
39	30	0.0%	20	26.2	28.4	17	0.0%	20	24.3	15.1
40	24	0.0%	17	21.4	16.5	13	0.0%	15	19.2	11.0
41	*****	*****	24	25.6	18.5	*****	*****	22	22.9	14.0
42	*****	*****	28	35.6	30.6	*****	*****	19	20.2	10.0
43	*****	*****	21	23.5	14.1	*****	*****	29	31.0	5.3
44	*****	*****	39	39.4	34.9	*****	*****	14	18.7	10.8
45	*****	*****	21	19.3	13.3	*****	*****	26	26.7	16.0
46	*****	*****	14	10.4	6.3	*****	*****	19	18.5	13.4
47	*****	*****	4	7.2	4.9	*****	*****	*****	*****	*****
48	*****	*****	16	13.3	6.4	*****	*****	*****	*****	*****
49	*****	*****	11	11.3	10.5	*****	*****	*****	*****	*****
50	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
51	0	0.0%				*****	*****	*****	*****	*****
52	0	0.0%				*****	*****	*****	*****	*****
53	0	0.0%				0	0.0%			
54	0	0.0%				0	0.0%			
55	0	0.0%				0	0.0%			
56	0	0.0%				0	0.0%			
57	0	0.0%				0	0.0%			
58	0	0.0%				0	0.0%			
59	0	0.0%				0	0.0%			
60	0	0.0%				0	0.0%			
61	0	0.0%				0	0.0%			
62	0	0.0%				0	0.0%			
63	0	0.0%				0	0.0%			
64	0	0.0%				0	0.0%			
65	0	0.0%				0	0.0%			
66	0	0.0%				0	0.0%			
67	0	0.0%				0	0.0%			
68	0	0.0%				0	0.0%			
69	0	0.0%				0	0.0%			
70	0	0.0%				0	0.0%			

Table 12b. Gaps between Non-Insulin Antidiabetic Drug Treatment Episodes in the Sentinel Distributed Database (SDD) between January 1, 2008 and January 31, 2018, Sensitivity Analysis, by Age Group

<u>Sitagliptin, continued</u>			65-74 years			75+ years				
Gap Number	Number of Episodes		Median Days per Gap	Mean Days per Gap	Standard Deviation	Number of Episodes		Median Days per Gap	Mean Days per Gap	Standard Deviation
	Percent					Percent				
71	0	0.0%				0	0.0%			
72	0	0.0%				0	0.0%			
Gap from last episode until censoring	558,774	37.7%	59	354.4	527.7	407,214	39.7%	41	317.5	489.6

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. List of Dates of Available Data for Each Data Partner (DP) in the Sentinel Distributed Database (SDD) as of Request Distribution Date (June 28, 2018)

DP ID	DP Start Date ¹	DP End Date ¹
DP01	1/1/2008	11/30/2017
DP02	1/1/2012	6/30/2017
DP03	1/1/2010	12/31/2015
DP04	1/1/2006	10/31/2017
DP05	1/1/2004	1/31/2018
DP06	1/1/2000	6/30/2017
DP07	1/1/2000	1/31/2017
DP08	1/1/2000	3/31/2016
DP09	1/1/2000	5/31/2015
DP10	6/1/2007	10/31/2017
DP11	1/1/2000	10/31/2017
DP12	1/1/2000	7/31/2017
DP13	1/1/2005	12/17/2017
DP14	1/1/2000	12/31/2017
DP15	1/1/2000	8/31/2017
DP16	1/1/2008	6/30/2017
DP17	1/1/2000	12/31/2016

¹The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
Albiglutide	
ALBIGLUTIDE	Tanzeum
Alogliptin	
ALOGLIPTIN BENZOATE	Nesina
ALOGLIPTIN BENZOATE	Alogliptin
ALOGLIPTIN BENZOATE/METFORMIN HCL	Kazano
ALOGLIPTIN BENZOATE/METFORMIN HCL	Alogliptin-Metformin
ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL	Oseni
ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL	Alogliptin-Pioglitazone
Canagliflozin	
CANAGLIFLOZIN	Invokana
CANAGLIFLOZIN/METFORMIN HCL	Invokamet
CANAGLIFLOZIN/METFORMIN HCL	Invokamet XR
Dapagliflozin	
DAPAGLIFLOZIN PROPANEDIOL	Farxiga
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL	Xigduo XR
DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL	Qtern
Dulaglutide	
DULAGLUTIDE	Trulicity
Empagliflozin	
EMPAGLIFLOZIN	Jardiance
EMPAGLIFLOZIN/METFORMIN HCL	Synjardy
EMPAGLIFLOZIN/METFORMIN HCL	Synjardy XR
EMPAGLIFLOZIN/LINAGLIPTIN	Glyxambi
Exenatide	
EXENATIDE	Byetta
EXENATIDE MICROSPHERES	Bydureon BCise
EXENATIDE MICROSPHERES	Bydureon
Glimepiride	
GLIMEPIRIDE	Glimepiride
GLIMEPIRIDE	Amaryl
PIOGLITAZONE HCL/GLIMEPIRIDE	Pioglitazone-Glimepiride
PIOGLITAZONE HCL/GLIMEPIRIDE	Duetact
ROSIGLITAZONE MALEATE/GLIMEPIRIDE	Avandaryl
Glipizide	
GLIPIZIDE	Glipizide
GLIPIZIDE	Glucotrol XL
GLIPIZIDE	Glucotrol
GLIPIZIDE/METFORMIN HCL	Glipizide-Metformin
GLIPIZIDE/METFORMIN HCL	Metaglip

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
Glyburide	
GLYBURIDE, MICRONIZED	Glyburide Micronized
GLYBURIDE, MICRONIZED	Glynase
GLYBURIDE, MICRONIZED	Glycron
GLYBURIDE	Glyburide
GLYBURIDE	Micronase
GLYBURIDE	Diabeta
GLYBURIDE/METFORMIN HCL	Glucovance
GLYBURIDE/METFORMIN HCL	Glyburide-Metformin
Linagliptin	
LINAGLIPTIN	Tradjenta
LINAGLIPTIN/METFORMIN HCL	Jentaduetto
LINAGLIPTIN/METFORMIN HCL	Jentaduetto XR
EMPAGLIFLOZIN/LINAGLIPTIN	Glyxambi
Liraglutide	
LIRAGLUTIDE	Victoza 3-Pak
LIRAGLUTIDE	Victoza 2-Pak
INSULIN DEGLUDEC/LIRAGLUTIDE	Xultophy 100/3.6
INSULIN DEGLUDEC/LIRAGLUTIDE	Xultophy 100/3.6
Metformin	
METFORMIN HCL/BLOOD SUGAR DIAGNOSTIC	DM2
METFORMIN HCL	Metformin
METFORMIN HCL	Glucophage
METFORMIN HCL	Glucophage XR
METFORMIN HCL	Riomet
METFORMIN HCL	Fortamet
METFORMIN HCL	Glumetza
CANAGLIFLOZIN/METFORMIN HCL	Invokamet
CANAGLIFLOZIN/METFORMIN HCL	Invokamet XR
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL	Xigduo XR
EMPAGLIFLOZIN/METFORMIN HCL	Synjardy
EMPAGLIFLOZIN/METFORMIN HCL	Synjardy XR
ALOGLIPTIN BENZOATE/METFORMIN HCL	Kazano
ALOGLIPTIN BENZOATE/METFORMIN HCL	Alogliptin-Metformin
LINAGLIPTIN/METFORMIN HCL	Jentaduetto

Appendix B. List of Generic and Brand Drug Names Used to Define Exposures in this Request

Generic Name	Brand Name
LINAGLIPTIN/METFORMIN HCL	Jentaducto XR
SAXAGLIPTIN HCL/METFORMIN HCL	Kombiglyze XR
SITAGLIPTIN PHOSPHATE/METFORMIN HCL	Janumet
SITAGLIPTIN PHOSPHATE/METFORMIN HCL	Janumet XR
REPAGLINIDE/METFORMIN HCL	Prandin
REPAGLINIDE/METFORMIN HCL	Repaglinide-Metformin
GLIPIZIDE/METFORMIN HCL	Glipizide-Metformin
GLIPIZIDE/METFORMIN HCL	Metaglip
GLYBURIDE/METFORMIN HCL	Glucovance
GLYBURIDE/METFORMIN HCL	Glyburide-Metformin
PIOGLITAZONE HCL/METFORMIN HCL	Actoplus MET
PIOGLITAZONE HCL/METFORMIN HCL	Pioglitazone-Metformin
PIOGLITAZONE HCL/METFORMIN HCL	Actoplus Met XR
ROSIGLITAZONE MALEATE/METFORMIN HCL	Avandamet
Pioglitazone	
PIOGLITAZONE HCL	Actos
PIOGLITAZONE HCL	Pioglitazone
PIOGLITAZONE HCL/METFORMIN HCL	Actoplus MET
PIOGLITAZONE HCL/METFORMIN HCL	Pioglitazone-Metformin
PIOGLITAZONE HCL/METFORMIN HCL	Actoplus Met XR
PIOGLITAZONE HCL/GLIMEPIRIDE	Pioglitazone-Glimepiride
PIOGLITAZONE HCL/GLIMEPIRIDE	DUETACT
ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL	Oseni
ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL	Alogliptin-Pioglitazone
Saxagliptin	
SAXAGLIPTIN HCL	Onglyza
SAXAGLIPTIN HCL/METFORMIN HCL	Kombiglyze XR
DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL	Qtern
Sitagliptin	
SITAGLIPTIN PHOSPHATE	Januvia
SITAGLIPTIN PHOSPHATE/METFORMIN HCL	Janumet
SITAGLIPTIN PHOSPHATE/METFORMIN HCL	Janumet XR

Appendix C. Specifications Defining Parameters in this Request

This request utilized the Cohort Identification and Descriptive Analysis (CIDA) tool, version 5.4.2, to estimate the duration of treatment with non-insulin antidiabetic drugs in the Sentinel Distributed Database (SDD).

Query Period: January 1, 2008 to January 31, 2018
Enrollment Requirement: 183 days
Enrollment Gap: 45 days
Coverage Requirement: At least drug
Age Groups: 18-44, 45-54, 55-64, 65-74, 75+ years
Sex: Male and Female
Results Stratified By: Age Group, Sex

Scenario	Exposure						Cohort Definition	Censor due to Evidence of Death
	Exposure	Incidence Criteria	Washout (Days)	Episode Gap Type	Episode Gap (Days)	Intent to Treat (Days)		
1	Metformin	Metformin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
2	Glyburide	Glyburide	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
3	Glipizide	Glipizide	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
4	Glimepiride	Glimepiride	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
5	Pioglitazone	Pioglitazone	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
6	Exenatide	Exenatide	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
7	Albiglutide	Albiglutide	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
8	Dulaglutide	Dulaglutide	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes

Appendix C. Specifications Defining Parameters in this Request								
9	Liraglutide recombinant	Liraglutide recombinant	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
10	Canagliflozin	Canagliflozin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
11	Dapagliflozin	Dapagliflozin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
12	Empagliflozin	Empagliflozin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
13	Sitagliptin	Sitagliptin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
14	Saxagliptin	Saxagliptin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
15	Linagliptin	Linagliptin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
16	Alogliptin	Alogliptin	183	Fixed	10	N/A	Include all valid episodes during the query period	Yes
17	Metformin	Metformin	183	Percentage	25%	N/A	Include all valid episodes during the query period	Yes
18	Glyburide	Glyburide	183	Percentage	25%	N/A	Include all valid episodes during the query period	Yes
19	Liraglutide recombinant	Liraglutide recombinant	183	Percentage	25%	N/A	Include all valid episodes during the query period	Yes
20	Sitagliptin	Sitagliptin	183	Percentage	25%	N/A	Include all valid episodes during the query period	Yes
National Drug Codes (NDC) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus"								